JP2023036970A - 極めて長い相補性決定領域を有するヒト化抗体 - Google Patents
極めて長い相補性決定領域を有するヒト化抗体 Download PDFInfo
- Publication number
- JP2023036970A JP2023036970A JP2023001446A JP2023001446A JP2023036970A JP 2023036970 A JP2023036970 A JP 2023036970A JP 2023001446 A JP2023001446 A JP 2023001446A JP 2023001446 A JP2023001446 A JP 2023001446A JP 2023036970 A JP2023036970 A JP 2023036970A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- amino acid
- antibody
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000295 complement effect Effects 0.000 title description 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 320
- 230000027455 binding Effects 0.000 abstract description 241
- 239000012634 fragment Substances 0.000 abstract description 226
- 238000000034 method Methods 0.000 abstract description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 428
- 235000001014 amino acid Nutrition 0.000 description 237
- 229940024606 amino acid Drugs 0.000 description 236
- 150000001413 amino acids Chemical class 0.000 description 207
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 183
- 150000007523 nucleic acids Chemical class 0.000 description 181
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 153
- 239000004473 Threonine Substances 0.000 description 153
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 117
- 235000004279 alanine Nutrition 0.000 description 117
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 115
- 239000004474 valine Substances 0.000 description 115
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 113
- 108090000623 proteins and genes Proteins 0.000 description 81
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 78
- 102000039446 nucleic acids Human genes 0.000 description 78
- 108020004707 nucleic acids Proteins 0.000 description 78
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 77
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 76
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 76
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 76
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 75
- 238000006467 substitution reaction Methods 0.000 description 74
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 66
- 125000000539 amino acid group Chemical group 0.000 description 65
- 241000283690 Bos taurus Species 0.000 description 50
- 210000004602 germ cell Anatomy 0.000 description 49
- 108090000765 processed proteins & peptides Proteins 0.000 description 48
- 239000000427 antigen Substances 0.000 description 46
- 108091007433 antigens Proteins 0.000 description 45
- 102000036639 antigens Human genes 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 45
- -1 Pro-TxII sequence Chemical group 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 43
- 102000004196 processed proteins & peptides Human genes 0.000 description 41
- 239000004475 Arginine Substances 0.000 description 39
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 39
- 239000004471 Glycine Substances 0.000 description 39
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 39
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 39
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 39
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 39
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 39
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 39
- 235000009582 asparagine Nutrition 0.000 description 39
- 229960001230 asparagine Drugs 0.000 description 39
- 235000003704 aspartic acid Nutrition 0.000 description 39
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 39
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 39
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 39
- 229960000310 isoleucine Drugs 0.000 description 39
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 38
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 38
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 37
- 108060003951 Immunoglobulin Proteins 0.000 description 35
- 102000018358 immunoglobulin Human genes 0.000 description 35
- 239000003053 toxin Substances 0.000 description 35
- 231100000765 toxin Toxicity 0.000 description 35
- 108700012359 toxins Proteins 0.000 description 35
- 229920001184 polypeptide Polymers 0.000 description 32
- 235000018417 cysteine Nutrition 0.000 description 29
- 108091033319 polynucleotide Proteins 0.000 description 29
- 102000040430 polynucleotide Human genes 0.000 description 29
- 239000002157 polynucleotide Substances 0.000 description 29
- 125000005647 linker group Chemical group 0.000 description 28
- 239000013598 vector Substances 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 25
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 24
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 22
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 20
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 19
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 19
- 101100242312 Oryza sativa subsp. japonica OSK1 gene Proteins 0.000 description 18
- 101100533605 Oryza sativa subsp. japonica SKP1 gene Proteins 0.000 description 18
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 14
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 13
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 12
- 101001049892 Scorpio palmatus Potassium channel toxin alpha-KTx 6.2 Proteins 0.000 description 12
- 108050003126 conotoxin Proteins 0.000 description 12
- VDNVVLOBNHIMQA-UHFFFAOYSA-N iberiotoxin Chemical compound C1SSCC(C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C1NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)CNC(=O)C(CC=1C=CC=CC=1)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CCCCN)NC1=O)CSSCC1NC(=O)C(C(C)C)NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)NC1=O)CSSCC1NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(O)=O)NC(=O)C(C(C)O)NC(=O)C(NC(=O)C1NC(=O)CC1)CC1=CC=CC=C1 VDNVVLOBNHIMQA-UHFFFAOYSA-N 0.000 description 12
- KECTXGMVIXOQAO-UHFFFAOYSA-N purotoxin 1 Chemical compound N1C(=O)C(CCCNC(N)=N)NC(=O)C(C(C)CC)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CCC(O)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)CN)CSSCC(C(NC(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)N2)C(C)O)=O)NC(=O)C(NC3=O)CSSCC(C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(CC(N)=O)NC(=O)C(CC=4C=CC(O)=CC=4)NC(=O)CNC(=O)C(CO)NC(=O)C(C)NC(=O)C(CC(N)=O)NC4=O)CSSCC4NC(=O)C(CCCCN)NC(=O)C2CSSCC1C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(=O)NC(C(C)CC)C(=O)NC3CC1=CNC=N1 KECTXGMVIXOQAO-UHFFFAOYSA-N 0.000 description 12
- 102000019034 Chemokines Human genes 0.000 description 11
- 108010012236 Chemokines Proteins 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 241000282849 Ruminantia Species 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 239000003102 growth factor Substances 0.000 description 11
- 229940072221 immunoglobulins Drugs 0.000 description 11
- 108090001007 Interleukin-8 Proteins 0.000 description 10
- 102000004890 Interleukin-8 Human genes 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 10
- 102100031109 Beta-catenin-like protein 1 Human genes 0.000 description 8
- 101000922061 Homo sapiens Beta-catenin-like protein 1 Proteins 0.000 description 8
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 102220357842 c.37G>T Human genes 0.000 description 8
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 102200097407 rs6586239 Human genes 0.000 description 8
- MXWDLLUGULWYIQ-BFRWRHKQSA-N scyllatoxin Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(N)=O)NC(=O)[C@H](C)N)C1=CC=CC=C1 MXWDLLUGULWYIQ-BFRWRHKQSA-N 0.000 description 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 8
- 101000795953 Ceratogyrus marshalli Beta-theraphotoxin-Cm1a Proteins 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 108091092195 Intron Proteins 0.000 description 7
- 101000761033 Paraphysa scrofa Beta-theraphotoxin-Ps1a Proteins 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- OVJBOPBBHWOWJI-FYNXUGHNSA-N (2S)-2-[[(2S)-1-[(2S)-2-[[(aS,1R,3aS,4S,10S,16S,19R,22S,25S,28S,34S,37S,40R,45R,48S,51S,57S,60S,63S,69S,72S,75S,78S,85R,88S,91R,94S)-40-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-25,48,78,88,94-pentakis(4-aminobutyl)-a-(2-amino-2-oxoethyl)-22,63,72-tris(3-amino-3-oxopropyl)-69-benzyl-37-[(1R)-1-hydroxyethyl]-34,60-bis(hydroxymethyl)-51,57,75-trimethyl-16-(2-methylpropyl)-3a-(2-methylsulfanylethyl)-2a,3,5a,9,15,18,21,24,27,33,36,39,47,50,53,56,59,62,65,68,71,74,77,80,87,90,93,96,99-nonacosaoxo-7a,8a,42,43,82,83-hexathia-1a,2,4a,8,14,17,20,23,26,32,35,38,46,49,52,55,58,61,64,67,70,73,76,79,86,89,92,95,98-nonacosazahexacyclo[43.35.25.419,91.04,8.010,14.028,32]nonahectane-85-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical group CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CO)NC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N3)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC2=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O OVJBOPBBHWOWJI-FYNXUGHNSA-N 0.000 description 6
- XTXGLOBWOMUGQB-UHFFFAOYSA-N 2-azaniumyl-3-(3-methoxyphenyl)propanoate Chemical group COC1=CC=CC(CC(N)C(O)=O)=C1 XTXGLOBWOMUGQB-UHFFFAOYSA-N 0.000 description 6
- 101710151106 Alpha-conotoxin AuIA Chemical group 0.000 description 6
- 101710151182 Alpha-conotoxin AuIC Chemical group 0.000 description 6
- 101710180810 Alpha-conotoxin PnIB Chemical group 0.000 description 6
- 101000795971 Ceratogyrus marshalli Beta-theraphotoxin-Cm1b Proteins 0.000 description 6
- 101000761016 Ceratogyrus marshalli Beta-theraphotoxin-Cm2a Proteins 0.000 description 6
- 108010023798 Charybdotoxin Proteins 0.000 description 6
- 102100040674 F-box only protein 38 Human genes 0.000 description 6
- 101000959500 Grammostola rosea Beta-theraphotoxin-Gr1b Proteins 0.000 description 6
- 101000959499 Grammostola rosea Kappa-theraphotoxin-Gr2c Proteins 0.000 description 6
- 101000844072 Grammostola rosea Toxin GTx1-15 Chemical group 0.000 description 6
- 101000892310 Homo sapiens F-box only protein 38 Proteins 0.000 description 6
- 101000709216 Hottentotta judaicus Beta-insect excitatory toxin Bj-xtrIT Proteins 0.000 description 6
- 101001049895 Hottentotta tamulus Potassium channel toxin alpha-KTx 5.4 Proteins 0.000 description 6
- 102100030704 Interleukin-21 Human genes 0.000 description 6
- 101001049894 Leiurus hebraeus Potassium channel toxin alpha-KTx 5.1 Proteins 0.000 description 6
- 101710150261 Mu-conotoxin PIIIA Proteins 0.000 description 6
- 101710204471 Neurotoxin B-IV Chemical group 0.000 description 6
- 101710094933 Purotoxin-1 Proteins 0.000 description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 6
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 6
- 101000844260 Thrixopelma pruriens Beta/omega-theraphotoxin-Tp1a Proteins 0.000 description 6
- KOXLLJFKLFSCAF-UHFFFAOYSA-N adwx 1 Chemical group N1C(=O)C(CCCNC(N)=N)NC(=O)C(CCSC)NC(=O)CNC(=O)C(C)NC(=O)C(CC(O)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C2CCCN2C(=O)C(CCCCN)NC(=O)C(CC(C)C)NC2=O)CSSCC(C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(O)=O)NC(=O)C(CC=3N=CNC=3)NC(=O)C(NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(N)=O)NC(=O)C(NC3=O)C(C)O)CSSCC2NC(=O)C(CCC(N)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CO)NC(=O)C(CC=2N=CNC=2)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)CNC(=O)C(N)C(C)C)C(C)CC)CSSCC3NC(=O)C(CCCCN)NC(=O)CNC(=O)C1CC1=CC=CC=C1 KOXLLJFKLFSCAF-UHFFFAOYSA-N 0.000 description 6
- MNSSWZUIQUJZTG-UHFFFAOYSA-N agitoxin 2 Chemical group C1SSCC(C(NC(CCSC)C(=O)NC(CC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)N2)=O)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC=3C=CC=CC=3)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCSC)NC(=O)CNC(=O)C(C)NC(=O)C(CC(O)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C3CCCN3C(=O)C(CCCCN)NC(=O)C(C(C)CC)NC3=O)CSSCC(C(=O)NC(C(C)O)C(=O)N4C(CCC4)C(=O)NC(CCCCN)C(O)=O)NC(=O)C(CC=4N=CNC=4)NC(=O)C2CSSCC3NC(=O)C(CCC(N)=O)NC(=O)C2CCCN2C(=O)C(CO)NC(=O)CNC(=O)C(C(C)O)NC(=O)C1NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CCCN1C(=O)C(NC(=O)CN)C(C)C MNSSWZUIQUJZTG-UHFFFAOYSA-N 0.000 description 6
- 108010040029 alpha-conotoxin EpI Chemical group 0.000 description 6
- AAQUWIGGQCWDOE-QANPVJDHSA-N chembl558599 Chemical group C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(NC[C@@H](CSSC[C@@H]2NC(=O)[C@@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1)C(N)=O)=O)CC(C)C)C1=CN=CN1 AAQUWIGGQCWDOE-QANPVJDHSA-N 0.000 description 6
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical group C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 description 6
- PEFQQQGFYPMQLH-WFQFKEFWSA-N crotamin Chemical group C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3CSSC[C@H](NC(=O)[C@H](CC=4NC=NC=4)NC(=O)CNC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=4C=CC(O)=CC=4)CSSC[C@@H](C(=O)N[C@@H](CSSC2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N1)=O)[C@@H](C)CC)C1=CC=CC=C1 PEFQQQGFYPMQLH-WFQFKEFWSA-N 0.000 description 6
- 108010088252 hanatoxin Proteins 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 108010068927 iberiotoxin Proteins 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 108010074108 interleukin-21 Proteins 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- XOAUGYVLRSCGBG-UHFFFAOYSA-N protx ii Chemical group O=C1NC(CCC(N)=O)C(=O)NC(CCCCN)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCSC)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(C(C)O)C(=O)NC(C(NC(CC(O)=O)C(=O)NC(CO)C(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CSSCC(NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC2=O)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC=3C4=CC=CC=C4NC=3)C(O)=O)C(=O)N3)=O)CSSCC2NC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C3CSSCC1NC(=O)C(N)CC1=CC=C(O)C=C1 XOAUGYVLRSCGBG-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical group C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical group C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 6
- SVNSCQIKKAACJG-SBLJLSJOSA-N α-conotoxin auib Chemical group C([C@H]1C(=O)N[C@@H](C)C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CSSC[C@@H]2NC(=O)[C@@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@@H]3CCCN3C(=O)[C@@H]3CCCN3C(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CO)NC2=O)C(=O)N1)C(N)=O)=O)[C@H](O)C)C1=CC=CC=C1 SVNSCQIKKAACJG-SBLJLSJOSA-N 0.000 description 6
- VUVGEYBNLLGGBG-MVPSLEAZSA-N α-conotoxin pnia Chemical group C([C@H]1C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](CSSC[C@H](NC(=O)CN)C(=O)N2)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(O)=O)C(=O)N1)=O)CC(C)C)C(N)=O)C1=CC=C(O)C=C1 VUVGEYBNLLGGBG-MVPSLEAZSA-N 0.000 description 6
- 108091058553 ω-conotoxin GVIA Proteins 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 5
- 101001037206 Hydra vulgaris Hydramacin-1 Proteins 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
- 101000800755 Naja oxiana Alpha-elapitoxin-Nno2a Proteins 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000003114 blood coagulation factor Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- MJMLBAPXMAOKDU-UHFFFAOYSA-N huwentoxin iv Chemical group C1SSCC(C(NC(CSSCC(NC(=O)C(N)CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)CC)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)N2)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(C(=O)N3)C(C)C)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)C4CCCN4C(=O)C(CC(N)=O)NC(=O)C2CSSCC3C(=O)NC(CO)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC1C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CCC(N)=O)C(=O)NC(C(C)CC)C(N)=O)CC1=CC=C(O)C=C1 MJMLBAPXMAOKDU-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229930182817 methionine Chemical group 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 102200093795 rs63750818 Human genes 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 101001049882 Anuroctonus phaiodactylus Potassium channel toxin alpha-KTx 6.12 Chemical group 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 101710185464 Beta-theraphotoxin-Gr1b Proteins 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 108091058545 Secretory proteins Proteins 0.000 description 2
- 102000040739 Secretory proteins Human genes 0.000 description 2
- 241000242736 Stichodactyla Species 0.000 description 2
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- VRARWAGTAUYUOO-UHFFFAOYSA-N kaliotoxin Chemical group N1C(=O)C(CCCNC(N)=N)NC(=O)C(CCSC)NC(=O)CNC(=O)C(C)NC(=O)C(CC(O)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C2CCCN2C(=O)C(CCCCN)NC(=O)C(CC(C)C)NC2=O)CSSCC(C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(O)=O)NC(=O)C(CC=3N=CNC=3)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(N)=O)NC(=O)C(CCSC)NC3=O)CSSCC2NC(=O)C(CCC(N)=O)NC(=O)C2CCCN2C(=O)C(CO)NC(=O)CNC(=O)C(CO)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)CN)C(C)C)C(C)CC)CSSCC3NC(=O)C(CCCCN)NC(=O)CNC(=O)C1CC1=CC=CC=C1 VRARWAGTAUYUOO-UHFFFAOYSA-N 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101001074560 Arabidopsis thaliana Aquaporin PIP1-2 Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101000658289 Chilobrachys guangxiensis Kappa-theraphotoxin-Pg1a Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical group NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000723151 Hemachatus haemachatus Short neurotoxin 2 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 102100020873 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 101000740663 Leiurus hebraeus Toxin Lqh4 Proteins 0.000 description 1
- 101000740664 Leiurus quinquestriatus quinquestriatus Alpha-toxin Lqq4 Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101000658303 Paraphysa scrofa Kappa-theraphotoxin-Ps1a Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 101001047016 Tityus serrulatus Potassium channel toxin alpha-KTx 4.1 Chemical group 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- SYJOLNGRHPSSMR-SFHVURJKSA-N [1-(2-aminopyrimidin-4-yl)-6-[2-(1-hydroxycyclohexyl)ethynyl]indol-3-yl]-[(3S)-3-methylpiperazin-1-yl]methanone Chemical compound C[C@H]1CN(CCN1)C(=O)C2=CN(C3=C2C=CC(=C3)C#CC4(CCCCC4)O)C5=NC(=NC=C5)N SYJOLNGRHPSSMR-SFHVURJKSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 150000008266 deoxy sugars Chemical class 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- SOKDRDMJNDICMO-UHFFFAOYSA-N phrixotoxin 3 Chemical compound C1SSCC(C(NC(CSSCC(NC(=O)C(N)CC(O)=O)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CC(C)C)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCCCN)C(=O)N2)C(=O)NC(CCCNC(N)=N)C(=O)N3CCCC3C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(C(=O)N3)C(C)C)=O)NC(=O)C(CCCCN)NC(=O)C(CC(O)=O)NC(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)C4CCCN4C(=O)C(CC(N)=O)NC(=O)C2CSSCC3C(=O)NC(CO)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CC(O)=O)C(=O)NC(CCCCN)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC1C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CCC(N)=O)C(=O)NC(C(C)CC)C(O)=O)CC1=CC=C(O)C=C1 SOKDRDMJNDICMO-UHFFFAOYSA-N 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102200083311 rs2275017 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5421—IL-8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本開示は、極めて長いCDR3を含む抗体を含む、ヒト化抗体に関する。
本出願は、その内容全体が参照により本明細書に組み入れられる、2013年7月18日に出願された米国仮出願第61/856,010号の優先権の恩典を主張する。
抗体は、脊椎動物の免疫系が、主に感染防御のために異物(抗原)に応答して形成する、天然タンパク質である。一世紀以上にわたって、抗体は、人工的条件のもとで動物において誘導され、疾患状態の治療もしくは診断に使用するため、または生物学的研究のために採取されてきた。個々の抗体産生細胞はそれぞれ、組成が化学的に定められている1種類のタイプの抗体を産生するが、抗原接種に応答した動物血清から直接得られる抗体は、個々の抗体産生細胞の集団(ensemble)から作られる非同一分子の集団(例えばポリクローナル抗体)を実際には含む。
本開示は、極めて長いCDR3を含む抗体を含むヒト化抗体、それを作製する方法、およびその使用を提供する。
からなる群より選択されるシステインモチーフ;ならびに(XaXb)zモチーフ(式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である)を含む。
からなる群より選択されるシステインモチーフ;ならびに(XaXb)zモチーフ(式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である)を含む。
からなる群より選択されるシステインモチーフ;ならびに(XaXb)zモチーフ(式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である)を含む。
からなる群より選択されるシステインモチーフ;ならびに(XaXb)zモチーフ(式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である)を含む。
からなる群より選択されるアミノ酸配列を含み;Xは、極めて長いCDR3を含み、Xは、極めて長いCDR3を含み、この極めて長いCDR3は、任意でCDR3の1つの部分(例えば、CDR3の1つもしくは複数のアミノ酸)またはCDR3配列全体(例えば、CDR3のアミノ酸の全てもしくは実質的に全て)を除去する場合を含む、抗体のCDR3配列中に挿入された非ヒト配列または非抗体配列(例えば非抗体ヒト配列)を含んでよく;かつV2は、
からなる群より選択されるアミノ酸配列を含む。
のいずれか1つのアミノ酸配列、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択される(selected of)アミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
のいずれか1つおよび
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、システインモチーフ、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
のアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、システインモチーフ、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、システインモチーフ、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、システインモチーフ、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、システインモチーフ、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、非抗体配列、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
のアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、非抗体配列、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、非抗体配列、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、非抗体配列、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
のいずれか1つのアミノ酸配列、非抗体配列、および
のいずれか1つのアミノ酸配列を含み、かつV2が、
より選択されるアミノ酸配列を含む、場合を含む。
からなる群より選択されるアミノ酸配列を含み、Xは、極めて長いCDR3を含み、Xは、極めて長いCDR3を含み、この極めて長いCDR3は、任意でCDR3の1つの部分(例えば、CDR3の1つもしくは複数のアミノ酸)またはCDR3配列全体(例えば、CDR3のアミノ酸の全てもしくは実質的に全て)を除去する場合を含む、抗体のCDR3配列中に挿入された非ヒト配列または非抗体配列(例えば非抗体ヒト配列)を含んでよく;かつV2は、
からなる群より選択されるアミノ酸配列を含む。
からなる群より選択されるアミノ酸配列を含み、Xは、極めて長いCDR3を含み、Xは、極めて長いCDR3を含み、この極めて長いCDR3は、任意でCDR3の1つの部分(例えば、CDR3の1つもしくは複数のアミノ酸)またはCDR3配列全体(例えば、CDR3のアミノ酸の全てもしくは実質的に全て)を除去する場合を含む、抗体のCDR3配列中に挿入された非ヒト配列または非抗体配列(例えば非抗体ヒト配列)を含んでよく;かつV2は、
からなる群より選択されるアミノ酸配列を含む。
[本発明1001]
(a)(i)SEQ ID NO: 734またはSEQ ID NO: 735、
(ii)SEQ ID NO: 736またはSEQ ID NO: 737、
(iii)SEQ ID NO: 738またはSEQ ID NO: 739、
(iv)SEQ ID NO: 740またはSEQ ID NO: 741、
(v)SEQ ID NO: 742またはSEQ ID NO: 743、
(vi)SEQ ID NO: 744またはSEQ ID NO: 745、
(vii)SEQ ID NO: 746またはSEQ ID NO: 747、および
(viii)SEQ ID NO: 748またはSEQ ID NO: 749からなる群より選択されるアミノ酸配列;ならびに
(b)極めて長いCDR3
を含む重鎖可変領域を含む、ヒト化抗体またはその結合断片。
[本発明1002]
極めて長いCDR3が、35アミノ酸長もしくはそれ以上、40アミノ酸長もしくはそれ以上、45アミノ酸長もしくはそれ以上、50アミノ酸長もしくはそれ以上、55アミノ酸長もしくはそれ以上、または60アミノ酸長もしくはそれ以上である、本発明1001のヒト化抗体またはその結合断片。
[本発明1003]
極めて長いCDR3が、35アミノ酸長またはそれ以上である、本発明1002のヒト化抗体またはその結合断片。
[本発明1004]
極めて長いCDR3が、3個もしくはそれ以上のシステイン残基、4個もしくはそれ以上のシステイン残基、5個もしくはそれ以上のシステイン残基、6個もしくはそれ以上のシステイン残基、7個もしくはそれ以上のシステイン残基、8個もしくはそれ以上のシステイン残基、9個もしくはそれ以上のシステイン残基、10個もしくはそれ以上のシステイン残基、11個もしくはそれ以上のシステイン残基、または12個もしくはそれ以上のシステイン残基を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1005]
極めて長いCDR3が、3個またはそれ以上のシステイン残基を含む、本発明1004のヒト化抗体またはその結合断片。
[本発明1006]
システインモチーフを含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1007]
システインモチーフが、
からなる群より選択される、本発明1006のヒト化抗体またはその結合断片。
[本発明1008]
システインモチーフが、
からなる群より選択される、本発明1006のヒト化抗体またはその結合断片。
[本発明1009]
極めて長いCDR3が、2~6個のジスルフィド結合を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1010]
極めて長いCDR3が、SEQ ID NO: 40またはその派生物を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1011]
極めて長いCDR3が、SEQ ID NO: 1~4のいずれか1つのアミノ酸残基3~6を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1012]
極めて長いCDR3が、非ヒトDHまたはその派生物を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1013]
非ヒトDHが、SEQ ID NO: 5、SEQ ID NO: 6、SEQ ID NO: 7、SEQ ID NO: 8、SEQ ID NO: 9、SEQ ID NO: 10、SEQ ID NO: 11、またはSEQ ID NO: 12である、本発明1012のヒト化抗体またはその結合断片。
[本発明1014]
極めて長いCDR3が、JH配列またはその派生物を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1015]
JH配列が、SEQ ID NO: 13、SEQ ID NO: 14、SEQ ID NO: 15、SEQ ID NO: 16、またはSEQ ID NO: 17の5~15位のアミノ酸を含む、本発明1014のヒト化抗体またはその結合断片。
[本発明1016]
極めて長いCDR3が、
-非ヒトVH配列もしくはその派生物に由来する配列;
-非ヒトDH配列もしくはその派生物に由来する配列;および/または
-JH配列もしくはその派生物に由来する配列
を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1017]
極めて長いCDR3が、VH配列とDH配列の間に位置する2~6個またはそれ以上のアミノ酸残基を含む付加的なアミノ酸配列を含む、本発明1016のヒト化抗体またはその結合断片。
[本発明1018]
付加的なアミノ酸配列が、IR、IF、SEQ ID NO: 18、SEQ ID NO: 19、SEQ ID NO: 20、またはSEQ ID NO: 21からなる群より選択される、本発明1017のヒト化抗体またはその結合断片。
[本発明1019]
極めて長いCDR3が、SEQ ID NO: 22、SEQ ID NO: 23、SEQ ID NO: 24、SEQ ID NO: 25、SEQ ID NO: 26、SEQ ID NO: 27、またはSEQ ID NO: 28に由来するかまたは基づく配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1020]
極めて長いCDR3が、非ウシ配列または非抗体配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1021]
非抗体配列が合成配列である、本発明1020のヒト化抗体またはその結合断片。
[本発明1022]
非抗体配列が、サイトカイン配列、リンフォカイン配列、ケモカイン配列、増殖因子配列、ホルモン配列、または毒素配列である、本発明1020のヒト化抗体またはその結合断片。
[本発明1023]
非抗体配列が、IL-8配列、IL-21配列、SDF-1(α)配列、ソマトスタチン配列、クロロトキシン配列、Pro-TxII配列、ジコノチド配列、ADWX-1配列、HsTx1配列、OSK1配列、Pi2配列、ホンゴトキシン(Hongotoxin)(HgTX)配列、マルガトキシン(Margatoxin)配列、アギトキシン(Agitoxin)-2配列、Pi3配列、カリオトキシン(Kaliotoxin)配列、アニュロクトキシン(Anuroctoxin)配列、カリブドトキシン(Charybdotoxin)配列、チチウストキシン(Tityustoxin)-K-α配列、マウロトキシン配列、セラトトキシン1(CcoTx1)配列、CcoTx2配列、CcoTx3配列、フリクソトキシン3(PaurTx3)配列、ハナトキシン1配列、フリクソトキシン1配列、フエントキシン-IV配列、α-コノトキシンImI配列、α-コノトキシンEpI配列、α-コノトキシンPnIA配列、α-コノトキシンPnIB配列、α-コノトキシンMII配列、α-コノトキシンAuIA配列、α-コノトキシンAuIB配列、α-コノトキシンAuIC配列、コノトキシンκ-PVIIA配列、カリブドトキシン配列、ニューロトキシンB-IV配列、クロタミン配列、ω-GVIA(コノトキシン)配列、κ-ヘフトキシン1配列、Css4配列、Bj-xtrIT配列、BcIV配列、Hm-1配列、Hm-2配列、GsAF-I(β-テラホトキシン(theraphotoxin)-Gr1b)配列、プロトキシンI(ProTx-I配列、β-テラホトキシン-Tp1a)配列、プロトキシンII(ProTx II)配列、フエントキシンI配列、μ-コノトキシンPIIIA配列、ジンザオトキシン-III(β-TRTX-Cj1α)配列、GsAF-II(κ-テラホトキシン-Gr2c)配列、ShK(スチコダクチラ(Stichodactyla)毒素)配列、HsTx1配列、ガンギシトキシン(Guangxitoxin)1E(GxTx-1E)配列、マウロトキシン配列、カリブドトキシン(ChTX)配列、イベリオトキシン(Iberiotoxin)(IbTx)配列、レイウロトキシン(Leiurotoxin)1(シラトキシン)配列、タマピン(Tamapin)配列、カリオトキシン-1(KTX)配列、ピューロトキシン(Purotoxin)1(PT-1)配列、もしくはGpTx-1配列、MOKA毒素配列、OSK1(P12、K16、D20)配列、OSK1(K16、D20)配列、HmK配列、ShK(K16、Y26、K29)配列、ShK(K16)配列、ShK-A(K16)配列、ShK(K16、E30)配列、ShK(Q21)配列、ShK(L21)配列、ShK(F21)配列、ShK(I21)配列、またはShK(A21)配列である、本発明1020のヒト化抗体またはその結合断片。
[本発明1024]
非抗体配列が、SEQ ID NO: 475~481、599~655、666~698、727~733、808~810、および831~835のいずれか1つである、本発明1020のヒト化抗体またはその結合断片。
[本発明1025]
抗体重鎖可変領域が、SEQ ID NO: 770~779、784~791、903~922、および925~955からなる群より選択されるアミノ酸配列を含む、本発明1020のヒト化抗体またはその結合断片。
[本発明1026]
SEQ ID NO: 956または959のアミノ酸配列を含む軽鎖可変領域を含む、本発明1020のヒト化抗体またはその結合断片。
[本発明1027]
抗体重鎖可変領域が、SEQ ID NO: 770~779、784~791、903~922、および925~955からなる群より選択されるアミノ酸配列を含み、かつヒト化抗体またはその結合断片が、SEQ ID NO: 959のアミノ酸配列を含む軽鎖可変領域を含む、本発明1020のヒト化抗体またはその結合断片。
[本発明1028]
抗体重鎖可変領域が、SEQ ID NO: 941のアミノ酸配列を含み、かつヒト化抗体またはその結合断片が、SEQ ID NO: 959のアミノ酸配列を含む軽鎖可変領域を含む、本発明1020のヒト化抗体またはその結合断片。
[本発明1029]
抗体重鎖可変領域が、SEQ ID NO: 770~779、784~791、903~922、および925~955からなる群より選択されるアミノ酸配列を含み、かつヒト化抗体またはその結合断片が、SEQ ID NO: 956のアミノ酸配列を含む軽鎖可変領域を含む、本発明1020のヒト化抗体またはその結合断片。
[本発明1030]
非抗体配列が、極めて長いCDR3の少なくとも1つの部分を置換する、本発明1020のヒト化抗体またはその結合断片。
[本発明1031]
極めて長いCDR3が、X1X2X3X4X5モチーフを含み、
式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)である、
本発明1001のヒト化抗体またはその結合断片。
[本発明1032]
X1X2X3X4X5モチーフが、
である、本発明1031のヒト化抗体またはその結合断片。
[本発明1033]
極めて長いCDR3がCX1X2X3X4X5モチーフを含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1034]
CX1X2X3X4X5モチーフが、
である、本発明1033のヒト化抗体またはその結合断片。
[本発明1035]
極めて長いCDR3が、(XaXb)zモチーフを含み、
式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である、
本発明1001のヒト化抗体またはその結合断片。
[本発明1036]
(XaXb)zモチーフが、
である、本発明1035のヒト化抗体またはその結合断片。
[本発明1037]
(XaXb)zモチーフが、YXYXYXである、本発明1035のヒト化抗体またはその結合断片。
[本発明1038]
極めて長いCDR3が、X1X2X3X4X5Xnモチーフを含み、
式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、X5は、グルタミン(Q)であり、かつnは27~54である、
本発明1001のヒト化抗体またはその結合断片。
[本発明1039]
極めて長いCDR3が、Xn(XaXb)zモチーフを含み、
式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、nは27~54であり、かつzは1~4である、
本発明1001のヒト化抗体またはその結合断片。
[本発明1040]
極めて長いCDR3が、X1X2X3X4X5Xn(XaXb)zモチーフを含み、
式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)であり、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、nは27~54であり、かつzは1~4である、
本発明1001のヒト化抗体またはその結合断片。
[本発明1041]
X1X2X3X4X5モチーフが、TTVHQ(SEQ ID NO: 153)またはTSVHQ(SEQ ID NO: 154)であり、かつ(XaXb)zモチーフが、YXYXYXである、本発明1040のヒト化抗体またはその結合断片。
[本発明1042]
極めて長いCDR3が、
-CX1X2X3X4X5モチーフであって、式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)である、CX1X2X3X4X5モチーフ;
-
からなる群より選択されるシステインモチーフ;
-(XaXb)zモチーフであって、式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である、(XaXb)zモチーフ
を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1043]
極めて長いCDR3が、
-CX1X2X3X4X5モチーフであって、式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)である、CX1X2X3X4X5モチーフ;
-
からなる群より選択されるシステインモチーフ;ならびに
-(XaXb)zモチーフであって、式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である、(XaXb)zモチーフ
を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1044]
極めて長いCDR3が、リンカーである付加的な配列を含む、本発明1020のヒト化抗体またはその結合断片。
[本発明1045]
リンカーが、非抗体配列のC末端、N末端、またはC末端およびN末端の両方に連結されている、本発明1044のヒト化抗体またはその結合断片。
[本発明1046]
極めて長いCDR3が、反芻動物のCDR3である、本発明1001のヒト化抗体またはその結合断片。
[本発明1047]
反芻動物がウシである、本発明1046のヒト化抗体またはその結合断片。
[本発明1048]
重鎖可変領域が、SEQ ID NO: 735のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1049]
重鎖可変領域が、SEQ ID NO: 737のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1050]
重鎖可変領域が、SEQ ID NO: 739のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1051]
重鎖可変領域が、SEQ ID NO: 741のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1052]
重鎖可変領域が、SEQ ID NO: 743のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1053]
重鎖可変領域が、SEQ ID NO: 745のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1054]
重鎖可変領域が、SEQ ID NO: 747のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1055]
重鎖可変領域が、SEQ ID NO: 749のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1056]
極めて長いCDR3が、
のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1057]
極めて長いCDR3が、
のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1058]
極めて長いCDR3が、
のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1059]
(i)SEQ ID NO: 750、(ii)SEQ ID NO: 751、(iii)SEQ ID NO: 752、および(iv)SEQ ID NO: 753の群より選択される配列を含む軽鎖可変領域を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1060]
軽鎖可変領域が、λ軽鎖可変領域配列を含む、本発明1059のヒト化抗体またはその結合断片。
[本発明1061]
軽鎖可変領域が、ヒトλ軽鎖可変領域配列を含む、本発明1059のヒト化抗体またはその結合断片。
[本発明1062]
軽鎖可変領域が、VL1-51生殖系列配列を含む、本発明1059のヒト化抗体またはその結合断片。
[本発明1063]
軽鎖可変領域が、VL1-51生殖系列配列に由来する、本発明1059のヒト化抗体またはその結合断片。
[本発明1064]
VL1-51生殖系列配列が、Kabatの番号付与に基づくIle29Val置換およびAsn32Gly置換を含むCDR1を含む、本発明1063のヒト化抗体またはその結合断片。
[本発明1065]
VL1-51生殖系列配列が、DNNからGDTへの置換を含むCDR2を含む、本発明1063のヒト化抗体またはその結合断片。
[本発明1066]
VL1-51生殖系列配列が、DNNKRP(SEQ ID NO: 471)からGDTSRA(SEQ ID NO: 472)への置換を含むCDR2を含む、本発明1063のヒト化抗体またはその結合断片。
[本発明1067]
VL1-51生殖系列配列が、Kabatの番号付与に基づくS2A置換、T5N置換、P8S置換、A12G置換、A13S置換、およびP14L置換を含む、本発明1063のヒト化抗体またはその結合断片。
[本発明1068]
VL1-51生殖系列配列が、Kabatの番号付与に基づくS2A置換、T5N置換、P8S置換、A12G置換、A13S置換、およびP14L置換と、DNNからGDTへの置換を含むCDR2とを含む、本発明1063のヒト化抗体またはその結合断片。
[本発明1069]
(a)SEQ ID NO: 740、SEQ ID NO: 741、SEQ ID NO: 742、およびSEQ ID NO: 743からなる群より選択される配列を含む重鎖可変領域;ならびに(b)SEQ ID NO: 750を含む軽鎖可変領域を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1070]
本発明1001~1069のいずれかのヒト化抗体またはその結合断片の重鎖可変領域をコードする、ポリヌクレオチド。
[本発明1071]
本発明1059~1069のいずれかのヒト化抗体またはその結合断片の軽鎖可変領域をコードする、ポリヌクレオチド。
[本発明1072]
極めて長いCDR3を含む重鎖可変領域をコードするポリヌクレオチドであって、SEQ ID NO: 490、SEQ ID NO: 491、SEQ ID NO: 492、SEQ ID NO: 493、SEQ ID NO: 494、SEQ ID NO: 495、SEQ ID NO: 496、およびSEQ ID NO: 497からなる群より選択される配列を含む、ポリヌクレオチド。
[本発明1073]
本発明1070~1072のいずれかのポリヌクレオチドを含む、ベクター。
[本発明1074]
本発明1073のベクターを含む、宿主細胞。
[本発明1075]
ヒト化抗体またはその結合断片をコードする配列を構成する複数のポリヌクレオチドを含む核酸ライブラリーであって、該抗体またはその結合断片が、
(a)(i)SEQ ID NO: 734またはSEQ ID NO: 735、
(ii)SEQ ID NO: 736またはSEQ ID NO: 737、
(iii)SEQ ID NO: 738またはSEQ ID NO: 739、
(iv)SEQ ID NO: 740またはSEQ ID NO: 741、
(v)SEQ ID NO: 742またはSEQ ID NO: 743、
(vi)SEQ ID NO: 744またはSEQ ID NO: 745、
(vii)SEQ ID NO: 746またはSEQ ID NO: 747、および
(viii)SEQ ID NO: 748またはSEQ ID NO: 749
からなる群より選択されるアミノ酸配列;ならびに
(b)極めて長いCDR3
を含む重鎖可変領域を含む、核酸ライブラリー。
[本発明1076]
ヒト化抗体またはその結合断片のライブラリーであって、該抗体またはその結合断片が、
(a)(i)SEQ ID NO: 734またはSEQ ID NO: 735、
(ii)SEQ ID NO: 736またはSEQ ID NO: 737、
(iii)SEQ ID NO: 738またはSEQ ID NO: 739、
(iv)SEQ ID NO: 740またはSEQ ID NO: 741、
(v)SEQ ID NO: 742またはSEQ ID NO: 743、
(vi)SEQ ID NO: 744またはSEQ ID NO: 745、
(vii)SEQ ID NO: 746またはSEQ ID NO: 747、および
(viii)SEQ ID NO: 748またはSEQ ID NO: 749
からなる群より選択されるアミノ酸配列;ならびに
(b)極めて長いCDR3
を含む重鎖可変領域を含む、ヒト化抗体またはその結合断片のライブラリー。
[本発明1077]
極めて長いCDR3が、35アミノ酸長もしくはそれ以上、40アミノ酸長もしくはそれ以上、45アミノ酸長もしくはそれ以上、50アミノ酸長もしくはそれ以上、55アミノ酸長もしくはそれ以上、または60アミノ酸長もしくはそれ以上である、本発明1075または1076のライブラリー。
[本発明1078]
極めて長いCDR3が、35アミノ酸長またはそれ以上である、本発明1077のライブラリー。
[本発明1079]
極めて長いCDR3が、3個もしくはそれ以上のシステイン残基、4個もしくはそれ以上のシステイン残基、5個もしくはそれ以上のシステイン残基、6個もしくはそれ以上のシステイン残基、7個もしくはそれ以上のシステイン残基、8個もしくはそれ以上のシステイン残基、9個もしくはそれ以上のシステイン残基、10個もしくはそれ以上のシステイン残基、11個もしくはそれ以上のシステイン残基、または12個もしくはそれ以上のシステイン残基を含む、本発明1075または1076のライブラリー。
[本発明1080]
極めて長いCDR3が、3個またはそれ以上のシステイン残基を含む、本発明1079のライブラリー。
[本発明1081]
抗体またはその結合断片が、システインモチーフを含む、本発明1076のライブラリー。
[本発明1082]
システインモチーフが、
からなる群より選択される、本発明1076のライブラリー。
[本発明1083]
システインモチーフが、
からなる群より選択される、本発明1081のライブラリー。
[本発明1084]
極めて長いCDR3が、2~6個のジスルフィド結合を含む、本発明1076のライブラリー。
[本発明1085]
極めて長いCDR3が、SEQ ID NO: 40またはその派生物を含む、本発明1076のライブラリー。
[本発明1086]
極めて長いCDR3が、SEQ ID NO: 1~4のいずれか1つのアミノ酸残基3~6を含む、本発明1076のライブラリー。
[本発明1087]
極めて長いCDR3が、非ヒトDHまたはその派生物を含む、本発明1076のライブラリー。
[本発明1088]
非ヒトDHが、SEQ ID NO: 5、SEQ ID NO: 6、SEQ ID NO: 7、SEQ ID NO: 8、SEQ ID NO: 9、SEQ ID NO: 10、SEQ ID NO: 11、またはSEQ ID NO: 12である、本発明1087のライブラリー。
[本発明1089]
極めて長いCDR3が、JH配列またはその派生物を含む、本発明1076のライブラリー。
[本発明1090]
JH配列が、SEQ ID NO: 13、SEQ ID NO: 14、SEQ ID NO: 15、SEQ ID NO: 16、またはSEQ ID NO: 17の5~15位のアミノ酸を含む、本発明1089のライブラリー。
[本発明1091]
極めて長いCDR3が、
-非ヒトVH配列もしくはその派生物に由来する配列;
-非ヒトDH配列もしくはその派生物に由来する配列;および/または
-JH配列もしくはその派生物に由来する配列
を含む、本発明1076のライブラリー。
[本発明1092]
極めて長いCDR3が、VH配列とDH配列の間に位置する2~6個またはそれ以上のアミノ酸残基を含む付加的なアミノ酸配列を含む、本発明1091のライブラリー。
[本発明1093]
付加的なアミノ酸配列が、IR、IF、SEQ ID NO: 18、SEQ ID NO: 19、SEQ ID NO: 20、またはSEQ ID NO: 21からなる群より選択される、本発明1092のライブラリー。
[本発明1094]
極めて長いCDR3が、SEQ ID NO: 22、SEQ ID NO: 23、SEQ ID NO: 24、SEQ ID NO: 25、SEQ ID NO: 26、SEQ ID NO: 27、またはSEQ ID NO: 28に由来するかまたは基づく配列を含む、本発明1076のライブラリー。
[本発明1095]
極めて長いCDR3が、非ウシ配列または非抗体配列を含む、本発明1076のライブラリー。
[本発明1096]
非抗体配列が合成配列である、本発明1095のライブラリー。
[本発明1097]
非抗体配列が、サイトカイン配列、リンフォカイン配列、ケモカイン配列、増殖因子配列、ホルモン配列、または毒素配列である、本発明1095のライブラリー。
[本発明1098]
非抗体配列が、IL-8配列、IL-21配列、SDF-1(α)配列、ソマトスタチン配列、クロロトキシン配列、Pro-TxII配列、ジコノチド配列、ADWX-1配列、HsTx1配列、OSK1配列、Pi2配列、ホンゴトキシン(HgTX)配列、マルガトキシン配列、アギトキシン-2配列、Pi3配列、カリオトキシン配列、アニュロクトキシン配列、カリブドトキシン配列、チチウストキシン-K-α配列、マウロトキシン配列、セラトトキシン1(CcoTx1)配列、CcoTx2配列、CcoTx3配列、フリクソトキシン3(PaurTx3)配列、ハナトキシン1配列、フリクソトキシン1配列、フエントキシン-IV配列、α-コノトキシンImI配列、α-コノトキシンEpI配列、α-コノトキシンPnIA配列、α-コノトキシンPnIB配列、α-コノトキシンMII配列、α-コノトキシンAuIA配列、α-コノトキシンAuIB配列、α-コノトキシンAuIC配列、コノトキシンκ-PVIIA配列、カリブドトキシン配列、ニューロトキシンB-IV配列、クロタミン配列、ω-GVIA(コノトキシン)配列、κ-ヘフトキシン1配列、Css4配列、Bj-xtrIT配列、BcIV配列、Hm-1配列、Hm-2配列、GsAF-I(β-テラホトキシン-Gr1b)配列、プロトキシンI(ProTx-I配列、β-テラホトキシン-Tp1a)配列、プロトキシンII(ProTx II)配列、フエントキシンI配列、μ-コノトキシンPIIIA配列、ジンザオトキシン-III(β-TRTX-Cj1α)配列、GsAF-II(κ-テラホトキシン-Gr2c)配列、ShK(スチコダクチラ毒素)配列、HsTx1配列、ガンギシトキシン1E(GxTx-1E)配列、マウロトキシン配列、カリブドトキシン(ChTX)配列、イベリオトキシン(IbTx)配列、レイウロトキシン1(シラトキシン)配列、タマピン配列、カリオトキシン-1(KTX)配列、ピューロトキシン1(PT-1)配列、もしくはGpTx-1配列、MOKA毒素配列、OSK1(P12、K16、D20)配列、OSK1(K16、D20)配列、HmK配列、ShK(K16、Y26、K29)配列、ShK(K16)配列、ShK-A(K16)配列、ShK(K16、E30)配列、ShK(Q21)配列、ShK(L21)配列、ShK(F21)配列、ShK(I21)配列、またはShK(A21)配列である、本発明1095のライブラリー。
[本発明1099]
非抗体配列が、SEQ ID NO: 475~481、599~655、666~698、727~733、808~810、および831~835のいずれか1つである、本発明1095のライブラリー。
[本発明1100]
極めて長いCDR3が、X1X2X3X4X5モチーフを含み、
式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)である、
本発明1076のライブラリー。
[本発明1101]
X1X2X3X4X5モチーフが、
である、本発明1100のライブラリー。
[本発明1102]
極めて長いCDR3が、CX1X2X3X4X5モチーフを含む、本発明1076のライブラリー。
[本発明1103]
CX1X2X3X4X5モチーフが、
である、本発明1102のライブラリー。
[本発明1104]
極めて長いCDR3が、(XaXb)zモチーフを含み、
式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である、
本発明1076のライブラリー。
[本発明1105]
(XaXb)zモチーフが、
である、本発明1104のライブラリー。
[本発明1106]
(XaXb)zモチーフがYXYXYXである、本発明1104のライブラリー。
[本発明1107]
極めて長いCDR3が、X1X2X3X4X5Xnモチーフを含み、
式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)であり、かつnは27~54である、
本発明1076のライブラリー。
[本発明1108]
極めて長いCDR3が、Xn(XaXb)zモチーフを含み、
式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、nは27~54であり、かつzは1~4である、
本発明1076のライブラリー。
[本発明1109]
極めて長いCDR3が、X1X2X3X4X5Xn(XaXb)zモチーフを含み、
式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、X5は、グルタミン(Q)であり、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、nは27~54であり、かつzは1~4である、
本発明1076のライブラリー。
[本発明1110]
X1X2X3X4X5モチーフが、TTVHQ(SEQ ID NO: 153)またはTSVHQ(SEQ ID NO: 154)であり、かつ(XaXb)zモチーフが、YXYXYXである、本発明1109のライブラリー。
[本発明1111]
極めて長いCDR3が、
-CX1X2X3X4X5モチーフであって、式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)である、CX1X2X3X4X5モチーフ;
-
からなる群より選択されるシステインモチーフ;ならびに
-(XaXb)zモチーフであって、式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である、(XaXb)zモチーフ
を含む、本発明1076のライブラリー。
[本発明1112]
極めて長いCDR3が、
-CX1X2X3X4X5モチーフであって、式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)である、CX1X2X3X4X5モチーフ;
-
からなる群より選択されるシステインモチーフ;ならびに
-(XaXb)zモチーフであって、式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である、(XaXb)zモチーフ
を含む、本発明1076のライブラリー。
[本発明1113]
極めて長いCDR3が、リンカーである付加的な配列を含む、本発明1095のライブラリー。
[本発明1114]
リンカーが、非抗体配列のC末端、N末端、またはC末端およびN末端の両方に連結されている、本発明1113のライブラリー。
[本発明1115]
極めて長いCDR3が、反芻動物のCDR3である、本発明1076のライブラリー。
[本発明1116]
反芻動物がウシである、本発明1115のライブラリー。
[本発明1117]
重鎖可変領域が、SEQ ID NO: 735のアミノ酸配列を含む、本発明1076のライブラリー。(113)重鎖可変領域が、SEQ ID NO: 737のアミノ酸配列を含む、本発明1071のライブラリー。
[本発明1118]
重鎖可変領域が、SEQ ID NO: 739のアミノ酸配列を含む、本発明1076のライブラリー。
[本発明1119]
重鎖可変領域が、SEQ ID NO: 741のアミノ酸配列を含む、本発明1076のライブラリー。
[本発明1120]
重鎖可変領域が、SEQ ID NO: 743のアミノ酸配列を含む、本発明1076のライブラリー。
[本発明1121]
重鎖可変領域が、SEQ ID NO: 745のアミノ酸配列を含む、本発明1076のライブラリー。
[本発明1122]
重鎖可変領域が、SEQ ID NO: 747のアミノ酸配列を含む、本発明1076のライブラリー。
[本発明1123]
重鎖可変領域が、SEQ ID NO: 749のアミノ酸配列を含む、本発明1076のライブラリー。
[本発明1124]
極めて長いCDR3が、
のアミノ酸配列を含む、本発明1076のライブラリー。
[本発明1125]
極めて長いCDR3が、
のアミノ酸配列を含む、本発明1076のライブラリー。
[本発明1126]
ヒト化抗体またはその結合断片が、(i)SEQ ID NO: 750、(ii)SEQ ID NO: 751、(iii)SEQ ID NO: 752、および(iv)SEQ ID NO: 753の群より選択される配列を含む軽鎖可変領域を含む、本発明1076のライブラリー。
[本発明1127]
軽鎖可変領域が、λ軽鎖可変領域配列を含む、本発明1126のライブラリー。
[本発明1128]
軽鎖可変領域配列が、ヒトλ軽鎖可変領域配列を含む、本発明1126のライブラリー。
[本発明1129]
軽鎖可変領域配列が、VL1-51生殖系列配列を含む、本発明1126のライブラリー。
[本発明1130]
軽鎖可変領域が、VL1-51生殖系列配列に由来する、本発明1126のライブラリー。
[本発明1131]
VL1-51生殖系列配列が、Kabatの番号付与に基づくIle29Val置換およびAsn32Gly置換を含むCDR1を含む、本発明1130のライブラリー。
[本発明1132]
VL1-51生殖系列配列が、DNNからGDTへの置換を含むCDR2を含む、本発明1130のライブラリー。
[本発明1133]
VL1-51生殖系列配列が、DNNKRP(SEQ ID NO: 471)からGDTSRA(SEQ ID NO: 472)への置換を含むCDR2を含む、本発明1130のライブラリー。
[本発明1134]
VL1-51生殖系列配列が、Kabatの番号付与に基づくS2A置換、T5N置換、P8S置換、A12G置換、A13S置換、およびP14L置換を含む、本発明1130のライブラリー。
[本発明1135]
VL1-51生殖系列配列が、Kabatの番号付与に基づくS2A置換、T5N置換、P8S置換、A12G置換、A13S置換、およびP14L置換と、DNNからGDTへの置換を含むCDR2とを含む、本発明1130のライブラリー。
[本発明1136]
ヒト化抗体またはその結合断片が、(a)SEQ ID NO: 740、SEQ ID NO: 741、SEQ ID NO: 742、およびSEQ ID NO: 743からなる群より選択される配列を含む重鎖可変領域;ならびに(b)SEQ ID NO: 750を含む軽鎖可変領域を含む、本発明1076のライブラリー。
[本発明1137]
ヒト化抗体またはその結合断片が、空間的にアドレス指定された(spatially addressed)形式で存在する、本発明1076~1136のいずれかのライブラリー。
[本発明1138]
極めて長いCDR3をコードする核酸配列を、
(i)SEQ ID NO: 734またはSEQ ID NO: 735、
(ii)SEQ ID NO: 736またはSEQ ID NO: 737、
(iii)SEQ ID NO: 738またはSEQ ID NO: 739、
(iv)SEQ ID NO: 740またはSEQ ID NO: 741、
(v)SEQ ID NO: 742またはSEQ ID NO: 743、
(vi)SEQ ID NO: 744またはSEQ ID NO: 745、
(vii)SEQ ID NO: 746またはSEQ ID NO: 747、および
(viii)SEQ ID NO: 748またはSEQ ID NO: 749
からなる群より選択される可変領域配列をコードする核酸配列と遺伝子的に組み合わせる段階
を含む、抗体可変領域をヒト化する方法。
[本発明1139]
a)極めて長いCDR3をコードする核酸配列を、
(i)SEQ ID NO: 734またはSEQ ID NO: 735、
(ii)SEQ ID NO: 736またはSEQ ID NO: 737、
(iii)SEQ ID NO: 738またはSEQ ID NO: 739、
(iv)SEQ ID NO: 740またはSEQ ID NO: 741、
(v)SEQ ID NO: 742またはSEQ ID NO: 743、
(vi)SEQ ID NO: 744またはSEQ ID NO: 745、
(vii)SEQ ID NO: 746またはSEQ ID NO: 747、および
(viii)SEQ ID NO: 748またはSEQ ID NO: 749
からなる群より選択される可変領域配列をコードする核酸配列と組み合わせて、
極めて長いCDR3を含むヒト化抗体をコードする核酸を作製する段階;ならびに
b)極めて長いCDR3を含むヒト化抗体をコードする核酸を発現させて、極めて長いCDR3を含むヒト化抗体のライブラリーを生成する段階
を含む、極めて長いCDR3を含むヒト化抗体のライブラリーを生成する方法。
[本発明1140]
a)極めて長いCDR3をコードする核酸配列と、
(i)SEQ ID NO: 734またはSEQ ID NO: 735、
(ii)SEQ ID NO: 736またはSEQ ID NO: 737、
(iii)SEQ ID NO: 738またはSEQ ID NO: 739、
(iv)SEQ ID NO: 740またはSEQ ID NO: 741、
(v)SEQ ID NO: 742またはSEQ ID NO: 743、
(vi)SEQ ID NO: 744またはSEQ ID NO: 745、
(vii)SEQ ID NO: 746またはSEQ ID NO: 747、および
(viii)SEQ ID NO: 748またはSEQ ID NO: 749
からなる群より選択される可変領域配列をコードする核酸と、
非抗体配列をコードする核酸配列とを組み合わせて、極めて長いCDR3および非抗体配列を含むヒト化抗体またはその結合断片をコードする核酸を作製する段階;ならびに
b)極めて長いCDR3および非抗体配列を含むヒト化抗体またはその結合断片をコードする核酸を発現させて、極めて長いCDR3および非抗体配列を含むヒト化抗体またはその結合断片のライブラリーを生成する段階
を含む、非抗体配列を含む極めて長いCDR3を含むヒト化抗体またはその結合断片のライブラリーを生成する方法。
[本発明1141]
非抗体配列を含む極めて長いCDR3を含むヒト化抗体またはその結合断片のライブラリー。
[本発明1142]
a)ヒト可変領域フレームワーク(FR)配列と極めて長いCDR3およびシステインモチーフをコードする核酸配列とを組み合わせる段階;
b)システインモチーフ中の1つまたは複数のシステイン残基の間に位置する1つまたは複数のアミノ酸残基をコードする核酸配列に1つまたは複数のヌクレオチド変化を導入して、異なるアミノ酸残基をコードするヌクレオチドから、極めて長いCDR3と1つまたは複数のヌクレオチド変化がシステインドメイン中の1つまたは複数のシステイン残基の間に導入されたシステインモチーフとを含むヒト化抗体またはその結合断片をコードする核酸を作製する段階;ならびに
c)極めて長いCDR3と1つまたは複数のヌクレオチド変化がシステインドメイン中の1つまたは複数のシステイン残基の間に導入されたシステインモチーフとを含むヒト化抗体またはその結合断片をコードする核酸を発現させて、極めて長いCDR3と1つまたは複数のアミノ酸変化がシステインドメイン中の1つまたは複数のシステイン残基の間に導入されたシステインモチーフとを含むヒト化抗体またはその結合断片のライブラリーを生成する段階
を含む、システインモチーフを含む極めて長いCDR3を含むヒト化抗体またはその結合断片のライブラリーを生成する方法。
[本発明1143]
システインモチーフを含む極めて長いCDR3を含むヒト化抗体またはその結合断片のライブラリーであって、抗体または結合断片が、システインモチーフ中のシステイン残基の間に位置するアミノ酸残基の1つまたは複数の置換を含む、ヒト化抗体またはその結合断片のライブラリー。
[本発明1144]
a)ヒト可変領域フレームワーク(FR)配列をコードする核酸配列とウシ由来の極めて長いCDR3をコードする核酸とを組み合わせる段階、ならびに
b)ヒト可変領域フレームワーク(FR)配列をコードする核酸およびウシ由来の極めて長いCDR3をコードする核酸を発現させて、ウシ由来の極めて長いCDR3を含むヒト化抗体またはその結合断片のライブラリーを生成する段階
を含む、ウシ由来の極めて長いCDR3を含むヒト化抗体またはその結合断片のライブラリーを生成する方法。
[本発明1145]
(a)(i)SEQ ID NO: 734またはSEQ ID NO: 735、
(ii)SEQ ID NO: 736またはSEQ ID NO: 737、
(iii)SEQ ID NO: 738またはSEQ ID NO: 739、
(iv)SEQ ID NO: 740またはSEQ ID NO: 741、
(v)SEQ ID NO: 742またはSEQ ID NO: 743、
(vi)SEQ ID NO: 744またはSEQ ID NO: 745、
(vii)SEQ ID NO: 746またはSEQ ID NO: 747、および
(viii)SEQ ID NO: 748またはSEQ ID NO: 749
からなる群より選択されるアミノ酸配列;ならびに
(b)ウシ由来の極めて長いCDR3
を含む重鎖可変領域を含むヒト化抗体またはその結合断片のライブラリー。
[本発明1146]
式V1-X-V2の配列を含む抗体重鎖可変領域であって、
式中、V1は、
からなる群より選択されるアミノ酸配列を含み;
Xは、極めて長いCDR3を含み;かつ
V2は、
からなる群より選択されるアミノ酸配列を含む、
抗体重鎖可変領域。
[本発明1147]
極めて長いCDR3が、
のアミノ酸配列を含む、本発明1146の抗体重鎖可変領域。
[本発明1148]
極めて長いCDR3が、
のアミノ酸配列を含む、本発明1146の抗体重鎖可変領域。
[本発明1149]
極めて長いCDR3が、
のアミノ酸配列を含む、本発明1146の抗体重鎖可変領域。
[本発明1150]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1151]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1152]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1153]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1154]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つ、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1155]
極めて長いCDR3が、35アミノ酸長もしくはそれ以上、40アミノ酸長もしくはそれ以上、45アミノ酸長もしくはそれ以上、50アミノ酸長もしくはそれ以上、55アミノ酸長もしくはそれ以上、または60アミノ酸長もしくはそれ以上である、本発明1146~1154のいずれかの抗体重鎖可変領域。
[本発明1156]
極めて長いCDR3が、35アミノ酸長またはそれ以上である、本発明1155の抗体重鎖可変領域。
[本発明1157]
極めて長いCDR3が、システインモチーフを含む、本発明1146~1156のいずれかの抗体重鎖可変領域。
[本発明1158]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、システインモチーフ、および
のいずれか1つのアミノ酸配列を含み、かつ
-V2が、
のアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1159]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、システインモチーフ、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1160]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、システインモチーフ、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1161]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、システインモチーフ、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1162]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、システインモチーフ、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1163]
-VIが、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、SEQ ID NO: 498であるアミノ酸配列およびSEQ ID NO: 499であるアミノ酸配列を含み、
-V2が、SEQ ID NO: 500であるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1164]
システインモチーフが、
からなる群より選択される、本発明1157~1163のいずれかの抗体重鎖可変領域。
[本発明1165]
システインモチーフが、
からなる群より選択される、本発明1157~1163のいずれかの抗体重鎖可変領域。
[本発明1166]
極めて長いCDR3が、2~6個のジスルフィド結合を含む、本発明1146~1165のいずれかの抗体重鎖可変領域。
[本発明1167]
極めて長いCDR3が非抗体配列を含む、本発明1146~1165のいずれかの抗体重鎖可変領域。
[本発明1168]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、非抗体配列、および
のいずれか1つのアミノ酸配列を含み、かつ
-V2が、
のアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1169]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、非抗体配列、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1170]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、非抗体配列、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1171]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、非抗体配列、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1172]
-V1が、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、
のいずれか1つのアミノ酸配列、非抗体配列、および
のいずれか1つのアミノ酸配列を含み、
-V2が、
より選択されるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1173]
-VIが、SEQ ID NO: 735、SEQ ID NO: 737、SEQ ID NO: 739、SEQ ID NO: 741、SEQ ID NO: 743、SEQ ID NO: 745、SEQ ID NO: 747、およびSEQ ID NO: 749からなる群より選択されるアミノ酸配列を含み、
-極めて長いCDR3が、SEQ ID NO: 498であるアミノ酸配列およびSEQ ID NO: 499であるアミノ酸配列を含み、
-V2が、SEQ ID NO: 500であるアミノ酸配列を含む、
本発明1146の抗体重鎖可変領域。
[本発明1174]
非抗体配列が合成配列である、本発明1167の抗体重鎖可変領域。
[本発明1175]
非抗体配列が、サイトカイン配列、リンフォカイン配列、ケモカイン配列、増殖因子配列、ホルモン配列、または毒素配列である、本発明1167の抗体重鎖可変領域。
[本発明1176]
非抗体配列が、IL-8配列、IL-21配列、SDF-1(α)配列、ソマトスタチン配列、クロロトキシン配列、Pro-TxII配列、ジコノチド配列、ADWX-1配列、HsTx1配列、OSK1配列、Pi2配列、ホンゴトキシン(HgTX)配列、マルガトキシン配列、アギトキシン-2配列、Pi3配列、カリオトキシン配列、アニュロクトキシン配列、カリブドトキシン配列、チチウストキシン-K-α配列、マウロトキシン配列、セラトトキシン1(CcoTx1)配列、CcoTx2配列、CcoTx3配列、フリクソトキシン3(PaurTx3)配列、ハナトキシン1配列、フリクソトキシン1配列、フエントキシン-IV配列、α-コノトキシンImI配列、α-コノトキシンEpI配列、α-コノトキシンPnIA配列、α-コノトキシンPnIB配列、α-コノトキシンMII配列、α-コノトキシンAuIA配列、α-コノトキシンAuIB配列、α-コノトキシンAuIC配列、コノトキシンκ-PVIIA配列、カリブドトキシン配列、ニューロトキシンB-IV配列、クロタミン配列、ω-GVIA(コノトキシン)配列、κ-ヘフトキシン1配列、Css4配列、Bj-xtrIT配列、BcIV配列、Hm-1配列、Hm-2配列、GsAF-I(β-テラホトキシン-Gr1b)配列、プロトキシンI(ProTx-I配列、β-テラホトキシン-Tp1a)配列、プロトキシンII(ProTx II)配列、フエントキシンI配列、μ-コノトキシンPIIIA配列、ジンザオトキシン-III(β-TRTX-Cj1α)配列、GsAF-II(κ-テラホトキシン-Gr2c)配列、ShK(スチコダクチラ毒素)配列、HsTx1配列、ガンギシトキシン1E(GxTx-1E)配列、マウロトキシン配列、カリブドトキシン(ChTX)配列、イベリオトキシン(IbTx)配列、レイウロトキシン1(シラトキシン)配列、タマピン配列、カリオトキシン-1(KTX)配列、ピューロトキシン1(PT-1)配列、もしくはGpTx-1配列、MOKA毒素配列、OSK1(P12、K16、D20)配列、OSK1(K16、D20)配列、HmK配列、ShK(K16、Y26、K29)配列、ShK(K16)配列、ShK-A(K16)配列、ShK(K16、E30)配列、ShK(Q21)配列、ShK(L21)配列、ShK(F21)配列、ShK(I21)配列、またはShK(A21)配列である、本発明1167の抗体重鎖可変領域。
[本発明1177]
非抗体配列が、SEQ ID NO: 475~481、599~655、666~698、727~733、808~810、および831~835のいずれか1つである、本発明1172の抗体重鎖可変領域。
[本発明1178]
SEQ ID NO: 770~779、784~791、903~922、および925~955からなる群より選択されるアミノ酸配列を含む、本発明1177の抗体重鎖可変領域。
[本発明1179]
SEQ ID NO: 941のアミノ酸配列を含む、本発明1167の抗体重鎖可変領域。
[本発明1180]
極めて長いCDR3がリンカー配列を含む、本発明1142~1172のいずれかの抗体重鎖可変領域。
[本発明1181]
リンカーが、非抗体配列のN末端、C末端、またはN末端およびC末端の両方に連結されている、本発明1180の抗体重鎖可変領域。
[本発明1182]
リンカーが、SEQ ID NO: 575~598、699~726、および813~830からなる群より選択される1つもしくは複数のアミノ酸配列またはそれらの任意の組み合わせを含む、本発明1180または1181の抗体重鎖可変領域。
[本発明1183]
N末端およびC末端の両方に連結されたリンカーが、同じまたは異なるアミノ酸配列を有する、本発明1181の抗体重鎖可変領域。
[本発明1184]
本発明1146~1183のいずれかの抗体重鎖可変領域を含む、抗体またはその結合断片。
[本発明1185]
重鎖可変領域が、重鎖定常領域1(CH1)をさらに含む、本発明1184の抗体またはその結合断片。
[本発明1186]
重鎖可変領域が、SEQ ID NO: 390のアミノ酸配列をさらに含む、本発明1184の抗体またはその結合断片。
[本発明1187]
軽鎖可変領域をさらに含む、本発明1184の抗体またはその結合断片。
[本発明1188]
軽鎖可変領域が、軽鎖定常領域(CL)をさらに含む、本発明1187の抗体またはその結合断片。
[本発明1189]
本発明1146~1183のいずれかの抗体重鎖可変領域をコードする、単離ポリヌクレオチド。
[本発明1190]
本発明1189のポリヌクレオチドを含む、ベクター。
[本発明1191]
本発明1190のベクターを含む、宿主細胞。
[本発明1192]
式V1-X-V2の配列を含む抗体重鎖可変領域をコードする核酸配列を構成する複数のポリヌクレオチドを含む、核酸ライブラリーであって、
式中、V1は、
からなる群より選択されるアミノ酸配列を含み;
Xは、極めて長いCDR3を含み;かつ
V2は、
からなる群より選択されるアミノ酸配列を含む、
核酸ライブラリー。
[本発明1193]
式V1-X-V2の配列を含む抗体重鎖可変領域を含む、抗体のライブラリーであって、
式中、V1は、
からなる群より選択されるアミノ酸配列を含み;
Xは、極めて長いCDR3を含み;かつ
V2は、
からなる群より選択されるアミノ酸配列を含む、
抗体のライブラリー。
[本発明1194]
極めて長いCDR3が、X1X2X3X4X5モチーフを含み、
式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)である、
本発明1146の抗体重鎖可変領域。
[本発明1195]
X1X2X3X4X5モチーフが、
である、本発明1194の抗体重鎖可変領域。
[本発明1196]
極めて長いCDR3が、(XaXb)zモチーフを含み、
式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である、
本発明1146の抗体重鎖可変領域。
[本発明1197]
(XaXb)zモチーフが、
である、本発明1196の抗体重鎖可変領域。
[本発明1198]
(XaXb)zモチーフがYXYXYXである、本発明1197の抗体重鎖可変領域。
[本発明1199]
極めて長いCDR3が、X1X2X3X4X5Xnモチーフを含み、
式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、X5は、グルタミン(Q)であり、かつnは27~54である、
本発明1146の抗体重鎖可変領域。
[本発明1200]
極めて長いCDR3が、Xn(XaXb)zモチーフを含み、
式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、nは27~54であり、かつzは1~4である、
本発明1146の抗体重鎖可変領域。
[本発明1201]
極めて長いCDR3が、X1X2X3X4X5Xn(XaXb)zモチーフを含み、式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)であり、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、nは27~54であり、かつzは1~4である、
本発明1146の抗体重鎖可変領域。
[本発明1202]
式V1-Xの配列を含む抗体重鎖可変領域であって、
式中、V1は、
(i)SEQ ID NO: 734またはSEQ ID NO: 735、
(ii)SEQ ID NO: 736またはSEQ ID NO: 737、
(iii)SEQ ID NO: 738またはSEQ ID NO: 739、
(iv)SEQ ID NO: 740またはSEQ ID NO: 741、
(v)SEQ ID NO: 742またはSEQ ID NO: 743、
(vi)SEQ ID NO: 744またはSEQ ID NO: 745、
(vii)SEQ ID NO: 746またはSEQ ID NO: 747、および
(viii)SEQ ID NO: 748またはSEQ ID NO: 749
からなる群より選択されるアミノ酸配列を含み;かつ
Xは、極めて長いCDR3を含む、
抗体重鎖可変領域。
[本発明1203]
極めて長いCDR3が、X1X2X3X4X5モチーフを含み、
式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)である、
本発明1202の抗体重鎖可変領域。
[本発明1204]
X1X2X3X4X5モチーフが、
である、本発明1203の抗体重鎖可変領域。
[本発明1205]
極めて長いCDR3が、CX1X2X3X4X5モチーフを含む、本発明1202の抗体重鎖可変領域。
[本発明1206]
CX1X2X3X4X5モチーフが、
である、本発明1205の抗体重鎖可変領域。
[本発明1207]
極めて長いCDR3が、(XaXb)zモチーフを含み、
式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、かつzは1~4である、
本発明1202の抗体重鎖可変領域。
[本発明1208]
(XaXb)zモチーフが、
である、本発明1207の抗体重鎖可変領域。
[本発明1209]
(XaXb)zモチーフがYXYXYXである、本発明1207の抗体重鎖可変領域。
[本発明1210]
極めて長いCDR3が、X1X2X3X4X5Xnモチーフを含み、
式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、X5は、グルタミン(Q)であり、かつnは27~54である、
本発明1202の抗体重鎖可変領域。
[本発明1211]
極めて長いCDR3が、Xn(XaXb)zモチーフを含み、
式中、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、nは27~54であり、かつzは1~4である、
本発明1202の抗体重鎖可変領域。
[本発明1212]
極めて長いCDR3が、X1X2X3X4X5Xn(XaXb)zモチーフを含み、
式中、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、かつX5は、グルタミン(Q)であり、Xaは、任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、nは27~54であり、かつzは1~4である、本発明1211の抗体重鎖可変領域。(206)V1が、SEQ ID NO: 737のアミノ酸配列を含み、極めて長いCDR3が、SEQ ID NO: 498およびSEQ ID NO: 499のアミノ酸配列を含み、かつV2が、SEQ ID NO: 500のアミノ酸配列を含む、本発明1142~1145のいずれかの抗体重鎖可変領域。
[本発明1213]
V1が、SEQ ID NO: 739のアミノ酸配列を含み、極めて長いCDR3が、SEQ ID NO: 498およびSEQ ID NO: 499のアミノ酸配列を含み、かつV2が、SEQ ID NO: 500のアミノ酸配列を含む、本発明1146~1149のいずれかの抗体重鎖可変領域。
[本発明1214]
軽鎖可変領域が、SEQ ID NO: 750のアミノ酸配列、SEQ ID NO: 754のアミノ酸配列、およびSEQ ID NO: 755のアミノ酸配列を含む、本発明1059のヒト化抗体またはその結合断片。
[本発明1215]
SEQ ID NO: 756のアミノ酸配列をさらに含む、本発明1214のヒト化抗体またはその結合断片。
[本発明1216]
軽鎖可変領域が、SEQ ID NO: 751のアミノ酸配列、SEQ ID NO: 754のアミノ酸配列、およびSEQ ID NO: 755のアミノ酸配列を含む、本発明1059のヒト化抗体またはその結合断片。
[本発明1217]
SEQ ID NO: 756のアミノ酸配列をさらに含む、本発明1216のヒト化抗体またはその結合断片。
[本発明1218]
軽鎖可変領域が、SEQ ID NO: 752のアミノ酸配列、SEQ ID NO: 754のアミノ酸配列、およびSEQ ID NO: 755のアミノ酸配列を含む、本発明1059のヒト化抗体またはその結合断片。
[本発明1219]
SEQ ID NO: 756のアミノ酸配列をさらに含む、本発明1218のヒト化抗体またはその結合断片。
[本発明1220]
軽鎖可変領域が、SEQ ID NO: 753のアミノ酸配列、SEQ ID NO: 754のアミノ酸配列、およびSEQ ID NO: 755のアミノ酸配列を含む、本発明1059のヒト化抗体またはその結合断片。
[本発明1221]
SEQ ID NO: 756のアミノ酸配列をさらに含む、本発明1220のヒト化抗体またはその結合断片。
[本発明1222]
重鎖可変領域が、SEQ ID NO: 737およびSEQ ID NO: 500のアミノ酸配列を含み、極めて長いCDR3が、SEQ ID NO: 498およびSEQ ID NO: 499のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1223]
SEQ ID NO: 750のアミノ酸配列、SEQ ID NO: 754のアミノ酸配列、およびSEQ ID NO: 755のアミノ酸配列を含む軽鎖可変領域をさらに含む、本発明1222のヒト化抗体またはその結合断片。
[本発明1224]
重鎖可変領域が、SEQ ID NO: 739およびSEQ ID NO: 500のアミノ酸配列を含み、極めて長いCDR3が、SEQ ID NO: 498およびSEQ ID NO: 499のアミノ酸配列を含む、本発明1001のヒト化抗体またはその結合断片。
[本発明1225]
SEQ ID NO: 750のアミノ酸配列、SEQ ID NO: 754のアミノ酸配列、およびSEQ ID NO: 755のアミノ酸配列を含む軽鎖可変領域をさらに含む、本発明1224のヒト化抗体またはその結合断片。
本開示は、(a)(i)SEQ ID NO:734またはSEQ ID NO:735、(ii)SEQ ID NO:736またはSEQ ID NO:737、(iii)SEQ ID NO:738またはSEQ ID NO:739、(iv)SEQ ID NO:740またはSEQ ID NO:741、(v)SEQ ID NO:742またはSEQ ID NO:743、(vi)SEQ ID NO:744またはSEQ ID NO:745、(vii)SEQ ID NO:746またはSEQ ID NO 747、および(viii)SEQ ID NO:748またはSEQ ID NO:749からなる群より選択されるアミノ酸配列;ならびに(b)極めて長いCDR3配列を含む重鎖可変領域を含むヒト化抗体と、前記抗体を作製するための材料(例えば、タンパク質配列、遺伝子配列、細胞、ライブラリー)および前記抗体を作製する方法(例えば、ヒト化方法、ライブラリー方法)を提供する。このようなヒト化抗体は、炎症性の疾患、障害、または状態、自己免疫性の疾患、障害、または状態、代謝性の疾患、障害、または状態、新生物性の疾患、障害、または状態、および癌を含む様々な疾患、障害、または状態の処置または予防に有用であり得る。
からなる群より選択される場合を含めて、システインモチーフを含んでもよい。または、極めて長いCDR3は、例えば、システインモチーフが、
からなる群より選択される場合を含めて、システインモチーフを含んでもよい。
でもよい。
でもよい。
からなる群より選択されるシステインモチーフ、ならびにXaが任意のアミノ酸残基であり、Xbが、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、zが1~4である(XaXb)zモチーフを含む、ヒト化抗体またはその結合断片を提供する。
からなる群より選択されるシステインモチーフ;ならびにXaが任意のアミノ酸残基であり、Xbが、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、zが1~4である(XaXb)zモチーフを含む、ヒト化抗体またはその結合断片を提供する。
本開示は、(a)(i)SEQ ID NO:734またはSEQ ID NO:735、(ii)SEQ ID NO:736またはSEQ ID NO:737、(iii)SEQ ID NO:738またはSEQ ID NO:739、(iv)SEQ ID NO:740またはSEQ ID NO:741、(v)SEQ ID NO:742またはSEQ ID NO:743、(vi)SEQ ID NO:744またはSEQ ID NO:745、(vii)SEQ ID NO:746またはSEQ ID NO:747、および(viii)SEQ ID NO:748またはSEQ ID NO:749からなる群より選択されるアミノ酸配列;ならびに(b)極めて長いCDR3配列を含む重鎖可変領域を含むヒト化抗体を提供する。
本開示は、(a)(i)SEQ ID NO:734またはSEQ ID NO:735、(ii)SEQ ID NO:736またはSEQ ID NO:737、(iii)SEQ ID NO:738またはSEQ ID NO:739、(iv)SEQ ID NO:740またはSEQ ID NO:741、(v)SEQ ID NO:742またはSEQ ID NO:743、(vi)SEQ ID NO:744またはSEQ ID NO:745、(vii)SEQ ID NO:746またはSEQ ID NO:747、および(viii)SEQ ID NO:748またはSEQ ID NO:749からなる群より選択されるアミノ酸配列;ならびに(b)極めて長いCDR3配列を含む重鎖可変領域を含むヒト化抗体をコードする遺伝子配列(例えば、遺伝子、核酸、ポリヌクレオチド)を提供する。
本開示は、極めて長いCDR3配列を含むヒト化抗体のコレクション、ライブラリー、およびアレイを提供する。
本開示は、(a)(i)SEQ ID NO:734またはSEQ ID NO:735、(ii)SEQ ID NO:736またはSEQ ID NO:737、(iii)SEQ ID NO:738またはSEQ ID NO:739、(iv)SEQ ID NO:740またはSEQ ID NO:741、(v)SEQ ID NO:742またはSEQ ID NO:743、(vi)SEQ ID NO:744またはSEQ ID NO:745、(vii)SEQ ID NO:746またはSEQ ID NO:747、および(viii)SEQ ID NO:748またはSEQ ID NO:749からなる群より選択されるアミノ酸配列;ならびに(b)極めて長いCDR3配列を含む重鎖可変領域を含むヒト化抗体をコードする遺伝子配列を含む細胞を提供する。
本開示は、非ヒトCDR3に由来する極めて長いCDR3配列を操作してヒトフレームワークに入れる段階を含む、極めて長いCDR3配列を含むヒト化抗体を作製するための方法を提供する。ヒトフレームワークは生殖系列由来でもよく、非生殖系列(例えば、変異した、または親和性成熟した)配列に由来してもよい。ヒトフレームワークおよび非ヒトの極めて長いCDR3を含有するハイブリッドDNA配列を生成するために、本明細書において開示された技法を含む当業者に周知の遺伝子工学技法が用いられ得る。7つのファミリーの1つに由来するV領域遺伝子によってコードされ得るヒト抗体と異なり、極めて長いCDR3配列を生じるウシ抗体は、ヒトVH4ファミリーと最も相同だと考えられ得る1つのV領域ファミリーを利用するように見える。ウシに由来する極めて長いCDR3配列がヒト化されて、極めて長いCDR3を含む抗体を産生する好ましい態様では、VH4ファミリーに由来するヒトV領域配列がウシ由来の極めて長いCDR3配列と遺伝子融合されてもよい。ヒト抗体遺伝子座にある例示的なVH4生殖系列遺伝子配列を図5A(例えば、SEQ ID NO:31~34;および368~371)に示した。
本開示は、(a)(i)SEQ ID NO:734またはSEQ ID NO:735、(ii)SEQ ID NO:736またはSEQ ID NO:737、(iii)SEQ ID NO:738またはSEQ ID NO:739、(iv)SEQ ID NO:740またはSEQ ID NO:741、(v)SEQ ID NO:742またはSEQ ID NO:743、(vi)SEQ ID NO:744またはSEQ ID NO:745、(vii)SEQ ID NO:746またはSEQ ID NO:747、および(viii)SEQ ID NO:748またはSEQ ID NO:749からなる群より選択されるアミノ酸配列;ならびに(b)極めて長いCDR3配列を含む重鎖可変領域を含むヒト化抗体を含むライブラリーを作製するための方法を提供する。空間的にアドレス指定されたライブラリーのライブラリーを作製するための方法はWO2010/054007に記載されている。酵母、ファージ、大腸菌、または哺乳動物細胞においてライブラリーを作製する方法は当技術分野において周知である。
「極めて長いCDR3」または「極めて長いCDR3配列」は本明細書において同義に用いられ、CDR3配列またはヒト抗体配列に由来しないCDR3配列を含む。極めて長いCDR3は、35アミノ酸長もしくはそれ以上、例えば、40アミノ酸長もしくはそれ以上、45アミノ酸長もしくはそれ以上、50アミノ酸長もしくはそれ以上、55アミノ酸長もしくはそれ以上、または60アミノ酸長もしくはそれ以上でもよい。極めて長いCDR3の長さは非抗体配列を含んでもよい。極めて長いCDR3は、例えば、インターロイキン配列、ホルモン配列、サイトカイン配列、毒素配列、リンフォカイン配列、増殖因子配列、ケモカイン配列、毒素配列、またはその組み合わせを含む非抗体配列を含んでもよい。好ましくは、極めて長いCDR3は重鎖CDR3(CDR-H3またはCDRH3)である。好ましくは、極めて長いCDR3は、反芻動物(例えば、ウシ)配列に由来するかまたは基づく配列である。好ましくは、極めて長いCDR3は、SEQ ID NO:498のアミノ酸配列、SEQ ID NO:499のアミノ酸配列、またはその両方を含む。または、もしくはさらに、極めて長いCDR3は、
のアミノ酸配列を含む。または、もしくはさらに、極めて長いCDR3は、
のアミノ酸配列を含む。
または、もしくはさらに、極めて長いCDR3は、
のアミノ酸配列を含む。極めて長いCDR3は、少なくとも3個もしくはそれ以上のシステイン残基、例えば、4個もしくはそれ以上のシステイン残基、6個もしくはそれ以上のシステイン残基、8個もしくはそれ以上のシステイン残基、10個もしくはそれ以上のシステイン残基、または12個もしくはそれ以上のシステイン残基(例えば、3個、4個、5個、6個、7個、8個、9個、10個、11個、12個、またはそれ以上)を含んでもよい。極めて長いCDR3は、以下のモチーフ:システインモチーフ、X1X2X3X4X5モチーフ、CX1X2X3X4X5モチーフ、または(XaXb)zモチーフの1つまたは複数を含んでもよい。「システインモチーフ」は、4個もしくはそれ以上のシステイン残基、5個もしくはそれ以上のシステイン残基、6個もしくはそれ以上のシステイン残基、7個もしくはそれ以上のシステイン残基、8個もしくはそれ以上のシステイン残基、9個もしくはそれ以上のシステイン残基、10個もしくはそれ以上のシステイン残基、11個もしくはそれ以上のシステイン残基、または12個もしくはそれ以上のシステイン残基を含む3個もしくはそれ以上のシステイン残基を含む、極めて長いCDR3にあるアミノ酸残基のセグメントである。システインモチーフは、
からなる群より選択されるアミノ酸配列を含んでもよい。または、システインモチーフは、
からなる群より選択されるアミノ酸配列を含んでもよい。システインモチーフは、好ましくは、極めて長いCDR3の中に、X1X2X3X4X5モチーフと(XaXb)zモチーフの間に配置される。「X1X2X3X4X5モチーフ」は極めて長いCDR3にある一続きの5個の連続したアミノ酸残基であり、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、X5はグルタミン(Q)である。一部の態様において、X1X2X3X4X5モチーフは、
でもよい。「CX1X2X3X4X5モチーフ」は極めて長いCDR3にある一続きの6個の連続したアミノ酸残基であり、1番目のアミノ酸残基はシステインであり、X1は、トレオニン(T)、グリシン(G)、アラニン(A)、セリン(S)、またはバリン(V)であり、X2は、セリン(S)、トレオニン(T)、プロリン(P)、イソロイシン(I)、アラニン(A)、バリン(V)、またはアスパラギン(N)であり、X3は、バリン(V)、アラニン(A)、トレオニン(T)、またはアスパラギン酸(D)であり、X4は、ヒスチジン(H)、トレオニン(T)、アルギニン(R)、チロシン(Y)、フェニルアラニン(F)、またはロイシン(L)であり、X5はグルタミン(Q)である。一部の態様において、CX1X2X3X4X5モチーフは、
である。「(XaXb)z」モチーフは、極めて長いCDR3にある2アミノ酸残基の反復シリーズであり、Xaは任意のアミノ酸残基であり、Xbは、チロシン(Y)、フェニルアラニン(F)、トリプトファン(W)、およびヒスチジン(H)からなる群より選択される芳香族アミノ酸であり、zは1~4である。一部の態様において、(XaXb)zモチーフは、
を含んでもよい。一部の態様において、(XaXb)zモチーフはYXYXYXである。極めて長いCDR3は、SEQ ID NO:40に由来するかまたは基づくアミノ酸配列を含んでもよい(例えば、SEQ ID NO:1~4のアミノ酸残基3~6を参照されたい;例えば、図2A~CにあるVH生殖系列配列も参照されたい)。極めて長いCDR3を含む可変領域は、SEQ ID NO:1(CTTVHQ)、SEQ ID NO:2(CTSVHQ)、SEQ ID NO:3(CSSVTQ)、またはSEQ ID NO:4(CTTVHP)であるアミノ酸配列を含んでもよい。このような配列はウシ生殖系列VH遺伝子配列(例えば、SEQ ID NO:1)に由来してもよく、ウシ生殖系列VH遺伝子配列(例えば、SEQ ID NO:1)に基づいてもよい。極めて長いCDR3は、非ヒトDH遺伝子配列、例えば、SEQ ID NO:5に由来するかまたは基づく配列を含んでもよく(例えば、Koti, et al. (2010) Mol. Immunol. 47: 2119-2128も参照されたい)、SEQ ID NO:6、7、8、9、10、11、または12などの代替配列を含んでもよい(例えば、図2A~CのDH2生殖系列配列も参照されたい)。極めて長いCDR3は、JH配列、例えば、SEQ ID NO:13に由来するかまたは基づく配列を含んでもよく(例えば、Hosseini, et al. (2004) Int. Immunol. 16: 843-852も参照されたい)、SEQ ID NO:14、15、16、または17などの代替配列を含んでもよい(例えば、図2A~CのJH1生殖系列配列も参照されたい)。一態様において、極めて長いCDR3は、非ヒトVH配列(例えば、SEQ ID NO:1、2、3、もしくは4;または図2A~CのVH配列)に由来するかまたは基づく配列、および/あるいは非ヒトDH配列(例えば、SEQ ID NO:5、6、7、8、9、10、11、もしくは12;または図2A~CのDH配列)に由来するかまたは基づく配列、および/あるいはJH配列(例えば、SEQ ID NO:13、14、15、16、もしくは17;または図2A~CのJH配列)に由来するかまたは基づく配列、任意で、例えば、VH由来配列とDH由来配列との間にある、2~6個もしくはそれ以上のアミノ酸を含むさらなる配列(例えば、IR、IF、SEQ ID NO:18、19、20、または21)を含んでもよい。別の態様において、極めて長いCDR3は、SEQ ID NO:22、23、24、25、26、27、もしくは28に由来するかまたは基づく配列を含んでもよい(例えば、図2A~CのSEQ ID NO:276~359も参照されたい)。
IMGTは、例えば、抗体についてIMGTにより指定されたCDRを含む、Lefrace et al., Nucl. Acids, Res. 37; D1006-D1012 (2009)に記載のような国際免疫遺伝学情報システム(international ImMunoGeneTics Information System)を指す。
本開示は組換え遺伝学の分野における慣用的な技法に頼る。この本開示における一般的な使用方法を開示する基本的な教科書には、Sambrook and Russell, Molecular Cloning: A Laboratory Manual 3d ed. (2001); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990);およびAusubel et al., Current Protocols in Molecular Biology (1994)が含まれる。
現在に至るまで、ウシは、極めて長いCDR3配列が同定されている唯一の種である。しかしながら、他の種、例えば他の反芻動物も、極めて長いCDR3配列を有する抗体を持っている可能性がある。
本開示は、例えば、極めて長いCDR3配列および/またはCDR3スキャフォールドを含むヒト化抗体遺伝子またはタンパク質を含む、抗体の遺伝子およびタンパク質を提供する。さらに、本開示は、極めて長いCDR3配列の調製において有用なVH配列、DH配列、およびJH配列を提供する。このような配列は、本明細書において開示された多くの態様に記載の配列を含む、本明細書に記載のモチーフ(例えば、システインモチーフ)を含み得る。一部の態様において、本明細書において開示された抗体は、標的タンパク質のエピトープを選択的または特異的に結合し得る。一部の態様において、抗体はアンタゴニスト(例えば、ブロッキング)抗体でもよくアゴニスト抗体でもよい。
本開示は抗体断片を包含する。ある特定の状況では、抗体全体ではなく抗体断片を使用する利点がある。小さなサイズの断片を用いると排除が迅速になり、固形腫瘍への接近が改善される可能性がある。抗体断片には、Fab、Fab'、Fab'-SH、F(ab')2、Fv、およびscFv断片、ならびに下記の他の断片が含まれるが、これに限定されない。ある特定の抗体断片の総説については、Hudson et al. Nat. Med. 9:129-134 (2003)を参照されたい。scFv断片の総説については、例えば、Pluckthun, The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994)を参照されたい。WO93/16185;および米国特許第5,571,894号および同第5,587,458号も参照されたい。サルベージ(salvage)受容体結合エピトープ残基を含み、長いインビボ半減期を有するFabおよびF(ab')2断片の考察については、米国特許第5,869,046号を参照されたい。
本開示は、極めて長いCDR3を含むヒト化抗体を提供する。ヒト化抗体は操作されたヒト抗体を含んでもよい(例えば、Studnicka et al. (1994) Protein Eng.. 7(6) 805-814;および米国特許第5,766,886号を参照されたい)。非ヒト抗体をヒト化するための様々な方法が当技術分野において公知である。例えば、ヒト化抗体は、ヒトまたは非ヒトの供給源に由来する1つまたは複数のアミノ酸残基が導入されてもよい。ヒト化は、改変された抗体可変ドメインの調製を含む、Studnicka(例えば、Studnicka et al. (1994) Protein Eng.. 7(6) 805-814;および米国特許第5,766,886号を参照されたい)の方法に従って行われてもよい。または、ヒト化は、ヒト抗体の対応する配列の代わりに超可変領域配列を置換することによって、Winterおよび共同研究者(Jones et al. (1986) Nature 321:522-525; Riechmann et al. (1988) Nature 332:323-327; Verhoeyen et al. (1988) Science 239:1534-1536)の方法に従って行われてもよい。従って、このような「ヒト化」抗体または「操作されたヒト」抗体は、インタクトなヒト可変ドメインより実質的に小さな配列が非ヒト種に由来する対応する配列で置換されているか、または非ヒト種に由来する対応する配列に組み込まれている場合を含めてキメラ抗体である。例えば、ヒト化抗体は、一部の超可変領域残基、場合によっては一部のFR残基がげっ歯類抗体の類似部位に由来する残基で置換されたヒト抗体でもよい。または、ヒト化抗体または操作されたヒト抗体は、一部の残基がヒト抗体の類似部位に由来する残基によって置換された非ヒト(例えば、げっ歯類)抗体でもよい(例えば、Studnicka et al. (1994) Protein Eng.. 7(6) 805-814;および米国特許第5,766,886号を参照されたい)。
二重特異性抗体は、少なくとも2つの異なる抗原に対する結合特異性を有する、モノクローナルの、好ましくは、ヒト抗体またはヒト化抗体である。例えば、結合特異性の一方は第1の抗原に対するものでもよく、他方は他の任意の抗原に対するものでもよい。例示的な二重特異性抗体は、同じタンパク質の2つの異なるエピトープに結合し得る。二重特異性抗体はまた、細胞傷害剤を、ある特定のタンパク質を発現する細胞に局在化させるのに用いられてもよい。これらの抗体は、特定のタンパク質に特異的な結合アームと、細胞傷害剤(例えば、サポリン、抗インターフェロン-α、ビンカアルカロイド、リシンA鎖、メトトレキセート、または放射性同位体ハプテン)に結合するアームを有する。二重特異性抗体は、完全長抗体または抗体断片(例えば、F(ab')2二重特異性抗体)として調製されてもよい。
多価抗体は、抗体が結合する抗原を発現する細胞によって二価抗体より速く内部移行(および/または異化)され得る。本開示の抗体は、3個もしくはそれ以上の抗原結合部位を持つ(IgMクラス以外の)多価抗体(例えば、四価抗体)でもよく、抗体のポリペプチド鎖をコードする核酸の組換え発現によって産生されてもよい。多価抗体は二量体化ドメインおよび3個もしくはそれ以上の抗原結合部位を含んでもよい。好ましい二量体化ドメインはFc領域もしくはヒンジ領域を含んでもよい(またはFc領域もしくはヒンジ領域からなってもよい)。このシナリオでは、抗体は、Fe領域のアミノ末端側にFc領域および3個もしくはそれ以上の抗原結合部位を含む。好ましい多価抗体は3個~約8個であるが、好ましくは4個の抗原結合部位を含んでもよい(または3個~約8個であるが、好ましくは4個の抗原結合部位からなってもよい)。多価抗体は少なくとも1個のポリペプチド鎖(好ましくは2個のポリペプチド鎖)を含み、ポリペプチド鎖は2個もしくはそれ以上の可変ドメインを含む。例えば、ポリペプチド鎖はVD1-(X1)n-VD2-(X2)n-Fcを含んでもよく、VD1は第1の可変ドメインであり、VD2は第2の可変ドメインであり、Fcは、Fc領域の1個のポリペプチド鎖であり、X1およびX2はアミノ酸またはポリペプチドを表し、nは0または1である。例えば、ポリペプチド鎖は、VH-CH1-柔軟なリンカー-VH-CH1-Fc領域鎖;またはVH-CH1-VH-CH1-Fc領域鎖を含んでもよい。多価抗体は、好ましくは、少なくとも2個の(好ましくは4個の)軽鎖可変ドメインポリペプチドをさらに含んでもよい。多価抗体は、例えば、約2個~約8個の軽鎖可変ドメインポリペプチドを含んでもよい。軽鎖可変ドメインポリペプチドは軽鎖可変ドメインを含んでもよく、任意で、CLドメインをさらに含んでもよい。
一部の態様において、本明細書に記載の極めて長いCDR3を含むヒト化抗体のアミノ酸配列改変が意図される。例えば、抗体の結合親和性および/または他の生物学的特性を改善することが望ましい場合がある。抗体のアミノ酸配列変種は、適切なヌクレオチド変化を抗体核酸に導入することによって、またはペプチド合成によって調製される。このような改変には、例えば、抗体のアミノ酸配列からの残基の欠失および/または抗体のアミノ酸配列への残基の挿入および/または抗体のアミノ酸配列内での残基の置換が含まれる。最終構築物が望ましい特徴を有するのであれば、最終構築物を得るように欠失、挿入、および置換の任意の組み合わせが作製される。アミノ酸変化は、対象の抗体アミノ酸配列に、その配列が作製されるときに導入されてもよい。
本明細書において開示された極めて長いCDR3を含むヒト化抗体は、当技術分野において公知であり、かつ容易に入手可能な、さらなる非タンパク質部分を含有するようにさらに改変されてもよい。好ましくは、抗体誘導体化に適した部分は水溶性ポリマーである。水溶性ポリマーの非限定的な例には、ポリエチレングリコール(PEG)、エチレングリコール/プロピレングリコールのコポリマー、カルボキシメチルセルロース、デキストラン、ポリビニルアルコール、ポリビニルピロリドン、ポリ-1,3-ジオキソラン、ポリ-1,3,6-トリオキサン、エチレン/マレイン酸無水物コポリマー、ポリアミノ酸(ホモポリマーまたはランダムコポリマーのいずれか)、およびデキストランまたはポリ(n-ビニルピロリドン)ポリエチレングリコール、プロプロピレン(propropylene)グリコールホモポリマー、プロリプロピレンオキシド(prolypropylene oxide)/エチレンオキシドコポリマー、ポリオキシエチル化ポリオール(例えば、グリセロール)、ポリビニルアルコール、ならびにその混合物が含まれるが、これに限定されない。ポリエチレングリコールプロピオンアルデヒドは、水中で安定であるために製造において利点がある可能性がある。ポリマーは任意の分子量でもよく、分枝または非分枝でもよい。抗体に取り付けられたポリマーの数は異なってもよく、複数のポリマーが取り付けられる場合、同じ分子でもよく異なる分子でもよい。一般的に、誘導体化に用いられるポリマーの数および/またはタイプは、改善しようとする抗体の特定の特性または機能、規定された条件下で抗体誘導体が療法に用いられるかどうかなどを含むが、これに限定されない考慮すべき事項に基づいて決定することができる。
本明細書において開示された抗体またはその断片を組換え産生する際、それをコードする核酸が単離され、さらなるクローニング(DNA増幅)または発現のための複製可能なベクターに挿入される。抗体をコードするDNAは、従来の手法を用いて(例えば、抗体の重鎖および軽鎖をコードする遺伝子に特異的に結合することができるオリゴヌクレオチドプローブを用いることによって)容易に単離および配列決定される。例示的な態様では、極めて長いCDR3を含むヒト化抗体、極めて長いCDR3を含む可変領域、または極めて長いCDR3をコードする核酸が単離され、さらにクローニング(DNA増幅)するか、または発現させるために複製可能なベクターに挿入される。多くのベクターが利用可能である。ベクターの選択は、一つには、使用しようとする宿主細胞に依存する。一般的に、好ましい宿主細胞は原核生物に由来するか、真核生物(一般的に哺乳動物)に由来する。この目的のために、IgG、IgM、IgA、IgD、およびIgE定常領域を含む任意のアイソタイプの定常領域を使用することができ、このような定常領域を任意のヒトまたは動物種から入手できることが認められるだろう。
i.ベクター構築
標準的な組換え法を用いて、本明細書において開示された抗体のポリペプチド成分をコードするポリヌクレオチド配列を入手することができる。望ましいポリヌクレオチド配列はハイブリドーマ細胞などの抗体産生細胞から単離および配列決定されてもよい。または、ポリヌクレオチドはヌクレオチド合成機またはPCR法を用いて合成することができる。ポリペプチドをコードする配列が得られたら、原核生物宿主において異種ポリヌクレオチドを複製および発現することができる組換えベクターに挿入する。本開示の目的に関して、当技術分野において利用可能な、かつ公知の多くのベクターを使用することができる。適切なベクターの選択は、主に、ベクターに挿入される核酸のサイズおよびベクターで形質転換しようとする特定の宿主細胞に依存する。それぞれのベクターは、その機能(異種ポリヌクレオチドの増幅もしくは発現またはその両方)およびベクターが中にある特定の宿主細胞との適合性に応じて様々な成分を含有する。一般的に、ベクター成分には、複製起点、選択マーカー遺伝子、プロモーター、リボソーム結合部位(RBS)、シグナル配列、異種核酸インサート、および転写終結配列が含まれるが、これに限定されない。さらに、極めて長いCDR3を含むV領域は、任意で、定常領域を含む抗体を産生するようにC領域と融合されてもよい。
部分的にヒトである極めて長いCDR3抗体を組換え産生する場合、宿主細胞において、さらにクローニングおよび/または発現するために、極めて長いCDR3を含むヒト化抗体をコードする核酸が1つまたは複数の発現ベクターに挿入される。このような核酸は、従来の手法を用いて(例えば、抗体の重鎖および軽鎖をコードする遺伝子に特異的に結合することができるオリゴヌクレオチドプローブを用いることによって)容易に単離および配列決定され得る。宿主細胞は、このような発現ベクターで形質転換され、プロモーターを誘導するために、形質転換体を選択するために、または望ましい配列をコードする遺伝子を増幅するために適宜、改変される従来の栄養培地中で培養される。
当技術分野において公知の標準的なタンパク質精製法を使用することができる。以下の手法:イムノアフィニティーカラムまたはイオン交換カラムによる分画、エタノール沈殿、逆相HPLC、シリカまたは陽イオン交換樹脂、例えば、DEAEによるクロマトグラフィー、等電点電気泳動、SDS-PAGE、硫安沈殿、および例えば、Sephadex G-75を用いたゲル濾過は適切な精製手法の例示である。
ベクター成分には、一般的に、シグナル配列、複製起点、1種または複数種のマーカー遺伝子、エンハンサーエレメント、プロモーター、および転写終結配列の1つまたは複数が含まれるが、これに限定されない。
真核生物宿主細胞において使用するためのベクターはまた、シグナル配列、または関心対象の成熟したタンパク質またはポリペプチドのN末端に特定の切断部位を有する他のポリペプチドも含有してもよい。選択される異種シグナル配列は、好ましくは、宿主細胞によって認識および処理される(例えば、シグナルペプチダーゼによって切断される)異種シグナル配列である。哺乳動物細胞発現では、哺乳動物シグナル配列ならびにウイルス分泌リーダー、例えば、単純ヘルペスgDシグナルを利用することができる。
一般的に、哺乳動物発現ベクターに複製起点成分は必要でない。例えば、初期プロモーターを含有しているという理由だけで、SV40起点が用いられ得る。
発現・クローニングベクターは、選択マーカーとも呼ばれる選択遺伝子を含有してもよい。典型的な選択遺伝子は、(a)抗生物質もしくは他の毒素、例えば、アンピシリン、ネオマイシン、メトトレキセート、もしくはテトラサイクリンに対する耐性を付与するタンパク質、(b)関連する場合、栄養要求欠損を補うタンパク質、または(c)複合培地から入手できない重要な栄養分を供給するタンパク質をコードする。
発現・クローニングベクターは、通常、宿主生物が認識し、抗体ポリペプチド核酸に機能的に連結しているプロモーターを含有する。真核生物のプロモーター配列が公知である。実質的に全ての真核生物遺伝子が、転写開始部位から約25~30塩基上流に位置するATリッチ領域を有する。多くの遺伝子の転写開始から70~80塩基上流に見出される別の配列がCNCAAT領域であり、式中、Nは任意のヌクレオチドでよい。ほとんどの真核生物遺伝子の3'末端には、ポリAテールをコード配列3'末端に付加するためのシグナルであり得るAATAAA配列がある。これらの配列は全て、適宜、真核生物発現ベクターに挿入される。
高等真核生物による本開示の抗体ポリペプチドをコードするDNAの転写は、多くの場合、エンハンサー配列をベクターに挿入することによって増加する。哺乳動物遺伝子(グロビン、エラスターゼ、アルブミン、α-フェトプロテイン、およびインシュリン)に由来する多くのエンハンサー配列が現在知られている。真核細胞ウイルスに由来するエンハンサーも用いられてもよい。例には、複製起点の後期側にあるSV40エンハンサー(bp100-270)、サイトメガロウイルス初期プロモーターエンハンサー、複製起点の後期側にあるポリオーマエンハンサー、およびアデノウイルスエンハンサーが含まれる。真核生物プロモーター活性化のための強化エレメントについてはYaniv, Nature 297:17-18 (1982)も参照されたい。エンハンサーは、抗体ポリペプチドをコードする配列の5'側または3'側にある位置でベクターの中にスプライスされてもよいが、好ましくは、プロモーターから5'側の部位に配置される。
真核宿主細胞において用いられる発現ベクターはまた、典型的には、転写終結およびmRNA安定化に必要な配列も含有する。このような配列は、一般的に、真核生物またはウイルスのDNAまたはcDNAの5'非翻訳領域、時として3'非翻訳領域から入手することができる。これらの領域は、抗体をコードするmRNAの非翻訳部分にあるポリアデニル化断片として転写されるヌクレオチドセグメントを含有する。有用な転写終結成分の1つはウシ成長ホルモンポリアデニル化領域である。WO94/11026およびWO94/11026において開示された発現ベクターを参照されたい。
本明細書においてベクター中のDNAをクローニングまたは発現するのに適した宿主細胞には、脊椎動物宿主細胞を含む本明細書に記載の高等真核生物細胞が含まれる。培養(組織培養)で脊椎動物細胞を増殖することは慣用的な手法になっている。有用な哺乳動物宿主細胞株の例は、SV40によって形質転換されたサル腎臓CV1株(COS-7、ATCC CRL 1651); ヒト胚腎臓株(293細胞または懸濁液培養で増殖させるためにサブクローニングされた293細胞、Graham et al., J. Gen Virol. 36:59 (1977)); ベビーハムスター腎臓細胞(BHK、ATCC CCL 10); チャイニーズハムスター卵巣細胞/-DHFR(CHO、Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); マウスセルトリ細胞(TM4、Mather, Biol. Reprod. 23:243-251 (1980); サル腎臓細胞(CV1 ATCC CCL 70); アフリカミドリザル腎臓細胞(VERO-76、ATCC CRL-1587); ヒト子宮頸癌細胞(HELA、ATCC CCL 2); イヌ腎臓細胞(MDCK、ATCC CCL 34); バッファローラット肝臓細胞(BRL 3A、ATCC CRL 1442); ヒト肺細胞(W138、ATCC CCL 75); ヒト肝臓細胞(Hep G2、HB 8065); マウス乳房腫瘍(MMT 060562、ATCC CCL51); TRI細胞(Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5細胞; FS4細胞; およびヒトヘパトーム株(Hep G2)である。
本開示の抗体を産生するのに用いられる宿主細胞は様々な培地中で培養されてもよい。宿主細胞を培養するには、Ham F10(Sigma)、最小必須培地((MEM)、(Sigma)、RPMI-1640(Sigma)、およびダルベッコ変法イーグル培地((DMEM), Sigma)などの市販の培地が適している。さらに、宿主細胞用の培養培地として、Ham et al., Meth. Enz. 58:44 (1979)、Barnes et al., Anal. Biochem. 102:255 (1980)、米国特許第4,767,704号;同第4,657,866号;同第4,927,762号;同第4,560,655号;もしくは同第5,122,469号; WO90/03430;WO87/00195;または米国再発行特許第30,985号に記載の任意の培地を使用することができる。これらの培地はいずれも、必要に応じて、ホルモンおよび/または他の増殖因子(例えば、インシュリン、トランスフェリン、もしくは上皮細胞増殖因子)、塩(例えば、塩化ナトリウム、カルシウム、マグネシウム、およびリン酸)、緩衝液(例えば、HEPES)、ヌクレオチド(例えば、アデノシンおよびチミジン)、抗生物質(例えば、GENTAMYCIN(商標)薬物)、微量元素(通常、マイクロモル範囲の最終濃度で存在する無機化合物と定義される)、ならびにグルコースまたは等価なエネルギー源を加えることができる。当業者に公知の他の任意の必要な補助剤も適切な濃度で含めることができる。培養条件、例えば、温度、pHなどは、発現があるかどうか選択された宿主細胞と共に以前に用いられたものであり、当業者に明らかになるだろう。
組換え法を用いた場合、抗体を細胞内で産生することができるか、または培地に直接分泌することができる。第1の工程として抗体を細胞内で産生するのであれば、宿主細胞または溶解断片のいずれかである粒子破片を、例えば、遠心分離または限外濾過によって除去する。抗体を培地に分泌させた場合、一般的に、このような発現系からの上清を、最初に、市販のタンパク質濃度フィルタ、例えば、AmiconまたはMillipore Pellicon(登録商標)限外濾過ユニットを用いて濃縮する。タンパク質分解を阻害するために前述の工程のいずれにおいてもPMSFなどのプロテアーゼインヒビターを組み込んでもよく、外来混入物質の増殖を阻止するために抗生物質を組み込んでもよい。
本開示はまた、細胞傷害剤、例えば、化学療法剤、薬物、増殖阻害剤、毒素(例えば、細菌由来、真菌由来、植物由来、もしくは動物由来の酵素活性のある毒素、またはその断片)、あるいは放射性同位体(例えば、放射性コンジュゲート(radioconjugate))とコンジュゲートしている本明細書に記載の任意の極めて長いCDR3を含むヒト化抗体を含む、イムノコンジュゲート(同義で「抗体-薬物コンジュゲート」または「ADC」と呼ばれる)を提供する。
一部の態様において、イムノコンジュゲートは、1つまたは複数のマイタンシノイド分子とコンジュゲートしている、本明細書において開示された極めて長いCDR3を含むヒト化抗体(完全長または断片)を含む。
一部の態様において、イムノコンジュゲートは、ドラスタチンまたはドロスタチンのペプチド類似体および誘導体であるアウリスタチン(米国特許第5,635,483号;同第5,780,588号)とコンジュゲートした本明細書において開示された抗体を含む。ドラスタチンおよびアウリスタチンは、微小管の動態、GTP加水分解、ならびに核分裂および細胞分裂を妨害し(Woyke et al (2001) Antimicrob. Agents and Chemother. 45(12):3580-3584)、抗癌活性(米国特許第5,663,149号)および抗真菌活性(Pettit et al (1998) Antimicrob. Agents Chemother.42:2961-2965)を有することが示されている。ドラスタチンまたはアウリスタチン薬物部分は、ペプチド薬物部分のN(アミノ)末端またはC(カルボキシル)末端を介して抗体に取り付けられてもよい(WO02/088172)。
他の態様において、イムノコンジュゲートは、1個または複数個のカリチアマイシン分子とコンジュゲートした本明細書において開示された抗体を含む。カリチアマイシン系抗生物質は、pM以下の濃度で二本鎖DNAを切断することができる。カリチアマイシン系のコンジュゲートの調製については、米国特許第5,712,374号、同第5,714,586号、同第5,739,116号、同第5,767,285号、同第5,770,701号、同第5,770,710号、同第5,773,001号、同第5,877,296号を参照されたい。使用され得るカリチアマイシン構造類似体には、γ1 I、α2 I、α3 I、N-アセチル-γ1 I、PSAG、およびθI 1が含まれるが、これに限定されない(例えば、Hinman et al., Cancer Research 53:3336-3342 (1993)、Lode et al., Cancer Research 58:2925-2928 (1998)、および前記の米国特許を参照されたい)。抗体をコンジュゲートすることができる別の抗腫瘍薬物は、葉酸代謝拮抗剤であるQFAである。カリチアマイシンおよびQFAはいずれも細胞内作用部位を有し、原形質膜を容易に通過しない。従って、抗体を介した内部移行によって、これらの薬剤が細胞に取り込まれると細胞傷害作用が大幅に高まる。
本明細書において開示された抗体とコンジュゲートすることができる他の抗癌剤には、BCNU、ストレプトゾイシン(streptozoicin)、ビンクリスチンおよび5-フルオロウラシル、米国特許第5,053,394号、同第5,770,710号に記載の、まとめてLL-E33288複合体と知られる薬剤のファミリー、ならびにエスペラミシン(米国特許第5,877,296号)が含まれる。
本明細書において開示された抗体薬物コンジュゲート(ADC)において、抗体(Ab)は、リンカー(L)を介して、1つまたは複数の薬物部分(D)、例えば、抗体1つ当たり約1~約20個の薬物とコンジュゲートされる。式I[Ab-(L-D) p]のADCは、(1)共有結合を介してAb-Lを形成する、抗体の求核基と二価リンカー試薬との反応と、それに続く薬物部分Dとの反応;ならびに(2)共有結合を介してD-Lを形成する、薬物部分の求核基と二価リンカー試薬との反応と、それに続く抗体の求核基との反応を含む、当業者に公知の有機化学反応、条件、および試薬を用いて、いくつかの経路によって調製されてもよい。ADCを調製するためのさらなる方法が本明細書に記載されている。
ハイブリドーマ細胞は、望ましい抗体を産生するB細胞を、不死化細胞株、通常、ミエローマ細胞株と融合させることによって生成することができ、その結果、結果として生じた融合細胞は、ある特定の抗体を分泌する不死化細胞になるようになる。同じ原理によって、ミエローマ細胞を、最初に、生殖系列抗体V領域をコードする核酸でトランスフェクトし、生殖系列V領域の発現についてスクリーニングすることができる。その後に、最も高いレベルのタンパク質分解性軽鎖発現を有するミエローマ細胞を、望ましい標的タンパク質特異性を持つ抗体を産生するB細胞と融合することができる。この融合細胞は2つのタイプの抗体を産生する。一方のタイプは、組換え生殖系列V領域(重鎖または軽鎖のいずれか)に機能的につながった内因性抗体鎖(重鎖または軽鎖のいずれか)を含有する異種抗体であり、他方は、親B細胞が分泌するものと同じ抗体(例えば、内因性重鎖および内因性軽鎖の両方)である。機能的につながった異種重鎖および異種軽鎖は、従来の方法、例えば、クロマトグラフィーによって単離することができ、標的タンパク質結合アッセイ、生殖系列ポリペプチドの独特のタグを同定するアッセイ、または本開示の他のセクションに記載のエンドペプチダーゼ活性アッセイによって識別情報を確認することができる。2つのタイプの抗体の中で異種抗体が量の点で多数を占めるタイプであるいくつかの場合では、このような単離は必要とされないことがある。ウシハイブリドーマを含むハイブリドーマは、極めて長いCDR3配列を含むウシ抗体遺伝子配列の供給源になり得る。
本開示の生殖系列抗体ポリペプチドをコードする核酸配列を非ヒト哺乳動物に導入して、生殖系列抗体ポリペプチドを発現するトランスジェニック動物を作製することができる。一般的に見られるトランスジェニック動物モデルと異なり、本開示のトランスジェニック哺乳動物が発現するトランスジーンは、体細胞組換え後に、抗体鎖可変領域を担う内因性コード配列の少なくとも1つの対立遺伝子に取って代わる必要はない。対立遺伝子排除により、外因性の体細胞再編成後バージョンの生殖系列V領域DNAが存在すると、体細胞再編成前Vミニ遺伝子の内因性対立遺伝子が体細胞再編成を受けて、この哺乳動物が産生し得る抗体鎖の構成に寄与することが抑えられる。従って、ある特定の抗原に曝露されると、哺乳動物は、内因的に再編成された1種類の抗体鎖と、アプリオリに再編成された1種類のトランスジェニック遺伝子を含む異種抗体を生じる。このような異種抗体は、生きている対象において、ある特定の状態を研究および処置する上で非常に貴重である。他方で、トランスジーンを内因性対立遺伝子の遺伝子座に組み込む方法も、本開示を実施するという目的に十分にかなう。
本明細書において開示された極めて長いCDR3を含むヒト化抗体、抗体断片、核酸、またはベクターは、組成物、特に、薬学的組成物に処方することができる。極めて長いCDR3を含むヒト化抗体を含む、このような組成物は、適切な担体、例えば、薬学的に許容される薬剤と混合して、治療的または予防的に有効な量の、本明細書において開示された極めて長いCDR3を含むヒト化抗体、抗体断片、核酸、またはベクターを含む。典型的に、本明細書において開示された極めて長いCDR3を含むヒト化抗体、抗体断片、核酸、またはベクターは、薬学的組成物に処方される前に、投与のために十分に精製される。
さらなる局面として、本開示は、本開示の方法を実施するために、1つまたは複数の化合物または組成物が使用しやすいように包装されたキットを含む。一態様において、このようなキットは、容器に包装された、本明細書に記載の化合物または組成物(例えば、極めて長いCDR3を含むヒト化抗体を単独で、または第2の薬剤と組み合わせて含む組成物)を、容器に貼られたラベル、または前記方法の実施における化合物もしくは組成物の使用について説明している添付文書と一緒に備える。適切な容器には、例えば、瓶、バイアル、注射器などが含まれる。容器は、様々な材料、例えば、ガラスまたはプラスチックから形成されてもよい。容器は滅菌アクセスポートを有してもよい(例えば、容器は、静脈内溶液バックまたは皮下注射針で穴を開けることができるストッパーを有するバイアルでもよい)。製造物品は、(a)本明細書において開示された、極めて長いCDR3を含むヒト化抗体を含む組成物が中に入れられている第1の容器;および(b)さらなる治療剤を含む組成物が中に入れられている第2の容器を備えてもよい。本明細書において開示された、この態様における製造物品は、ある特定の状態を処置するために第1の組成物および第2の組成物を使用することができることを示す添付文書をさらに備えてもよい。または、もしくはさらに、製造物品は、薬学的に許容される緩衝液、例えば、無菌注射用水(BWFI)、リン酸緩衝食塩水、リンガー溶液、およびデキストロース溶液を含む第2の(または第3の)容器をさらに備えてもよい。製造物品は、他の緩衝液、希釈剤、フィルタ、針、および注射器を含む、商業的観点および使用者の観点から望ましい他の材料をさらに備えてもよい。好ましくは、前記化合物または組成物は単位剤形で包装される。キットは、特定の投与経路に従って組成物を投与するのに適した、またはスクリーニングアッセイを実施するのに適した装置をさらに備えてもよい。好ましくは、キットは、極めて長いCDR3を含むヒト化抗体組成物の使用について説明しているラベルを備える。
ウシ起源の極めて長いCDR3を含む少なくとも7種の抗体重鎖可変領域配列が、公に入手可能である。これらの配列は、図1のアライメントに示される。図1に示されるように、これらの可変領域配列内に存在する極めて長いCDR3の長さは、56~61アミノ酸の範囲である。際だったことに、配列アライメントは、CDR3のN末端に位置するアミノ酸残基が特に保存されていることを示す。これらの可変領域配列の各々において、最初のシステイン残基の後に、「TTVHQ」というアミノ酸配列パターンおよびその変種が見出された。大部分の種の大部分の重鎖可変領域が、アミノ酸配列「CAK」または「CAR」を末端に有するため、これは稀である。この稀な配列モチーフ(例えば、「TTVHQ」)は、極めて長いCDR3の構造の特徴であり得る。
)をコードするDNAを、「TTVHQ」モチーフをコードするポリヌクレオチドの3'末端に融合させる。最後に、J領域配列に共通の保存されたトリプトファン残基から開始する、部分的なヒトJH4領域をコードするDNAを、BLV1H12に由来する極めて長いCDR3配列の一部の3'末端に付加する。極めて長いCDR3を含む部分的にヒトである抗体をコードする以下の抗体遺伝子が得られる:
-普通フォント-ヒトVH4-39由来
-下線-VH-UL由来
-太字-ウシBLVH12由来の極めて長いCDR3
-イタリック体-ヒトJH4由来
-普通フォント-ヒトVH4-39由来
-下線-VH-UL由来
-太字-ウシBLVH12由来の極めて長いCDR3
-イタリック体-ヒトJH2由来
極めて長いCDR3を含む抗体をコードするポリヌクレオチドのライブラリーを、当技術分野において公知の方法によって構築することができる。そのようなポリヌクレオチドライブラリーは、複数のベクターに存在してもよく(例えば、ベクターのライブラリー)、例えば、複数の宿主細胞に存在するベクターに存在してもよい(例えば、宿主細胞のライブラリー)。ライブラリーは、空間的にアドレス指定された形式(例えば、WO 11/056997;およびMao et al.(2010)Nat Biotech 28:1195-1202を参照)を含む、公知の形式で存在し得る。
を使用して、実施例9において調製されたcDNAから、ウシVH領域を増幅した。次に、VH領域の混合物を、ウシCH1およびヒトIgG Fcと共にオーバーラップPCRによって組み立てた。簡単に説明すると、全長重鎖ライブラリーを哺乳動物細胞における発現のために準備するため、pFUSE発現ベクターへのライゲーションのためのEcoRI部位およびNheI部位を組み入れた。ライゲーション産物を大腸菌へ形質転換し、500個の単一大腸菌形質転換体を選び取った。次いで、各形質転換体を、別々の容器において一晩増殖させ、Qiagen minprepキット(Qiagen, Inc.)を使用して各コロニーからDNAを抽出し、オリゴ
を使用してBATJ, Inc.(San Diego, CA)によって配列決定した。配列をVectorNTI(Invitrogen, Inc. Carlsbad, CA)を使用して分析した。重複している配列、インサートを有しない配列、および35残基より短いCDRをコードする配列を除外した。独特の長いCDR重鎖配列を含有している132個のクローンを選択した。次いで、132メンバーライブラリーの各重鎖を、不変ウシ軽鎖BLV1H12(SEQ ID NO:412)をコードするpFUSE発現ベクターと平行して293T細胞へコトランスフェクトして、空間的にアドレス指定された小さいライブラリー(Mao et al.(2010)Nat Biotech 28:1195-1202)を生成した。1ウェル当たり130,000個の293T細胞を、24穴プレートに播種し、10%FBS(Invitrogen)およびペニシリン/ストレプトマイシン/グルタミン(Invitrogen)を含む500ulのDMEM培地(Invitrogen)において37℃および5%CO2で一晩増殖させた。HcをコードするpFuseベクター0.5μgおよびLcをコードするpFuseベクター0.5μgを、25μlのoptimem(Invitrogen)に添加した。1μlのリポフェクタミン2000または293Fectinトランスフェクション試薬(Invitrogen)を、25μlのoptimemに添加し、5分インキュベートした。次に、DNA-optimem混合物およびトランスフェクション試薬-optimem混合物を合わせ、15分インキュベートし、293T細胞に添加し、細胞上で4~6時間インキュベートした。次いで、培地をウェルから吸引し、新鮮な培地に交換し、細胞を4日間増殖させ培地中へIgGを分泌させた。IgGを含有している細胞培養上清を、さらなる試験のため、96穴フォーマットに採集した。キメラ抗体を、ヒトFcを検出するサンドイッチELISAによって定量化し、ELISAによってBVDVとの結合についてスクリーニングした。
極めて長いCDR3を含む重鎖可変領域をコードするヌクレオチド配列のクローニングおよび/または発現のため、当技術分野において公知のベクターを使用するか、または使用するために修飾することができる。そのようなベクターは、任意で、極めて長いCDR3を含む重鎖可変領域をコードするヌクレオチド配列に連結されたヒト免疫グロブリン(例えば、IgG)のFc部分をコードするヌクレオチド配列を含むか、または含むよう修飾されてもよい。さらに、極めて長いCDR3が、例えば、制限酵素による一方向クローニングによって、非ウシ(非抗体またはヒト)配列をコードするヌクレオチド配列を受容することができるよう、極めて長いCDR3を含む重鎖可変領域をコードするヌクレオチド配列を、公知の方法に従って修飾することができる。軽鎖可変領域をコードするヌクレオチド配列のクローニングおよび/または発現のためにも、当技術分野において公知のベクターを使用するか、または使用するために修飾することができる。
極めて長いCDR3を含む抗体をコードするポリヌクレオチドを、当技術分野において公知の方法によって、宿主細胞において発現、例えば、一過性発現させることができる。
非ウシ配列を含む極めて長いCDR3の発現を可能にするヒト生殖系列配列を同定するため、極めて長いCDR3を含むヒト生殖系列配列を、当技術分野において公知の方法によって評価することができる。
非ウシ配列を含む極めて長いCDR3(例えば、CDR3の少なくとも一部の非ウシ配列への交換)を含む抗体、例えば、ヒト化抗体を、非ウシ配列の結合パートナーとの結合について、当技術分野において公知の方法、例えば、フローサイトメトリーによって評価することができる。
実施例5において生成されたヒト化抗体を、重鎖のCDR1および/またはCDR2に1個以上のアミノ酸置換を含むよう修飾することができる。そのようなアミノ酸置換は、CDR3と相互作用すると仮定されている位置において、ヒト生殖系列CDR1およびCDR2へ導入され得る。
極めて長いCDR3を含む抗体、例えば、CDR3の少なくとも一部が非ウシ配列に交換されている極めて長いCDR3を含む抗体を、ヒト軽鎖と対形成させることができる。
ヒト生殖系列軽鎖、例えば、極めて長いCDR3を含む重鎖と対形成され得る軽鎖を、当技術分野において公知の方法によって修飾することができる。そのような修飾には、ヒト軽鎖のある種のアミノ酸残基の、ウシ軽鎖配列の対応する位置にある残基への置換が含まれ得る。修飾された軽鎖は、極めて長いCDR3を含む抗体の収量を改善し、かつ/または結合特異性を増加させ得る。
極めて長いCDR3を含むライブラリー、例えば、抗体フレームワーク(例えば、重鎖フレームワーク)内に極めて長いCDR3の少なくとも一部を含むライブラリーを、生成することができる。そのようなライブラリーは、極めて長いCDR3配列の多様性、極めて長いCDR3のシステインドメインの1個以上のシステイン残基の間に位置する1個以上の残基の多様性、または極めて長いCDR3に挿入され得る(例えば、その一部を交換する)非ウシペプチドの多様性を含み得る。抗体フレームワークは、VH-ULなどのウシ配列、ヒト生殖系列配列、または実施例7に記載されたような修飾されたヒト生殖系列配列に由来し得る。多様な極めて長いCDR3を含む抗体または抗体断片のライブラリーの発現のため、多様な極めて長いCDR3を含む重鎖を、ウシ、ヒト、または修飾された組成物(例えば、実施例9を参照すること)の軽鎖と対形成させることができる。
ヒト生殖系列軽鎖、例えば、極めて長いCDR3を含む重鎖とさせられ得る軽鎖を、当技術分野において公知の方法によって修飾することができる。そのような修飾には、ヒト軽鎖のある種のアミノ酸残基の置換が含まれ得る。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRの発現を可能にする配列を同定し特徴決定するため、極めて長いCDR3を含む、ヒト化生殖系列配列、例えば、修飾されたヒト生殖系列配列を、当技術分野において公知の方法によって評価することができる。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRの発現を可能にする配列を同定し特徴決定するため、極めて長いCDR3を含む、ヒト化生殖系列配列、例えば、修飾されたヒト生殖系列配列を、当技術分野において公知の方法によって評価することができる。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む抗体を、(例えば、フローサイトメトリーを介して)非抗体配列の結合パートナーとの結合について、かつ/または(例えば、細胞ベースの発光アッセイを介して)活性化について、当技術分野において公知の方法によって評価することができる。
極めて長いCDR3を含む、ヒト化生殖系列配列、例えば、修飾されたヒト生殖系列配列を、極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRの発現を可能にする配列を同定し特徴決定するため、当技術分野において公知の方法によって評価することができる。
であった。もう一つの例において、BsaI含有ヌクレオチド配列は、
であった。BsaI部位の周囲のリンカーは、CDR3の上流ストーク部分(SEQ ID NO:498)とCDR3の下流ストーク部分(SEQ ID NO:499)との間に、表25にリストされるように作製された。
のBsaI部位へ導入して、ヒトJを含み(G4S)3リンカーが隣接しているBLV1H12のCDR3内のこれらの毒素の各々(図21および22のBID番号220~224)を作製した。これらの重鎖を、ウシULVL-ヒトλC(SEQ ID NO:474;SEQ ID NO:807)と対形成させ、実施例4に記載されたようにトランスフェクトした。結果としてのIgGの上清中の収量を実施例4と同様に決定し、表28に提示した。ヒトJ修飾を含まないBLV1H12 CDR3毒素構築物(SEQ ID NO:775~779)を、実施例4に記載されたように、大規模トランスフェクションのため、ウシULVL-ヒトλC(SEQ ID NO:474;SEQ ID NO:807)と対形成させ、実施例6および14に記載されたように精製した。
極めて長いCDR3、例えば、非抗体配列(例えば、毒素)を含む極めて長いCDRを含む抗体を、当技術分野において公知の方法によって(例えば、細胞ベースの阻害アッセイを介して)評価することができる。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む抗体を、当技術分野において公知の方法によって評価することができる。例えば、極めて長いCDR3を含むヒト化抗体をコードするポリヌクレオチドを、当技術分野において公知の方法によって、宿主細胞において、発現、例えば、一過性発現させることができる。極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む例示的なヒト化抗体配列を、発現させ特徴決定した。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む抗体を、当技術分野において公知の方法によって評価することができる。例えば、極めて長いCDR3を含むヒト化抗体をコードするポリヌクレオチドを、当技術分野において公知の方法によって、宿主細胞において、発現、例えば、一過性発現させることができる。極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む例示的なヒト化抗体配列を、発現させ特徴決定した。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む抗体を、当技術分野において公知の方法によって(例えば、活性化アッセイ、細胞ベースの発光アッセイ、動的光散乱(DLS)を介して)評価することができる。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む抗体を、当技術分野において公知の方法によって評価することができる。例えば、極めて長いCDR3を含むヒト化抗体をコードするポリヌクレオチドを、当技術分野において公知の方法によって、宿主細胞において、発現、例えば、一過性発現させることができる。極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む例示的なヒト化抗体配列を、発現させ特徴決定した。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む抗体を、当技術分野において公知の方法によって評価することができる。例えば、極めて長いCDR3を含むヒト化抗体をコードするポリヌクレオチドを、当技術分野において公知の方法によって、宿主細胞において、発現、例えば、一過性発現させることができる。極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む例示的なヒト化抗体配列を、発現させ(例えば、HPLC、DLS、およびDSFを介して)特徴決定した。
へ組み入れた。次いで、様々なリンカー配列をコードするオリゴヌクレオチドを使用して、ShK毒素配列(SEQ ID NO:648)を増幅し、ShK毒素(SEQ ID NO:648)および隣接リンカーをコードする得られた配列を、VH4-34MutE-CDR3-BsaIへ導入して、VH4-34 MutE CDR3(図21のBID 48、104、56 66、65、67、61、60、および59)内のShK毒素に隣接する一連の次第に短くなるリンカー、およびノブの代わりに3xGGSを含むストークのみをコードするVH4-34 MutE(図21のBID 55)を作製した。重鎖をコードするこれらのベクターを、以下の修飾を加えて、実施例4に記載されたように、大規模トランスフェクションのため、軽鎖VL1-51 S2A T5N P8S A12G A13S P14L K46R L47T D51G N52D N53LK(SEQ ID NO:486、図22を参照すること)と対形成させ、実施例6および14に記載されたように精製した。細胞培養上清を5000×gで10分間スピンすることによって細胞から分離した。Protein A sepharose Fast Flow(GE Healthcare、番号17-1279-03)を使い捨てカラムへ分配した。樹脂の量は増殖のサイズによって決定された。樹脂を、20カラム体積の1×PBS(137mM NaCl、2.7mM KCl、10mMリン酸水素ナトリウム、2mMリン酸水素カリウム)で洗浄した。洗浄の後、IgGを含有している上清を、樹脂の製造業者の規格を越えないよう流速をモニタリングしながら、樹脂へロードした。その後、20カラム体積の1×PBSでの洗浄を実施し、タンパク質を0.7Mアルギニン緩衝液(pH4.3)を使用して、カラムから溶出させた。タンパク質を含有している画分を合わせ、1×PBSへ透析した。透析の後、タンパク質溶液を0.2μm PES膜で濾過した。試料を4℃で保管した。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む抗体を、当技術分野において公知の方法によって評価することができる。例えば、極めて長いCDR3を含むヒト化抗体をコードするポリヌクレオチドを、当技術分野において公知の方法によって、宿主細胞において、発現、例えば、一過性発現させることができる。極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む例示的なヒト化抗体配列を、発現させ(例えば、SDS-PAGEを介して)特徴決定した。
極めて長いCDR、例えば、非抗体配列(例えば、毒素)を含む極めて長いCDR3を含む抗体を、当技術分野において公知の方法によって(例えば、細胞ベースの阻害アッセイおよびELISAアッセイを介して)評価することができる。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む抗体を、当技術分野において公知の方法によって(例えば、T細胞活性化アッセイまたは阻害アッセイを介して)評価することができる。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む抗体を、当技術分野において公知の方法によって(例えば、T細胞阻害アッセイを介して)評価することができる。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む抗体を、当技術分野において公知の方法によって(例えば、Kv1.3阻害アッセイを介して)評価することができる。
極めて長いCDR3、例えば、非抗体配列を含む極めて長いCDRを含む抗体を、当技術分野において公知の方法によって(例えば、T細胞活性化アッセイまたは阻害アッセイを介して)評価することができる。
SEQUENCE LISTING
<110> TAURUS BIOSCIENCES, LLC
<120> HUMANIZED ANTIBODIES WITH ULTRALONG COMPLEMENTARITY DETERMINING REGIONS
<150> US 61/856,010
<151> 2013-07-18
<160> 959
<170> PatentIn version 3.5
<210> 1
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH sequence (germline, BLV5B8, BLV8C11, BF4E9, and
F18)
<400> 1
Cys Thr Thr Val His Gln
1 5
<210> 2
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH sequence (BLV1H12)
<400> 2
Cys Thr Ser Val His Gln
1 5
<210> 3
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH sequence (BLV5D3)
<400> 3
Cys Ser Ser Val Thr Gln
1 5
<210> 4
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH sequence (BF1H1)
<400> 4
Cys Thr Thr Val His Pro
1 5
<210> 5
<211> 48
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Germline sequence derived from DH2 gene
<400> 5
Ser Cys Pro Asp Gly Tyr Ser Tyr Gly Tyr Gly Cys Gly Tyr Gly Tyr
1 5 10 15
Gly Cys Ser Gly Tyr Asp Cys Tyr Gly Tyr Gly Gly Tyr Gly Gly Tyr
20 25 30
Gly Gly Tyr Gly Tyr Ser Ser Tyr Ser Tyr Ser Tyr Thr Tyr Glu Tyr
35 40 45
<210> 6
<211> 48
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from DH gene (BLV1H12)
<400> 6
Ser Cys Pro Asp Gly Tyr Arg Glu Arg Ser Asp Cys Ser Asn Arg Pro
1 5 10 15
Ala Cys Gly Thr Ser Asp Cys Cys Arg Val Ser Val Phe Gly Asn Cys
20 25 30
Leu Thr Thr Leu Pro Val Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp
35 40 45
<210> 7
<211> 44
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from DH gene (BLV5B8)
<400> 7
Cys Ser Asp Gly Tyr Ile Ala Val Asp Ser Cys Gly Arg Gly Gln Ser
1 5 10 15
Asp Gly Cys Val Asn Asp Cys Asn Ser Cys Tyr Tyr Gly Trp Arg Asn
20 25 30
Cys Arg Arg Gln Pro Ala Ile His Ser Tyr Glu Phe
35 40
<210> 8
<211> 44
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from DH gene (BLV5D3)
<400> 8
Ser Cys Pro Asp Gly Cys Ser Asp Gly Asp Gly Cys Val Asp Gly Cys
1 5 10 15
Cys Cys Ser Ala Tyr Arg Cys Tyr Thr Pro Gly Val Arg Asp Leu Ser
20 25 30
Cys Thr Ser Tyr Ser Ile Thr Tyr Thr Tyr Glu Trp
35 40
<210> 9
<211> 45
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from DH gene (BLV8C11)
<400> 9
Cys Cys Ser Asp Ala Tyr Arg Tyr Asp Ser Gly Cys Gly Ser Gly Cys
1 5 10 15
Asp Cys Cys Gly Ala Asp Cys Tyr Val Phe Gly Ala Cys Thr Phe Gly
20 25 30
Leu Asp Ser Ser Tyr Ser Tyr Ile Tyr Ile Tyr Gln Trp
35 40 45
<210> 10
<211> 47
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from DH gene (BF4E9)
<400> 10
Cys Pro Asp Gly Tyr Ser Tyr Gly Tyr Gly Cys Gly Tyr Gly Tyr Gly
1 5 10 15
Cys Ser Gly Tyr Asp Cys Tyr Gly Tyr Gly Gly Tyr Gly Tyr Gly Gly
20 25 30
Tyr Gly Gly Tyr Ser Ser Tyr Ser Tyr Ser Tyr Ser Tyr Glu Tyr
35 40 45
<210> 11
<211> 44
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from DH gene (BF1H1)
<400> 11
Ser Pro Asp Gly Tyr Ser Tyr Gly Tyr Gly Cys Gly Tyr Gly Tyr Gly
1 5 10 15
Cys Ser Gly Tyr Asp Cys Tyr Gly Tyr Gly Gly Tyr Gly Tyr Gly Gly
20 25 30
Tyr Gly Gly Tyr Ser Ser Tyr Ser Tyr Ser Tyr Ser
35 40
<210> 12
<211> 42
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from DH gene (F18)
<400> 12
Cys Pro Asp Gly Tyr Gly Tyr Gly Tyr Gly Cys Gly Tyr Gly Ser Tyr
1 5 10 15
Gly Tyr Ser Gly Tyr Asp Cys Tyr Gly Tyr Gly Gly Tyr Gly Gly Tyr
20 25 30
Gly Gly Tyr Gly Gly Tyr Ser Ser Tyr Ser
35 40
<210> 13
<211> 15
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Germline sequence derived from JH1 gene
<400> 13
Tyr Val Asp Ala Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
1 5 10 15
<210> 14
<211> 15
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from JH gene (BLV1H12)
<400> 14
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
1 5 10 15
<210> 15
<211> 15
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from JH gene (BLV5B8)
<400> 15
His Val Asp Ala Trp Gly Arg Gly Leu Leu Val Thr Val Ser Ser
1 5 10 15
<210> 16
<211> 15
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from JH gene (BLV5D3)
<400> 16
Asn Val Asp Ala Trp Gly Arg Gly Leu Leu Val Thr Val Ser Ser
1 5 10 15
<210> 17
<211> 15
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from JH gene (BLV8C11 or BF4E9)
<400> 17
Tyr Gly Asp Ala Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
1 5 10 15
<210> 18
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from CDR3 (BLV1H12)
<400> 18
Glu Thr Lys Lys Tyr Gln
1 5
<210> 19
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from CDR3 (BLV5B8)
<400> 19
Glu Thr Arg Lys Thr
1 5
<210> 20
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from CDR3 (BLV5D3)
<400> 20
Arg Thr His Val Ser Arg
1 5
<210> 21
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Sequence derived from CDR3 (BLV8C11)
<400> 21
Lys Thr Thr Arg Lys Thr
1 5
<210> 22
<211> 61
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: ultralong CDR3 sequence (BLV1H12)
<400> 22
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Cys Pro Asp Gly Tyr
1 5 10 15
Arg Glu Arg Ser Asp Cys Ser Asn Arg Pro Ala Cys Gly Thr Ser Asp
20 25 30
Cys Cys Arg Val Ser Val Phe Gly Asn Cys Leu Thr Thr Leu Pro Val
35 40 45
Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp
50 55 60
<210> 23
<211> 56
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: ultralong CDR3 sequence (BLV5B8)
<400> 23
Thr Val His Gln Glu Thr Arg Lys Thr Cys Ser Asp Gly Tyr Ile Ala
1 5 10 15
Val Asp Ser Cys Gly Arg Gly Gln Ser Asp Gly Cys Val Asn Asp Cys
20 25 30
Asn Ser Cys Tyr Tyr Gly Trp Arg Asn Cys Arg Arg Gln Pro Ala Ile
35 40 45
His Ser Tyr Glu Phe His Val Asp
50 55
<210> 24
<211> 57
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: ultralong CDR3 sequence (BLV5D3)
<400> 24
Ser Val Thr Gln Arg Thr His Val Ser Arg Ser Cys Pro Asp Gly Cys
1 5 10 15
Ser Asp Gly Asp Gly Cys Val Asp Gly Cys Cys Cys Ser Ala Tyr Arg
20 25 30
Cys Tyr Thr Pro Gly Val Arg Asp Leu Ser Cys Thr Ser Tyr Ser Ile
35 40 45
Thr Tyr Thr Tyr Glu Trp Asn Val Asp
50 55
<210> 25
<211> 58
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: ultralong CDR3 sequence (BLV8C11)
<400> 25
Thr Val His Gln Lys Thr Thr Arg Lys Thr Cys Cys Ser Asp Ala Tyr
1 5 10 15
Arg Tyr Asp Ser Gly Cys Gly Ser Gly Cys Asp Cys Cys Gly Ala Asp
20 25 30
Cys Tyr Val Phe Gly Ala Cys Thr Phe Gly Leu Asp Ser Ser Tyr Ser
35 40 45
Tyr Ile Tyr Ile Tyr Gln Trp Tyr Val Asp
50 55
<210> 26
<211> 56
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: ultralong CDR3 sequence (BF4E9)
<400> 26
Thr Val His Gln Ile Phe Cys Pro Asp Gly Tyr Ser Tyr Gly Tyr Gly
1 5 10 15
Cys Gly Tyr Gly Tyr Gly Cys Ser Gly Tyr Asp Cys Tyr Gly Tyr Gly
20 25 30
Gly Tyr Gly Tyr Gly Gly Tyr Gly Gly Tyr Ser Ser Tyr Ser Tyr Ser
35 40 45
Tyr Ser Tyr Glu Tyr Tyr Gly Asp
50 55
<210> 27
<211> 48
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: ultralong CDR3 sequence (BF1H1)
<400> 27
Thr Val His Pro Ser Pro Asp Gly Tyr Ser Tyr Gly Tyr Gly Cys Gly
1 5 10 15
Tyr Gly Tyr Gly Cys Ser Gly Tyr Asp Cys Tyr Gly Tyr Gly Gly Tyr
20 25 30
Gly Tyr Gly Gly Tyr Gly Gly Tyr Ser Ser Tyr Ser Tyr Ser Tyr Ser
35 40 45
<210> 28
<211> 48
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: ultralong CDR3 sequence (F18)
<400> 28
Thr Val His Gln Ile Arg Cys Pro Asp Gly Tyr Gly Tyr Gly Tyr Gly
1 5 10 15
Cys Gly Tyr Gly Ser Tyr Gly Tyr Ser Gly Tyr Asp Cys Tyr Gly Tyr
20 25 30
Gly Gly Tyr Gly Gly Tyr Gly Gly Tyr Gly Gly Tyr Ser Ser Tyr Ser
35 40 45
<210> 29
<211> 100
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: exemplary heavy chain variable region sequence
suitable for modification or use with an ultralong CDR3 sequence
(VH-UL)
<400> 29
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Gly Ile Asp Thr Gly Gly Ser Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Thr Val His Gln
100
<210> 30
<211> 97
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: exemplary light chain variable region sequence
suitable for modification or use with an ultralong CDR3 sequence
(VL1X)
<400> 30
Gln Ala Val Leu Thr Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Arg Val Ser Ile Thr Cys Ser Gly Ser Ser Ser Asn Val Gly Asn Gly
20 25 30
Tyr Val Ser Trp Tyr Gln Leu Ile Pro Gly Ser Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Ser Arg Ala Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Arg Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Ser Leu Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser
<210> 31
<211> 99
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: exemplary heavy chain variable region sequence
suitable for modification or use with an ultralong CDR 3 sequence
(VH4-39)
<400> 31
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg
<210> 32
<211> 96
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Human germline heavy chain variable region sequence
4-59*03
<400> 32
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
<210> 33
<211> 97
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Human germline heavy chain variable region sequence
4-34*02
<400> 33
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg
<210> 34
<211> 97
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Human germline heavy chain variable region sequence
4-34*09
<400> 34
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg
<210> 35
<211> 110
<212> PRT
<213> Artificial sequence
<220>
<223> Synthsized: Bovine light chain variable region sequence BLV1H12
<400> 35
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Arg Val Ser Ile Thr Cys Ser Gly Ser Ser Ser Asn Val Gly Asn Gly
20 25 30
Tyr Val Ser Trp Tyr Gln Leu Ile Pro Gly Ser Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Ser Arg Ala Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Arg Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Ser Leu Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu
100 105 110
<210> 36
<211> 98
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Human germline light chain variable region sequence
VL1-47
<400> 36
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Ser Gly
<210> 37
<211> 99
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Human germline light chain variable region sequence
VL1-40*1
<400> 37
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly
<210> 38
<211> 98
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Human germline light chain variable region sequence
VL1-51*01
<400> 38
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90 95
Ser Ala
<210> 39
<211> 99
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Human germline light chain variable region sequence
VL2-18*02
<400> 39
Gln Ser Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr
20 25 30
Asn Arg Val Ser Trp Tyr Gln Gln Pro Pro Gly Thr Ala Pro Lys Leu
35 40 45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Phe
<210> 40
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: optional sequence in ultralong CDR3
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is threonine or serine
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X is histidine or threonine
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X is glutamine or proline
<400> 40
Xaa Val Xaa Xaa
1
<210> 41
<211> 28
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 1
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(27)
<223> Xaa can be any naturally occurring amino acid
<400> 41
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
20 25
<210> 42
<211> 43
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 2
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(42)
<223> Xaa can be any naturally occurring amino acid
<400> 42
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
35 40
<210> 43
<211> 21
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 3
<220>
<221> misc_feature
<222> (2)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(20)
<223> Xaa can be any naturally occurring amino acid
<400> 43
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Cys
20
<210> 44
<211> 35
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 4
<220>
<221> misc_feature
<222> (2)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(34)
<223> Xaa can be any naturally occurring amino acid
<400> 44
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Cys
35
<210> 45
<211> 41
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 5
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(40)
<223> Xaa can be any naturally occurring amino acid
<400> 45
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
35 40
<210> 46
<211> 34
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 6
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(33)
<223> Xaa can be any naturally occurring amino acid
<400> 46
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Cys
<210> 47
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 7
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 47
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Cys
35
<210> 48
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 8
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 48
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Cys
35
<210> 49
<211> 35
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 9
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(34)
<223> Xaa can be any naturally occurring amino acid
<400> 49
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Cys
35
<210> 50
<211> 33
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 10
<220>
<221> misc_feature
<222> (2)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(32)
<223> Xaa can be any naturally occurring amino acid
<400> 50
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Cys
<210> 51
<211> 35
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 11
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(34)
<223> Xaa can be any naturally occurring amino acid
<400> 51
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Cys
35
<210> 52
<211> 24
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 12
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(23)
<223> Xaa can be any naturally occurring amino acid
<400> 52
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys
20
<210> 53
<211> 35
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 13
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(34)
<223> Xaa can be any naturally occurring amino acid
<400> 53
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Cys
35
<210> 54
<211> 43
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 14
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(32)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (34)..(42)
<223> Xaa can be any naturally occurring amino acid
<400> 54
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
35 40
<210> 55
<211> 35
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 15
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(34)
<223> Xaa can be any naturally occurring amino acid
<400> 55
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Cys
35
<210> 56
<211> 37
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 16
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(36)
<223> Xaa can be any naturally occurring amino acid
<400> 56
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Cys
35
<210> 57
<211> 37
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 17
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(36)
<223> Xaa can be any naturally occurring amino acid
<400> 57
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Cys
35
<210> 58
<211> 45
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 18
<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(33)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (35)..(44)
<223> Xaa can be any naturally occurring amino acid
<400> 58
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa
20 25 30
Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
35 40 45
<210> 59
<211> 34
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 19
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(29)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (31)..(33)
<223> Xaa can be any naturally occurring amino acid
<400> 59
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Cys Xaa Xaa
20 25 30
Xaa Cys
<210> 60
<211> 26
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 20
<220>
<221> misc_feature
<222> (2)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(25)
<223> Xaa can be any naturally occurring amino acid
<400> 60
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys
20 25
<210> 61
<211> 26
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 21
<220>
<221> misc_feature
<222> (2)..(7)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (9)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(25)
<223> Xaa can be any naturally occurring amino acid
<400> 61
Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa
1 5 10 15
Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys
20 25
<210> 62
<211> 35
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 22
<220>
<221> misc_feature
<222> (2)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(30)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (32)..(34)
<223> Xaa can be any naturally occurring amino acid
<400> 62
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa
20 25 30
Xaa Xaa Cys
35
<210> 63
<211> 26
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 23
<220>
<221> misc_feature
<222> (2)..(9)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (11)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(25)
<223> Xaa can be any naturally occurring amino acid
<400> 63
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys
20 25
<210> 64
<211> 37
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 24
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(36)
<223> Xaa can be any naturally occurring amino acid
<400> 64
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Cys
35
<210> 65
<211> 28
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 25
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(20)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (22)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(27)
<223> Xaa can be any naturally occurring amino acid
<400> 65
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Cys
20 25
<210> 66
<211> 29
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 26
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(28)
<223> Xaa can be any naturally occurring amino acid
<400> 66
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Cys
20 25
<210> 67
<211> 27
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 27
<220>
<221> misc_feature
<222> (2)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (17)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<400> 67
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Cys Xaa Cys
20 25
<210> 68
<211> 25
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 28
<220>
<221> misc_feature
<222> (2)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(24)
<223> Xaa can be any naturally occurring amino acid
<400> 68
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys
20 25
<210> 69
<211> 38
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 29
<220>
<221> misc_feature
<222> (2)..(5)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (7)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(37)
<223> Xaa can be any naturally occurring amino acid
<400> 69
Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Cys
35
<210> 70
<211> 38
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 30
<220>
<221> misc_feature
<222> (2)..(7)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (9)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(37)
<223> Xaa can be any naturally occurring amino acid
<400> 70
Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Cys
35
<210> 71
<211> 38
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 31
<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(37)
<223> Xaa can be any naturally occurring amino acid
<400> 71
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Cys Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Cys
35
<210> 72
<211> 25
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 32
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<400> 72
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys
20 25
<210> 73
<211> 35
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 33
<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(34)
<223> Xaa can be any naturally occurring amino acid
<400> 73
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Cys
35
<210> 74
<211> 20
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 34
<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(19)
<223> Xaa can be any naturally occurring amino acid
<400> 74
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa
1 5 10 15
Cys Xaa Xaa Cys
20
<210> 75
<211> 21
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 35
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(20)
<223> Xaa can be any naturally occurring amino acid
<400> 75
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Cys
20
<210> 76
<211> 43
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 36
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (17)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(33)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (35)..(35)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (37)..(42)
<223> Xaa can be any naturally occurring amino acid
<400> 76
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys
1 5 10 15
Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys
35 40
<210> 77
<211> 39
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 37
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(35)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (37)..(38)
<223> Xaa can be any naturally occurring amino acid
<400> 77
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Cys Xaa Xaa Cys
35
<210> 78
<211> 43
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 38
<220>
<221> misc_feature
<222> (2)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(28)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (30)..(38)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (40)..(42)
<223> Xaa can be any naturally occurring amino acid
<400> 78
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Cys Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys
35 40
<210> 79
<211> 41
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 39
<220>
<221> misc_feature
<222> (2)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(37)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (39)..(40)
<223> Xaa can be any naturally occurring amino acid
<400> 79
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys
35 40
<210> 80
<211> 39
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 40
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(38)
<223> Xaa can be any naturally occurring amino acid
<400> 80
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Cys
35
<210> 81
<211> 43
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 41
<220>
<221> misc_feature
<222> (2)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(42)
<223> Xaa can be any naturally occurring amino acid
<400> 81
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
35 40
<210> 82
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 42
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(28)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (30)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 82
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Cys
35
<210> 83
<211> 37
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 43
<220>
<221> misc_feature
<222> (2)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(33)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (35)..(36)
<223> Xaa can be any naturally occurring amino acid
<400> 83
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Cys Xaa Xaa Cys
35
<210> 84
<211> 37
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 44
<220>
<221> misc_feature
<222> (2)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(36)
<223> Xaa can be any naturally occurring amino acid
<400> 84
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Cys
35
<210> 85
<211> 44
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 45
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(31)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (33)..(33)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (35)..(43)
<223> Xaa can be any naturally occurring amino acid
<400> 85
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Cys
20 25 30
Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
35 40
<210> 86
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 46
<220>
<221> misc_feature
<222> (2)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(32)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (34)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 86
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Cys Xaa Xaa Cys
35
<210> 87
<211> 37
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 47
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(33)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (35)..(36)
<223> Xaa can be any naturally occurring amino acid
<400> 87
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Cys Xaa Xaa Cys
35
<210> 88
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 48
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 88
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Cys
35
<210> 89
<211> 43
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 49
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(30)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (32)..(39)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (41)..(42)
<223> Xaa can be any naturally occurring amino acid
<400> 89
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Cys Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys
35 40
<210> 90
<211> 38
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 50
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(28)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (30)..(37)
<223> Xaa can be any naturally occurring amino acid
<400> 90
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Cys
35
<210> 91
<211> 43
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 51
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(29)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (31)..(36)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (38)..(42)
<223> Xaa can be any naturally occurring amino acid
<400> 91
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Cys Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys
35 40
<210> 92
<211> 34
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 52
<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (17)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(33)
<223> Xaa can be any naturally occurring amino acid
<400> 92
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10 15
Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Cys
<210> 93
<211> 39
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 53
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(32)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (34)..(38)
<223> Xaa can be any naturally occurring amino acid
<400> 93
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Cys Xaa Xaa Xaa Xaa Xaa Cys
35
<210> 94
<211> 46
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 54
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(39)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (41)..(45)
<223> Xaa can be any naturally occurring amino acid
<400> 94
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys
35 40 45
<210> 95
<211> 44
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 55
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(29)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (31)..(38)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (40)..(43)
<223> Xaa can be any naturally occurring amino acid
<400> 95
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Cys Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys
35 40
<210> 96
<211> 42
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 56
<220>
<221> misc_feature
<222> (3)..(5)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (7)..(7)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (9)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (17)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(33)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (35)..(39)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (41)..(41)
<223> Xaa can be any naturally occurring amino acid
<400> 96
Cys Cys Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Cys Cys
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys
35 40
<210> 97
<211> 39
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 57
<220>
<221> misc_feature
<222> (2)..(7)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (9)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(29)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (31)..(36)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (38)..(38)
<223> Xaa can be any naturally occurring amino acid
<400> 97
Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Cys Xaa Cys
35
<210> 98
<211> 38
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 58
<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(28)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (30)..(35)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (37)..(37)
<223> Xaa can be any naturally occurring amino acid
<400> 98
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Cys Xaa Cys
35
<210> 99
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 59
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(30)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (32)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 99
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa
1 5 10 15
Cys Xaa Xaa Cys Xaa Cys Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa
20 25 30
Xaa Xaa Xaa Cys
35
<210> 100
<211> 39
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 60
<220>
<221> misc_feature
<222> (2)..(6)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (8)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(34)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (36)..(37)
<223> Xaa can be any naturally occurring amino acid
<400> 100
Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Cys Xaa Xaa Cys Cys
35
<210> 101
<211> 38
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 61
<220>
<221> misc_feature
<222> (2)..(6)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(37)
<223> Xaa can be any naturally occurring amino acid
<400> 101
Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Cys Xaa Cys Xaa Xaa Xaa
1 5 10 15
Cys Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Cys
35
<210> 102
<211> 37
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 62
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(29)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (31)..(36)
<223> Xaa can be any naturally occurring amino acid
<400> 102
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Cys Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Cys
35
<210> 103
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 63
<220>
<221> misc_feature
<222> (3)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(30)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (33)..(33)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (35)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 103
Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Cys
20 25 30
Xaa Cys Xaa Cys
35
<210> 104
<211> 41
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 64
<220>
<221> misc_feature
<222> (3)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (11)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(40)
<223> Xaa can be any naturally occurring amino acid
<400> 104
Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Cys
1 5 10 15
Cys Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
35 40
<210> 105
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 65
<220>
<221> misc_feature
<222> (2)..(7)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (9)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(31)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (33)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 105
Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Cys Cys
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys
20 25 30
Xaa Xaa Xaa Cys
35
<210> 106
<211> 39
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 66
<220>
<221> misc_feature
<222> (2)..(4)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (6)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(31)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (33)..(36)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (38)..(38)
<223> Xaa can be any naturally occurring amino acid
<400> 106
Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys
20 25 30
Xaa Xaa Xaa Xaa Cys Xaa Cys
35
<210> 107
<211> 41
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 67
<220>
<221> misc_feature
<222> (2)..(5)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (7)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(35)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (37)..(38)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (40)..(40)
<223> Xaa can be any naturally occurring amino acid
<400> 107
Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Cys
35 40
<210> 108
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 68
<220>
<221> misc_feature
<222> (2)..(6)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (8)..(9)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 108
Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Cys
35
<210> 109
<211> 38
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 69
<220>
<221> misc_feature
<222> (2)..(6)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (8)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(35)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (37)..(37)
<223> Xaa can be any naturally occurring amino acid
<400> 109
Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Cys Xaa Cys Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Cys Xaa Cys
35
<210> 110
<211> 37
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 70
<220>
<221> misc_feature
<222> (2)..(4)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (6)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(33)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (35)..(36)
<223> Xaa can be any naturally occurring amino acid
<400> 110
Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa
20 25 30
Xaa Cys Xaa Xaa Cys
35
<210> 111
<211> 38
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 71
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(28)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (32)..(37)
<223> Xaa can be any naturally occurring amino acid
<400> 111
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Cys Cys Cys Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Cys
35
<210> 112
<211> 38
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 72
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(29)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (31)..(33)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (35)..(37)
<223> Xaa can be any naturally occurring amino acid
<400> 112
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa
1 5 10 15
Cys Xaa Xaa Cys Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa
20 25 30
Xaa Cys Xaa Xaa Xaa Cys
35
<210> 113
<211> 33
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 73
<220>
<221> misc_feature
<222> (2)..(9)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(32)
<223> Xaa can be any naturally occurring amino acid
<400> 113
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Cys Xaa Xaa Xaa
1 5 10 15
Cys Cys Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
20 25 30
Cys
<210> 114
<211> 34
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 74
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(29)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (31)..(33)
<223> Xaa can be any naturally occurring amino acid
<400> 114
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Cys Xaa Cys Cys Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa
20 25 30
Xaa Cys
<210> 115
<211> 37
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 75
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(20)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (22)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(28)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (30)..(34)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (36)..(36)
<223> Xaa can be any naturally occurring amino acid
<400> 115
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Cys Xaa Cys Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
20 25 30
Xaa Xaa Cys Xaa Cys
35
<210> 116
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 76
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(33)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (35)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 116
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Cys Xaa Cys Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
20 25 30
Xaa Cys Xaa Cys
35
<210> 117
<211> 34
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 77
<220>
<221> misc_feature
<222> (2)..(7)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(30)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (32)..(33)
<223> Xaa can be any naturally occurring amino acid
<400> 117
Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa
20 25 30
Xaa Cys
<210> 118
<211> 28
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 78
<220>
<221> misc_feature
<222> (2)..(7)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(26)
<223> Xaa can be any naturally occurring amino acid
<400> 118
Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Cys Xaa Xaa Xaa Cys Xaa
1 5 10 15
Cys Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Cys
20 25
<210> 119
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 79
<220>
<221> misc_feature
<222> (2)..(7)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 119
Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Cys Xaa Xaa Xaa Cys Xaa
1 5 10 15
Cys Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Cys
35
<210> 120
<211> 29
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 80
<220>
<221> misc_feature
<222> (2)..(5)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (7)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (11)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (17)..(20)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(28)
<223> Xaa can be any naturally occurring amino acid
<400> 120
Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Cys Xaa Xaa Xaa Cys Xaa Cys
1 5 10 15
Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Cys Xaa Xaa Xaa Cys
20 25
<210> 121
<211> 32
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 81
<220>
<221> misc_feature
<222> (2)..(4)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (6)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(31)
<223> Xaa can be any naturally occurring amino acid
<400> 121
Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Cys
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
20 25 30
<210> 122
<211> 29
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 82
<220>
<221> misc_feature
<222> (3)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (17)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(28)
<223> Xaa can be any naturally occurring amino acid
<400> 122
Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys
1 5 10 15
Xaa Cys Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys
20 25
<210> 123
<211> 35
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 83
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(28)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (30)..(34)
<223> Xaa can be any naturally occurring amino acid
<400> 123
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
20 25 30
Xaa Xaa Cys
35
<210> 124
<211> 39
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 84
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(26)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (28)..(34)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (36)..(38)
<223> Xaa can be any naturally occurring amino acid
<400> 124
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Cys Xaa Xaa Xaa Cys
35
<210> 125
<211> 35
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 85
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(30)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (32)..(34)
<223> Xaa can be any naturally occurring amino acid
<400> 125
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Cys
1 5 10 15
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa
20 25 30
Xaa Xaa Cys
35
<210> 126
<211> 41
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 86
<220>
<221> misc_feature
<222> (2)..(4)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (6)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(33)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (35)..(40)
<223> Xaa can be any naturally occurring amino acid
<400> 126
Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys
35 40
<210> 127
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 87
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(30)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (32)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 127
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa
20 25 30
Xaa Xaa Xaa Cys
35
<210> 128
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 88
<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 128
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Cys Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Cys
35
<210> 129
<211> 32
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 89
<220>
<221> misc_feature
<222> (2)..(9)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (11)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(23)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(27)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (29)..(31)
<223> Xaa can be any naturally occurring amino acid
<400> 129
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Xaa Cys Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys
20 25 30
<210> 130
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 90
<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(30)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (32)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 130
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa
20 25 30
Xaa Xaa Xaa Cys
35
<210> 131
<211> 36
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 91
<220>
<221> misc_feature
<222> (2)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(32)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (34)..(35)
<223> Xaa can be any naturally occurring amino acid
<400> 131
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Cys Xaa Xaa Cys
35
<210> 132
<211> 41
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 92
<220>
<221> misc_feature
<222> (2)..(3)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (5)..(7)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (9)..(12)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(24)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (26)..(40)
<223> Xaa can be any naturally occurring amino acid
<400> 132
Cys Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
35 40
<210> 133
<211> 31
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 93
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(30)
<223> Xaa can be any naturally occurring amino acid
<400> 133
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
20 25 30
<210> 134
<211> 33
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 94
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(18)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (20)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(25)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (27)..(32)
<223> Xaa can be any naturally occurring amino acid
<400> 134
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Cys
<210> 135
<211> 38
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 95
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(37)
<223> Xaa can be any naturally occurring amino acid
<400> 135
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Cys
35
<210> 136
<211> 32
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 96
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(31)
<223> Xaa can be any naturally occurring amino acid
<400> 136
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
20 25 30
<210> 137
<211> 26
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 97
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (25)..(25)
<223> Xaa can be any naturally occurring amino acid
<400> 137
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Cys Cys Xaa Cys
20 25
<210> 138
<211> 33
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 98
<220>
<221> misc_feature
<222> (2)..(6)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (9)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (17)..(20)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (22)..(33)
<223> Xaa can be any naturally occurring amino acid
<400> 138
Cys Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10 15
Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa
<210> 139
<211> 27
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 99
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (17)..(20)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(26)
<223> Xaa can be any naturally occurring amino acid
<400> 139
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys
1 5 10 15
Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Cys
20 25
<210> 140
<211> 28
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 100
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(27)
<223> Xaa can be any naturally occurring amino acid
<400> 140
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys
1 5 10 15
Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys
20 25
<210> 141
<211> 31
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 101
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (17)..(20)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (22)..(28)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (30)..(30)
<223> Xaa can be any naturally occurring amino acid
<400> 141
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys
1 5 10 15
Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys
20 25 30
<210> 142
<211> 27
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 102
<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(19)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (21)..(22)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (24)..(26)
<223> Xaa can be any naturally occurring amino acid
<400> 142
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Cys
20 25
<210> 143
<211> 29
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 103
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (17)..(20)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (23)..(28)
<223> Xaa can be any naturally occurring amino acid
<400> 143
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys
1 5 10 15
Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys
20 25
<210> 144
<211> 24
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 104
<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(14)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (16)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(23)
<223> Xaa can be any naturally occurring amino acid
<400> 144
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Cys Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys
20
<210> 145
<211> 23
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 105
<220>
<221> misc_feature
<222> (2)..(8)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (10)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(15)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (17)..(17)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (19)..(22)
<223> Xaa can be any naturally occurring amino acid
<400> 145
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa Xaa Xaa Cys
1 5 10 15
Xaa Cys Xaa Xaa Xaa Xaa Cys
20
<210> 146
<211> 22
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 106
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (12)..(16)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (18)..(21)
<223> Xaa can be any naturally occurring amino acid
<400> 146
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys Xaa Xaa Xaa Xaa Cys
20
<210> 147
<211> 21
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 107
<220>
<221> misc_feature
<222> (2)..(4)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (6)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(20)
<223> Xaa can be any naturally occurring amino acid
<400> 147
Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Cys
20
<210> 148
<211> 19
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 108
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (13)..(13)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (15)..(18)
<223> Xaa can be any naturally occurring amino acid
<400> 148
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys Xaa Xaa
1 5 10 15
Xaa Xaa Cys
<210> 149
<211> 18
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 109
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<220>
<221> misc_feature
<222> (14)..(17)
<223> Xaa can be any naturally occurring amino acid
<400> 149
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Xaa
1 5 10 15
Xaa Cys
<210> 150
<211> 17
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 110
<220>
<221> misc_feature
<222> (2)..(16)
<223> Xaa can be any naturally occurring amino acid
<400> 150
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Cys
<210> 151
<211> 12
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 111
<220>
<221> misc_feature
<222> (2)..(11)
<223> Xaa can be any naturally occurring amino acid
<400> 151
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10
<210> 152
<211> 11
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: cysteine motif 112
<220>
<221> misc_feature
<222> (2)..(10)
<223> Xaa can be any naturally occurring amino acid
<400> 152
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10
<210> 153
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 1
<400> 153
Thr Thr Val His Gln
1 5
<210> 154
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 2
<400> 154
Thr Ser Val His Gln
1 5
<210> 155
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 3
<400> 155
Ser Ser Val Thr Gln
1 5
<210> 156
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 4
<400> 156
Ser Thr Val His Gln
1 5
<210> 157
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 5
<400> 157
Ala Thr Val Arg Gln
1 5
<210> 158
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 6
<400> 158
Thr Thr Val Tyr Gln
1 5
<210> 159
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 7
<400> 159
Ser Pro Val His Gln
1 5
<210> 160
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 8
<400> 160
Ala Thr Val Tyr Gln
1 5
<210> 161
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 9
<400> 161
Thr Ala Val Tyr Gln
1 5
<210> 162
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 10
<400> 162
Thr Asn Val His Gln
1 5
<210> 163
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 11
<400> 163
Ala Thr Val His Gln
1 5
<210> 164
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 12
<400> 164
Ser Thr Val Tyr Gln
1 5
<210> 165
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 13
<400> 165
Thr Ile Val His Gln
1 5
<210> 166
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 14
<400> 166
Ala Ile Val Tyr Gln
1 5
<210> 167
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 15
<400> 167
Thr Thr Val Phe Gln
1 5
<210> 168
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 16
<400> 168
Ala Ala Val Phe Gln
1 5
<210> 169
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 17
<400> 169
Gly Thr Val His Gln
1 5
<210> 170
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 18
<400> 170
Ala Ser Val His Gln
1 5
<210> 171
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 19
<400> 171
Thr Ala Val Phe Gln
1 5
<210> 172
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 20
<400> 172
Ala Thr Val Phe Gln
1 5
<210> 173
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 21
<400> 173
Ala Ala Ala His Gln
1 5
<210> 174
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 22
<400> 174
Val Val Val Tyr Gln
1 5
<210> 175
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 23
<400> 175
Gly Thr Val Phe Gln
1 5
<210> 176
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 24
<400> 176
Thr Ala Val His Gln
1 5
<210> 177
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 25
<400> 177
Ile Thr Val His Gln
1 5
<210> 178
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 26
<400> 178
Ile Thr Ala His Gln
1 5
<210> 179
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 27
<400> 179
Val Thr Val His Gln
1 5
<210> 180
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 28
<400> 180
Ala Ala Val His Gln
1 5
<210> 181
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 29
<400> 181
Gly Thr Val Tyr Gln
1 5
<210> 182
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 30
<400> 182
Thr Thr Val Leu Gln
1 5
<210> 183
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 31
<400> 183
Thr Thr Thr His Gln
1 5
<210> 184
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: X1X2X3X4X5 motif 32
<400> 184
Thr Thr Asp Tyr Gln
1 5
<210> 185
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 1
<400> 185
Cys Thr Thr Val His Gln
1 5
<210> 186
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 2
<400> 186
Cys Thr Ser Val His Gln
1 5
<210> 187
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 3
<400> 187
Cys Ser Ser Val Thr Gln
1 5
<210> 188
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 4
<400> 188
Cys Ser Thr Val His Gln
1 5
<210> 189
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 5
<400> 189
Cys Ala Thr Val Arg Gln
1 5
<210> 190
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 6
<400> 190
Cys Thr Thr Val Tyr Gln
1 5
<210> 191
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 7
<400> 191
Cys Ser Pro Val His Gln
1 5
<210> 192
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 8
<400> 192
Cys Ala Thr Val Tyr Gln
1 5
<210> 193
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 9
<400> 193
Cys Thr Ala Val Tyr Gln
1 5
<210> 194
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 10
<400> 194
Cys Thr Asn Val His Gln
1 5
<210> 195
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 11
<400> 195
Cys Ala Thr Val His Gln
1 5
<210> 196
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 12
<400> 196
Cys Ser Thr Val Tyr Gln
1 5
<210> 197
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 13
<400> 197
Cys Thr Ile Val His Gln
1 5
<210> 198
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 14
<400> 198
Cys Ala Ile Val Tyr Gln
1 5
<210> 199
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 15
<400> 199
Cys Thr Thr Val Phe Gln
1 5
<210> 200
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 16
<400> 200
Cys Ala Ala Val Phe Gln
1 5
<210> 201
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 17
<400> 201
Cys Gly Thr Val His Gln
1 5
<210> 202
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 18
<400> 202
Cys Ala Ser Val His Gln
1 5
<210> 203
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 19
<400> 203
Cys Thr Ala Val Phe Gln
1 5
<210> 204
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 20
<400> 204
Cys Ala Thr Val Phe Gln
1 5
<210> 205
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 21
<400> 205
Cys Ala Ala Ala His Gln
1 5
<210> 206
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 22
<400> 206
Cys Val Val Val Tyr Gln
1 5
<210> 207
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 23
<400> 207
Cys Gly Thr Val Phe Gln
1 5
<210> 208
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 24
<400> 208
Cys Thr Ala Val His Gln
1 5
<210> 209
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 25
<400> 209
Cys Ile Thr Val His Gln
1 5
<210> 210
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 26
<400> 210
Cys Ile Thr Ala His Gln
1 5
<210> 211
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 27
<400> 211
Cys Val Thr Val His Gln
1 5
<210> 212
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 28
<400> 212
Cys Ala Ala Val His Gln
1 5
<210> 213
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 29
<400> 213
Cys Gly Thr Val Tyr Gln
1 5
<210> 214
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 30
<400> 214
Cys Thr Thr Val Leu Gln
1 5
<210> 215
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 31
<400> 215
Cys Thr Thr Thr His Gln
1 5
<210> 216
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: CX1X2X3X4X5 motif 32
<400> 216
Cys Thr Thr Asp Tyr Gln
1 5
<210> 217
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 1
<400> 217
Cys Tyr Thr Tyr Asn Tyr Glu Phe
1 5
<210> 218
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 2
<400> 218
His Tyr Thr Tyr Thr Tyr Asp Phe
1 5
<210> 219
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 3
<400> 219
His Tyr Thr Tyr Thr Tyr Glu Trp
1 5
<210> 220
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 4
<400> 220
Lys His Arg Tyr Thr Tyr Glu Trp
1 5
<210> 221
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 5
<400> 221
Asn Tyr Ile Tyr Lys Tyr Ser Phe
1 5
<210> 222
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 6
<400> 222
Pro Tyr Ile Tyr Thr Tyr Gln Phe
1 5
<210> 223
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 7
<400> 223
Ser Phe Thr Tyr Thr Tyr Glu Trp
1 5
<210> 224
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 8
<400> 224
Ser Tyr Ile Tyr Ile Tyr Gln Trp
1 5
<210> 225
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 9
<400> 225
Ser Tyr Asn Tyr Thr Tyr Ser Trp
1 5
<210> 226
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 10
<400> 226
Ser Tyr Ser Tyr Ser Tyr Glu Tyr
1 5
<210> 227
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 11
<400> 227
Ser Tyr Thr Tyr Asn Tyr Asp Phe
1 5
<210> 228
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 12
<400> 228
Ser Tyr Thr Tyr Asn Tyr Glu Trp
1 5
<210> 229
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 13
<400> 229
Ser Tyr Thr Tyr Asn Tyr Gln Phe
1 5
<210> 230
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 14
<400> 230
Ser Tyr Val Trp Thr His Asn Phe
1 5
<210> 231
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 15
<400> 231
Thr Tyr Lys Tyr Val Tyr Glu Trp
1 5
<210> 232
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 16
<400> 232
Thr Tyr Thr Tyr Thr Tyr Glu Phe
1 5
<210> 233
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 17
<400> 233
Thr Tyr Thr Tyr Thr Tyr Glu Trp
1 5
<210> 234
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 18
<400> 234
Val Phe Thr Tyr Thr Tyr Glu Phe
1 5
<210> 235
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 19
<400> 235
Ala Tyr Thr Tyr Glu Trp
1 5
<210> 236
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 20
<400> 236
Asp Tyr Ile Tyr Thr Tyr
1 5
<210> 237
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 21
<400> 237
Ile His Ser Tyr Glu Phe
1 5
<210> 238
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 22
<400> 238
Ser Phe Thr Tyr Glu Phe
1 5
<210> 239
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 23
<400> 239
Ser His Ser Tyr Glu Phe
1 5
<210> 240
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 24
<400> 240
Thr His Thr Tyr Glu Phe
1 5
<210> 241
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 25
<400> 241
Thr Trp Thr Tyr Glu Phe
1 5
<210> 242
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 26
<400> 242
Thr Tyr Asn Tyr Glu Trp
1 5
<210> 243
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 27
<400> 243
Thr Tyr Ser Tyr Glu Phe
1 5
<210> 244
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 28
<400> 244
Thr Tyr Ser Tyr Glu His
1 5
<210> 245
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 29
<400> 245
Thr Tyr Thr Tyr Asp Phe
1 5
<210> 246
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 30
<400> 246
Thr Tyr Thr Tyr Glu Phe
1 5
<210> 247
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 31
<400> 247
Thr Tyr Thr Tyr Glu Trp
1 5
<210> 248
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 32
<400> 248
Ala Tyr Glu Phe
1
<210> 249
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 33
<400> 249
Ala Tyr Ser Phe
1
<210> 250
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 34
<400> 250
Ala Tyr Ser Tyr
1
<210> 251
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 35
<400> 251
Cys Tyr Ser Phe
1
<210> 252
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 36
<400> 252
Asp Tyr Thr Tyr
1
<210> 253
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 37
<400> 253
Lys Tyr Glu His
1
<210> 254
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 38
<400> 254
Lys Tyr Glu Trp
1
<210> 255
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 39
<400> 255
Met Tyr Glu Phe
1
<210> 256
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 40
<400> 256
Asn Trp Ile Tyr
1
<210> 257
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 41
<400> 257
Asn Tyr Asp Tyr
1
<210> 258
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 42
<400> 258
Asn Tyr Gln Trp
1
<210> 259
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 43
<400> 259
Asn Tyr Ser Phe
1
<210> 260
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 44
<400> 260
Pro Tyr Glu Trp
1
<210> 261
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 45
<400> 261
Arg Tyr Asn Trp
1
<210> 262
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 46
<400> 262
Arg Tyr Thr Tyr
1
<210> 263
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 47
<400> 263
Ser Tyr Glu Phe
1
<210> 264
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 48
<400> 264
Ser Tyr Glu His
1
<210> 265
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 49
<400> 265
Ser Tyr Glu Trp
1
<210> 266
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 50
<400> 266
Ser Tyr Lys Trp
1
<210> 267
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 51
<400> 267
Ser Tyr Thr Tyr
1
<210> 268
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 52
<400> 268
Thr Tyr Asp Phe
1
<210> 269
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 53
<400> 269
Thr Tyr Glu Phe
1
<210> 270
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 54
<400> 270
Thr Tyr Glu Trp
1
<210> 271
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 55
<400> 271
Thr Tyr Gln Trp
1
<210> 272
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 56
<400> 272
Thr Tyr Thr Tyr
1
<210> 273
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: XAXBZ motif 57
<400> 273
Val Tyr Glu Trp
1
<210> 274
<211> 48
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: DH2 Germline sequence
<400> 274
Ser Cys Pro Asp Gly Tyr Ser Tyr Gly Tyr Gly Cys Gly Tyr Gly Tyr
1 5 10 15
Gly Cys Ser Gly Tyr Asp Cys Tyr Gly Tyr Gly Gly Tyr Gly Gly Tyr
20 25 30
Gly Gly Tyr Gly Tyr Ser Ser Tyr Ser Tyr Ser Tyr Thr Tyr Glu Tyr
35 40 45
<210> 275
<211> 15
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: JH1 Germline sequence
<400> 275
Tyr Val Asp Ala Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
1 5 10 15
<210> 276
<211> 65
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: BLV1H12
<400> 276
Cys Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Cys Pro Asp
1 5 10 15
Gly Tyr Arg Glu Arg Ser Asp Cys Ser Asn Arg Pro Ala Cys Gly Thr
20 25 30
Ser Asp Cys Cys Arg Val Ser Val Phe Gly Asn Cys Leu Thr Thr Leu
35 40 45
Pro Val Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val
50 55 60
Trp
65
<210> 277
<211> 60
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: BLV5B8
<400> 277
Cys Thr Thr Val His Gln Glu Thr Arg Lys Thr Cys Ser Asp Gly Tyr
1 5 10 15
Ile Ala Val Asp Ser Cys Gly Arg Gly Gln Ser Asp Gly Cys Val Asn
20 25 30
Asp Cys Asn Ser Cys Tyr Tyr Gly Trp Arg Asn Cys Arg Arg Gln Pro
35 40 45
Ala Ile His Ser Tyr Glu Phe His Val Asp Ala Trp
50 55 60
<210> 278
<211> 61
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: BLV5D3
<400> 278
Cys Ser Ser Val Thr Gln Arg Thr His Val Ser Arg Ser Cys Pro Asp
1 5 10 15
Gly Cys Ser Asp Gly Asp Gly Cys Val Asp Gly Cys Cys Cys Ser Ala
20 25 30
Tyr Arg Cys Tyr Thr Pro Gly Val Arg Asp Leu Ser Cys Thr Ser Tyr
35 40 45
Ser Ile Thr Tyr Thr Tyr Glu Trp Asn Val Asp Ala Trp
50 55 60
<210> 279
<211> 62
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: BLV8C11
<400> 279
Cys Thr Thr Val His Gln Lys Thr Thr Arg Lys Thr Cys Cys Ser Asp
1 5 10 15
Ala Tyr Arg Tyr Asp Ser Gly Cys Gly Ser Gly Cys Asp Cys Cys Gly
20 25 30
Ala Asp Cys Tyr Val Phe Gly Ala Cys Thr Phe Gly Leu Asp Ser Ser
35 40 45
Tyr Ser Tyr Ile Tyr Ile Tyr Gln Trp Tyr Val Asp Ala Trp
50 55 60
<210> 280
<211> 60
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: BF4E9
<400> 280
Cys Thr Thr Val His Gln Ile Phe Cys Pro Asp Gly Tyr Ser Tyr Gly
1 5 10 15
Tyr Gly Cys Gly Tyr Gly Tyr Gly Cys Ser Gly Tyr Asp Cys Tyr Gly
20 25 30
Tyr Gly Gly Tyr Gly Tyr Gly Gly Tyr Gly Gly Tyr Ser Ser Tyr Ser
35 40 45
Tyr Ser Tyr Ser Tyr Glu Tyr Tyr Gly Asp Ala Trp
50 55 60
<210> 281
<211> 70
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: B-L1
<400> 281
Cys Ser Thr Val His Gln Lys Thr Arg Thr Thr Gln Gly Asn Thr Cys
1 5 10 15
Pro Asp Gly Tyr Thr Leu Lys Asp Asp Cys Pro Arg Cys Arg Gly Gly
20 25 30
Cys Asp Gly Tyr Asp Cys Cys Trp Gly Asp Ala Cys Arg Ser Ser Gly
35 40 45
Leu Cys Trp Gly His Asn Pro Leu Val Thr Glu Thr Tyr Thr Tyr Glu
50 55 60
Phe Tyr Ile Asp Ala Trp
65 70
<210> 282
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: B-L2
<400> 282
Cys Ala Thr Val Arg Gln Thr Thr Leu Arg Asp Cys Pro Gly Gly Tyr
1 5 10 15
Thr Glu Asp Arg Ser Cys Val Asn Thr Tyr Ser Cys Gly Ala Asp Asp
20 25 30
Cys Cys Gly Arg Gly Asp Val Gly Tyr Pro Ala Leu Tyr Gly Tyr Arg
35 40 45
Cys Ala Ala His Ile Gln Arg Tyr Asn Trp His Ala Asp Ala Trp
50 55 60
<210> 283
<211> 71
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL1
<400> 283
Cys Ser Thr Val His Gln Lys Thr Arg Thr Thr Gln Gly Glu Tyr Leu
1 5 10 15
Ser Leu Met Val Thr Leu Leu Lys Asp Asp Cys Pro Arg Cys Arg Gly
20 25 30
Gly Cys Asp Gly Tyr Asp Cys Cys Trp Gly Asp Ala Cys Arg Ser Ser
35 40 45
Gly Leu Cys Trp Gly His Asn Pro Leu Val Thr Glu Thr Tyr Thr Tyr
50 55 60
Glu Phe Tyr Ile Asp Ala Trp
65 70
<210> 284
<211> 71
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL2
<400> 284
Cys Ser Thr Val His Gln Lys Thr Arg Thr Thr Gln Gly Asn Asn Leu
1 5 10 15
Ser Leu Met Val Thr Leu Leu Lys Asp Asp Cys Pro Arg Cys Arg Gly
20 25 30
Gly Cys Asp Gly Tyr Asp Cys Cys Trp Gly Asp Ala Cys Arg Ser Ser
35 40 45
Gly Leu Cys Trp Gly His Asn Pro Leu Val Thr Glu Thr Tyr Thr Tyr
50 55 60
Glu Phe Tyr Ile Asp Ala Trp
65 70
<210> 285
<211> 70
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL3
<400> 285
Cys Ser Thr Val His Gln Lys Thr Arg Thr Thr Gln Gly Asn Thr Cys
1 5 10 15
Pro Asp Gly Tyr Thr Leu Lys Asp Asp Cys Pro Arg Cys Arg Gly Gly
20 25 30
Cys Asp Gly Tyr Asp Cys Cys Trp Gly Asp Ala Cys Arg Ser Ser Gly
35 40 45
Leu Cys Trp Gly His Asn Pro Leu Val Thr Glu Thr Tyr Thr Tyr Glu
50 55 60
Phe Tyr Ile Asp Ala Trp
65 70
<210> 286
<211> 70
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL4
<400> 286
Cys Ser Thr Val His Gln Lys Thr Arg Thr Thr Gln Gly Asn Thr Cys
1 5 10 15
Pro Asp Gly Tyr Thr Phe Lys Asp Asp Cys Pro Arg Cys Arg Gly Gly
20 25 30
Cys Asp Gly Tyr Asp Cys Cys Trp Gly Asp Ala Cys Arg Ser Ser Gly
35 40 45
Leu Cys Trp Gly His Asn Pro Leu Val Thr Glu Thr Tyr Thr Tyr Glu
50 55 60
Phe Tyr Ile Asp Ala Trp
65 70
<210> 287
<211> 70
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL5
<400> 287
Cys Thr Thr Val His Gln Lys Thr Arg Thr Thr Gln Gly Asn Thr Cys
1 5 10 15
Pro Asp Gly Tyr Thr Leu Lys Asp Asp Cys Pro Arg Cys Arg Gly Gly
20 25 30
Cys Asp Gly Tyr Asp Cys Cys Trp Gly Asp Ala Cys Arg Ser Ser Gly
35 40 45
Leu Cys Trp Gly His Asn Pro Leu Val Thr Glu Thr Tyr Thr Tyr Glu
50 55 60
Phe Tyr Ile Asp Ala Trp
65 70
<210> 288
<211> 70
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL6
<400> 288
Cys Ser Thr Val His Gln Lys Thr Arg Thr Thr Gln Gly Asn Thr Cys
1 5 10 15
Pro Asp Gly Tyr Thr Leu Lys Asn Asp Cys Pro Arg Cys Arg Gly Gly
20 25 30
Cys Asp Gly Tyr Asp Cys Cys Trp Gly Asp Ala Cys Arg Ser Ser Gly
35 40 45
Leu Cys Trp Gly His Asn Pro Leu Val Thr Glu Thr Tyr Thr Tyr Glu
50 55 60
Phe Tyr Ile Asp Ala Trp
65 70
<210> 289
<211> 70
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL7
<400> 289
Cys Thr Thr Val Tyr Gln Lys Thr Arg Thr Thr Gln Gly Asn Thr Cys
1 5 10 15
Pro Asp Gly Tyr Thr Leu Lys Asp Asp Cys Pro Arg Cys Arg Gly Gly
20 25 30
Cys Asp Gly Tyr Asp Cys Cys Trp Gly Asp Ala Cys Arg Ser Ser Gly
35 40 45
Leu Cys Trp Gly His Asn Pro Leu Val Thr Glu Thr Tyr Thr Tyr Glu
50 55 60
Phe Tyr Ile Asp Ala Trp
65 70
<210> 290
<211> 70
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL8
<400> 290
Cys Ser Thr Val His Gln Lys Pro Gly Gln His Lys Gly Ile Leu Val
1 5 10 15
Leu Met Val Thr Leu Leu Lys Asp Asp Cys Pro Arg Cys Arg Gly Gly
20 25 30
Cys Asp Gly Tyr Asp Cys Cys Trp Gly Asp Ala Cys Arg Ser Ser Gly
35 40 45
Leu Cys Trp Gly His Asn Pro Leu Val Thr Glu Thr Tyr Thr Tyr Glu
50 55 60
Phe Tyr Ile Asp Ala Trp
65 70
<210> 291
<211> 70
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL9
<400> 291
Cys Ser Thr Val His Gln Lys Thr Arg Thr Thr Gln Gly Ile Leu Val
1 5 10 15
Leu Met Val Thr Leu Leu Lys Asp Asp Cys Pro Arg Cys Arg Gly Gly
20 25 30
Cys Asp Gly Tyr Asp Cys Cys Trp Gly Asp Ala Cys Arg Ser Ser Gly
35 40 45
Leu Cys Trp Gly His Asn Pro Leu Val Thr Glu Thr Tyr Thr Tyr Glu
50 55 60
Phe Tyr Ile Asp Ala Trp
65 70
<210> 292
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL10
<400> 292
Cys Ser Pro Val His Gln Glu Ile Arg Lys Cys Cys Pro Ala Gly Cys
1 5 10 15
Gln Cys Gly Arg Ser Cys Gly Ala Cys Cys Gly Cys Ala Gly Asp Glu
20 25 30
Phe Cys Gly Ile Asn Val Tyr Gly Tyr Val Thr Cys Gly Gly Tyr Arg
35 40 45
Thr Cys Ser Cys Ile Asp Thr Tyr Asp Phe Tyr Val Asp Ala Trp
50 55 60
<210> 293
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL11
<400> 293
Cys Ser Pro Val His Gln Gln Thr Arg Lys Cys Cys Pro Ala Gly Cys
1 5 10 15
Gln Cys Gly Arg Ser Cys Gly Ala Cys Cys Gly Cys Ala Gly Asp Glu
20 25 30
Phe Cys Gly Ile Asn Val Tyr Gly Tyr Ile Thr Cys Gly Gly Tyr Arg
35 40 45
Thr Cys Ser Cys Ile Asp Thr Tyr Asp Phe Tyr Val Glu Ala Trp
50 55 60
<210> 294
<211> 68
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL12
<400> 294
Cys Ala Thr Val Tyr Gln Lys Thr Asn Gln Ser Lys Asn Cys Pro Glu
1 5 10 15
Gly Ser Ala Trp Cys Arg Ser Cys Asp Gly Gly Ala Gly Cys Ala Asp
20 25 30
Tyr Glu Cys Cys Arg Cys Gly Trp Ser Gly Cys Ser Trp Arg Asn Gly
35 40 45
Ala Cys Glu Cys Ser Ser Leu Ser Ser Ser Tyr Thr Tyr Glu Leu His
50 55 60
Val Asp Ala Trp
65
<210> 295
<211> 65
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL13
<400> 295
Cys Ser Thr Val His Gln Thr Thr His Gln Ile His Thr Cys Pro Asn
1 5 10 15
Gly Trp Thr Gly Gly Cys Val Cys Ser Ser Arg Phe Asn Cys Arg Gly
20 25 30
Asn Asn Cys Cys Cys Arg Thr Ala Tyr Cys Ser Val Asp Arg Tyr Val
35 40 45
Cys Ala Cys Pro Thr Val Thr Tyr Thr Tyr Glu Phe Asn Val Asp Ser
50 55 60
Trp
65
<210> 296
<211> 65
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL14
<400> 296
Cys Thr Ala Val Tyr Gln Lys Thr Thr Ser Ile Arg Ser Cys Pro Gly
1 5 10 15
Gly Thr Thr Leu Arg Asn Gly Cys Arg Ser Ala Cys Gly Cys Asn Asp
20 25 30
Cys Asp Cys Cys Cys Gly Ser Ser Trp Asp Ile Cys Tyr Met Ser Lys
35 40 45
Cys Thr Ser Ala Pro Glu Thr Tyr Thr Tyr Glu Leu His Ile Asp Ala
50 55 60
Trp
65
<210> 297
<211> 65
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL15
<400> 297
Cys Thr Asn Val His Gln Lys Thr Lys Lys Thr Cys Pro Asp Asp Tyr
1 5 10 15
Thr Cys Gly Val Ser Cys Ser Cys Ser Ser Ser Gly Cys Ala Asp Tyr
20 25 30
Gly Cys Cys Ser Tyr Ile Thr Tyr Gly Val Pro Gly Asp Cys Gly Gly
35 40 45
Cys Cys Ser Tyr Lys His Arg Tyr Thr Tyr Glu Trp Asn Val Asp Ala
50 55 60
Trp
65
<210> 298
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL16
<400> 298
Cys Thr Thr Val His Gln Lys Thr Lys Lys Leu Cys Pro Asn Gly Arg
1 5 10 15
Thr Cys Gly Cys Gly Cys Asp Cys Gly Ser Gly Cys Cys Thr Ser Tyr
20 25 30
Cys Asp Ser Phe Gly Cys Trp Gly Gly Arg Asp Thr Phe Gly Ser Ser
35 40 45
Cys Thr Ser Ala Thr Tyr Thr Tyr Glu Trp Gly Val Asp Ala Trp
50 55 60
<210> 299
<211> 64
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL17
<400> 299
Cys Ala Thr Val His Gln His Thr Asn Lys Lys Arg Cys Pro Asp Gly
1 5 10 15
Tyr Glu Phe Ser Ala Gly Cys Cys Cys Gly Glu Gly Cys Ser Gly Ser
20 25 30
Asp Cys Cys Cys Asn Ser Arg Leu Arg Cys Ser Trp Tyr Glu Ile Tyr
35 40 45
Cys Ser Val Ser Pro Ser Asp Thr Tyr Glu Phe His Val Asp Ala Trp
50 55 60
<210> 300
<211> 64
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL18
<400> 300
Cys Thr Thr Val His Gln His Thr Asn Lys Lys Arg Cys Pro Asp Gly
1 5 10 15
Tyr Arg Phe Ser Ala Ala Cys Cys Cys Gly Glu Gly Cys Ser Gly Asn
20 25 30
Glu Cys Cys Cys Asn Thr Arg Leu Arg Cys Ser Trp Tyr Glu Ile Tyr
35 40 45
Cys Ser Val Ser Pro Ser Asp Thr Tyr Glu Phe His Val Asp Ala Trp
50 55 60
<210> 301
<211> 64
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL19
<400> 301
Cys Thr Thr Val His Gln His Thr Asn Gln Asn Arg Cys Pro Thr Gly
1 5 10 15
Tyr Lys His Ser Ala Gly Cys Cys Cys Gly Val Gly Cys Ser Gly Asn
20 25 30
Asp Cys Cys Cys Asn Ser Arg Leu Arg Cys Ser Trp Tyr Glu Thr Tyr
35 40 45
Cys Ser Leu Ser Pro Thr Asp Met Tyr Glu Phe Tyr Val Asp Ala Trp
50 55 60
<210> 302
<211> 64
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL20
<400> 302
Cys Ser Thr Val His Gln His Thr Asn Gln Asn Arg Cys Pro Ala Gly
1 5 10 15
Tyr Lys His Ser Ala Gly Cys Cys Cys Gly Val Gly Cys Ser Gly Asn
20 25 30
Asp Cys Cys Cys Asn Ser Arg Leu Arg Cys Ser Trp Tyr Glu Thr Tyr
35 40 45
Cys Ser Leu Ser Pro Thr Asp Met Tyr Glu Phe Tyr Val Asp Ala Trp
50 55 60
<210> 303
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL21
<400> 303
Cys Thr Thr Val His Gln Lys Thr Asn Glu Arg Cys Cys Arg Val Val
1 5 10 15
Ser Asp Asp Gly Glu Cys Gly Asp Gly Asn Ser Cys His Arg Trp Leu
20 25 30
Cys Ser Asp Tyr Cys Tyr Ser Gly Asp Cys Cys Ala Cys Gly Cys Arg
35 40 45
Ala Tyr His Tyr Thr Tyr Thr Tyr Glu Trp Asn Ile Asp Ala Trp
50 55 60
<210> 304
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL22
<400> 304
Cys Thr Thr Val His Gln Lys Thr Asn Glu Arg Cys Cys Arg Val Val
1 5 10 15
Ser Asp Asp Gly Glu Cys Gly Asp Gly Asn Ser Cys His Arg Trp Leu
20 25 30
Cys Ser Asp Tyr Cys Tyr Ser Gly Asp Cys Cys Ala Cys Gly Cys Arg
35 40 45
Ala Tyr His Tyr Thr Tyr Thr Tyr Asp Phe Arg Ile Asp Val Trp
50 55 60
<210> 305
<211> 64
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL23
<400> 305
Cys Thr Thr Val His Gln Lys Thr Asn Arg Glu Arg Cys Cys Pro Asp
1 5 10 15
Gly Tyr Tyr Tyr Cys Cys Arg Ser Val Ser Asp Cys Cys Cys Ser Thr
20 25 30
Arg Ala Cys Val Gly Asp Ser Cys Gly Trp Thr Asp Phe Gly Ser Thr
35 40 45
His Asn Val Asp Cys Ser Phe Thr Tyr Glu Phe His Val Asp Ala Trp
50 55 60
<210> 306
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL24
<400> 306
Cys Thr Thr Val His Gln Gln Thr Arg Lys Ser Cys Pro Asp Gly Tyr
1 5 10 15
Thr Tyr Cys His Asp Cys Gly Tyr Gly Cys Cys Cys Gly Ala Ser Phe
20 25 30
Cys Arg Asp Tyr Gly Gly Cys Gly Ser Leu Cys Gly Arg Tyr Cys Thr
35 40 45
Ser Phe Asp Tyr Ile Tyr Thr Tyr Glu Asn Tyr Val Glu Thr Trp
50 55 60
<210> 307
<211> 64
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL25
<400> 307
Cys Thr Thr Val His Gln Glu Thr Lys Lys Asn Cys Pro Asp Asn Cys
1 5 10 15
Tyr Tyr Glu Asn Ser Cys Gly Asp Tyr Gly Ser Gly Cys Asn Gly Gly
20 25 30
Asp Cys Cys Arg Cys Gly Thr Trp Leu Thr Cys Ser Val Ser Gly Cys
35 40 45
Thr Cys Ile Arg Ala Thr Asn Thr Tyr Gln Trp Tyr Val Asn Ala Trp
50 55 60
<210> 308
<211> 64
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL26
<400> 308
Cys Thr Thr Val His Gln Ser Thr Asn Lys Lys Ser Cys Pro Asp Arg
1 5 10 15
Val Cys Trp Ala Val Gly Cys Cys Phe Gly Glu Asp Cys Thr Ser Ser
20 25 30
Asp Cys Thr Cys Tyr Ala Ser Pro Gly Asn Pro Tyr Arg His Asp Cys
35 40 45
Gly Asn Cys Asp Cys Arg Ser Ser Tyr Glu His His Val Asp Ala Trp
50 55 60
<210> 309
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL27
<400> 309
Cys Thr Thr Val Arg Gln Glu Thr Leu Ile Arg Cys Arg Asp Gly Pro
1 5 10 15
Ser Cys Ala Ala Cys Cys Arg Ser Gly Arg Arg Cys Ser Gly Tyr Gly
20 25 30
Cys Cys Thr Asp Gly Cys Cys Ser Asp Asn Asp Tyr Ala Asp Cys Ile
35 40 45
Arg Gly Glu Phe Val Asp Val Tyr Glu Trp Asn Val Asp Ala Trp
50 55 60
<210> 310
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL28
<400> 310
Cys Ser Thr Val Tyr Gln Lys Thr Arg Thr Thr Cys Pro Asp Gly Tyr
1 5 10 15
Thr Cys Gly Asp Gly Ala Arg Cys Glu Lys Ala Cys Arg Gly Cys Asp
20 25 30
Cys Cys Arg Thr Thr Val Cys Asp Thr Val Trp Ser Ser Tyr Cys Ser
35 40 45
Cys Tyr Ser Phe Thr Asp Ser Tyr Glu Phe Tyr Val Asp Ala Trp
50 55 60
<210> 311
<211> 66
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL29
<400> 311
Cys Ala Thr Val Tyr Gln Lys Thr Asn Arg Glu Met Ser Cys Pro Asp
1 5 10 15
Gly Cys Arg Ile His Asn Ala Arg Leu Cys Leu Ser Gly Cys Ser Gly
20 25 30
Ser Asp Cys Cys Ser Cys Gly Asp Cys Val Ser Asp Ala Arg Cys Tyr
35 40 45
Asn Cys Arg Ser Ala Val Phe Thr Tyr Thr Tyr Glu Phe His Val Asp
50 55 60
Ala Trp
65
<210> 312
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL30
<400> 312
Cys Thr Ile Val His Gln Glu Thr Lys Arg Ser Cys Pro Asp Gly Tyr
1 5 10 15
Asn Thr Gly Thr Arg Cys Phe Gly Ser Cys Gly Cys Ile Gly Ser Asn
20 25 30
Cys Cys Arg Ser Thr Thr Ser Cys Cys Cys Ala Gly Ile Tyr Ser Gln
35 40 45
Cys Thr Thr Ser Thr Leu Thr Tyr Glu Trp His Ala Asp Val Trp
50 55 60
<210> 313
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL31
<400> 313
Cys Ala Ile Val Tyr Gln Arg Thr Arg Gln Arg Cys Pro Asp Gly Tyr
1 5 10 15
Asn Thr Gly Thr Arg Cys Phe Gly Thr Cys Gly Cys Asn Gly Ser Asn
20 25 30
Cys Cys Arg Phe Thr Thr Ser Cys Cys Cys Ala Gly Val Tyr Ser Gln
35 40 45
Cys Thr Thr Ser Thr Leu Thr Tyr Glu Trp His Ala Asp Val Trp
50 55 60
<210> 314
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL32
<400> 314
Cys Thr Thr Val His Gln Lys Thr Glu Thr Arg Cys Pro Asp Gly Tyr
1 5 10 15
Ser Ser Thr Asn Gly Cys Asp Ala Arg Cys Gly Cys Ser Asp Cys Asp
20 25 30
Cys Cys Asn Val Gly Arg Trp Gly Cys Pro Leu Ile Cys Ser Arg Asn
35 40 45
Cys Arg Ser Phe Thr Tyr Thr Tyr Glu Trp Tyr Ala Asp Ala Trp
50 55 60
<210> 315
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL33
<400> 315
Cys Thr Thr Val His Gln Lys Thr Asn Lys Lys Glu Ser Cys Pro Asp
1 5 10 15
Gly Tyr Thr Met Asn Glu Cys Cys Gly Cys Gly Tyr Gly Cys Cys Arg
20 25 30
Gly Gly Cys Val Cys Ser Ala Tyr Cys Ser Arg Pro Asn Cys Trp Arg
35 40 45
Glu Leu Thr Tyr Thr Tyr Thr Tyr Glu Phe Tyr Val Asp Thr Trp
50 55 60
<210> 316
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL34
<400> 316
Cys Thr Thr Val Tyr Gln Lys Ser Arg Lys Glu Ser Ser Cys Pro Asn
1 5 10 15
Gly Trp Ile Tyr Gly Lys Asp Cys Cys Ser Trp Ser Tyr Cys Thr Asp
20 25 30
Cys Asp Cys Cys Leu Cys Gly Asp Leu His Cys Tyr Asp Gly Cys Ser
35 40 45
Ser Phe Gly Val Thr Trp Thr Tyr Glu Phe His Val Asp Ala Trp
50 55 60
<210> 317
<211> 62
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL35
<400> 317
Cys Thr Thr Val Phe Gln Glu Thr Arg Lys Ser Cys Pro Thr Gly Phe
1 5 10 15
Tyr Val Asp Gly Ser Thr Cys Gly Cys Ala Thr Tyr Cys Arg Thr Cys
20 25 30
Asp Cys Cys Gly Gly Tyr Arg Cys Ser Gly Gly Gly Ser Cys Ala Cys
35 40 45
Ser Ser Tyr Thr Tyr Asn Tyr Asp Phe His Val Asp Ala Trp
50 55 60
<210> 318
<211> 61
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL36
<400> 318
Cys Ala Ala Val Phe Gln Glu Thr Arg Thr Asn Cys Pro Ser Gly Tyr
1 5 10 15
Gly Asn Ala Phe Ser Cys Gly Cys Pro Ile Ala Cys Arg Asp Cys Asp
20 25 30
Cys Cys Gly Gly Tyr Trp Cys Ser Gly Gly Ala Asp Cys His Cys Val
35 40 45
Ser Tyr Asn Tyr Thr Tyr Ser Trp His Val Asp Ala Trp
50 55 60
<210> 319
<211> 62
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL37
<400> 319
Cys Ala Thr Val Tyr Gln Lys Thr Glu Lys His Cys Pro Leu Phe His
1 5 10 15
Ser Ile Cys Cys His Cys Gly Glu Gly Val Gly Cys Ser Gly Gly Asp
20 25 30
Cys Cys Gly Cys Glu Arg Arg Ser Gly Cys Val Val Cys Thr Met Arg
35 40 45
Asn Ser Tyr Thr Tyr Asn Tyr Gln Phe His Val Asp Ala Trp
50 55 60
<210> 320
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL38
<400> 320
Cys Gly Thr Val His Gln Lys Thr Lys Glu Leu Cys Pro Asp Asp Ser
1 5 10 15
Thr Tyr Cys Cys Gly Cys Val Ser Gly Cys Ala Cys Cys Thr Tyr Gly
20 25 30
Cys Asp Gly Val Gly Cys Cys Arg Val Ser Leu Trp Thr Thr Tyr Ile
35 40 45
Lys Asp Ile Val Gly Val Ser Tyr Glu Trp His Val Asp Ala Trp
50 55 60
<210> 321
<211> 61
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL39
<400> 321
Cys Ala Ser Val His Gln His Thr Glu Pro Thr Cys Pro Ala Gly Tyr
1 5 10 15
Thr Tyr Cys Cys Gly Cys Leu Tyr Lys Cys Asn Cys Gly Asp Cys Gly
20 25 30
Cys Tyr Asn Val Gly Cys Gly Ser Gly Trp Leu Gly Lys Ala Cys Gly
35 40 45
Asp Tyr Arg Glu Thr Tyr Glu Trp Tyr Val Asp Ala Trp
50 55 60
<210> 322
<211> 61
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL40
<400> 322
Cys Ala Ser Val His Gln His Thr Glu Pro Thr Cys Pro Ala Gly Tyr
1 5 10 15
Thr Tyr Cys Cys Gly Cys Leu Tyr Lys Cys Asn Cys Gly Asp Cys Gly
20 25 30
Cys Tyr Asn Ala Gly Cys Gly Ser Gly Trp Leu Gly Lys Ala Cys Gly
35 40 45
Asp Tyr Arg Glu Thr Tyr Glu Trp Tyr Val Asp Ala Trp
50 55 60
<210> 323
<211> 61
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL41
<400> 323
Cys Thr Thr Val Phe Gln Glu Thr Arg Lys Ser Cys Pro Ser Gly Phe
1 5 10 15
Arg Asp Arg Asp Ala Cys Gly Cys Ala Val Thr Cys Arg Asn Cys Asp
20 25 30
Cys Cys Gly Gly Gly Pro Cys Asn Gly Gly Gly Ser Cys Arg Cys Asn
35 40 45
Asn Tyr Ile Tyr Lys Tyr Ser Phe His Val Asp Ala Trp
50 55 60
<210> 324
<211> 61
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL42
<400> 324
Cys Thr Ala Val Phe Gln Glu Thr Arg Lys Asp Cys Pro Ser Gly Tyr
1 5 10 15
Gly Ser Ala Phe Thr Cys Gly Cys Leu Ala Ala Cys His Gly Cys Asp
20 25 30
Cys Cys Gly Gly Gly Trp Cys Ser Gly Gly Gly Asp Cys Arg Cys Arg
35 40 45
Ser Tyr Ser Thr Ala Tyr Ser Phe His Ile Asp Ala Trp
50 55 60
<210> 325
<211> 61
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL43
<400> 325
Cys Ala Thr Val Phe Gln Glu Thr Arg Lys Ser Cys Pro Ser Gly Tyr
1 5 10 15
Ala Asp Arg Phe Thr Cys Asp Cys Val Tyr Tyr Cys Gln Thr Cys Asp
20 25 30
Cys Cys Gly Gly Asn Arg Cys Ser Gly Gly Gly Pro Cys Arg Cys Ser
35 40 45
Ser Tyr Ser Ile Asn Tyr Ser Phe His Val Asp Thr Trp
50 55 60
<210> 326
<211> 58
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL44
<400> 326
Cys Ala Ala Ala His Gln Glu Thr Lys Lys Ser Cys Pro Asp Gly Thr
1 5 10 15
Cys Arg Gln Cys Cys Gly Gly Val Cys Arg Cys His Ala Ser Gly Cys
20 25 30
Cys Tyr Trp Cys Thr Thr Gly Cys Val Gly Arg Ala Leu Ser Glu Ser
35 40 45
His Ser Tyr Glu Phe His Val Asp Thr Trp
50 55
<210> 327
<211> 70
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL45
<400> 327
Cys Ser Thr Val His Gln Lys Thr Arg Thr Thr Gln Gly Asn Thr Cys
1 5 10 15
Pro Asp Gly Tyr Thr Leu Lys Asp Asp Cys Pro Arg Cys Arg Gly Gly
20 25 30
Cys Asp Gly Tyr Asp Cys Cys Trp Gly Asp Ala Cys Arg Ser Ser Gly
35 40 45
Leu Cys Trp Gly His Asn Pro Leu Val Thr Glu Thr Tyr Thr Tyr Glu
50 55 60
Phe Tyr Ile Asp Ala Trp
65 70
<210> 328
<211> 68
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL46
<400> 328
Cys Val Val Val Tyr Gln Lys Thr Asn Ser Gln Lys Ser Cys Pro Arg
1 5 10 15
Gly Tyr Thr Glu Arg Glu Thr Cys Asn Arg Arg Tyr Gly Trp Gly Cys
20 25 30
Gly Arg Tyr Asp Cys Cys Asp Cys Asp Arg Trp Val Ser Gly Asn Cys
35 40 45
Ala Asn Ile Cys Thr Asp Tyr Thr Asp Thr His Thr Tyr Glu Phe His
50 55 60
Ala Asp Ala Trp
65
<210> 329
<211> 64
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL47
<400> 329
Cys Gly Thr Val Phe Gln Gln Thr His Lys Val Arg Asp Cys Pro Asp
1 5 10 15
Gly Phe Thr Ala Ala Pro Arg Cys Gly Gly Glu Cys Cys Cys Ser Asn
20 25 30
Val Asn Ser Arg Ser Gly Gly Trp Cys Arg Tyr Cys Gly Arg Asp Cys
35 40 45
Thr Ala Pro Thr Glu Thr Ser Thr Tyr Glu Phe His Val Asp Ala Trp
50 55 60
<210> 330
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL48
<400> 330
Cys Thr Ala Val Tyr Gln Arg Thr Gly Gln Lys Cys Pro Glu Gly Cys
1 5 10 15
Glu Ser Arg Asn Thr Cys Leu Tyr Ser Arg Asn Cys Gly Asp Tyr Thr
20 25 30
Cys Cys Gly Gly Ser Arg Ala Ser Gly Ser Gly Ala Cys Gly Trp Asn
35 40 45
Ser Val Asp Cys Lys Asn Lys Tyr Glu His His Val Asp Ala Trp
50 55 60
<210> 331
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL49
<400> 331
Cys Thr Thr Val Tyr Gln Lys Thr Lys Gln Asn Cys Pro Asp Gly Tyr
1 5 10 15
Asp Phe Arg Asp Thr Cys Gly Ser Gln Ser Tyr Cys Ser Gly Tyr Asp
20 25 30
Cys Cys Arg Cys Ser Arg Phe Gly Gly Cys Ser Ile Gly Thr Cys Ile
35 40 45
Ser Tyr Ser Asp Ala Tyr Thr Tyr Glu Trp Tyr Val Asp Ala Trp
50 55 60
<210> 332
<211> 63
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL50
<400> 332
Cys Thr Thr Val His Gln Gln Thr His Glu Lys Arg Ser Cys Pro Glu
1 5 10 15
Ser Tyr Ser Tyr Ser Cys Ser Cys Ala Ser Gly Val Val Gly Cys Gly
20 25 30
Pro Asp Asp Cys Cys Cys Thr Tyr Arg Ile Ser Ile Arg Gly Tyr Thr
35 40 45
Cys Ser Ser Leu Ser Asn Ser Tyr Glu Trp Tyr Val Asp Ala Trp
50 55 60
<210> 333
<211> 61
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL51
<400> 333
Cys Thr Ala Val His Gln Gln Thr Lys Arg Lys Ser Gly Cys Pro Asp
1 5 10 15
Gly Tyr Ser Asp Glu Ser Cys Ser Tyr Cys Gly Ser Ser Trp Cys Cys
20 25 30
Pro Val Tyr Trp Cys Gly Ser Pro Cys Ser Tyr Arg Cys Leu Arg His
35 40 45
Thr Asp Thr Tyr Ser Tyr Glu His His Val Asp Ala Trp
50 55 60
<210> 334
<211> 60
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL52
<400> 334
Cys Ala Thr Val Tyr Gln Glu Thr Lys Arg Thr Cys Ala Gly Gly His
1 5 10 15
Ser Val Glu Cys Asp Ser Pro Tyr Asp Cys Asn Cys Arg Gly Gly Asp
20 25 30
Cys Cys Arg Ser Pro Ile Phe Asn Asp Cys Trp Ala Ala Ser Cys Ser
35 40 45
Ala Thr Lys Thr Tyr Glu Trp His Val Glu Ser Trp
50 55 60
<210> 335
<211> 58
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL53
<400> 335
Cys Ile Thr Val His Gln Glu Thr Gln Lys Ser Cys Pro Asp Asp Tyr
1 5 10 15
Thr Tyr Tyr Gly Asp Gly Thr Cys Ala Tyr Val Cys Ser Ile Asp Lys
20 25 30
Cys Cys Cys Gly Arg Thr Trp Leu Ser Ser Gly Cys Leu Pro Cys Arg
35 40 45
Tyr Thr Tyr Asn Leu His Val Asp Ala Trp
50 55
<210> 336
<211> 58
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL54
<400> 336
Cys Ile Thr Val His Gln Glu Thr Gln Lys Ser Cys Pro Asp Asp Tyr
1 5 10 15
Thr Ser Tyr Gly Asp Ala Thr Cys Ala Tyr Val Cys Ser Thr Asp Glu
20 25 30
Cys Cys Cys Gly Arg Thr Trp Leu Ser Ala Gly Cys Arg Pro Cys Arg
35 40 45
Tyr Thr Tyr Asn Leu His Val Asp Ala Trp
50 55
<210> 337
<211> 58
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL55
<400> 337
Cys Ile Thr Val His Gln Glu Thr Gln Lys Ser Cys Phe Asp Asp Tyr
1 5 10 15
Thr Tyr Tyr Gly Asp Ala Ser Cys Ala Tyr Val Cys Ser Thr Asp Glu
20 25 30
Cys Cys Cys Gly Arg Thr Trp Leu Ser Ala Gly Cys Arg Pro Cys Arg
35 40 45
Tyr Thr Tyr Asn Leu His Val Asp Ala Trp
50 55
<210> 338
<211> 58
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL56
<400> 338
Cys Ile Thr Ala His Gln Glu Thr Gln Lys Ser Cys Ser Asp Asp Tyr
1 5 10 15
Thr Tyr Tyr Gly Asp Ala Thr Cys Ala Tyr Val Cys Ser Thr Asp Glu
20 25 30
Cys Cys Cys Gly Arg Thr Trp Leu Ser Ala Gly Cys Arg Pro Cys Arg
35 40 45
Tyr Thr Tyr Asn Leu His Val Asp Ala Trp
50 55
<210> 339
<211> 58
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL57
<400> 339
Cys Ile Thr Val His Gln Glu Thr Gln Lys Ser Cys Pro Asp Asp Tyr
1 5 10 15
Thr Tyr Tyr Gly Asp Gly Thr Cys Ala Tyr Val Cys Ser Ile Asp Asn
20 25 30
Cys Cys Cys Gly Arg Thr Trp Leu Ser Ser Gly Cys Leu Pro Cys Arg
35 40 45
Tyr Thr Tyr Asn Leu His Val Asp Ala Trp
50 55
<210> 340
<211> 61
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL58
<400> 340
Cys Val Thr Val His Gln Gln Thr His Ala Thr Arg Arg Cys Pro Asp
1 5 10 15
Gly Tyr Gly Asp Ser Tyr Ala Cys Lys Ser Asn Tyr Gly Cys Ser Ala
20 25 30
Glu Gly Cys Cys Arg Trp Gly Pro Gly Ser Gly Ala Cys Thr Gly Ala
35 40 45
Ile Tyr Thr Ser Pro Tyr Glu Trp Tyr Val Asp Ala Trp
50 55 60
<210> 341
<211> 60
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL59
<400> 341
Cys Ala Ala Val His Gln Arg Thr Glu Gly Gln Gln Ser Cys Pro Asp
1 5 10 15
Gly Tyr Leu Glu Thr Arg Val Cys Pro Tyr Arg Met Tyr Arg Cys Ile
20 25 30
Gly Trp Asp Cys Cys Arg Cys Ser Asp Gly Ser Arg Asp Asn Tyr Ile
35 40 45
Met Thr Tyr Ser Tyr Glu Phe His Val Asp Val Trp
50 55 60
<210> 342
<211> 59
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL60
<400> 342
Cys Thr Thr Val Tyr Gln Glu Thr Lys Thr Lys Ser Gly Cys Pro Asp
1 5 10 15
Gly Tyr Ser Cys Cys Tyr Asn Gly Arg Ser Arg Ser Cys Arg Pro Asn
20 25 30
Asp Cys Ser Thr Tyr Gly Glu Val Arg Ser Leu Ser Arg Ser Cys Tyr
35 40 45
Thr Tyr Asn Tyr Glu Phe Tyr Val Asp Ala Trp
50 55
<210> 343
<211> 58
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL61
<400> 343
Cys Gly Thr Val Tyr Gln His Thr Lys Glu Ile Lys Thr Cys Pro Asp
1 5 10 15
Gly Tyr Ser Asp Val Phe Thr Tyr Cys Pro Val Thr Cys Pro Gly Trp
20 25 30
Asp Cys Cys Arg Arg Asn Asp Cys Gly Arg Thr Arg Tyr Thr Val Ala
35 40 45
Tyr Ser Tyr Ala Leu His Val Asp Val Trp
50 55
<210> 344
<211> 57
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL62
<400> 344
Cys Thr Thr Val Leu Gln Glu Thr His Gln Gln Arg Gly Cys Pro Ala
1 5 10 15
Gly Tyr Gln Val Val Asp Gly Cys Pro Tyr Gly Asp Cys Cys Arg Thr
20 25 30
Ser Tyr Val Cys Gly Pro Leu Thr Cys Thr Ser Asn Thr Ala Thr Arg
35 40 45
Asn Tyr Gln Trp Tyr Val Asp Ala Trp
50 55
<210> 345
<211> 56
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL63
<400> 345
Cys Ser Thr Val Tyr Gln Lys Thr Glu Lys Lys Cys Pro Asp Gly Tyr
1 5 10 15
Thr Asp Arg Arg Asp Glu Cys Pro Asn Thr Cys Lys Asn Phe Asp Cys
20 25 30
Glu Asn Glu Gly Gly Leu Arg Cys Leu Cys Ser Ala Tyr Ile Ser Ala
35 40 45
Tyr Glu Phe His Val Asp Ala Trp
50 55
<210> 346
<211> 55
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL64
<400> 346
Cys Thr Thr Thr His Gln Arg Thr Gln Lys Ser Cys Pro Asp Tyr Ala
1 5 10 15
Ser Tyr Asp Cys Gly Ser Pro Asp Asp Glu Glu Cys Ser Ser Cys Arg
20 25 30
Ser Cys Thr Arg Trp Cys Ala Pro Thr Ala Pro Tyr Ile Tyr Thr Tyr
35 40 45
Gln Phe Tyr Ile Asp Ala Trp
50 55
<210> 347
<211> 54
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL65
<400> 347
Cys Thr Thr Val His Gln Gln Thr Asn Lys Arg Cys Pro Thr Gly Tyr
1 5 10 15
Asn Ser Gly Thr Leu Cys Asn Met Ile Gly Cys Ser Gly Asp Glu Cys
20 25 30
Cys Asn Tyr Gly Arg Val Glu Cys Thr Ser Tyr Val Trp Thr His Asn
35 40 45
Phe Tyr Val Asp Ala Trp
50
<210> 348
<211> 53
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL66
<400> 348
Cys Thr Thr Val His Gln Glu Thr Gln Arg Thr Ser Cys Pro Ser Gly
1 5 10 15
Trp Thr Tyr Thr Cys Asn Cys Arg Asn Gly Cys Gly Cys Tyr Arg Pro
20 25 30
Ser Gln Leu Cys Gly Ala Tyr Val Ala Val Thr His Thr Tyr Glu Phe
35 40 45
His Val Asp Ala Trp
50
<210> 349
<211> 53
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL67
<400> 349
Cys Ala Thr Val His Gln Lys Asp Lys His Cys Pro Ala Gly Tyr Arg
1 5 10 15
Ser Gly Thr Leu Cys Arg Met Ile Gly Cys Thr Gly Asp Asp Cys Cys
20 25 30
Asn Tyr Asp Arg Val Glu Cys Thr Asn Tyr Asp Tyr Thr Asn Asn Phe
35 40 45
Tyr Val Asp Ala Trp
50
<210> 350
<211> 52
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL68
<400> 350
Cys Thr Ala Val His Gln Gln Thr Thr Glu Lys Gly Lys Thr Cys Pro
1 5 10 15
Pro Arg Ser Arg Asp Met Gly Thr Arg Cys Arg Asp Asp Arg Tyr Tyr
20 25 30
Pro Trp Arg Tyr Ser Asp Tyr Thr Tyr Thr Tyr Thr Tyr Glu Trp His
35 40 45
Val Asp Ala Trp
50
<210> 351
<211> 51
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL69
<400> 351
Cys Thr Ser Val His Gln Lys Thr Asp Val Thr Cys Pro Ser Gly Ala
1 5 10 15
Thr Tyr Arg Cys Asp Cys Gly Gly Arg Gly Cys Gly Cys Tyr Asp Pro
20 25 30
Trp Cys Ser Thr Thr Tyr Arg Gly Thr Tyr Thr Tyr Asp Phe His Val
35 40 45
Glu Thr Trp
50
<210> 352
<211> 50
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL70
<400> 352
Cys Gly Thr Val His Gln Glu Thr His Thr Gln Arg Thr Cys Pro Asp
1 5 10 15
Ala Cys Asp Val Thr Gly Asp Asn Cys Lys Val Arg Arg Asn Gly Asp
20 25 30
Trp Cys Gly Arg Ala Ser Lys Thr Asp Thr Tyr Asp Phe Tyr Val Asp
35 40 45
Ala Trp
50
<210> 353
<211> 49
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL71
<400> 353
Cys Thr Thr Asp Tyr Gln Lys Thr Glu Lys Ser Cys Pro Glu Asn Tyr
1 5 10 15
Tyr Ala Glu Thr Gly Tyr Cys Met Cys Gly Ser Trp Arg Cys Gly Tyr
20 25 30
Gly Ser Thr Thr Ser Leu Ile Val Ser Tyr Lys Trp Tyr Val Asp Ala
35 40 45
Trp
<210> 354
<211> 49
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL72
<400> 354
Cys Thr Thr Val His Gln Lys Thr Asn Gln Lys Trp Gly Cys Pro Asp
1 5 10 15
Gly Tyr Val His Met Ser Gly Ser Cys Cys Arg Gly Ser Ile Cys Thr
20 25 30
Asn Gly Leu Phe Arg Asn Thr Tyr Thr Tyr Glu Phe Asn Val Glu Ala
35 40 45
Trp
<210> 355
<211> 48
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL73
<400> 355
Cys Thr Thr Val Tyr Gln Glu Thr Arg Thr Asn Cys Pro Asp Gly Tyr
1 5 10 15
Asn Tyr Arg Ser Gly Asp Cys Arg Arg Trp Asn His Trp Leu Gly Glu
20 25 30
Gln Arg Val Ser Pro Thr Tyr Asn Tyr Glu Trp Tyr Val Asp Ser Trp
35 40 45
<210> 356
<211> 47
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL74
<400> 356
Cys Thr Thr Val Tyr Gln Lys Thr Thr Thr Thr Lys Ser Cys Pro Gly
1 5 10 15
Gly Phe Asp Asn Gly Arg Arg Cys Ile Met Gly Leu Gly Asp Leu Arg
20 25 30
Asp Tyr Thr Tyr Phe Asn Lys Tyr Glu Trp Tyr Val Glu Thr Trp
35 40 45
<210> 357
<211> 46
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL75
<400> 357
Cys Ser Thr Val His Gln Lys Thr Glu Gln Arg Cys Leu Asp Gly Tyr
1 5 10 15
Asp Asp Arg Gly Ala Tyr Cys Tyr Asp Ser Val Arg Gly Leu Met Ser
20 25 30
Trp Thr Tyr Lys Tyr Val Tyr Glu Trp Arg Val Asp Thr Trp
35 40 45
<210> 358
<211> 45
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL76
<400> 358
Cys Thr Asn Val His Gln Met Thr Ile Lys Thr Cys Pro Asp Gly Gly
1 5 10 15
Ser Tyr Gly Trp Tyr Trp Pro Tyr Gly Tyr Gly Cys Asn Gly Gly Val
20 25 30
Ser Ala Thr Tyr Thr Tyr Glu Phe Tyr Val Asp Ala Trp
35 40 45
<210> 359
<211> 44
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: UL77
<400> 359
Cys Thr Thr Val Tyr Gln Lys Thr Glu Ser Val Arg Ser Cys Pro Asp
1 5 10 15
Gly Ser Met Asp Gly Trp Arg Cys Arg Leu Gly Thr Met Asn Trp Ile
20 25 30
Tyr Ser Asn Thr Tyr Glu Phe Tyr Val Asp Ala Trp
35 40
<210> 360
<211> 75
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: BLV1H12
<400> 360
Cys Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Cys Pro Asp
1 5 10 15
Gly Tyr Arg Glu Arg Ser Asp Cys Ser Asn Arg Pro Ala Cys Gly Thr
20 25 30
Ser Asp Cys Cys Arg Val Ser Val Phe Gly Asn Cys Leu Thr Thr Leu
35 40 45
Pro Val Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val
50 55 60
Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
65 70 75
<210> 361
<211> 70
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: BLV5B8
<400> 361
Cys Thr Thr Val His Gln Glu Thr Arg Lys Thr Cys Ser Asp Gly Tyr
1 5 10 15
Ile Ala Val Asp Ser Cys Gly Arg Gly Gln Ser Asp Gly Cys Val Asn
20 25 30
Asp Cys Asn Ser Cys Tyr Tyr Gly Trp Arg Asn Cys Arg Arg Gln Pro
35 40 45
Ala Ile His Ser Tyr Glu Phe His Val Asp Ala Trp Gly Arg Gly Leu
50 55 60
Leu Val Thr Val Ser Ser
65 70
<210> 362
<211> 71
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: BLV5D3
<400> 362
Cys Ser Ser Val Thr Gln Arg Thr His Val Ser Arg Ser Cys Pro Asp
1 5 10 15
Gly Cys Ser Asp Gly Asp Gly Cys Val Asp Gly Cys Cys Cys Ser Ala
20 25 30
Tyr Arg Cys Tyr Thr Pro Gly Val Arg Asp Leu Ser Cys Thr Ser Tyr
35 40 45
Ser Ile Thr Tyr Thr Tyr Glu Trp Asn Val Asp Ala Trp Gly Arg Gly
50 55 60
Leu Leu Val Thr Val Ser Ser
65 70
<210> 363
<211> 72
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: BLV8C11
<400> 363
Cys Thr Thr Val His Gln Lys Thr Thr Arg Lys Thr Cys Cys Ser Asp
1 5 10 15
Ala Tyr Arg Tyr Asp Ser Gly Cys Gly Ser Gly Cys Asp Cys Cys Gly
20 25 30
Ala Asp Cys Tyr Val Phe Gly Ala Cys Thr Phe Gly Leu Asp Ser Ser
35 40 45
Tyr Ser Tyr Ile Tyr Ile Tyr Gln Trp Tyr Val Asp Ala Trp Gly Gln
50 55 60
Gly Leu Leu Val Thr Val Ser Ser
65 70
<210> 364
<211> 70
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: BF4E9
<400> 364
Cys Thr Thr Val His Gln Ile Phe Cys Pro Asp Gly Tyr Ser Tyr Gly
1 5 10 15
Tyr Gly Cys Gly Tyr Gly Tyr Gly Cys Ser Gly Tyr Asp Cys Tyr Gly
20 25 30
Tyr Gly Gly Tyr Gly Tyr Gly Gly Tyr Gly Gly Tyr Ser Ser Tyr Ser
35 40 45
Tyr Ser Tyr Ser Tyr Glu Tyr Tyr Gly Asp Ala Trp Gly Gln Gly Leu
50 55 60
Leu Val Thr Val Ser Ser
65 70
<210> 365
<211> 50
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: BF1H1
<400> 365
Cys Thr Thr Val His Pro Ser Pro Asp Gly Tyr Ser Tyr Gly Tyr Gly
1 5 10 15
Cys Gly Tyr Gly Tyr Gly Cys Ser Gly Tyr Asp Cys Tyr Gly Tyr Gly
20 25 30
Gly Tyr Gly Tyr Gly Gly Tyr Gly Gly Tyr Ser Ser Tyr Ser Tyr Ser
35 40 45
Tyr Ser
50
<210> 366
<211> 50
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: F18
<400> 366
Cys Thr Thr Val His Gln Ile Arg Cys Pro Asp Gly Tyr Gly Tyr Gly
1 5 10 15
Tyr Gly Cys Gly Tyr Gly Ser Tyr Gly Tyr Ser Gly Tyr Asp Cys Tyr
20 25 30
Gly Tyr Gly Gly Tyr Gly Gly Tyr Gly Gly Tyr Gly Gly Tyr Ser Ser
35 40 45
Tyr Ser
50
<210> 367
<211> 300
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: Bovine VH-UL
<400> 367
caggtgcagc tgcgggagtc gggccccagc ctggtgaagc cctcacagac cctctcgctc 60
acctgcacgg cctctggatt ctcattgagc gacaaggctg taggctgggt ccgccaggct 120
ccagggaagg cgctggagtg gctcggtggt atagacactg gtggaagcac aggctataac 180
ccaggcctga aatcccggct cagcatcacc aaggacaact ccaagagcca agtctctctg 240
tcagtgagca gcgtgacaac tgaggactcg gccacatact actgtactac tgtgcaccag 300
<210> 368
<211> 311
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: 4-39
<400> 368
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagc agtagtagtt actactgggg ctggatccgc 120
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gagcacctac 180
tacaacccgt ccctcaagag tcgagtcacc atatccgtag acacgtccaa gaaccagttc 240
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattactg tgcgagacac 300
acagtgaggg g 311
<210> 369
<211> 288
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: 4-59*03
<400> 369
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagt agttactact ggagctggat ccggcagccc 120
ccagggaagg gactggagtg gattgggtat atctattaca gtgggagcac caactacaac 180
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca attctccctg 240
aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcg 288
<210> 370
<211> 291
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: 4-34*09
<400> 370
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt ggttactact ggagctggat ccgccagccc 120
ccagggaagg gactggagtg gattggggaa atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt taccatatca gtagacacgt ctaagaacca gttctccctg 240
aagctgagct ctgtgactgc cgcggacacg gccgtgtatt actgtgcgag a 291
<210> 371
<211> 293
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: 4-34*02
<400> 371
caggtgcagc tacaacagtg gggcgcagga ctgttgaagc cttcggagac cctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt ggttactact ggagctggat ccgccagccc 120
ccagggaagg ggctggagtg gattggggaa atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtgcgag agg 293
<210> 372
<211> 330
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: BLV1H12 VL
<400> 372
caggctgtgc tgaatcagcc atcatccgtg tccgggtccc tgggccagag ggtctccatc 60
acctgctctg gaagcagcag caatgttgga aatggatatg tgagctggta ccaactgatc 120
ccaggatcgg cccccagaac cctcatctat ggtgacacca gtcgagcctc gggggtcccc 180
gaccgattct ccggctccag gtctgggaac acagccaccc tgaccatcag ctcgctccag 240
gctgaggacg aggcagatta tttctgtgca tctgctgagg atagtagcag taatgctgtt 300
ttcggcagcg ggaccacact gaccgtcctg 330
<210> 373
<211> 296
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: Vl1-47
<400> 373
cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc 60
tcttgttctg gaagcagctc caacatcgga agtaattatg tatactggta ccagcagctc 120
ccaggaacgg cccccaaact cctcatctat aggaataatc agcggccctc aggggtccct 180
gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccgg 240
tccgaggatg aggctgatta ttactgtgca gcatgggatg acagcctgag tggtcc 296
<210> 374
<211> 299
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: Vl1-40*1
<400> 374
cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc 60
tcctgcactg ggagcagctc caacatcggg gcaggttatg atgtacactg gtaccagcag 120
cttccaggaa cagcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc 180
cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc 240
caggctgagg atgaggctga ttattactgc cagtcctatg acagcagcct gagtggttc 299
<210> 375
<211> 296
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: Vl1-51 *01
<400> 375
cagtctgtgt tgacgcagcc gccctcagtg tctgcggccc caggacagaa ggtcaccatc 60
tcctgctctg gaagcagctc caacattggg aataattatg tatcctggta ccagcagctc 120
ccaggaacag cccccaaact cctcatttat gacaataata agcgaccctc agggattcct 180
gaccgattct ctggctccaa gtctggcacg tcagccaccc tgggcatcac cggactccag 240
actggggacg aggccgatta ttactgcgga acatgggata gcagcctgag tgctgg 296
<210> 376
<211> 297
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: Vl2-18*02
<400> 376
cagtctgccc tgactcagcc tccctccgtg tccgggtctc ctggacagtc agtcaccatc 60
tcctgcactg gaaccagcag tgacgttggt agttataacc gtgtctcctg gtaccagcag 120
cccccaggca cagcccccaa actcatgatt tatgaggtca gtaatcggcc ctcaggggtc 180
cctgatcgct tctctgggtc caagtctggc aacacggcct ccctgaccat ctctgggctc 240
caggctgagg acgaggctga ttattactgc agctcatata caagcagcag cactttc 297
<210> 377
<211> 514
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: partially human antibody comprising an ultralong
CDR3
<400> 377
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagc agtagtagtt actactgggg ctggatccgc 120
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gagcacctac 180
tacaacccgt ccctcaagag tcgagtcacc atatccgtag acacgtccaa gaaccagttc 240
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattactg tactactgtg 300
caccaggaaa caaaaaaata ccaaagttgt cctgatgggt atagagaacg ttcggattgt 360
agtaacagac ctgcttgtgg tactagtgat tgttgtcgtg ttagtgtttt tggtaattgt 420
cttactactc ttcctgtgag ttatagttat acttacaatt acgaatggca cgtcgatgtc 480
tggggccagg gaaccctggt caccgtctcc tcag 514
<210> 378
<211> 171
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: partially human antibody comprising an ultralong
CDR3 amino acid sequence
<400> 378
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Thr Thr Val His Gln Glu Thr Lys Lys Tyr Gln Ser Cys Pro Asp
100 105 110
Gly Tyr Arg Glu Arg Ser Asp Cys Ser Asn Arg Pro Ala Cys Gly Thr
115 120 125
Ser Asp Cys Cys Arg Val Ser Val Phe Gly Asn Cys Leu Thr Thr Leu
130 135 140
Pro Val Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val
145 150 155 160
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
165 170
<210> 379
<211> 493
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: partially human antibody V region comprised of an
ultralong CDR3
<400> 379
caggtgcagc tacaacagtg gggcgcagga ctgttgaagc cttcggagac cctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt ggttactact ggagctggat ccgccagccc 120
ccagggaagg ggctggagtg gattggggaa atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtactac tgtgcaccag 300
gaaaccagaa aaacctgttc tgatggttat atggctgtag atagttgtgg tcgtggtcag 360
agtgatggtt gtgtcaatga ttgcaattgt tgttattatg gttggcggaa ctgtcgcagg 420
cagcctgcaa ttcaaagtta cgaatttcac gtcgatgcct ggggccgtgg caccctggtc 480
actgtctcct cag 493
<210> 380
<211> 164
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: partially human antibody V region comprised of an
ultralong CDR3
<400> 380
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Thr Val His Gln Glu Thr Arg Lys Thr Cys Ser Asp Gly Tyr Met Ala
100 105 110
Val Asp Ser Cys Gly Arg Gly Gln Ser Asp Gly Cys Val Asn Asp Cys
115 120 125
Asn Cys Cys Tyr Tyr Gly Trp Arg Asn Cys Arg Arg Gln Pro Ala Ile
130 135 140
Gln Ser Tyr Glu Phe His Val Asp Ala Trp Gly Arg Gly Thr Leu Val
145 150 155 160
Thr Val Ser Ser
<210> 381
<211> 63
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: MID1 FW
<400> 381
cctatcccct gtgtgccttg gcagtctcag acgagtgcgt ttgagcgaca aggctgtagg 60
ctg 63
<210> 382
<211> 62
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: MID1 RV
<400> 382
ccatctcatc cctgcgtgtc tccgactcag acgagtgcgt ctttcggggc tgtggtggag 60
gc 62
<210> 383
<211> 63
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: MID10 FW
<400> 383
cctatcccct gtgtgccttg gcagtctcag tctctatgcg ttgagcgaca aggctgtagg 60
ctg 63
<210> 384
<211> 66
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: MID10 RV
<400> 384
ccatctcatc cctgcgtgtc tccgactcag tctctatgcg agtgaagact ctcgggtgtg 60
attcac 66
<210> 385
<211> 63
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: MID11 FW
<400> 385
cctatcccct gtgtgccttg gcagtctcag tgatacgtct ttgagcgaca aggctgtagg 60
ctg 63
<210> 386
<211> 66
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: MID11 RV
<400> 386
ccatctcatc cctgcgtgtc tccgactcag tgatacgtct agtgaagact ctcgggtgtg 60
attcac 66
<210> 387
<211> 23
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: primer 1 for bovine VH region
<400> 387
ttgagcgaca aggctgtagg ctg 23
<210> 388
<211> 22
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: primer 2 for bovine VH region
<400> 388
ctttcggggc tgtggtggag gc 22
<210> 389
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: sequencing primer
<400> 389
agatccaagc tgtgaccggc 20
<210> 390
<211> 1002
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: CH1 CH2 CH3 of human IgG1
<220>
<221> CDS
<222> (1)..(1002)
<400> 390
gct agc acc aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc aag 48
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac 96
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
ttc ccc gag ccg gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc 144
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
ggc gtg cac acc ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc 192
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
ctc agc agc gtg gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc 240
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
tac atc tgc aac gtg aat cac aag ccc agc aac acc aag gtg gac aag 288
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
aaa gtt gag ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc 336
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca 384
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc 432
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg 480
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag 528
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg 576
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtg tcc aac 624
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg 672
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag 720
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
225 230 235 240
ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat 768
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac 816
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc 864
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac 912
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg 960
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
cag aag agc ctc tcc ctg tct ccg ggt aaa tga taa tct aga 1002
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Arg
325 330
<210> 391
<211> 330
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 391
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
225 230 235 240
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330
<210> 392
<211> 513
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: BLV1H12 V region
<400> 392
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag ctgtcctgac ggctatcggg agagatctga ttgcagtaat 360
aggccagctt gtggcacatc cgactgctgt cgcgtgtctg tcttcgggaa ctgcctgact 420
accctgcctg tgtcctactc ttatacctac aattatgaat ggcatgtgga tgtctgggga 480
cagggcctgc tggtgacagt ctctagtgct agc 513
<210> 393
<211> 1563
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: (Sig Seq- VRegion - CH1CH2CH3) BLV1H12 V in human
IgG
<220>
<221> CDS
<222> (1)..(1563)
<400> 393
atg cgc agg atg caa ctc ctg ttg ctg att gca cta agt ctt gca ctt 48
Met Arg Arg Met Gln Leu Leu Leu Leu Ile Ala Leu Ser Leu Ala Leu
1 5 10 15
gtc acg aat tcg cag gtc cag ctg aga gag agc ggc cct tca ctg gtc 96
Val Thr Asn Ser Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val
20 25 30
aag cca tcc cag aca ctg agc ctg aca tgc aca gca agc ggg ttt tca 144
Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser
35 40 45
ctg agc gac aag gca gtg gga tgg gtc cga cag gca cca gga aaa gcc 192
Leu Ser Asp Lys Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala
50 55 60
ctg gaa tgg ctg ggc agc atc gat acc ggc ggg aac aca ggg tac aat 240
Leu Glu Trp Leu Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn
65 70 75 80
ccc gga ctg aag agc aga ctg tcc att acc aag gac aac tct aaa agt 288
Pro Gly Leu Lys Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser
85 90 95
cag gtg tca ctg agc gtg agc tcc gtc acc aca gag gat agt gca act 336
Gln Val Ser Leu Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr
100 105 110
tac tat tgc acc tct gtg cac cag gaa act aag aaa tac cag agc tgt 384
Tyr Tyr Cys Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Cys
115 120 125
cct gac ggc tat cgg gag aga tct gat tgc agt aat agg cca gct tgt 432
Pro Asp Gly Tyr Arg Glu Arg Ser Asp Cys Ser Asn Arg Pro Ala Cys
130 135 140
ggc aca tcc gac tgc tgt cgc gtg tct gtc ttc ggg aac tgc ctg act 480
Gly Thr Ser Asp Cys Cys Arg Val Ser Val Phe Gly Asn Cys Leu Thr
145 150 155 160
acc ctg cct gtg tcc tac tct tat acc tac aat tat gaa tgg cat gtg 528
Thr Leu Pro Val Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val
165 170 175
gat gtc tgg gga cag ggc ctg ctg gtg aca gtc tct agt gct agc acc 576
Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser Thr
180 185 190
aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct 624
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
195 200 205
ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gag 672
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
210 215 220
ccg gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac 720
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
225 230 235 240
acc ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc 768
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
245 250 255
gtg gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc 816
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
260 265 270
aac gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag 864
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
275 280 285
ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct 912
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
290 295 300
gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag 960
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
305 310 315 320
gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg 1008
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
325 330 335
gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac 1056
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
340 345 350
ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac 1104
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
355 360 365
aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac 1152
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
370 375 380
tgg ctg aat ggc aag gag tac aag tgc aag gtg tcc aac aaa gcc ctc 1200
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
385 390 395 400
cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga 1248
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
405 410 415
gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag 1296
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
420 425 430
aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac 1344
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
435 440 445
atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag 1392
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
450 455 460
acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc 1440
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
465 470 475 480
aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca 1488
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
485 490 495
tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 1536
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
500 505 510
ctc tcc ctg tct ccg ggt aaa tga taa 1563
Leu Ser Leu Ser Pro Gly Lys
515
<210> 394
<211> 519
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 394
Met Arg Arg Met Gln Leu Leu Leu Leu Ile Ala Leu Ser Leu Ala Leu
1 5 10 15
Val Thr Asn Ser Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val
20 25 30
Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser
35 40 45
Leu Ser Asp Lys Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala
50 55 60
Leu Glu Trp Leu Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn
65 70 75 80
Pro Gly Leu Lys Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser
85 90 95
Gln Val Ser Leu Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr
100 105 110
Tyr Tyr Cys Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Cys
115 120 125
Pro Asp Gly Tyr Arg Glu Arg Ser Asp Cys Ser Asn Arg Pro Ala Cys
130 135 140
Gly Thr Ser Asp Cys Cys Arg Val Ser Val Phe Gly Asn Cys Leu Thr
145 150 155 160
Thr Leu Pro Val Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val
165 170 175
Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser Thr
180 185 190
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
195 200 205
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
210 215 220
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
225 230 235 240
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
245 250 255
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
260 265 270
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
275 280 285
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
290 295 300
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
305 310 315 320
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
325 330 335
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
340 345 350
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
355 360 365
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
370 375 380
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
385 390 395 400
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
405 410 415
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
420 425 430
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
435 440 445
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
450 455 460
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
465 470 475 480
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
485 490 495
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
500 505 510
Leu Ser Leu Ser Pro Gly Lys
515
<210> 395
<211> 1470
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: BLV1H12 V in human IgG with BsaI cassette in CDR3
<220>
<221> CDS
<222> (1)..(1470)
<400> 395
atg cgc agg atg caa ctc ctg ttg ctg att gca cta agt ctt gca ctt 48
Met Arg Arg Met Gln Leu Leu Leu Leu Ile Ala Leu Ser Leu Ala Leu
1 5 10 15
gtc acg aat tcg cag gtc cag ctg aga gag agc ggc cct tca ctg gtc 96
Val Thr Asn Ser Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val
20 25 30
aag cca tcc cag aca ctg agc ctg aca tgc aca gca agc ggg ttt tca 144
Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser
35 40 45
ctg agc gac aag gca gtg gga tgg gtc cga cag gca cca gga aaa gcc 192
Leu Ser Asp Lys Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala
50 55 60
ctg gaa tgg ctg ggc agc atc gat acc ggc ggg aac aca ggg tac aat 240
Leu Glu Trp Leu Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn
65 70 75 80
ccc gga ctg aag agc aga ctg tcc att acc aag gac aac tct aaa agt 288
Pro Gly Leu Lys Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser
85 90 95
cag gtg tca ctg agc gtg agc tcc gtc acc aca gag gat agt gca act 336
Gln Val Ser Leu Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr
100 105 110
tac tat tgc acc tct gtg cac cag gaa act aag aaa tac cag agc gag 384
Tyr Tyr Cys Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Glu
115 120 125
acc tac tat ggt tcg ggt ctc tct tat acc tac aat tat gaa tgg cat 432
Thr Tyr Tyr Gly Ser Gly Leu Ser Tyr Thr Tyr Asn Tyr Glu Trp His
130 135 140
gtg gat gtc tgg gga cag ggc ctg ctg gtg aca gtc tct agt gct agc 480
Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
145 150 155 160
acc aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc aag agc acc 528
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr
165 170 175
tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc 576
Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
180 185 190
gag ccg gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc gtg 624
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
195 200 205
cac acc ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc 672
His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
210 215 220
agc gtg gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc 720
Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile
225 230 235 240
tgc aac gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt 768
Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val
245 250 255
gag ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca 816
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
260 265 270
cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc 864
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
275 280 285
aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg 912
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
290 295 300
gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg 960
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
305 310 315 320
gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag 1008
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
325 330 335
tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag 1056
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
340 345 350
gac tgg ctg aat ggc aag gag tac aag tgc aag gtg tcc aac aaa gcc 1104
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
355 360 365
ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc 1152
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
370 375 380
cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc 1200
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
385 390 395 400
aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc 1248
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
405 410 415
gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac 1296
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
420 425 430
aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac 1344
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
435 440 445
agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc 1392
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
450 455 460
tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag 1440
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
465 470 475 480
agc ctc tcc ctg tct ccg ggt aaa tga taa 1470
Ser Leu Ser Leu Ser Pro Gly Lys
485
<210> 396
<211> 488
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 396
Met Arg Arg Met Gln Leu Leu Leu Leu Ile Ala Leu Ser Leu Ala Leu
1 5 10 15
Val Thr Asn Ser Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val
20 25 30
Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser
35 40 45
Leu Ser Asp Lys Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala
50 55 60
Leu Glu Trp Leu Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn
65 70 75 80
Pro Gly Leu Lys Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser
85 90 95
Gln Val Ser Leu Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr
100 105 110
Tyr Tyr Cys Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Glu
115 120 125
Thr Tyr Tyr Gly Ser Gly Leu Ser Tyr Thr Tyr Asn Tyr Glu Trp His
130 135 140
Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
145 150 155 160
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr
165 170 175
Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
180 185 190
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
195 200 205
His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
210 215 220
Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile
225 230 235 240
Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val
245 250 255
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
260 265 270
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
275 280 285
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
290 295 300
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
305 310 315 320
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
325 330 335
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
340 345 350
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
355 360 365
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
370 375 380
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
385 390 395 400
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
405 410 415
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
420 425 430
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
435 440 445
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
450 455 460
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
465 470 475 480
Ser Leu Ser Leu Ser Pro Gly Lys
485
<210> 397
<211> 258
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: IL-8 26-99 Insert
<220>
<221> CDS
<222> (1)..(258)
<400> 397
aat tcg ggt ctc aag agc cca agg agt gct aaa gaa ctt aga tgt cag 48
Asn Ser Gly Leu Lys Ser Pro Arg Ser Ala Lys Glu Leu Arg Cys Gln
1 5 10 15
tgc ata aag aca tac tcc aaa cct ttc cac ccc aag ttc atc aag gag 96
Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro Lys Phe Ile Lys Glu
20 25 30
ctg aga gtg att gag agt gga cca cac tgc gcc aac aca gag att att 144
Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala Asn Thr Glu Ile Ile
35 40 45
gta aag ctt tct gat ggg aga gag ctc tgc ctg gac ccc aag gaa aac 192
Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu Asp Pro Lys Glu Asn
50 55 60
tgg gtg cag agg gtc gtg gag aag ttc ttg aag agg gct gag aac tca 240
Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys Arg Ala Glu Asn Ser
65 70 75 80
tct tat gag acc agc taa 258
Ser Tyr Glu Thr Ser
85
<210> 398
<211> 85
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 398
Asn Ser Gly Leu Lys Ser Pro Arg Ser Ala Lys Glu Leu Arg Cys Gln
1 5 10 15
Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro Lys Phe Ile Lys Glu
20 25 30
Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala Asn Thr Glu Ile Ile
35 40 45
Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu Asp Pro Lys Glu Asn
50 55 60
Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys Arg Ala Glu Asn Ser
65 70 75 80
Ser Tyr Glu Thr Ser
85
<210> 399
<211> 267
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: IL8 26-99 + GlySerGly Linker Insert
<220>
<221> CDS
<222> (1)..(267)
<400> 399
aat tcg ggt ctc aag agc cca agg agt gct aaa gaa ctt aga tgt cag 48
Asn Ser Gly Leu Lys Ser Pro Arg Ser Ala Lys Glu Leu Arg Cys Gln
1 5 10 15
tgc ata aag aca tac tcc aaa cct ttc cac ccc aag ttc atc aag gag 96
Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro Lys Phe Ile Lys Glu
20 25 30
ctg aga gtg att gag agt gga cca cac tgc gcc aac aca gag att att 144
Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala Asn Thr Glu Ile Ile
35 40 45
gta aag ctt tct gat ggg aga gag ctc tgc ctg gac ccc aag gaa aac 192
Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu Asp Pro Lys Glu Asn
50 55 60
tgg gtg cag agg gtc gtg gag aag ttc ttg aag agg gct gag aac tca 240
Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys Arg Ala Glu Asn Ser
65 70 75 80
ggc agc ggt tct tat gag acc agc taa 267
Gly Ser Gly Ser Tyr Glu Thr Ser
85
<210> 400
<211> 88
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 400
Asn Ser Gly Leu Lys Ser Pro Arg Ser Ala Lys Glu Leu Arg Cys Gln
1 5 10 15
Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro Lys Phe Ile Lys Glu
20 25 30
Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala Asn Thr Glu Ile Ile
35 40 45
Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu Asp Pro Lys Glu Asn
50 55 60
Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys Arg Ala Glu Asn Ser
65 70 75 80
Gly Ser Gly Ser Tyr Glu Thr Ser
85
<210> 401
<211> 435
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: IL-21 Insert
<220>
<221> CDS
<222> (1)..(435)
<400> 401
aat tcg ggt ctc aag agc caa ggt caa gat cgc cac atg atc aga atg 48
Asn Ser Gly Leu Lys Ser Gln Gly Gln Asp Arg His Met Ile Arg Met
1 5 10 15
cgt cag ctc ata gat att gtt gat cag ctg aag aac tac gtg aac gac 96
Arg Gln Leu Ile Asp Ile Val Asp Gln Leu Lys Asn Tyr Val Asn Asp
20 25 30
ttg gtc cct gaa ttt ctg cca gct ccc gaa gat gta gag aca aac tgt 144
Leu Val Pro Glu Phe Leu Pro Ala Pro Glu Asp Val Glu Thr Asn Cys
35 40 45
gag tgg tca gcc ttc tcc tgc ttt cag aag gcc caa cta aag tca gca 192
Glu Trp Ser Ala Phe Ser Cys Phe Gln Lys Ala Gln Leu Lys Ser Ala
50 55 60
aat acc ggc aac aac gag agg ata atc aat gta tca atc aaa aag ctg 240
Asn Thr Gly Asn Asn Glu Arg Ile Ile Asn Val Ser Ile Lys Lys Leu
65 70 75 80
aag agg aag cca cct tcc aca aat gca ggg aga cgg cag aaa cac cgc 288
Lys Arg Lys Pro Pro Ser Thr Asn Ala Gly Arg Arg Gln Lys His Arg
85 90 95
ctg aca tgc cct tca tgt gat tct tac gag aag aag cca ccc aaa gag 336
Leu Thr Cys Pro Ser Cys Asp Ser Tyr Glu Lys Lys Pro Pro Lys Glu
100 105 110
ttc cta gag cgg ttc aag tca ctt ctc gac aag atg att gat cag cat 384
Phe Leu Glu Arg Phe Lys Ser Leu Leu Asp Lys Met Ile Asp Gln His
115 120 125
ctg tcc tct cgc aca cac gga agt gaa gat tcc tct tat gag acc agc 432
Leu Ser Ser Arg Thr His Gly Ser Glu Asp Ser Ser Tyr Glu Thr Ser
130 135 140
taa 435
<210> 402
<211> 144
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 402
Asn Ser Gly Leu Lys Ser Gln Gly Gln Asp Arg His Met Ile Arg Met
1 5 10 15
Arg Gln Leu Ile Asp Ile Val Asp Gln Leu Lys Asn Tyr Val Asn Asp
20 25 30
Leu Val Pro Glu Phe Leu Pro Ala Pro Glu Asp Val Glu Thr Asn Cys
35 40 45
Glu Trp Ser Ala Phe Ser Cys Phe Gln Lys Ala Gln Leu Lys Ser Ala
50 55 60
Asn Thr Gly Asn Asn Glu Arg Ile Ile Asn Val Ser Ile Lys Lys Leu
65 70 75 80
Lys Arg Lys Pro Pro Ser Thr Asn Ala Gly Arg Arg Gln Lys His Arg
85 90 95
Leu Thr Cys Pro Ser Cys Asp Ser Tyr Glu Lys Lys Pro Pro Lys Glu
100 105 110
Phe Leu Glu Arg Phe Lys Ser Leu Leu Asp Lys Met Ile Asp Gln His
115 120 125
Leu Ser Ser Arg Thr His Gly Ser Glu Asp Ser Ser Tyr Glu Thr Ser
130 135 140
<210> 403
<211> 435
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: IL-21 (Q116D, H120D) Insert
<220>
<221> CDS
<222> (1)..(435)
<400> 403
aat tcg ggt ctc aag agc caa ggt caa gat cgc cac atg atc aga atg 48
Asn Ser Gly Leu Lys Ser Gln Gly Gln Asp Arg His Met Ile Arg Met
1 5 10 15
cgt cag ctc ata gat att gtt gat cag ctg aag aac tac gtg aac gac 96
Arg Gln Leu Ile Asp Ile Val Asp Gln Leu Lys Asn Tyr Val Asn Asp
20 25 30
ttg gtc cct gaa ttt ctg cca gct ccc gaa gat gta gag aca aac tgt 144
Leu Val Pro Glu Phe Leu Pro Ala Pro Glu Asp Val Glu Thr Asn Cys
35 40 45
gag tgg tca gcc ttc tcc tgc ttt cag aag gcc caa cta aag tca gca 192
Glu Trp Ser Ala Phe Ser Cys Phe Gln Lys Ala Gln Leu Lys Ser Ala
50 55 60
aat acc ggc aac aac gag agg ata atc aat gta tca atc aaa aag ctg 240
Asn Thr Gly Asn Asn Glu Arg Ile Ile Asn Val Ser Ile Lys Lys Leu
65 70 75 80
aag agg aag cca cct tcc aca aat gca ggg aga cgg cag aaa cac cgc 288
Lys Arg Lys Pro Pro Ser Thr Asn Ala Gly Arg Arg Gln Lys His Arg
85 90 95
ctg aca tgc cct tca tgt gat tct tac gag aag aag cca ccc aaa gag 336
Leu Thr Cys Pro Ser Cys Asp Ser Tyr Glu Lys Lys Pro Pro Lys Glu
100 105 110
ttc cta gag cgg ttc aag tca ctt ctc gac aag atg att gat cag cat 384
Phe Leu Glu Arg Phe Lys Ser Leu Leu Asp Lys Met Ile Asp Gln His
115 120 125
ctg tcc tct cgc aca cac gga agt gaa gat tcc tct tat gag acc agc 432
Leu Ser Ser Arg Thr His Gly Ser Glu Asp Ser Ser Tyr Glu Thr Ser
130 135 140
taa 435
<210> 404
<211> 144
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 404
Asn Ser Gly Leu Lys Ser Gln Gly Gln Asp Arg His Met Ile Arg Met
1 5 10 15
Arg Gln Leu Ile Asp Ile Val Asp Gln Leu Lys Asn Tyr Val Asn Asp
20 25 30
Leu Val Pro Glu Phe Leu Pro Ala Pro Glu Asp Val Glu Thr Asn Cys
35 40 45
Glu Trp Ser Ala Phe Ser Cys Phe Gln Lys Ala Gln Leu Lys Ser Ala
50 55 60
Asn Thr Gly Asn Asn Glu Arg Ile Ile Asn Val Ser Ile Lys Lys Leu
65 70 75 80
Lys Arg Lys Pro Pro Ser Thr Asn Ala Gly Arg Arg Gln Lys His Arg
85 90 95
Leu Thr Cys Pro Ser Cys Asp Ser Tyr Glu Lys Lys Pro Pro Lys Glu
100 105 110
Phe Leu Glu Arg Phe Lys Ser Leu Leu Asp Lys Met Ile Asp Gln His
115 120 125
Leu Ser Ser Arg Thr His Gly Ser Glu Asp Ser Ser Tyr Glu Thr Ser
130 135 140
<210> 405
<211> 249
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: SDF-1alpha-GSG Insert
<400> 405
aattcgggtc tcaagagcaa gcccgtcagc ctgagctaca gatgcccatg ccgattcttc 60
gaaagccatg ttgccagagc caacgtcaag catctcaaaa ttctcaacac tccaaactgt 120
gcccttcaga ttgtagcccg gctgaagaac aacaacagac aagtgtgcat tgacccgaag 180
ctaaagtgga ttcaggagta cctggagaaa gctttaaaca agggcagcgg ttcttatgag 240
accagctaa 249
<210> 406
<211> 78
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: Somatostatin-14
<220>
<221> CDS
<222> (1)..(78)
<400> 406
aat tcg ggt ctc aag agc gct ggc tgc aag aat ttc ttc tgg aag act 48
Asn Ser Gly Leu Lys Ser Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr
1 5 10 15
ttc aca tcc tgt tct tat gag acc agc taa 78
Phe Thr Ser Cys Ser Tyr Glu Thr Ser
20 25
<210> 407
<211> 25
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 407
Asn Ser Gly Leu Lys Ser Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr
1 5 10 15
Phe Thr Ser Cys Ser Tyr Glu Thr Ser
20 25
<210> 408
<211> 126
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: ProTx-II Insert
<220>
<221> CDS
<222> (1)..(126)
<400> 408
aat tcg ggt ctc aag agc tat tgc cag aag tgg atg tgg acc tgc gat 48
Asn Ser Gly Leu Lys Ser Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp
1 5 10 15
agc gaa cgg aaa tgt tgc gaa ggc atg gtg tgc cgc ctg tgg tgc aag 96
Ser Glu Arg Lys Cys Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys
20 25 30
aag aaa ctc tgg tct tat gag acc agc taa 126
Lys Lys Leu Trp Ser Tyr Glu Thr Ser
35 40
<210> 409
<211> 41
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 409
Asn Ser Gly Leu Lys Ser Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp
1 5 10 15
Ser Glu Arg Lys Cys Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys
20 25 30
Lys Lys Leu Trp Ser Tyr Glu Thr Ser
35 40
<210> 410
<211> 138
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: Chlorotoxin Insert
<400> 410
aattcgggtc tcaagagcat gtgtatgccc tgcttcacga ccgatcacca gatggcgcgc 60
aaatgcgatg actgttgcgg cggtaaaggt cgcggaaagt gctatggccc gcagtgtctg 120
tcttatgaga ccagctaa 138
<210> 411
<211> 111
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: Ziconotide Insert
<400> 411
aattcgggtc tcaagagctg caagggcaaa ggtgcgaaat gcagccgcct gatgtatgat 60
tgctgtaccg ggtcctgccg cagtggcaag tgctcttatg agaccagcta a 111
<210> 412
<211> 672
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: BLV1H12 Light Chain
<220>
<221> CDS
<222> (1)..(672)
<400> 412
tca cga att cgc agg ccg tcc tga acc agc caa gca gcg tct ccg ggt 48
Ser Arg Ile Arg Arg Pro Ser Thr Ser Gln Ala Ala Ser Pro Gly
1 5 10 15
ctc tgg ggc agc ggg tct caa tca cct gta gcg ggt ctt cct cca atg 96
Leu Trp Gly Ser Gly Ser Gln Ser Pro Val Ala Gly Leu Pro Pro Met
20 25 30
tcg gca acg gct acg tgt ctt ggt atc agc tga tcc ctg gca gtg ccc 144
Ser Ala Thr Ala Thr Cys Leu Gly Ile Ser Ser Leu Ala Val Pro
35 40 45
cac gaa ccc tga tct acg gcg aca cat cca gag ctt ctg ggg tcc ccg 192
His Glu Pro Ser Thr Ala Thr His Pro Glu Leu Leu Gly Ser Pro
50 55 60
atc ggt tct cag gga gca gat ccg gaa aca cag cta ctc tga cca tca 240
Ile Gly Ser Gln Gly Ala Asp Pro Glu Thr Gln Leu Leu Pro Ser
65 70 75
gct ccc tgc agg ctg agg acg aag cag att att tct gcg cat ctg ccg 288
Ala Pro Cys Arg Leu Arg Thr Lys Gln Ile Ile Ser Ala His Leu Pro
80 85 90
agg act cta gtt caa atg ccg tgt ttg gaa gcg gca cca cac tga cag 336
Arg Thr Leu Val Gln Met Pro Cys Leu Glu Ala Ala Pro His Gln
95 100 105
tcc tgg ggc agc cca aga gtc ccc ctt cag tga ctc tgt tcc cac cct 384
Ser Trp Gly Ser Pro Arg Val Pro Leu Gln Leu Cys Ser His Pro
110 115 120
cta ccg agg aac tga acg gaa aca agg cca cac tgg tgt gtc tga tca 432
Leu Pro Arg Asn Thr Glu Thr Arg Pro His Trp Cys Val Ser
125 130 135
gcg act ttt acc ctg gat ccg tca ctg tgg tct gga agg cag atg gca 480
Ala Thr Phe Thr Leu Asp Pro Ser Leu Trp Ser Gly Arg Gln Met Ala
140 145 150
gca caa tta cta gga acg tgg aaa cta ccc gcg cct cca agc agt cta 528
Ala Gln Leu Leu Gly Thr Trp Lys Leu Pro Ala Pro Pro Ser Ser Leu
155 160 165
ata gta aat acg ccg cca gct cct atc tga gcc tga cct cta gtg att 576
Ile Val Asn Thr Pro Pro Ala Pro Ile Ala Pro Leu Val Ile
170 175 180
gga agt cca aag ggt cat ata gct gcg aag tga ccc atg aag gct caa 624
Gly Ser Pro Lys Gly His Ile Ala Ala Lys Pro Met Lys Ala Gln
185 190 195
ccg tga cta aga ctg tga aac cat ccg agt gct cct agg cta gct ggc 672
Pro Leu Arg Leu Asn His Pro Ser Ala Pro Arg Leu Ala Gly
200 205 210
<210> 413
<211> 7
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 413
Ser Arg Ile Arg Arg Pro Ser
1 5
<210> 414
<211> 34
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 414
Thr Ser Gln Ala Ala Ser Pro Gly Leu Trp Gly Ser Gly Ser Gln Ser
1 5 10 15
Pro Val Ala Gly Leu Pro Pro Met Ser Ala Thr Ala Thr Cys Leu Gly
20 25 30
Ile Ser
<210> 415
<211> 8
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 415
Ser Leu Ala Val Pro His Glu Pro
1 5
<210> 416
<211> 25
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 416
Ser Thr Ala Thr His Pro Glu Leu Leu Gly Ser Pro Ile Gly Ser Gln
1 5 10 15
Gly Ala Asp Pro Glu Thr Gln Leu Leu
20 25
<210> 417
<211> 32
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 417
Pro Ser Ala Pro Cys Arg Leu Arg Thr Lys Gln Ile Ile Ser Ala His
1 5 10 15
Leu Pro Arg Thr Leu Val Gln Met Pro Cys Leu Glu Ala Ala Pro His
20 25 30
<210> 418
<211> 11
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 418
Gln Ser Trp Gly Ser Pro Arg Val Pro Leu Gln
1 5 10
<210> 419
<211> 9
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 419
Leu Cys Ser His Pro Leu Pro Arg Asn
1 5
<210> 420
<211> 9
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 420
Thr Glu Thr Arg Pro His Trp Cys Val
1 5
<210> 421
<211> 42
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 421
Ser Ala Thr Phe Thr Leu Asp Pro Ser Leu Trp Ser Gly Arg Gln Met
1 5 10 15
Ala Ala Gln Leu Leu Gly Thr Trp Lys Leu Pro Ala Pro Pro Ser Ser
20 25 30
Leu Ile Val Asn Thr Pro Pro Ala Pro Ile
35 40
<210> 422
<211> 14
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 422
Pro Leu Val Ile Gly Ser Pro Lys Gly His Ile Ala Ala Lys
1 5 10
<210> 423
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 423
Pro Met Lys Ala Gln Pro
1 5
<210> 424
<211> 10
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic Construct
<400> 424
Asn His Pro Ser Ala Pro Arg Leu Ala Gly
1 5 10
<210> 425
<211> 641
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH1-24+CDR3-IL8
<400> 425
tcacgaattc gcaggtccag ctggtacagt ctggggctga ggtgaagaag cctggggcct 60
cagtgaaggt gtcctgcaag gtttccggat acaccctcac tgaattatcc atgcactggg 120
tgcgacaggc tcctggaaaa gggcttgagt ggatgggagg ttttgatcct gaagatggtg 180
aaacaatcta cgcacagaag ttccagggca gagtcaccat gaccgaggac acatctacag 240
acacagccta catggagctg agcagcctga gatctgagga cacggccgtg tattactgca 300
cctctgtgca ccaggaaact aagaaatacc agagcccaag gagtgctaaa gaacttagat 360
gtcagtgcat aaagacatac tccaaacctt tccaccccaa gttcatcaag gagctgagag 420
tgattgagag tggaccacac tgcgccaaca cagagattat tgtaaagctt tctgatggga 480
gagagctctg cctggacccc aaggaaaact gggtgcagag ggtcgtggag aagttcttga 540
agagggctga gaactcaggc agcggttctt atacctacaa ttatgaatgg catgtggatg 600
tctggggaca gggcctgctg gtgacagtct ctagtgctag c 641
<210> 426
<211> 641
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH1-46+CDR3-IL8
<400> 426
tcacgaattc gcaggtgcag ctggtgcagt ctggggctga ggtgaagaag cctggggcct 60
cagtgaaggt ttcctgcaag gcatctggat acaccttcac cagctactat atgcactggg 120
tgcgacaggc ccctggacaa gggcttgagt ggatgggaat aatcaaccct agtggtggta 180
gcacaagcta cgcacagaag ttccagggca gagtcaccat gaccagggac acgtccacga 240
gcacagtcta catggagctg agcagcctga gatctgagga cacggccgtg tattactgca 300
cctctgtgca ccaggaaact aagaaatacc agagcccaag gagtgctaaa gaacttagat 360
gtcagtgcat aaagacatac tccaaacctt tccaccccaa gttcatcaag gagctgagag 420
tgattgagag tggaccacac tgcgccaaca cagagattat tgtaaagctt tctgatggga 480
gagagctctg cctggacccc aaggaaaact gggtgcagag ggtcgtggag aagttcttga 540
agagggctga gaactcaggc agcggttctt atacctacaa ttatgaatgg catgtggatg 600
tctggggaca gggcctgctg gtgacagtct ctagtgctag c 641
<210> 427
<211> 641
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH1-69+CDR3-IL8
<400> 427
tcacgaattc gcaggtgcag ctggtgcagt ctggggctga ggtgaagaag cctgggtcct 60
cggtgaaggt gtcctgcaag gcttctggag gcaccttcag cagctatgct atcagctggg 120
tgcgacaggc ccctggacaa gggcttgagt ggatgggagg gatcatccct atctttggta 180
cagcaaacta cgcacagaag ttccagggca gagtcacgat taccgcggac aaatccacga 240
gcacagccta catggagctg agcagcctga gatctgagga cacggccgtg tattactgca 300
cctctgtgca ccaggaaact aagaaatacc agagcccaag gagtgctaaa gaacttagat 360
gtcagtgcat aaagacatac tccaaacctt tccaccccaa gttcatcaag gagctgagag 420
tgattgagag tggaccacac tgcgccaaca cagagattat tgtaaagctt tctgatggga 480
gagagctctg cctggacccc aaggaaaact gggtgcagag ggtcgtggag aagttcttga 540
agagggctga gaactcaggc agcggttctt atacctacaa ttatgaatgg catgtggatg 600
tctggggaca gggcctgctg gtgacagtct ctagtgctag c 641
<210> 428
<211> 641
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH3-23+CDR3-IL8
<400> 428
tcacgaattc ggaggtgcag ctgttggagt ctgggggagg cttggtacag cctggggggt 60
ccctgagact ctcctgtgca gcctctggat tcacctttag cagctatgcc atgagctggg 120
tccgccaggc tccagggaag gggctggagt gggtgagcgc aattagtggt agtggcggta 180
gcacatacta cgcagactcc gtgaagggcc ggttcaccat ctcacgtgac aattccaaga 240
acacgctgta tctgcaaatg aacagcctga gagccgagga cacggccgtg tattactgca 300
cctctgtgca ccaggaaact aagaaatacc agagcccaag gagtgctaaa gaacttagat 360
gtcagtgcat aaagacatac tccaaacctt tccaccccaa gttcatcaag gagctgagag 420
tgattgagag tggaccacac tgcgccaaca cagagattat tgtaaagctt tctgatggga 480
gagagctctg cctggacccc aaggaaaact gggtgcagag ggtcgtggag aagttcttga 540
agagggctga gaactcaggc agcggttctt atacctacaa ttatgaatgg catgtggatg 600
tctggggaca gggcctgctg gtgacagtct ctagtgctag c 641
<210> 429
<211> 638
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH4-4+CDR3-IL8
<400> 429
tcacgaattc gcaggtgcag ctgcaggagt cgggcccagg actggtgaag ccttcggaga 60
cgctgtccct cacctgcact gtctctggtg gctccatcag tagttactac tggagctgga 120
ttcggcagcc cgccgggaag ggactggagt ggattgggcg tatctatacc agtgggagca 180
ccaactacaa cccctccctc aagagtcgag tcaccatgtc agtagacacg tccaagaacc 240
agttctccct gaagctgagc tctgtgaccg ccgcggacac ggccgtgtat tactgcacct 300
ctgtgcacca ggaaactaag aaataccaga gcccaaggag tgctaaagaa cttagatgtc 360
agtgcataaa gacatactcc aaacctttcc accccaagtt catcaaggag ctgagagtga 420
ttgagagtgg accacactgc gccaacacag agattattgt aaagctttct gatgggagag 480
agctctgcct ggaccccaag gaaaactggg tgcagagggt cgtggagaag ttcttgaaga 540
gggctgagaa ctcaggcagc ggttcttata cctacaatta tgaatggcat gtggatgtct 600
ggggacaggg cctgctggtg acagtctcta gtgctagc 638
<210> 430
<211> 638
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3-IL8
<400> 430
tcacgaattc gcaggtgcag ctacagcagt ggggcgcagg actgttgaag ccttcggaga 60
cgctgtccct cacctgcgct gtctatggtg ggtccttcag tggttactac tggagctgga 120
ttcgccagcc cccagggaag gggctggagt ggattgggga aatcaatcat agtggaagca 180
ccaactacaa cccgtccctc aagagtcgag tcaccatatc agtagacacg tccaagaacc 240
agttctccct gaagctgagc tctgtgaccg ccgcggacac ggctgtgtat tactgtacct 300
ctgtgcacca ggaaactaag aaataccaga gcccaaggag tgctaaagaa cttagatgtc 360
agtgcataaa gacatactcc aaacctttcc accccaagtt catcaaggag ctgagagtga 420
ttgagagtgg accacactgc gccaacacag agattattgt aaagctttct gatgggagag 480
agctctgcct ggaccccaag gaaaactggg tgcagagggt cgtggagaag ttcttgaaga 540
gggctgagaa ctcaggcagc ggttcttata cctacaatta tgaatggcat gtggatgtct 600
ggggacaggg cctgctggtg acagtctcta gtgctagc 638
<210> 431
<211> 431
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: IgGVH4-4 CDR3 BsaI (lacking the IL-8 insert)
<400> 431
tcacgaattc gcaggtgcag ctgcaggagt cgggcccagg actggtgaag ccttcggaga 60
cgctgtccct cacctgcact gtctctggtg gctccatcag tagttactac tggagctgga 120
ttcggcagcc cgccgggaag ggactggagt ggattgggcg tatctatacc agtgggagca 180
ccaactacaa cccctccctc aagagtcgag tcaccatgtc agtagacacg tccaagaacc 240
agttctccct gaagctgagc tctgtgaccg ccgcggacac ggccgtgtat tactgcacct 300
ctgtgcacca ggaaactaag aaataccaga gcgagaccta ctatggttcg ggtctctctt 360
atacctacaa ttatgaatgg catgtggatg tctggggaca gggcctgctg gtgacagtct 420
ctagtgctag c 431
<210> 432
<211> 638
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3-IL8_CDR1 Cow
<400> 432
tcacgaattc gcaggtgcag ctacagcagt ggggcgcagg actgttgaag ccttcggaga 60
cgctgtccct cacctgcaca gcaagcgggt tttcactgag cgacaaggca gtgggatgga 120
ttcgccagcc cccagggaag gggctggagt ggattgggga aatcaatcat agtggaagca 180
ccaactacaa cccgtccctc aagagtcgag tcaccatatc agtagacacg tccaagaacc 240
agttctccct gaagctgagc tctgtgaccg ccgcggacac ggctgtgtat tactgtacct 300
ctgtgcacca ggaaactaag aaataccaga gcccaaggag tgctaaagaa cttagatgtc 360
agtgcataaa gacatactcc aaacctttcc accccaagtt catcaaggag ctgagagtga 420
ttgagagtgg accacactgc gccaacacag agattattgt aaagctttct gatgggagag 480
agctctgcct ggaccccaag gaaaactggg tgcagagggt cgtggagaag ttcttgaaga 540
gggctgagaa ctcaggcagc ggttcttata cctacaatta tgaatggcat gtggatgtct 600
ggggacaggg cctgctggtg acagtctcta gtgctagc 638
<210> 433
<211> 638
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3-IL8_CDR2 Cow
<400> 433
tcacgaattc gcaggtgcag ctacagcagt ggggcgcagg actgttgaag ccttcggaga 60
cgctgtccct cacctgcgct gtctatggtg ggtccttcag tggttactac tggagctgga 120
ttcgccagcc cccagggaag gggctggagt ggctgggcag catcgatacc ggcgggaaca 180
cagggtacaa cccgtccctc aagagtcgag tcaccatatc agtagacacg tccaagaacc 240
agttctccct gaagctgagc tctgtgaccg ccgcggacac ggctgtgtat tactgtacct 300
ctgtgcacca ggaaactaag aaataccaga gcccaaggag tgctaaagaa cttagatgtc 360
agtgcataaa gacatactcc aaacctttcc accccaagtt catcaaggag ctgagagtga 420
ttgagagtgg accacactgc gccaacacag agattattgt aaagctttct gatgggagag 480
agctctgcct ggaccccaag gaaaactggg tgcagagggt cgtggagaag ttcttgaaga 540
gggctgagaa ctcaggcagc ggttcttata cctacaatta tgaatggcat gtggatgtct 600
ggggacaggg cctgctggtg acagtctcta gtgctagc 638
<210> 434
<211> 638
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3-IL8_CDR1 G31D, Y32K
<400> 434
tcacgaattc gcaggtgcag ctacagcagt ggggcgcagg actgttgaag ccttcggaga 60
cgctgtccct cacctgcgct gtctatggtg ggtccttcag tgacaagtac tggagctgga 120
ttcgccagcc cccagggaag gggctggagt ggattgggga aatcaatcat agtggaagca 180
ccaactacaa cccgtccctc aagagtcgag tcaccatatc agtagacacg tccaagaacc 240
agttctccct gaagctgagc tctgtgaccg ccgcggacac ggctgtgtat tactgtacct 300
ctgtgcacca ggaaactaag aaataccaga gcccaaggag tgctaaagaa cttagatgtc 360
agtgcataaa gacatactcc aaacctttcc accccaagtt catcaaggag ctgagagtga 420
ttgagagtgg accacactgc gccaacacag agattattgt aaagctttct gatgggagag 480
agctctgcct ggaccccaag gaaaactggg tgcagagggt cgtggagaag ttcttgaaga 540
gggctgagaa ctcaggcagc ggttcttata cctacaatta tgaatggcat gtggatgtct 600
ggggacaggg cctgctggtg acagtctcta gtgctagc 638
<210> 435
<211> 638
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3-IL8_CDR2 E50S
<400> 435
tcacgaattc gcaggtgcag ctacagcagt ggggcgcagg actgttgaag ccttcggaga 60
cgctgtccct cacctgcgct gtctatggtg ggtccttcag tggttactac tggagctgga 120
ttcgccagcc cccagggaag gggctggagt ggattgggag catcaatcat agtggaagca 180
ccaactacaa cccgtccctc aagagtcgag tcaccatatc agtagacacg tccaagaacc 240
agttctccct gaagctgagc tctgtgaccg ccgcggacac ggctgtgtat tactgtacct 300
ctgtgcacca ggaaactaag aaataccaga gcccaaggag tgctaaagaa cttagatgtc 360
agtgcataaa gacatactcc aaacctttcc accccaagtt catcaaggag ctgagagtga 420
ttgagagtgg accacactgc gccaacacag agattattgt aaagctttct gatgggagag 480
agctctgcct ggaccccaag gaaaactggg tgcagagggt cgtggagaag ttcttgaaga 540
gggctgagaa ctcaggcagc ggttcttata cctacaatta tgaatggcat gtggatgtct 600
ggggacaggg cctgctggtg acagtctcta gtgctagc 638
<210> 436
<211> 638
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3-IL8_CDR1 Cow_CDR2 Cow
<400> 436
tcacgaattc gcaggtgcag ctacagcagt ggggcgcagg actgttgaag ccttcggaga 60
cgctgtccct cacctgcaca gcaagcgggt tttcactgag cgacaaggca gtgggatgga 120
ttcgccagcc cccagggaag gggctggagt ggctgggcag catcgatacc ggcgggaaca 180
cagggtacaa cccgtccctc aagagtcgag tcaccatatc agtagacacg tccaagaacc 240
agttctccct gaagctgagc tctgtgaccg ccgcggacac ggctgtgtat tactgtacct 300
ctgtgcacca ggaaactaag aaataccaga gcccaaggag tgctaaagaa cttagatgtc 360
agtgcataaa gacatactcc aaacctttcc accccaagtt catcaaggag ctgagagtga 420
ttgagagtgg accacactgc gccaacacag agattattgt aaagctttct gatgggagag 480
agctctgcct ggaccccaag gaaaactggg tgcagagggt cgtggagaag ttcttgaaga 540
gggctgagaa ctcaggcagc ggttcttata cctacaatta tgaatggcat gtggatgtct 600
ggggacaggg cctgctggtg acagtctcta gtgctagc 638
<210> 437
<211> 638
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3-IL8_CDR1 Cow_CDR2 E50S
<400> 437
tcacgaattc gcaggtgcag ctacagcagt ggggcgcagg actgttgaag ccttcggaga 60
cgctgtccct cacctgcaca gcaagcgggt tttcactgag cgacaaggca gtgggatgga 120
ttcgccagcc cccagggaag gggctggagt ggattgggag catcaatcat agtggaagca 180
ccaactacaa cccgtccctc aagagtcgag tcaccatatc agtagacacg tccaagaacc 240
agttctccct gaagctgagc tctgtgaccg ccgcggacac ggctgtgtat tactgtacct 300
ctgtgcacca ggaaactaag aaataccaga gcccaaggag tgctaaagaa cttagatgtc 360
agtgcataaa gacatactcc aaacctttcc accccaagtt catcaaggag ctgagagtga 420
ttgagagtgg accacactgc gccaacacag agattattgt aaagctttct gatgggagag 480
agctctgcct ggaccccaag gaaaactggg tgcagagggt cgtggagaag ttcttgaaga 540
gggctgagaa ctcaggcagc ggttcttata cctacaatta tgaatggcat gtggatgtct 600
ggggacaggg cctgctggtg acagtctcta gtgctagc 638
<210> 438
<211> 638
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3-IL8_CDR1 G31D,Y32K_CDR2 Cow
<400> 438
tcacgaattc gcaggtgcag ctacagcagt ggggcgcagg actgttgaag ccttcggaga 60
cgctgtccct cacctgcgct gtctatggtg ggtccttcag tgacaagtac tggagctgga 120
ttcgccagcc cccagggaag gggctggagt ggctgggcag catcgatacc ggcgggaaca 180
cagggtacaa cccgtccctc aagagtcgag tcaccatatc agtagacacg tccaagaacc 240
agttctccct gaagctgagc tctgtgaccg ccgcggacac ggctgtgtat tactgtacct 300
ctgtgcacca ggaaactaag aaataccaga gcccaaggag tgctaaagaa cttagatgtc 360
agtgcataaa gacatactcc aaacctttcc accccaagtt catcaaggag ctgagagtga 420
ttgagagtgg accacactgc gccaacacag agattattgt aaagctttct gatgggagag 480
agctctgcct ggaccccaag gaaaactggg tgcagagggt cgtggagaag ttcttgaaga 540
gggctgagaa ctcaggcagc ggttcttata cctacaatta tgaatggcat gtggatgtct 600
ggggacaggg cctgctggtg acagtctcta gtgctagc 638
<210> 439
<211> 638
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3-IL8_CDR1 G31D,Y32K_CDR2 E50S
<400> 439
tcacgaattc gcaggtgcag ctacagcagt ggggcgcagg actgttgaag ccttcggaga 60
cgctgtccct cacctgcgct gtctatggtg ggtccttcag tgacaagtac tggagctgga 120
ttcgccagcc cccagggaag gggctggagt ggattgggag catcaatcat agtggaagca 180
ccaactacaa cccgtccctc aagagtcgag tcaccatatc agtagacacg tccaagaacc 240
agttctccct gaagctgagc tctgtgaccg ccgcggacac ggctgtgtat tactgtacct 300
ctgtgcacca ggaaactaag aaataccaga gcccaaggag tgctaaagaa cttagatgtc 360
agtgcataaa gacatactcc aaacctttcc accccaagtt catcaaggag ctgagagtga 420
ttgagagtgg accacactgc gccaacacag agattattgt aaagctttct gatgggagag 480
agctctgcct ggaccccaag gaaaactggg tgcagagggt cgtggagaag ttcttgaaga 540
gggctgagaa ctcaggcagc ggttcttata cctacaatta tgaatggcat gtggatgtct 600
ggggacaggg cctgctggtg acagtctcta gtgctagc 638
<210> 440
<211> 671
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V1-51, I29V, N32G
<400> 440
tcacgaattc gcagtccgtg ctgacccaac ccccgtcagt gtctgctgcc cccgggcaga 60
aggtgactat cagctgctct ggctcatcct ccaatgtcgg caacggctac gtcagctggt 120
accagcagct gcctggaaca gctcctaaac tgctcattta tgacaataac aagcgcccat 180
ccggaatccc tgaccgattc agcggaagca aatcagggac ctctgcaact ctgggaatca 240
ctgggcttca gacaggagat gaggcagatt actattgcgc ctctgcagag gacagctcca 300
gcaatgccgt gttcgggtct ggtaccactc ttacagtcct aggtcagccc aaggctgccc 360
cctcggtcac tctgttcccg ccctcctctg aggagcttca agccaacaag gccacactgg 420
tgtgtctcat aagtgacttc tacccgggag ccgtgacagt ggcctggaag gcagatagca 480
gccccgtcaa ggcgggagtg gaaacaacca caccctccaa acaaagcaac aacaagtacg 540
cggccagcag ctatctgagc ctgacgcctg agcagtggaa gtcccacaga agctacagct 600
gccaggtcac gcatgaaggg agcaccgtgg agaagacagt ggcccctaca gaatgttcat 660
aatgagctag c 671
<210> 441
<211> 671
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V1-51, DNN (aa51-53) changed to GDT
<400> 441
tcacgaattc gcagtccgtg ctgacccaac ccccgtcagt gtctgctgcc cccgggcaga 60
aggtgactat cagctgctct ggctcatcaa gcaacatcgg gaataattac gtcagctggt 120
accagcagct gcctggaaca gctcctaaac tgctcattta tggcgacaca aagcgcccat 180
ccggaatccc tgaccgattc agcggaagca aatcagggac ctctgcaact ctgggaatca 240
ctgggcttca gacaggagat gaggcagatt actattgcgc ctctgcagag gacagctcca 300
gcaatgccgt gttcgggtct ggtaccactc ttacagtcct aggtcagccc aaggctgccc 360
cctcggtcac tctgttcccg ccctcctctg aggagcttca agccaacaag gccacactgg 420
tgtgtctcat aagtgacttc tacccgggag ccgtgacagt ggcctggaag gcagatagca 480
gccccgtcaa ggcgggagtg gaaacaacca caccctccaa acaaagcaac aacaagtacg 540
cggccagcag ctatctgagc ctgacgcctg agcagtggaa gtcccacaga agctacagct 600
gccaggtcac gcatgaaggg agcaccgtgg agaagacagt ggcccctaca gaatgttcat 660
aatgagctag c 671
<210> 442
<211> 671
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V1-51, DNNKRP (aa51-56) changed to GDTSRA
<400> 442
tcacgaattc gcagtccgtg ctgacccaac ccccgtcagt gtctgctgcc cccgggcaga 60
aggtgactat cagctgctct ggctcatcaa gcaacatcgg gaataattac gtcagctggt 120
accagcagct gcctggaaca gctcctaaac tgctcattta tggcgacaca tccagagctt 180
ccggaatccc tgaccgattc agcggaagca aatcagggac ctctgcaact ctgggaatca 240
ctgggcttca gacaggagat gaggcagatt actattgcgc ctctgcagag gacagctcca 300
gcaatgccgt gttcgggtct ggtaccactc ttacagtcct aggtcagccc aaggctgccc 360
cctcggtcac tctgttcccg ccctcctctg aggagcttca agccaacaag gccacactgg 420
tgtgtctcat aagtgacttc tacccgggag ccgtgacagt ggcctggaag gcagatagca 480
gccccgtcaa ggcgggagtg gaaacaacca caccctccaa acaaagcaac aacaagtacg 540
cggccagcag ctatctgagc ctgacgcctg agcagtggaa gtcccacaga agctacagct 600
gccaggtcac gcatgaaggg agcaccgtgg agaagacagt ggcccctaca gaatgttcat 660
aatgagctag c 671
<210> 443
<211> 671
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V1-51, S2A,T5N,P8S,A12G,A13S, and P14L
<400> 443
tcacgaattc gcaggccgtc ctgaaccagc caagcagcgt ctccgggtct ctggggcaga 60
aggtgactat cagctgctct ggctcatcaa gcaacatcgg gaataattac gtcagctggt 120
accagcagct gcctggaaca gctcctaaac tgctcattta tgacaataac aagcgcccat 180
ccggaatccc tgaccgattc agcggaagca aatcagggac ctctgcaact ctgggaatca 240
ctgggcttca gacaggagat gaggcagatt actattgcgc ctctgcagag gacagctcca 300
gcaatgccgt gttcgggtct ggtaccactc ttacagtcct aggtcagccc aaggctgccc 360
cctcggtcac tctgttcccg ccctcctctg aggagcttca agccaacaag gccacactgg 420
tgtgtctcat aagtgacttc tacccgggag ccgtgacagt ggcctggaag gcagatagca 480
gccccgtcaa ggcgggagtg gaaacaacca caccctccaa acaaagcaac aacaagtacg 540
cggccagcag ctatctgagc ctgacgcctg agcagtggaa gtcccacaga agctacagct 600
gccaggtcac gcatgaaggg agcaccgtgg agaagacagt ggcccctaca gaatgttcat 660
aatgagctag c 671
<210> 444
<211> 671
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V1-51, S2A,T5N,P8S,A12G,A13S, P14L, and DNN
(aa51-53) changed to GDT
<400> 444
tcacgaattc gcaggccgtc ctgaaccagc caagcagcgt ctccgggtct ctggggcaga 60
aggtgactat cagctgctct ggctcatcaa gcaacatcgg gaataattac gtcagctggt 120
accagcagct gcctggaaca gctcctaaac tgctcattta tggcgacaca aagcgcccat 180
ccggaatccc tgaccgattc agcggaagca aatcagggac ctctgcaact ctgggaatca 240
ctgggcttca gacaggagat gaggcagatt actattgcgc ctctgcagag gacagctcca 300
gcaatgccgt gttcgggtct ggtaccactc ttacagtcct aggtcagccc aaggctgccc 360
cctcggtcac tctgttcccg ccctcctctg aggagcttca agccaacaag gccacactgg 420
tgtgtctcat aagtgacttc tacccgggag ccgtgacagt ggcctggaag gcagatagca 480
gccccgtcaa ggcgggagtg gaaacaacca caccctccaa acaaagcaac aacaagtacg 540
cggccagcag ctatctgagc ctgacgcctg agcagtggaa gtcccacaga agctacagct 600
gccaggtcac gcatgaaggg agcaccgtgg agaagacagt ggcccctaca gaatgttcat 660
aatgagctag c 671
<210> 445
<211> 657
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: A20J1
<400> 445
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcgagtca gggcattagc aattatttag cctggtatca gcagaaacca 120
gggaaagttc ctaagctcct gatctatgct gcatccactt tgcaatcagg ggtcccatct 180
cggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
gaagatgttg caacttatta ctgtcaaaag tataacagtg cccctccgtg gacgttcggc 300
caagggacca aggtggaaat caaacgtacg gtggctgcac catctgtctt catcttcccg 360
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 420
tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 480
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 540
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag 600
ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttaatg agctagc 657
<210> 446
<211> 657
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: L6J1
<400> 446
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agctacttag cctggtacca acagaaacct 120
ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc 180
aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct 240
gaagattttg cagtttatta ctgtcagcag cgtagcaact ggcctccgtg gacgttcggc 300
caagggacca aggtggaaat caaacgtacg gtggctgcac catctgtctt catcttcccg 360
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 420
tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 480
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 540
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag 600
ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttaatg agctagc 657
<210> 447
<211> 660
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: L25J1
<400> 447
gaaatagtga tgacgcagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcagctact tatcctggta ccagcagaaa 120
cctgggcagg ctcccaggct cctcatctat ggtgcatcca ccagggccac tggcatccca 180
gccaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagcctgcag 240
cctgaagatt ttgcagttta ttactgtcag caggattata acttacctcc gtggacgttc 300
ggccaaggga ccaaggtgga aatcaaacgt acggtggctg caccatctgt cttcatcttc 360
ccgccatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataac 420
ttctatccca gagaggccaa agtacagtgg aaggtggata acgccctcca atcgggtaac 480
tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct cagcagcacc 540
ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct acgcctgcga agtcacccat 600
cagggcctga gctcgcccgt cacaaagagc ttcaacaggg gagagtgtta atgagctagc 660
<210> 448
<211> 663
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V1-2J7
<400> 448
cagtctgccc tgactcagcc tccctccgcg tccgggtctc ctggacagtc agtcaccatc 60
tcctgcactg gaaccagcag tgacgttggt ggttataact atgtctcctg gtaccaacag 120
cacccaggca aagcccccaa actcatgatt tatgaggtca gtaagcggcc ctcaggggtc 180
cctgatcgct tctctggctc caagtctggc aacacggcct ccctgaccgt ctctgggctc 240
caggctgagg atgaggctga ttattactgc agctcatatg caggcagcaa caatttcgct 300
gtgttcggag gaggcaccca gctgaccgtc ctaggtcagc ccaaggctgc cccctcggtc 360
actctgttcc cgccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc 420
ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc 480
aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc 540
agctatctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag ctgccaggtc 600
acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc ataatgagct 660
agc 663
<210> 449
<211> 663
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V1-7J1
<400> 449
cagtctgccc tgactcagcc tgcctccgtg tctggctccc ctggacagtc gatcaccatc 60
tcctgcactg gaaccagcag tgatgttggg agttataacc ttgtctcctg gtaccaacag 120
cacccaggca aagcccccaa actcatgatt tatgagggca gtaagcggcc ctcaggggtt 180
tctaatcgct tctctggctc caagtctggc aacacggcct ccctgacaat ctctgggctc 240
caggctgagg acgaggctga ttattactgc tgctcatatg caggtagtag cactttctat 300
gtcttcggaa ctgggaccaa ggtcaccgtc ctaggtcagc ccaaggctgc cccctcggtc 360
actctgttcc cgccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc 420
ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc 480
aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc 540
agctatctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag ctgccaggtc 600
acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc ataatgagct 660
agc 663
<210> 450
<211> 663
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V1-11J2
<400> 450
cagtctgtgc tgactcagcc accctcggtg tctgaagccc ccaggcagag ggtcaccatc 60
tcctgttctg gaagcagctc caacatcgga aataatgctg taaactggta ccagcagctc 120
ccaggaaagg ctcccaaact cctcatctat tatgatgatc tgctgccctc aggggtctct 180
gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccag 240
tctgaggatg aggctgatta ttactgtgca gcatgggatg acagcctgaa tggtcctgtg 300
gtattcggcg gagggaccaa gctgaccgtc ctaggtcagc ccaaggctgc cccctcggtc 360
actctgttcc cgccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc 420
ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc 480
aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc 540
agctatctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag ctgccaggtc 600
acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc ataatgagct 660
agc 663
<210> 451
<211> 336
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V1-16J6
<400> 451
ccagtctgtg ctgactcagc caccctcagc gtctgggacc cccgggcaga gggtcaccat 60
ctcttgttct ggaagcagct ccaacatcgg aagtaatact gtaaactggt accagcagct 120
cccaggaacg gcccccaaac tcctcatcta tagtaataat cagcggccct caggggtccc 180
tgaccgattc tctggctcca agtctggcac ctcagcctcc ctggccatca gtgggctcca 240
gtctgaggat gaggctgatt attactgtgc agcatgggat gacagcctga atggtcctaa 300
tgtgttcggc agtggcacca aggtgaccgt cctagg 336
<210> 452
<211> 657
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V2-17J2
<400> 452
tcctatgagc tgacacagcc accctcggtg tcagtgtccc caggacagac ggccaggatc 60
acctgctctg gagatgcatt gccaaagcaa tatgcttatt ggtaccagca gaagccaggc 120
caggcccctg tgctggtgat atataaagac agtgagaggc cctcaggcat ccctgagcga 180
ttctctggct ccagctcagg gacaacagtc acgttgacca tcagtggagt ccaggcagaa 240
gatgaggctg actattactg tcaatcagca gacagcagtg gtacttatcc tgtggtattc 300
ggcggaggga ccaagctgac cgtcctaggt cagcccaagg ctgccccctc ggtcactctg 360
ttcccgccct cctctgagga gcttcaagcc aacaaggcca cactggtgtg tctcataagt 420
gacttctacc cgggagccgt gacagtggcc tggaaggcag atagcagccc cgtcaaggcg 480
ggagtggaaa caaccacacc ctccaaacaa agcaacaaca agtacgcggc cagcagctat 540
ctgagcctga cgcctgagca gtggaagtcc cacagaagct acagctgcca ggtcacgcat 600
gaagggagca ccgtggagaa gacagtggcc cctacagaat gttcataatg agctagc 657
<210> 453
<211> 663
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V3-4J1
<400> 453
cagactgtgg tgacccagga gccatcgttc tcagtgtccc ctggagggac agtcacactc 60
acttgtggct tgagctctgg ctcagtctct actagttact accccagctg gtaccagcag 120
accccaggcc aggctccacg cacgctcatc tacagcacaa acactcgctc ttctggggtc 180
cctgatcgct tctctggctc catccttggg aacaaagctg ccctcaccat cacgggggcc 240
caggcagatg atgaatctga ttattactgt gtgctgtata tgggtagtgg catttcttat 300
gtcttcggaa ctgggaccaa ggtcaccgtc ctaggtcagc ccaaggctgc cccctcggtc 360
actctgttcc cgccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc 420
ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc 480
aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc 540
agctatctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag ctgccaggtc 600
acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc ataatgagct 660
agc 663
<210> 454
<211> 666
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V5-4J2
<400> 454
cagcctgtgc tgactcaatc atcctctgcc tctgcttccc tgggctcctc ggtcaagctc 60
acctgcactc tgagcagtgg gcacagtagc tacatcatcg catggcatca gcagcagcca 120
gggaaggccc ctcggtactt gatgaagctt gaaggtagtg gaagctacaa caaggggagc 180
ggagttcctg atcgcttctc aggctccagc tctggggctg accgctacct caccatctcc 240
aacctccagt ttgaggatga ggctgattat tactgtgaga cctgggacag taacactcat 300
gtggtattcg gcggagggac caagctgacc gtcctaggtc agcccaaggc tgccccctcg 360
gtcactctgt tcccgccctc ctctgaggag cttcaagcca acaaggccac actggtgtgt 420
ctcataagtg acttctaccc gggagccgtg acagtggcct ggaaggcaga tagcagcccc 480
gtcaaggcgg gagtggagac caccacaccc tccaaacaaa gcaacaacaa gtacgcggcc 540
agcagctatc tgagcctgac gcctgagcag tggaagtccc acagaagcta cagctgccag 600
gtcacgcatg aagggagcac cgtggagaag acagtggccc ctacagaatg ttcataatga 660
gctagc 666
<210> 455
<211> 660
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V1-47
<400> 455
caatcagttt tgacccagcc accctccgca tccggcaccc ccgggcaacg cgttacaata 60
agctgtagcg gcagctcatc taatattggc agcaactacg tttattggta ccagcagctt 120
ccagggaccg cccccaaatt gcttatctac cggaataatc agaggccttc cggggtgcca 180
gataggttct ctgggagtaa atctggcact agcgcaagtc tggctatcag cgggctccgg 240
tctgaggatg aagccgacta ttattgcgcg agcgctgagg actcatcttc taatgctgtg 300
tttggctccg gtaccacact caccgtccta ggtcagccca aggctgcccc ctcggtcact 360
ctgttcccgc cctcctctga ggagcttcaa gccaacaagg ccacactggt gtgtctcata 420
agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag 480
gcgggagtgg aaacaaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc 540
tatctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg 600
catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttcata atgagctagc 660
<210> 456
<211> 660
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: V1-51
<400> 456
cagtccgtgc tgacccaacc cccgtcagtg tctgctgccc ccgggcagaa ggtgactatc 60
agctgctctg gctcatcaag caacatcggg aataattacg tcagctggta ccagcagctg 120
cctggaacag ctcctaaact gctcatttat gacaataaca agcgcccatc cggaatccct 180
gaccgattca gcggaagcaa atcagggacc tctgcaactc tgggaatcac tgggcttcag 240
acaggagatg aggcagatta ctattgcgcc tctgcagagg acagctccag caatgccgtg 300
ttcgggtctg gtaccactct tacagtccta ggtcagccca aggctgcccc ctcggtcact 360
ctgttcccgc cctcctctga ggagcttcaa gccaacaagg ccacactggt gtgtctcata 420
agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag 480
gcgggagtgg aaacaaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc 540
tatctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg 600
catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttcata atgagctagc 660
<210> 457
<211> 4188
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: vector pFUSE-hIgG2-Fc2
<400> 457
ggatctgcga tcgctccggt gcccgtcagt gggcagagcg cacatcgccc acagtccccg 60
agaagttggg gggaggggtc ggcaattgaa cgggtgccta gagaaggtgg cgcggggtaa 120
actgggaaag tgatgtcgtg tactggctcc gcctttttcc cgagggtggg ggagaaccgt 180
atataagtgc agtagtcgcc gtgaacgttc tttttcgcaa cgggtttgcc gccagaacac 240
agctgaagct tcgaggggct cgcatctctc cttcacgcgc ccgccgccct acctgaggcc 300
gccatccacg ccggttgagt cgcgttctgc cgcctcccgc ctgtggtgcc tcctgaactg 360
cgtccgccgt ctaggtaagt ttaaagctca ggtcgagacc gggcctttgt ccggcgctcc 420
cttggagcct acctagactc agccggctct ccacgctttg cctgaccctg cttgctcaac 480
tctacgtctt tgtttcgttt tctgttctgc gccgttacag atccaagctg tgaccggcgc 540
ctacctgaga tcaccggcga aggagggcca ccatgtacag gatgcaactc ctgtcttgca 600
ttgcactaag tcttgcactt gtcacgaatt cgatatcggc catggttaga tctgtggagt 660
gcccaccttg cccagcacca cctgtggcag gaccttcagt cttcctcttc cccccaaaac 720
ccaaggacac cctgatgatc tccagaaccc ctgaggtcac gtgcgtggtg gtggacgtga 780
gccacgaaga ccccgaggtc cagttcaact ggtacgtgga cggcatggag gtgcataatg 840
ccaagacaaa gccacgggag gagcagttca acagcacgtt ccgtgtggtc agcgtcctca 900
ccgtcgtgca ccaggactgg ctgaacggca aggagtacaa gtgcaaggtc tccaacaaag 960
gcctcccagc ccccatcgag aaaaccatct ccaaaaccaa agggcagccc cgagaaccac 1020
aggtgtacac cctgccccca tcccgggagg agatgaccaa gaaccaggtc agcctgacct 1080
gcctggtcaa aggcttctac cccagcgaca tcgccgtgga gtgggagagc aatgggcagc 1140
cggagaacaa ctacaagacc acacctccca tgctggactc cgacggctcc ttcttcctct 1200
acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg 1260
tgatgcatga ggctctgcac aaccactaca cacagaagag cctctccctg tctccgggta 1320
aatgagtgcc acggctagct ggccagacat gataagatac attgatgagt ttggacaaac 1380
cacaactaga atgcagtgaa aaaaatgctt tatttgtgaa atttgtgatg ctattgcttt 1440
atttgtaacc attataagct gcaataaaca agttaacaac aacaattgca ttcattttat 1500
gtttcaggtt cagggggagg tgtgggaggt tttttaaagc aagtaaaacc tctacaaatg 1560
tggtatggaa ttaattctaa aatacagcat agcaaaactt taacctccaa atcaagcctc 1620
tacttgaatc cttttctgag ggatgaataa ggcataggca tcaggggctg ttgccaatgt 1680
gcattagctg tttgcagcct caccttcttt catggagttt aagatatagt gtattttccc 1740
aaggtttgaa ctagctcttc atttctttat gttttaaatg cactgacctc ccacattccc 1800
tttttagtaa aatattcaga aataatttaa atacatcatt gcaatgaaaa taaatgtttt 1860
ttattaggca gaatccagat gctcaaggcc cttcataata tcccccagtt tagtagttgg 1920
acttagggaa caaaggaacc tttaatagaa attggacagc aagaaagcga gcttctagct 1980
tatcctcagt cctgctcctc tgccacaaag tgcacgcagt tgccggccgg gtcgcgcagg 2040
gcgaactccc gcccccacgg ctgctcgccg atctcggtca tggccggccc ggaggcgtcc 2100
cggaagttcg tggacacgac ctccgaccac tcggcgtaca gctcgtccag gccgcgcacc 2160
cacacccagg ccagggtgtt gtccggcacc acctggtcct ggaccgcgct gatgaacagg 2220
gtcacgtcgt cccggaccac accggcgaag tcgtcctcca cgaagtcccg ggagaacccg 2280
agccggtcgg tccagaactc gaccgctccg gcgacgtcgc gcgcggtgag caccggaacg 2340
gcactggtca acttggccat gatggctcct cctgtcagga gaggaaagag aagaaggtta 2400
gtacaattgc tatagtgagt tgtattatac tatgcagata tactatgcca atgattaatt 2460
gtcaaactag ggctgcaggg ttcatagtgc cacttttcct gcactgcccc atctcctgcc 2520
caccctttcc caggcataga cagtcagtga cttaccaaac tcacaggagg gagaaggcag 2580
aagcttgaga cagacccgcg ggaccgccga actgcgaggg gacgtggcta gggcggcttc 2640
ttttatggtg cgccggccct cggaggcagg gcgctcgggg aggcctagcg gccaatctgc 2700
ggtggcagga ggcggggccg aaggccgtgc ctgaccaatc cggagcacat aggagtctca 2760
gccccccgcc ccaaagcaag gggaagtcac gcgcctgtag cgccagcgtg ttgtgaaatg 2820
ggggcttggg ggggttgggg ccctgactag tcaaaacaaa ctcccattga cgtcaatggg 2880
gtggagactt ggaaatcccc gtgagtcaaa ccgctatcca cgcccattga tgtactgcca 2940
aaaccgcatc atcatggtaa tagcgatgac taatacgtag atgtactgcc aagtaggaaa 3000
gtcccataag gtcatgtact gggcataatg ccaggcgggc catttaccgt cattgacgtc 3060
aatagggggc gtacttggca tatgatacac ttgatgtact gccaagtggg cagtttaccg 3120
taaatactcc acccattgac gtcaatggaa agtccctatt ggcgttacta tgggaacata 3180
cgtcattatt gacgtcaatg ggcgggggtc gttgggcggt cagccaggcg ggccatttac 3240
cgtaagttat gtaacgcctg caggttaatt aagaacatgt gagcaaaagg ccagcaaaag 3300
gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg cccccctgac 3360
gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga 3420
taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac cctgccgctt 3480
accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca tagctcacgc 3540
tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc 3600
cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caacccggta 3660
agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggtat 3720
gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac tagaagaaca 3780
gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct 3840
tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt 3900
acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct 3960
cagtggaacg aaaactcacg ttaagggatt ttggtcatgg ctagttaatt aacatttaaa 4020
tcagcggccg caataaaata tctttatttt cattacatct gtgtgttggt tttttgtgtg 4080
aatcgtaact aacatacgct ctccatcaaa acaaaacgaa acaaaacaaa ctagcaaaat 4140
aggctgtccc cagtgcaagt gcaggtgcca gaacatttct ctatcgaa 4188
<210> 458
<211> 4495
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: vector HC pFuse
<400> 458
ggatctgcga tcgctccggt gcccgtcagt gggcagagcg cacatcgccc acagtccccg 60
agaagttggg gggaggggtc ggcaattgaa cgggtgccta gagaaggtgg cgcggggtaa 120
actgggaaag tgatgtcgtg tactggctcc gcctttttcc cgagggtggg ggagaaccgt 180
atataagtgc agtagtcgcc gtgaacgttc tttttcgcaa cgggtttgcc gccagaacac 240
agctgaagct tcgaggggct cgcatctctc cttcacgcgc ccgccgccct acctgaggcc 300
gccatccacg ccggttgagt cgcgttctgc cgcctcccgc ctgtggtgcc tcctgaactg 360
cgtccgccgt ctaggtaagt ttaaagctca ggtccagacc gggcctttgt ccggcgctcc 420
cttggagcct acctagactc agccggctct ccacgctttg cctgaccctg cttgctcaac 480
tctacgtctt tgtttcgttt tctgttctgc gccgttacag atccaagctg tgaccggcgc 540
ctacctgaga tcaccggcga aggagggcca ccatgcgcag gatgcaactc ctgttgctga 600
ttgcactaag tcttgcactt gtcacgaatt cgccatggct cctcagctag caccaagggc 660
ccatcggtct tccccctggc accctcctcc aagagcacct ctgggggcac agcggccctg 720
ggctgcctgg tcaaggacta cttccccgag ccggtgacgg tgtcgtggaa ctcaggcgcc 780
ctgaccagcg gcgtgcacac cttcccggct gtcctacagt cctcaggact ctactccctc 840
agcagcgtgg tgaccgtgcc ctccagcagc ttgggcaccc agacctacat ctgcaacgtg 900
aatcacaagc ccagcaacac caaggtggac aagaaagttg agcccaaatc ttgtgacaaa 960
actcacacat gcccaccgtg cccagcacct gaactcctgg ggggaccgtc agtcttcctc 1020
ttccccccaa aacccaagga caccctcatg atctcccgga cccctgaggt cacatgcgtg 1080
gtggtggacg tgagccacga agaccctgag gtcaagttca actggtacgt ggacggcgtg 1140
gaggtgcata atgccaagac aaagccgcgg gaggagcagt acaacagcac gtaccgtgtg 1200
gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta caagtgcaag 1260
gtgtccaaca aagccctccc agcccccatc gagaaaacca tctccaaagc caaagggcag 1320
ccccgagaac cacaggtgta caccctgccc ccatcccggg atgagctgac caagaaccag 1380
gtcagcctga cctgcctggt caaaggcttc tatcccagcg acatcgccgt ggagtgggag 1440
agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1500
tccttcttcc tctacagcaa gctcaccgtg gacaagagca ggtggcagca ggggaacgtc 1560
ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacgcagaa gagcctctcc 1620
ctgtctccgg gtaaatgata atctagtggc cagacatgat aagatacatt gatgagtttg 1680
gacaaaccac aactagaatg cagtgaaaaa aatgctttat ttgtgaaatt tgtgatgcta 1740
ttgctttatt tgtaaccatt ataagctgca ataaacaagt taacaacaac aattgcattc 1800
attttatgtt tcaggttcag ggggaggtgt gggaggtttt ttaaagcaag taaaacctct 1860
acaaatgtgg tatggaatta attctaaaat acagcatagc aaaactttaa cctccaaatc 1920
aagcctctac ttgaatcctt ttctgaggga tgaataaggc ataggcatca ggggctgttg 1980
ccaatgtgca ttagctgttt gcagcctcac cttctttcat ggagtttaag atatagtgta 2040
ttttcccaag gtttgaacta gctcttcatt tctttatgtt ttaaatgcac tgacctccca 2100
cattcccttt ttagtaaaat attcagaaat aatttaaata catcattgca atgaaaataa 2160
atgtttttta ttaggcagaa tccagatgct caaggccctt cataatatcc cccagtttag 2220
tagttggact tagggaacaa aggaaccttt aatagaaatt ggacagcaag aaagcgagct 2280
tctagcttat cctcagtcct gctcctctgc cacaaagtgc acgcagttgc cggccgggtc 2340
gcgcagggcg aactcccgcc cccacggctg ctcgccgatc tcggtcatgg ccggcccgga 2400
ggcgtcccgg aagttcgtgg acacgacctc cgaccactcg gcgtacagct cgtccaggcc 2460
gcgcacccac acccaggcca gggtgttgtc cggcaccacc tggtcctgga ccgcgctgat 2520
gaacagggtc acgtcgtccc ggaccacacc ggcgaagtcg tcctccacga agtcccggga 2580
gaacccgagc cggtcggtcc agaactcgac cgctccggcg acgtcgcgcg cggtgagcac 2640
cggaacggca ctggtcaact tggccatgat ggctcctcct gtcaggagag gaaagagaag 2700
aaggttagta caattgctat agtgagttgt attatactat gcagatatac tatgccaatg 2760
attaattgtc aaactagggc tgcagggttc atagtgccac ttttcctgca ctgccccatc 2820
tcctgcccac cctttcccag gcatagacag tcagtgactt accaaactca caggagggag 2880
aaggcagaag cttgagacag acccgcggga ccgccgaact gcgaggggac gtggctaggg 2940
cggcttcttt tatggtgcgc cggccctcgg aggcagggcg ctcggggagg cctagcggcc 3000
aatctgcggt ggcaggaggc ggggccgaag gccgtgcctg accaatccgg agcacatagg 3060
agtctcagcc ccccgcccca aagcaagggg aagtcacgcg cctgtagcgc cagcgtgttg 3120
tgaaatgggg gcttgggggg gttggggccc tgactagtca aaacaaactc ccattgacgt 3180
caatggggtg gagacttgga aatccccgtg agtcaaaccg ctatccacgc ccattgatgt 3240
actgccaaaa ccgcatcatc atggtaatag cgatgactaa tacgtagatg tactgccaag 3300
taggaaagtc ccataaggtc atgtactggg cataatgcca ggcgggccat ttaccgtcat 3360
tgacgtcaat agggggcgta cttggcatat gatacacttg atgtactgcc aagtgggcag 3420
tttaccgtaa atactccacc cattgacgtc aatggaaagt ccctattggc gttactatgg 3480
gaacatacgt cattattgac gtcaatgggc gggggtcgtt gggcggtcag ccaggcgggc 3540
catttaccgt aagttatgta acgcctgcag gttaattaag aacatgtgag caaaaggcca 3600
gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc 3660
ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact 3720
ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct 3780
gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcatag 3840
ctcacgctgt aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca 3900
cgaacccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa 3960
cccggtaaga cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc 4020
gaggtatgta ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag 4080
aagaacagta tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg 4140
tagctcttga tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca 4200
gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc 4260
tgacgctcag tggaacgaaa actcacgtta agggattttg gtcatggcta gttaattaac 4320
atttaaatca gcggccgcaa taaaatatct ttattttcat tacatctgtg tgttggtttt 4380
ttgtgtgaat cgtaactaac atacgctctc catcaaaaca aaacgaaaca aaacaaacta 4440
gcaaaatagg ctgtccccag tgcaagtgca ggtgccagaa catttctcta tcgaa 4495
<210> 459
<211> 3822
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: vector LC-pFuse
<400> 459
ggatctgcga tcgctccggt gcccgtcagt gggcagagcg cacatcgccc acagtccccg 60
agaagttggg gggaggggtc ggcaattgaa cgggtgccta gagaaggtgg cgcggggtaa 120
actgggaaag tgatgtcgtg tactggctcc gcctttttcc cgagggtggg ggagaaccgt 180
atataagtgc agtagtcgcc gtgaacgttc tttttcgcaa cgggtttgcc gccagaacac 240
agctgaagct tcgaggggct cgcatctctc cttcacgcgc ccgccgccct acctgaggcc 300
gccatccacg ccggttgagt cgcgttctgc cgcctcccgc ctgtggtgcc tcctgaactg 360
cgtccgccgt ctaggtaagt ttaaagctca ggtccagacc gggcctttgt ccggcgctcc 420
cttggagcct acctagactc agccggctct ccacgctttg cctgaccctg cttgctcaac 480
tctacgtctt tgtttcgttt tctgttctgc gccgttacag atccaagctg tgaccggcgc 540
ctacctgaga tcaccggcga aggagggcca ccatgcgcag gatgcaactc ctgttgctga 600
ttgcactaag tcttgcactt gtcacgaatt cgccatggcc ctaggtcagc ccaaggctgc 660
cccctcggtc actctgttcc cgccctcctc tgaggagctt caagccaaca aggccacact 720
ggtgtgtctc ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag 780
cagccccgtc aaggcgggag tggaaacaac cacaccctcc aaacaaagca acaacaagta 840
cgcggccagc agctatctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag 900
ctgccaggtc acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc 960
ataatgagct agctggccag acatgataag atacattgat gagtttggac aaaccacaac 1020
tagaatgcag tgaaaaaaat gctttatttg tgaaatttgt gatgctattg ctttatttgt 1080
aaccattata agctgcaata aacaagttaa caacaacaat tgcattcatt ttatgtttca 1140
ggttcagggg gaggtgtggg aggtttttta aagcaagtaa aacctctaca aatgtggtat 1200
ggaattaatt ctaaaataca gcatagcaaa actttaacct ccaaatcaag cctctacttg 1260
aatccttttc tgagggatga ataaggcata ggcatcaggg gctgttgcca atgtgcatta 1320
gctgtttgca gcctcacctt ctttcatgga gtttaagata tagtgtattt tcccaaggtt 1380
tgaactagct cttcatttct ttatgtttta aatgcactga cctcccacat tcccttttta 1440
gtaaaatatt cagaaataat ttaaatacat cattgcaatg aaaataaatg ttttttatta 1500
ggcagaatcc agatgctcaa ggcccttcat aatatccccc agtttagtag ttggacttag 1560
ggaacaaagg aacctttaat agaaattgga cagcaagaaa gcgagcttct agcttatcct 1620
cagtcctgct cctctgccac aaagtgcacg cagttgccgg ccgggtcgcg cagggcgaac 1680
tcccgccccc acggctgctc gccgatctcg gtcatggccg gcccggaggc gtcccggaag 1740
ttcgtggaca cgacctccga ccactcggcg tacagctcgt ccaggccgcg cacccacacc 1800
caggccaggg tgttgtccgg caccacctgg tcctggaccg cgctgatgaa cagggtcacg 1860
tcgtcccgga ccacaccggc gaagtcgtcc tccacgaagt cccgggagaa cccgagccgg 1920
tcggtccaga actcgaccgc tccggcgacg tcgcgcgcgg tgagcaccgg aacggcactg 1980
gtcaacttgg ccatgatggc tcctcctgtc aggagaggaa agagaagaag gttagtacaa 2040
ttgctatagt gagttgtatt atactatgca gatatactat gccaatgatt aattgtcaaa 2100
ctagggctgc agggttcata gtgccacttt tcctgcactg ccccatctcc tgcccaccct 2160
ttcccaggca tagacagtca gtgacttacc aaactcacag gagggagaag gcagaagctt 2220
gagacagacc cgcgggaccg ccgaactgcg aggggacgtg gctagggcgg cttcttttat 2280
ggtgcgccgg ccctcggagg cagggcgctc ggggaggcct agcggccaat ctgcggtggc 2340
aggaggcggg gccgaaggcc gtgcctgacc aatccggagc acataggagt ctcagccccc 2400
cgccccaaag caaggggaag tcacgcgcct gtagcgccag cgtgttgtga aatgggggct 2460
tgggggggtt ggggccctga ctagtcaaaa caaactccca ttgacgtcaa tggggtggag 2520
acttggaaat ccccgtgagt caaaccgcta tccacgccca ttgatgtact gccaaaaccg 2580
catcatcatg gtaatagcga tgactaatac gtagatgtac tgccaagtag gaaagtccca 2640
taaggtcatg tactgggcat aatgccaggc gggccattta ccgtcattga cgtcaatagg 2700
gggcgtactt ggcatatgat acacttgatg tactgccaag tgggcagttt accgtaaata 2760
ctccacccat tgacgtcaat ggaaagtccc tattggcgtt actatgggaa catacgtcat 2820
tattgacgtc aatgggcggg ggtcgttggg cggtcagcca ggcgggccat ttaccgtaag 2880
ttatgtaacg cctgcaggtt aattaagaac atgtgagcaa aaggccagca aaaggccagg 2940
aaccgtaaaa aggccgcgtt gctggcgttt ttccataggc tccgcccccc tgacgagcat 3000
cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga caggactata aagataccag 3060
gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga 3120
tacctgtccg cctttctccc ttcgggaagc gtggcgcttt ctcatagctc acgctgtagg 3180
tatctcagtt cggtgtaggt cgttcgctcc aagctgggct gtgtgcacga accccccgtt 3240
cagcccgacc gctgcgcctt atccggtaac tatcgtcttg agtccaaccc ggtaagacac 3300
gacttatcgc cactggcagc agccactggt aacaggatta gcagagcgag gtatgtaggc 3360
ggtgctacag agttcttgaa gtggtggcct aactacggct acactagaag aacagtattt 3420
ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa gagttggtag ctcttgatcc 3480
ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt gcaagcagca gattacgcgc 3540
agaaaaaaag gatctcaaga agatcctttg atcttttcta cggggtctga cgctcagtgg 3600
aacgaaaact cacgttaagg gattttggtc atggctagtt aattaacatt taaatcagcg 3660
gccgcaataa aatatcttta ttttcattac atctgtgtgt tggttttttg tgtgaatcgt 3720
aactaacata cgctctccat caaaacaaaa cgaaacaaaa caaactagca aaataggctg 3780
tccccagtgc aagtgcaggt gccagaacat ttctctatcg aa 3822
<210> 460
<211> 107
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3
<400> 460
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser
100 105
<210> 461
<211> 107
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3_CDR1 Cow
<400> 461
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser
100 105
<210> 462
<211> 107
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3_CDR2 Cow
<400> 462
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser
100 105
<210> 463
<211> 107
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3_CDR1 G31D, Y32K
<400> 463
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser
100 105
<210> 464
<211> 107
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3_CDR2 E50S
<400> 464
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser
100 105
<210> 465
<211> 107
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3_CDR1 Cow_CDR2 Cow
<400> 465
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser
100 105
<210> 466
<211> 107
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3_CDR1 Cow_CDR2 E50S
<400> 466
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser
100 105
<210> 467
<211> 107
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3_CDR1 G31D,Y32K_CDR2 Cow
<400> 467
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser
100 105
<210> 468
<211> 107
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VH4-34+CDR3_CDR1 G31D,Y32K_CDR2 E50S
<400> 468
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser
100 105
<210> 469
<211> 25
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: J region of antibody comprising UL CDR3
<400> 469
Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly
1 5 10 15
Leu Leu Val Thr Val Ser Ser Ala Ser
20 25
<210> 470
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VL1-51 CDR2 substituted amino acid resides
<400> 470
Asp Asn Asn Lys Arg Pro
1 5
<210> 471
<211> 6
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: VL1-51 CDR2 substituted amino acids
<400> 471
Gly Asp Thr Ser Arg Ala
1 5
<210> 472
<211> 420
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: HC-pFuse vector with BsaI cassette
<400> 472
caggtgcagc tacagcagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcacag caagcgggtt ttcactgagc gacaaggcag tgggatggat tcgccagccc 120
ccagggaagg ggctggagtg gattggggaa atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cgagacctac tatggttcgg gtctctctta tacctacaat 360
tatgaatggc atgtggatgt ctggggacag ggcctgctgg tgacagtctc tagtgctagc 420
<210> 473
<211> 133
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Hc-pFuse vector with non-bovine sequence insert
<220>
<221> MISC_FEATURE
<222> (107)..(107)
<223> X is an insert of a non-bovine sequence
<220>
<221> misc_feature
<222> (108)..(108)
<223> Xaa can be any naturally occurring amino acid
<400> 473
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Xaa Ser Tyr Thr Tyr
100 105 110
Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr
115 120 125
Val Ser Ser Ala Ser
130
<210> 474
<211> 662
<212> DNA
<213> Artificial sequence
<220>
<223> Synthesized: BLV1H12 LV-human lambda LC
<400> 474
tcacgaattc gcaggccgtc ctgaaccagc caagcagcgt ctccgggtct ctggggcagc 60
gggtctcaat cacctgtagc gggtcttcct ccaatgtcgg caacggctac gtgtcttggt 120
atcagctgat ccctggcagt gccccacgaa ccctgatcta cggcgacaca tccagagctt 180
ctggggtccc cgatcggttc tcagggagca gatccggaaa cacagctact ctgaccatca 240
gctccctgca ggctgaggac gaagcagatt atttctgcgc atctgccgag gactctagtt 300
caaatgccgt gtttggaagc ggcaccacac tgacagtcct aggtcagccc aaggctgccc 360
cctcggtcac tctgttcccg ccctcctctg aggagcttca agccaacaag gccacactgg 420
tgtgtctcat aagtgacttc tacccgggag ccgtgacagt ggcctggaag gcagatagca 480
gccccgtcaa ggcgggagtg gagaccacca caccctccaa acaaagcaac aacaagtacg 540
cggccagcag ctatctgagc ctgacgcctg agcagtggaa gtcccacaga agctacagct 600
gccaggtcac gcatgaaggg agcaccgtgg agaagacagt ggcccctaca gaatgttcat 660
aa 662
<210> 475
<211> 74
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: IL-8 sequence
<400> 475
Pro Arg Ser Ala Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser
1 5 10 15
Lys Pro Phe His Pro Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser
20 25 30
Gly Pro His Cys Ala Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly
35 40 45
Arg Glu Leu Cys Leu Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val
50 55 60
Glu Lys Phe Leu Lys Arg Ala Glu Asn Ser
65 70
<210> 476
<211> 25
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: ziconotide sequence
<400> 476
Cys Lys Gly Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys
1 5 10 15
Thr Gly Ser Cys Arg Ser Gly Lys Cys
20 25
<210> 477
<211> 15
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: somatostatin sequence
<400> 477
Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Gly
1 5 10 15
<210> 478
<211> 34
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: chlorotoxin sequence
<400> 478
Met Cys Met Pro Cys Phe Thr Thr Asp His Gln Met Ala Arg Lys Cys
1 5 10 15
Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr Gly Pro Gln
20 25 30
Cys Leu
<210> 479
<211> 68
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: SDF1(alpha) sequence
<400> 479
Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
1 5 10 15
His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
20 25 30
Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
35 40 45
Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
50 55 60
Ala Leu Asn Lys
65
<210> 480
<211> 133
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: IL-21 sequence
<400> 480
Gln Gly Gln Asp Arg His Met Ile Arg Met Arg Gln Leu Ile Asp Ile
1 5 10 15
Val Asp Gln Leu Lys Asn Tyr Val Asn Asp Leu Val Pro Glu Phe Leu
20 25 30
Pro Ala Pro Glu Asp Val Glu Thr Asn Cys Glu Trp Ser Ala Phe Ser
35 40 45
Cys Phe Gln Lys Ala Gln Leu Lys Ser Ala Asn Thr Gly Asn Asn Glu
50 55 60
Arg Ile Ile Asn Val Ser Ile Lys Lys Leu Lys Arg Lys Pro Pro Ser
65 70 75 80
Thr Asn Ala Gly Arg Arg Gln Lys His Arg Leu Thr Cys Pro Ser Cys
85 90 95
Asp Ser Tyr Glu Lys Lys Pro Pro Lys Glu Phe Leu Glu Arg Phe Lys
100 105 110
Ser Leu Leu Gln Lys Met Ile His Gln His Leu Ser Ser Arg Thr His
115 120 125
Gly Ser Glu Asp Ser
130
<210> 481
<211> 30
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: ProTxII sequence
<400> 481
Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys Cys
1 5 10 15
Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp
20 25 30
<210> 482
<211> 274
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Hc BLV1H12
<400> 482
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Cys Pro Asp Gly Tyr
100 105 110
Arg Glu Arg Ser Asp Cys Ser Asn Arg Pro Ala Cys Gly Thr Ser Asp
115 120 125
Cys Cys Arg Val Ser Val Phe Gly Asn Cys Leu Thr Thr Leu Pro Val
130 135 140
Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly
145 150 155 160
Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser Thr Thr Ala Pro Lys
165 170 175
Val Tyr Pro Leu Ser Ser Cys Cys Gly Asp Lys Ser Ser Ser Thr Val
180 185 190
Thr Leu Gly Cys Leu Val Ser Ser Tyr Met Pro Glu Pro Val Thr Val
195 200 205
Thr Trp Asn Ser Gly Ala Leu Lys Ser Gly Val His Thr Phe Pro Ala
210 215 220
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Met Val Thr Val
225 230 235 240
Pro Gly Ser Thr Ser Gly Gln Thr Phe Thr Cys Asn Val Ala His Pro
245 250 255
Ala Ser Ser Thr Lys Val Asp Lys Ala Val Glu Pro Lys Ser Cys Asp
260 265 270
Gly Ser
<210> 483
<211> 216
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Lc BLV1H12
<400> 483
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Arg Val Ser Ile Thr Cys Ser Gly Ser Ser Ser Asn Val Gly Asn Gly
20 25 30
Tyr Val Ser Trp Tyr Gln Leu Ile Pro Gly Ser Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Ser Arg Ala Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Arg Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Ser Leu Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ser Pro Pro Ser Val Thr Leu Phe Pro Pro Ser Thr Glu Glu
115 120 125
Leu Asn Gly Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ser Val Thr Val Val Trp Lys Ala Asp Gly Ser Thr Ile Thr
145 150 155 160
Arg Asn Val Glu Thr Thr Arg Ala Ser Lys Gln Ser Asn Ser Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Ser Ser Asp Trp Lys Ser Lys
180 185 190
Gly Ser Tyr Ser Cys Glu Val Thr His Glu Gly Ser Thr Val Thr Lys
195 200 205
Thr Val Lys Pro Ser Glu Cys Ser
210 215
<210> 484
<211> 269
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Hc BLV5B8
<400> 484
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Gln Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Ser Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Thr Val His Gln Glu Thr Arg Lys Thr Cys Ser Asp Gly Tyr Ile Ala
100 105 110
Val Asp Ser Cys Gly Arg Gly Gln Ser Asp Gly Cys Val Asn Asp Cys
115 120 125
Asn Ser Cys Tyr Tyr Gly Trp Arg Asn Cys Arg Arg Gln Pro Ala Ile
130 135 140
His Ser Tyr Glu Phe His Val Asp Ala Trp Gly Arg Gly Leu Leu Val
145 150 155 160
Thr Val Ser Ser Ala Ser Thr Thr Ala Pro Lys Val Tyr Pro Leu Ser
165 170 175
Ser Cys Cys Gly Asp Lys Ser Ser Ser Thr Val Thr Leu Gly Cys Leu
180 185 190
Val Ser Ser Tyr Met Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly
195 200 205
Ala Leu Lys Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
210 215 220
Gly Leu Tyr Ser Leu Ser Ser Met Val Thr Val Pro Gly Ser Thr Ser
225 230 235 240
Gly Gln Thr Phe Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys
245 250 255
Val Asp Lys Ala Val Glu Pro Lys Ser Cys Asp Gly Ser
260 265
<210> 485
<211> 216
<212> PRT
<213> Artificial sequence
<220>
<223> Synthesized: Lc BLV5B8
<400> 485
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Arg Val Ser Ile Thr Cys Ser Gly Ser Ser Ser Asn Val Gly Asn Gly
20 25 30
Tyr Val Ser Trp Tyr Gln Leu Ile Pro Gly Ser Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Ser Arg Ala Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Arg Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Ser Leu Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ser Pro Pro Ser Val Thr Leu Phe Pro Pro Ser Thr Glu Glu
115 120 125
Leu Asn Gly Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ser Val Thr Val Val Trp Lys Ala Asp Gly Ser Thr Ile Thr
145 150 155 160
Arg Asn Val Glu Thr Thr Arg Ala Ser Lys Gln Ser Asn Ser Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Ser Ser Asp Trp Lys Ser Lys
180 185 190
Gly Ser Tyr Ser Cys Glu Val Thr His Glu Gly Ser Thr Val Thr Lys
195 200 205
Thr Val Lys Pro Ser Glu Cys Ser
210 215
<210> 486
<211> 648
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VL-CL of VL1-51 S2A, T5N, P8S, A12G ,A13S, P14L,
K46R, L47T, D51G, N52D, N53T
<400> 486
caggccgtcc tgaaccagcc aagcagcgtc tccgggtctc tggggcagaa ggtgactatc 60
agctgctctg gctcatcaag caacatcggg aataattacg tcagctggta ccagcagctg 120
cctggaacag ctcctagaac cctcatttat ggcgacacaa agcgcccatc cggaatccct 180
gaccgattca gcggaagcaa atcagggacc tctgcaactc tgggaatcac tgggcttcag 240
acaggagatg aggcagatta ctattgcgcc tctgcagagg acagctccag caatgccgtg 300
ttcgggtctg gtaccactct tacagtccta ggtcagccca aggctgcccc ctcggtcact 360
ctgttcccgc cctcctctga ggagcttcaa gccaacaagg ccacactggt gtgtctcata 420
agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag 480
gcgggagtgg aaacaaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc 540
tatctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg 600
catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttca 648
<210> 487
<211> 648
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VL-CL of VL1-51 S2A, T5N, P8S, A12G ,A13S, P14L,
K46R, L47T, D51G, N52D, N53T, K54S, P56A
<400> 487
caggccgtcc tgaaccagcc aagcagcgtc tccgggtctc tggggcagaa ggtgactatc 60
agctgctctg gctcatcaag caacatcggg aataattacg tcagctggta ccagcagctg 120
cctggaacag ctcctagaac cctcatttat ggcgacacat ccagagcttc cggaatccct 180
gaccgattca gcggaagcaa atcagggacc tctgcaactc tgggaatcac tgggcttcag 240
acaggagatg aggcagatta ctattgcgcc tctgcagagg acagctccag caatgccgtg 300
ttcgggtctg gtaccactct tacagtccta ggtcagccca aggctgcccc ctcggtcact 360
ctgttcccgc cctcctctga ggagcttcaa gccaacaagg ccacactggt gtgtctcata 420
agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag 480
gcgggagtgg aaacaaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc 540
tatctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg 600
catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttca 648
<210> 488
<211> 648
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VL-CL of VL1-51 I29V, N32G, K46R, L47T, D51G,
N52D, N53T
<400> 488
cagtccgtgc tgacccaacc cccgtcagtg tctgctgccc ccgggcagaa ggtgactatc 60
agctgctctg gctcatcctc caatgtcggc aacggctacg tcagctggta ccagcagctg 120
cctggaacag ctcctagaac cctcatttat ggcgacacaa agcgcccatc cggaatccct 180
gaccgattca gcggaagcaa atcagggacc tctgcaactc tgggaatcac tgggcttcag 240
acaggagatg aggcagatta ctattgcgcc tctgcagagg acagctccag caatgccgtg 300
ttcgggtctg gtaccactct tacagtccta ggtcagccca aggctgcccc ctcggtcact 360
ctgttcccgc cctcctctga ggagcttcaa gccaacaagg ccacactggt gtgtctcata 420
agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag 480
gcgggagtgg aaacaaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc 540
tatctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg 600
catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttca 648
<210> 489
<211> 648
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VL-CL of VL1-51 I29V, N32G, K46R, L47T, D51G,
N52D, N53T, K54S, P56A
<400> 489
cagtccgtgc tgacccaacc cccgtcagtg tctgctgccc ccgggcagaa ggtgactatc 60
agctgctctg gctcatcctc caatgtcggc aacggctacg tcagctggta ccagcagctg 120
cctggaacag ctcctagaac cctcatttat ggcgacacat ccagagcttc cggaatccct 180
gaccgattca gcggaagcaa atcagggacc tctgcaactc tgggaatcac tgggcttcag 240
acaggagatg aggcagatta ctattgcgcc tctgcagagg acagctccag caatgccgtg 300
ttcgggtctg gtaccactct tacagtccta ggtcagccca aggctgcccc ctcggtcact 360
ctgttcccgc cctcctctga ggagcttcaa gccaacaagg ccacactggt gtgtctcata 420
agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag 480
gcgggagtgg aaacaaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc 540
tatctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg 600
catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttca 648
<210> 490
<211> 621
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VH of VH4-34+CDR3-IL8_Q5RQ6E
<400> 490
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt ggttactact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattggggaa atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag t 621
<210> 491
<211> 621
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VH of VH4-34+CDR3-IL8_CDR1-G31DY32K_Q5RQ6E
<400> 491
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattggggaa atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag t 621
<210> 492
<211> 621
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VH of VH4-34+CDR3-IL8_CDR2-E50S_Q5RQ6E
<400> 492
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt ggttactact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag t 621
<210> 493
<211> 621
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VH of VH4-34+CDR3-IL8_CDR1-G31DY32K_CDR2-E50S_Q5RQ6E
<400> 493
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag t 621
<210> 494
<211> 621
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VH of VH4-34+CDR3-IL8_CDR1-Cow_Q5RQ6E
<400> 494
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcacag caagcgggtt ttcactgagc gacaaggcag tgggatggat tcgccagccc 120
ccagggaagg ggctggagtg gattggggaa atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag t 621
<210> 495
<211> 621
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VH of VH4-34+CDR3-IL8_CDR2-Cow_Q5RQ6E
<400> 495
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gctgggcagc atcgataccg gcgggaacac agggtccttc 120
agtggttact actggagctg gattcgccag cccccaggga aggggctgga gtggtacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag t 621
<210> 496
<211> 621
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VH of VH4-34+CDR3-IL8_CDR1-Cow_CDR2-E50S_Q5RQ6E
<400> 496
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcacag caagcgggtt ttcactgagc gacaaggcag tgggatggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag t 621
<210> 497
<211> 621
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: VH of VH4-34+CDR3-IL8_CDR1-Cow_CDR2-Cow_Q5RQ6E
<400> 497
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcacag caagcgggtt ttcactgagc gacaaggcag tgggatggat tcgccagccc 120
ccagggaagg ggctggagtg gctgggcagc atcgataccg gcgggaacac agggtacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag t 621
<210> 498
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Heavy Chain CDR3 Ascending Stalk
<400> 498
Thr Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser
1 5 10
<210> 499
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Heavy Chain CDR3 Descending Stalk
<400> 499
Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val
1 5 10
<210> 500
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12 Heavy Chain J region outside of CDR3
<400> 500
Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
1 5 10
<210> 501
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PGT145
<400> 501
Gly Ser Lys His Arg Leu Arg Asp Tyr Phe Leu Tyr Asn Glu
1 5 10
<210> 502
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PGT145
<400> 502
Gly Ser Lys His Arg Leu Arg Asp Tyr Phe Leu Tyr Asn
1 5 10
<210> 503
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PGT145
<400> 503
Gly Ser Lys His Arg Leu Arg Asp Tyr Phe Leu Tyr
1 5 10
<210> 504
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PGT145
<400> 504
Gly Ser Lys His Arg Leu Arg Asp Tyr Phe Leu
1 5 10
<210> 505
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PGT145
<400> 505
Gly Ser Lys His Arg Leu Arg Asp Tyr Phe
1 5 10
<210> 506
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PGT145
<400> 506
Gly Ser Lys His Arg Leu Arg Asp Tyr
1 5
<210> 507
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PGT145
<400> 507
Gly Ser Lys His Arg Leu Arg Asp
1 5
<210> 508
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG9
<400> 508
Glu Ala Gly Gly Pro Asp Tyr Arg Asn Gly Tyr Asn Tyr
1 5 10
<210> 509
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG9
<400> 509
Glu Ala Gly Gly Pro Asp Tyr Arg Asn Gly Tyr Asn
1 5 10
<210> 510
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG9
<400> 510
Glu Ala Gly Gly Pro Asp Tyr Arg Asn Gly Tyr
1 5 10
<210> 511
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG9
<400> 511
Glu Ala Gly Gly Pro Asp Tyr Arg Asn Gly
1 5 10
<210> 512
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG9
<400> 512
Glu Ala Gly Gly Pro Asp Tyr Arg Asn
1 5
<210> 513
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG9
<400> 513
Glu Ala Gly Gly Pro Asp Tyr Arg
1 5
<210> 514
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG9
<400> 514
Glu Ala Gly Gly Pro Asp Tyr
1 5
<210> 515
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG9
<400> 515
Glu Ala Gly Gly Pro Asp
1 5
<210> 516
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG16
<400> 516
Glu Ala Gly Gly Pro Ile Trp His Asp Asp Val Lys Tyr
1 5 10
<210> 517
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG16
<400> 517
Glu Ala Gly Gly Pro Ile Trp His Asp Asp Val Lys
1 5 10
<210> 518
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG16
<400> 518
Glu Ala Gly Gly Pro Ile Trp His Asp Asp Val
1 5 10
<210> 519
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG16
<400> 519
Glu Ala Gly Gly Pro Ile Trp His Asp Asp
1 5 10
<210> 520
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG16
<400> 520
Glu Ala Gly Gly Pro Ile Trp His Asp
1 5
<210> 521
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG16
<400> 521
Glu Ala Gly Gly Pro Ile Trp His
1 5
<210> 522
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG16
<400> 522
Glu Ala Gly Gly Pro Ile Trp
1 5
<210> 523
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody PG16
<400> 523
Glu Ala Gly Gly Pro Ile
1 5
<210> 524
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody CHO4
<400> 524
Gly Thr Asp Tyr Thr Ile Asp Asp Gln Gly Ile
1 5 10
<210> 525
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody CHO4
<400> 525
Gly Thr Asp Tyr Thr Ile Asp Asp Gln Gly
1 5 10
<210> 526
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody CHO4
<400> 526
Gly Thr Asp Tyr Thr Ile Asp Asp Gln
1 5
<210> 527
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody CHO4
<400> 527
Gly Thr Asp Tyr Thr Ile Asp Asp
1 5
<210> 528
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody CHO4
<400> 528
Gly Thr Asp Tyr Thr Ile Asp
1 5
<210> 529
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody CHO4
<400> 529
Gly Thr Asp Tyr Thr Ile
1 5
<210> 530
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody 2909
<400> 530
Asp Lys Gly Asp Ser Asp Tyr Asp Tyr Asn Leu
1 5 10
<210> 531
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody 2909
<400> 531
Asp Lys Gly Asp Ser Asp Tyr Asp Tyr Asn
1 5 10
<210> 532
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody 2909
<400> 532
Asp Lys Gly Asp Ser Asp Tyr Asp Tyr
1 5
<210> 533
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody 2909
<400> 533
Asp Lys Gly Asp Ser Asp Tyr Asp
1 5
<210> 534
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody 2909
<400> 534
Asp Lys Gly Asp Ser Asp Tyr
1 5
<210> 535
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: A region of antibody 2909
<400> 535
Asp Lys Gly Asp Ser Asp
1 5
<210> 536
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PGT145
<400> 536
Tyr Gly Pro Asn Tyr Glu Glu Trp Gly Asp Tyr Leu Ala Thr Leu Asp
1 5 10 15
Val
<210> 537
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PGT145
<400> 537
Gly Pro Asn Tyr Glu Glu Trp Gly Asp Tyr Leu Ala Thr Leu Asp Val
1 5 10 15
<210> 538
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PGT145
<400> 538
Pro Asn Tyr Glu Glu Trp Gly Asp Tyr Leu Ala Thr Leu Asp Val
1 5 10 15
<210> 539
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PGT145
<400> 539
Asn Tyr Glu Glu Trp Gly Asp Tyr Leu Ala Thr Leu Asp Val
1 5 10
<210> 540
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PGT145
<400> 540
Tyr Glu Glu Trp Gly Asp Tyr Leu Ala Thr Leu Asp Val
1 5 10
<210> 541
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PGT145
<400> 541
Glu Glu Trp Gly Asp Tyr Leu Ala Thr Leu Asp Val
1 5 10
<210> 542
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG9
<400> 542
Tyr Asp Phe Tyr Asp Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10 15
<210> 543
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG9
<400> 543
Asp Phe Tyr Asp Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10
<210> 544
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG9
<400> 544
Phe Tyr Asp Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10
<210> 545
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG9
<400> 545
Tyr Asp Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10
<210> 546
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG9
<400> 546
Asp Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10
<210> 547
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG9
<400> 547
Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10
<210> 548
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG9
<400> 548
Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5
<210> 549
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG16
<400> 549
Tyr Asp Phe Asn Asp Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10 15
<210> 550
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG16
<400> 550
Asp Phe Tyr Asp Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10
<210> 551
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG16
<400> 551
Phe Tyr Asp Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10
<210> 552
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG16
<400> 552
Tyr Asp Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10
<210> 553
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG16
<400> 553
Asp Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10
<210> 554
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody PG16
<400> 554
Gly Tyr Tyr Asn Tyr His Tyr Met Asp Val
1 5 10
<210> 555
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody CHO4
<400> 555
Gln Gly Ile Arg Tyr Gln Gly Ser Gly Thr Phe Trp Tyr Phe Asp Val
1 5 10 15
<210> 556
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody CHO4
<400> 556
Gly Ile Arg Tyr Gln Gly Ser Gly Thr Phe Trp Tyr Phe Asp Val
1 5 10 15
<210> 557
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody CHO4
<400> 557
Ile Arg Tyr Gln Gly Ser Gly Thr Phe Trp Tyr Phe Asp Val
1 5 10
<210> 558
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody CHO4
<400> 558
Arg Tyr Gln Gly Ser Gly Thr Phe Trp Tyr Phe Asp Val
1 5 10
<210> 559
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody CHO4
<400> 559
Tyr Gln Gly Ser Gly Thr Phe Trp Tyr Phe Asp Val
1 5 10
<210> 560
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody CHO4
<400> 560
Gln Gly Ser Gly Thr Phe Trp Tyr Phe Asp Val
1 5 10
<210> 561
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody CHO4
<400> 561
Gly Ser Gly Thr Phe Trp Tyr Phe Asp Val
1 5 10
<210> 562
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody CHO4
<400> 562
Ser Gly Thr Phe Trp Tyr Phe Asp Val
1 5
<210> 563
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody CHO4
<400> 563
Gly Thr Phe Trp Tyr Phe Asp Val
1 5
<210> 564
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody 2909
<400> 564
Tyr Asn Leu Gly Tyr Ser Tyr Phe Tyr Tyr Met Asp Gly
1 5 10
<210> 565
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody 2909
<400> 565
Asn Leu Gly Tyr Ser Tyr Phe Tyr Tyr Met Asp Gly
1 5 10
<210> 566
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody 2909
<400> 566
Leu Gly Tyr Ser Tyr Phe Tyr Tyr Met Asp Gly
1 5 10
<210> 567
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody 2909
<400> 567
Gly Tyr Ser Tyr Phe Tyr Tyr Met Asp Gly
1 5 10
<210> 568
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody 2909
<400> 568
Tyr Ser Tyr Phe Tyr Tyr Met Asp Gly
1 5
<210> 569
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: D region of antibody 2909
<400> 569
Ser Tyr Phe Tyr Tyr Met Asp Gly
1 5
<210> 570
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V2 region of antibody PGT145
<400> 570
Trp Gly His Gly Thr Ala Val Thr Val Ser Ser
1 5 10
<210> 571
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V2 region of antibody PG9
<400> 571
Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser
1 5 10
<210> 572
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V2 region of antibody PG16
<400> 572
Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser
1 5 10
<210> 573
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V2 region of antibody CHO4
<400> 573
Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser
1 5 10
<210> 574
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V2 region of antibody 2909
<400> 574
Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser
1 5 10
<210> 575
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 575
Gly Gly Gly Gly Ser
1 5
<210> 576
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 576
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10
<210> 577
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 577
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
<210> 578
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 578
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser
20
<210> 579
<211> 3
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 579
Gly Gly Ser
1
<210> 580
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 580
Gly Gly Ser Gly Gly Ser
1 5
<210> 581
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 581
Gly Gly Ser Gly Gly Ser Gly Gly Ser
1 5
<210> 582
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 582
Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
1 5 10
<210> 583
<211> 3
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 583
Ala Ser Gly
1
<210> 584
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 584
Ala Ser Gly Ala Ser Gly
1 5
<210> 585
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 585
Ala Ser Gly Ala Ser Gly Ala Ser Gly
1 5
<210> 586
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 586
Ala Ser Gly Ala Ser Gly Ala Ser Gly Ala Ser Gly
1 5 10
<210> 587
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 587
Gly Cys Gly Gly Gly Gly Ser
1 5
<210> 588
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 588
Gly Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10
<210> 589
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 589
Gly Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
1 5 10 15
Ser
<210> 590
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 590
Gly Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
1 5 10 15
Ser Gly Gly Gly Gly Ser
20
<210> 591
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 591
Gly Cys Gly Gly Ser
1 5
<210> 592
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 592
Gly Cys Gly Gly Ser Gly Gly Ser
1 5
<210> 593
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 593
Gly Cys Gly Gly Ser Gly Gly Ser Gly Gly Ser
1 5 10
<210> 594
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 594
Gly Cys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
1 5 10
<210> 595
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 595
Gly Cys Ala Ser Gly
1 5
<210> 596
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 596
Gly Cys Gly Cys Ala Ser Gly Ala Ser Gly
1 5 10
<210> 597
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 597
Gly Cys Ala Ser Gly Ala Ser Gly Ala Ser Gly
1 5 10
<210> 598
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 598
Gly Cys Ala Ser Gly Ala Ser Gly Ala Ser Gly Ala Ser Gly
1 5 10
<210> 599
<211> 37
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ADWX-1
<400> 599
Val Gly Ile Asn Val Lys Cys Lys His Ser Arg Gln Cys Leu Lys Pro
1 5 10 15
Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Thr Asn Gly Lys Cys
20 25 30
His Cys Thr Pro Lys
35
<210> 600
<211> 34
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: HsTx1
<400> 600
Ala Ser Cys Arg Thr Pro Lys Asp Cys Ala Asp Pro Cys Arg Lys Glu
1 5 10 15
Thr Gly Cys Pro Tyr Gly Lys Cys Met Asn Arg Lys Cys Lys Cys Asn
20 25 30
Arg Cys
<210> 601
<211> 38
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: OSK1
<400> 601
Gly Val Ile Ile Asn Val Lys Cys Lys Ile Ser Arg Gln Cys Leu Glu
1 5 10 15
Pro Cys Lys Lys Ala Gly Met Arg Phe Gly Lys Cys Met Asn Gly Lys
20 25 30
Cys His Cys Thr Pro Lys
35
<210> 602
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Pi2
<400> 602
Thr Ile Ser Cys Thr Asn Pro Lys Gln Cys Tyr Pro His Cys Lys Lys
1 5 10 15
Glu Thr Gly Tyr Pro Asn Ala Lys Cys Met Asn Arg Lys Cys Lys Cys
20 25 30
Phe Gly Arg
35
<210> 603
<211> 39
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Hongotoxin (HgTX)
<400> 603
Thr Val Ile Asp Val Lys Cys Thr Ser Pro Lys Gln Cys Leu Pro Pro
1 5 10 15
Cys Lys Ala Gln Phe Gly Ile Arg Ala Gly Ala Lys Cys Met Asn Gly
20 25 30
Lys Cys Lys Cys Tyr Pro His
35
<210> 604
<211> 39
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Margatoxin
<400> 604
Thr Ile Ile Asn Val Lys Cys Thr Ser Pro Lys Gln Cys Leu Pro Pro
1 5 10 15
Cys Lys Ala Gln Phe Gly Gln Ser Ala Gly Ala Lys Cys Met Asn Gly
20 25 30
Lys Cys Lys Cys Tyr Pro His
35
<210> 605
<211> 38
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Agitoxin-2
<400> 605
Gly Val Pro Ile Asn Val Ser Cys Thr Gly Ser Pro Gln Cys Ile Lys
1 5 10 15
Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Arg Lys
20 25 30
Cys His Cys Thr Pro Lys
35
<210> 606
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Pi3
<400> 606
Thr Ile Ser Cys Thr Asn Glu Lys Gln Cys Tyr Pro His Cys Lys Lys
1 5 10 15
Glu Thr Gly Tyr Pro Asn Ala Lys Cys Met Asn Arg Lys Cys Lys Cys
20 25 30
Phe Gly Arg
35
<210> 607
<211> 38
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Kaliotoxin
<400> 607
Gly Val Glu Ile Asn Val Lys Cys Ser Gly Ser Pro Gln Cys Leu Lys
1 5 10 15
Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Arg Lys
20 25 30
Cys His Cys Thr Pro Lys
35
<210> 608
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Anuroctoxin
<400> 608
Glx Lys Glu Cys Thr Gly Pro Gln His Cys Thr Asn Phe Cys Arg Lys
1 5 10 15
Asn Lys Cys Thr His Gly Lys Cys Met Asn Arg Lys Cys Lys Cys Phe
20 25 30
Asn Cys Lys
35
<210> 609
<211> 37
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Charybdotoxin
<400> 609
Glx Phe Thr Asn Val Ser Cys Thr Thr Ser Lys Glu Cys Trp Ser Val
1 5 10 15
Cys Gln Arg Leu His Asn Thr Ser Arg Gly Lys Cys Met Asn Lys Lys
20 25 30
Cys Arg Cys Tyr Ser
35
<210> 610
<211> 37
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Tityustoxin -K- alpha
<400> 610
Val Phe Ile Asn Ala Lys Cys Arg Gly Ser Pro Glu Cys Leu Pro Lys
1 5 10 15
Cys Lys Glu Ala Ile Gly Lys Ala Ala Gly Lys Cys Met Asn Gly Lys
20 25 30
Cys Lys Cys Tyr Pro
35
<210> 611
<211> 34
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Maurotoxin
<400> 611
Val Ser Cys Thr Gly Ser Lys Asp Cys Tyr Ala Pro Cys Arg Lys Gln
1 5 10 15
Thr Gly Cys Pro Asn Ala Lys Cys Ile Asn Lys Ser Cys Lys Cys Tyr
20 25 30
Gly Cys
<210> 612
<211> 33
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Ceratotoxin 1 (CcoTx1)
<400> 612
Asp Cys Leu Gly Trp Phe Lys Ser Cys Asp Pro Lys Asn Asp Lys Cys
1 5 10 15
Cys Lys Asn Tyr Thr Cys Ser Arg Arg Asp Arg Trp Cys Lys Tyr Asp
20 25 30
Leu
<210> 613
<211> 33
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: CcoTx2
<400> 613
Asp Cys Leu Gly Trp Phe Lys Ser Cys Asp Pro Lys Asn Asp Lys Cys
1 5 10 15
Cys Lys Asn Tyr Thr Cys Ser Arg Arg Asp Arg Trp Cys Lys Tyr Tyr
20 25 30
Leu
<210> 614
<211> 39
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: CcoTx3
<400> 614
Gly Val Asp Lys Glu Gly Cys Arg Lys Leu Leu Gly Gly Cys Thr Ile
1 5 10 15
Asp Asp Asp Cys Cys Pro His Leu Gly Cys Asn Lys Lys Tyr Trp His
20 25 30
Cys Gly Trp Asp Gly Thr Phe
35
<210> 615
<211> 34
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Phrixotoxin 3 (PaurTx3)
<400> 615
Asp Cys Leu Gly Phe Leu Trp Lys Cys Asn Pro Ser Asn Asp Lys Cys
1 5 10 15
Cys Arg Pro Asn Leu Val Cys Ser Arg Lys Asp Lys Trp Cys Lys Tyr
20 25 30
Gln Ile
<210> 616
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Hanatoxin 1
<400> 616
Glu Cys Arg Tyr Leu Phe Gly Gly Cys Lys Thr Thr Ser Asp Cys Cys
1 5 10 15
Lys His Leu Gly Cys Lys Phe Arg Asp Lys Tyr Cys Ala Trp Asp Phe
20 25 30
Thr Phe Ser
35
<210> 617
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Phrixotoxin 1
<400> 617
Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Ala Arg Lys Cys Cys
1 5 10 15
Glu Gly Leu Val Cys Arg Leu Trp Cys Lys Lys Ile Ile
20 25
<210> 618
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Huwentoxin-IV
<400> 618
Glu Cys Leu Glu Ile Phe Lys Ala Cys Asn Pro Ser Asn Asp Gln Cys
1 5 10 15
Cys Lys Ser Ser Lys Leu Val Cys Ser Arg Lys Thr Arg Trp Cys Lys
20 25 30
Tyr Gln Ile
35
<210> 619
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: alpha-conotoxin ImI
<400> 619
Gly Cys Cys Ser Asp Pro Arg Cys Ala Trp Arg Cys
1 5 10
<210> 620
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: alpha-conotoxin EpI
<400> 620
Gly Cys Cys Ser Asp Pro Arg Cys Asn Met Asn Asn Pro Asp Tyr Cys
1 5 10 15
<210> 621
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: alpha-conotoxin PnIA
<400> 621
Gly Cys Cys Ser Leu Pro Pro Cys Ala Ala Asn Asn Pro Asp Tyr Cys
1 5 10 15
<210> 622
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: alpha-conotoxin PnIB
<400> 622
Gly Cys Cys Ser Leu Pro Pro Cys Ala Leu Ser Asn Pro Asp Tyr Cys
1 5 10 15
<210> 623
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: alpha-conotoxin MII
<400> 623
Gly Cys Cys Ser Asn Pro Val Cys His Leu Glu His Ser Asn Leu Cys
1 5 10 15
<210> 624
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: alpha-conotoxin AuIA
<400> 624
Gly Cys Cys Ser Tyr Pro Pro Cys Phe Ala Thr Asn Ser Asp Tyr Cys
1 5 10 15
<210> 625
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: alpha-conotoxin AuIB
<400> 625
Gly Cys Cys Ser Tyr Pro Pro Cys Phe Ala Thr Asn Pro Asp Cys
1 5 10 15
<210> 626
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: alpha-conotoxin AuIC
<400> 626
Gly Cys Cys Ser Tyr Pro Pro Cys Phe Ala Thr Asn Ser Gly Tyr Cys
1 5 10 15
<210> 627
<211> 27
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: conotoxin kappa-PVIIA
<400> 627
Cys Arg Ile Pro Asn Gln Lys Cys Phe Gln His Leu Asp Asp Cys Cys
1 5 10 15
Ser Arg Lys Cys Asn Arg Phe Asn Lys Cys Val
20 25
<210> 628
<211> 37
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: charybdotoxin
<400> 628
Glx Phe Thr Asn Val Ser Cys Thr Thr Ser Lys Glu Cys Trp Ser Val
1 5 10 15
Cys Gln Arg Leu His Asn Thr Ser Arg Gly Lys Cys Met Asn Lys Lys
20 25 30
Cys Arg Cys Tyr Ser
35
<210> 629
<211> 55
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: neurotoxin B-IV
<400> 629
Ala Ser Ala Thr Trp Gly Ala Ala Tyr Pro Ala Cys Glu Asn Asn Cys
1 5 10 15
Arg Lys Lys Tyr Asp Leu Cys Ile Arg Cys Gln Gly Lys Trp Ala Gly
20 25 30
Lys Arg Gly Lys Cys Ala Ala His Cys Ile Ile Gln Lys Asn Asn Cys
35 40 45
Lys Gly Lys Cys Lys Lys Glu
50 55
<210> 630
<211> 43
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: crotamine
<400> 630
Tyr Lys Gln Cys His Lys Lys Gly Gly His Cys Phe Pro Lys Glu Lys
1 5 10 15
Ile Cys Leu Pro Pro Ser Ser Asp Phe Gly Lys Met Asp Cys Cys Arg
20 25 30
Trp Arg Trp Lys Cys Cys Lys Lys Gly Ser Gly
35 40
<210> 631
<211> 27
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: omega-GVIA (conotoxin)
<400> 631
Cys Lys Ser Pro Gly Ser Ser Cys Ser Pro Thr Ser Tyr Asn Cys Cys
1 5 10 15
Arg Ser Cys Asn Pro Tyr Thr Lys Arg Cys Tyr
20 25
<210> 632
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: kappa-hefutoxin 1
<400> 632
Gly His Ala Cys Tyr Arg Asn Cys Trp Arg Glu Gly Asn Asp Glu Glu
1 5 10 15
Thr Cys Lys Glu Arg Cys
20
<210> 633
<211> 66
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Css4
<400> 633
Lys Glu Gly Tyr Leu Val Asn Ser Tyr Thr Gly Cys Lys Phe Glu Cys
1 5 10 15
Phe Lys Leu Gly Asp Asn Asp Tyr Cys Leu Arg Glu Cys Arg Gln Gln
20 25 30
Tyr Gly Lys Gly Ser Gly Gly Tyr Cys Tyr Ala Phe Gly Cys Trp Cys
35 40 45
Thr His Leu Tyr Glu Gln Ala Val Val Trp Pro Leu Pro Asn Lys Thr
50 55 60
Cys Asn
65
<210> 634
<211> 76
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Bj-xtrIT
<400> 634
Lys Lys Asn Gly Tyr Pro Leu Asp Arg Asn Gly Lys Thr Thr Glu Cys
1 5 10 15
Ser Gly Val Asn Ala Ile Ala Pro His Tyr Cys Asn Ser Glu Cys Thr
20 25 30
Lys Val Tyr Val Ala Glu Ser Gly Tyr Cys Cys Trp Gly Ala Cys Tyr
35 40 45
Cys Phe Gly Leu Glu Asp Asp Lys Pro Ile Gly Pro Met Lys Asp Ile
50 55 60
Thr Lys Lys Tyr Cys Asp Val Gln Ile Ile Pro Ser
65 70 75
<210> 635
<211> 41
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BcIV
<400> 635
Gly Leu Pro Cys Asp Cys His Gly His Thr Gly Thr Tyr Trp Leu Asn
1 5 10 15
Tyr Tyr Ser Lys Cys Pro Lys Gly Tyr Gly Tyr Thr Gly Arg Cys Arg
20 25 30
Tyr Leu Val Gly Ser Cys Cys Tyr Lys
35 40
<210> 636
<211> 37
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Hm-1
<400> 636
Gly Cys Ile Pro Tyr Gly Lys Thr Cys Glu Phe Trp Ser Gly Pro Trp
1 5 10 15
Cys Cys Ala Gly Lys Cys Lys Leu Asn Val Trp Ser Met Thr Leu Ser
20 25 30
Cys Thr Arg Asn Phe
35
<210> 637
<211> 40
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Hm-2
<400> 637
Gly Cys Ile Pro Ser Phe Gly Glu Cys Ala Trp Phe Ser Gly Glu Ser
1 5 10 15
Cys Cys Thr Gly Ile Cys Lys Trp Val Phe Phe Thr Ser Lys Phe Met
20 25 30
Cys Arg Arg Val Trp Gly Lys Asp
35 40
<210> 638
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: GsAF-I(beta-theraphotoxin-Gr1b)
<400> 638
Tyr Cys Gln Lys Trp Leu Trp Thr Cys Asp Ser Glu Arg Lys Cys Cys
1 5 10 15
Glu Asp Met Val Cys Arg Leu Trp Cys Lys Lys Arg Leu
20 25
<210> 639
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Protoxin I (ProTx-I, beta-theraphotoxin-Tp1-alpha)
<400> 639
Glu Cys Arg Tyr Trp Leu Gly Gly Cys Ser Ala Gly Gln Thr Cys Cys
1 5 10 15
Lys His Leu Val Cys Ser Arg Arg His Gly Trp Cys Val Trp Asp Gly
20 25 30
Thr Phe Ser
35
<210> 640
<211> 30
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Protoxin II (ProTx II)
<400> 640
Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys Cys
1 5 10 15
Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp
20 25 30
<210> 641
<211> 33
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Huwentoxin I
<400> 641
Ala Cys Lys Gly Val Phe Asp Ala Cys Thr Pro Gly Lys Asn Glu Cys
1 5 10 15
Cys Pro Asn Arg Val Cys Ser Asp Lys His Lys Trp Cys Lys Trp Lys
20 25 30
Leu
<210> 642
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: mu-Conotoxin PIIIA
<400> 642
Glu Arg Leu Cys Cys Gly Phe Pro Lys Ser Cys Arg Ser Arg Gln Cys
1 5 10 15
Lys Pro His Arg Cys Cys
20
<210> 643
<211> 36
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Jingzhaotoxin-III(beta-TRTX-Cj1-alpha)
<400> 643
Asp Gly Glu Cys Gly Gly Phe Trp Trp Lys Cys Gly Arg Gly Lys Pro
1 5 10 15
Pro Cys Cys Lys Gly Tyr Ala Cys Ser Lys Thr Trp Gly Trp Cys Ala
20 25 30
Val Glu Ala Pro
35
<210> 644
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: GsAF-II (Kappa-theraphotoxin-Gr2c)
<400> 644
Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Glu Glu Arg Lys Cys Cys
1 5 10 15
Glu Gly Leu Val Cys Arg Leu Trp Cys Lys Lys Lys Ile Glu Trp
20 25 30
<210> 645
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ShK, K16,E30
<400> 645
Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Lys
1 5 10 15
Cys Lys His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Glu Thr Cys
20 25 30
Gly Thr Cys
35
<210> 646
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ShK (Stichodactyla toxin)
<400> 646
Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln
1 5 10 15
Cys Lys His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys
20 25 30
Gly Thr Cys
35
<210> 647
<211> 34
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: HsTx1
<400> 647
Ala Ser Cys Arg Thr Pro Lys Asp Cys Ala Asp Pro Cys Arg Lys Glu
1 5 10 15
Thr Gly Cys Pro Tyr Gly Lys Cys Met Asn Arg Lys Cys Lys Cys Asn
20 25 30
Arg Cys
<210> 648
<211> 36
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Guangxitoxin 1E, GxTx-1E
<400> 648
Glu Gly Glu Cys Gly Gly Phe Trp Trp Lys Cys Gly Ser Gly Lys Pro
1 5 10 15
Ala Cys Cys Pro Lys Tyr Val Cys Ser Pro Lys Trp Gly Leu Cys Asn
20 25 30
Phe Pro Met Pro
35
<210> 649
<211> 37
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Charybdotoxin, ChTX
<400> 649
Glu Phe Thr Asn Val Ser Cys Thr Thr Ser Lys Glu Cys Trp Ser Val
1 5 10 15
Cys Gln Arg Leu His Asn Thr Ser Arg Gly Lys Cys Met Asn Lys Lys
20 25 30
Cys Arg Cys Tyr Ser
35
<210> 650
<211> 37
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Iberiotoxin, IbTx
<400> 650
Glu Phe Thr Asp Val Asp Cys Ser Val Ser Lys Glu Cys Trp Ser Val
1 5 10 15
Cys Lys Asp Leu Phe Gly Val Asp Arg Gly Lys Cys Met Gly Lys Lys
20 25 30
Cys Arg Cys Tyr Gln
35
<210> 651
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Leiurotoxin 1, scyllatoxin
<400> 651
Ala Phe Cys Asn Leu Arg Met Cys Gln Leu Ser Cys Arg Ser Leu Gly
1 5 10 15
Leu Leu Gly Lys Cys Ile Gly Asp Lys Cys Glu Cys Val Lys His
20 25 30
<210> 652
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Tamapin
<400> 652
Ala Phe Cys Asn Leu Arg Arg Cys Glu Leu Ser Cys Arg Ser Leu Gly
1 5 10 15
Leu Leu Gly Lys Cys Ile Gly Glu Glu Cys Lys Cys Val Pro Tyr
20 25 30
<210> 653
<211> 38
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Kaliotoxin-1, KTX
<400> 653
Gly Val Glu Ile Asn Val Lys Cys Ser Gly Ser Pro Gln Cys Leu Lys
1 5 10 15
Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Arg Lys
20 25 30
Cys His Cys Thr Pro Lys
35
<210> 654
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Purotoxin1, PT-1
<400> 654
Gly Tyr Cys Ala Glu Lys Gly Ile Arg Cys Asp Asp Ile His Cys Cys
1 5 10 15
Thr Gly Leu Lys Cys Lys Cys Asn Ala Ser Gly Tyr Asn Cys Val Cys
20 25 30
Arg Lys Lys
35
<210> 655
<211> 34
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: GpTx-1
<400> 655
Asp Cys Leu Gly Phe Met Arg Lys Cys Ile Pro Asp Asn Asp Lys Cys
1 5 10 15
Cys Arg Pro Asn Leu Val Cys Ser Arg Thr His Lys Trp Cys Lys Tyr
20 25 30
Val Phe
<210> 656
<400> 656
000
<210> 657
<400> 657
000
<210> 658
<400> 658
000
<210> 659
<400> 659
000
<210> 660
<400> 660
000
<210> 661
<400> 661
000
<210> 662
<400> 662
000
<210> 663
<400> 663
000
<210> 664
<400> 664
000
<210> 665
<400> 665
000
<210> 666
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-1 sequence of ADWX-1
<400> 666
Val Gly Ile Asn Val Lys Cys Lys His Ser Arg
1 5 10
<210> 667
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-1 sequence of HsTx1
<400> 667
Ala Ser Cys Arg Thr Pro Lys
1 5
<210> 668
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-1 sequence of OSK1
<400> 668
Gly Val Ile Ile Asn Val Lys Cys Lys Ile Ser Arg
1 5 10
<210> 669
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-1 sequence of Pi2
<400> 669
Thr Ile Ser Cys Thr Asn Pro Lys
1 5
<210> 670
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-1 sequence of Hongotoxin (HgTX)
<400> 670
Thr Val Ile Asp Val Lys Cys Thr Ser Pro Lys
1 5 10
<210> 671
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-1 sequence of Margatoxin
<400> 671
Thr Ile Ile Asn Val Lys Cys Thr Ser Pro Lys
1 5 10
<210> 672
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-1 sequence of Agitoxin-2
<400> 672
Gly Val Pro Ile Asn Val Ser Cys Thr Gly Ser Pro
1 5 10
<210> 673
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-1 sequence of Pi3
<400> 673
Thr Ile Ser Cys Thr Asn Glu Lys
1 5
<210> 674
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-1 sequence of Kaliotoxin
<400> 674
Gly Val Glu Ile Asn Val Lys Cys Ser Gly Ser Pro
1 5 10
<210> 675
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-1 sequence of Anuroctoxin
<400> 675
Glx Lys Glu Cys Thr Gly Pro Gln
1 5
<210> 676
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-1 sequence of Charybdotoxin
<400> 676
Glx Phe Thr Asn Val Ser Cys Thr Thr Ser Lys
1 5 10
<210> 677
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-2 sequence of ADWX-1
<400> 677
Leu Lys Pro Cys Lys Asp Ala Gly Met Arg Phe Gly
1 5 10
<210> 678
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-2 sequence of HsTx1
<400> 678
Ala Asp Pro Cys Arg Lys Glu Thr Gly Cys Pro Tyr Gly
1 5 10
<210> 679
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-2 sequence of OSK1
<400> 679
Leu Glu Pro Cys Lys Lys Ala Gly Met Arg Phe Gly
1 5 10
<210> 680
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-2 sequence of Pi2
<400> 680
Tyr Pro His Cys Lys Lys Glu Thr Gly Tyr Pro Asn Ala
1 5 10
<210> 681
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-2 sequence of Hongotoxin (HgTX)
<400> 681
Leu Pro Pro Cys Lys Ala Gln Phe Gly Ile Arg Ala Gly Ala
1 5 10
<210> 682
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-2 sequence of Margatoxin
<400> 682
Leu Pro Pro Cys Lys Ala Gln Phe Gly Gln Ser Ala Gly Ala
1 5 10
<210> 683
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-2 sequence of Agitoxin-2
<400> 683
Ile Lys Pro Cys Lys Asp Ala Gly Met Arg Phe Gly
1 5 10
<210> 684
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-2 sequence of Pi3
<400> 684
Tyr Pro His Cys Lys Lys Glu Thr Gly Tyr Pro Asn Ala
1 5 10
<210> 685
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-2 sequence of Kaliotoxin
<400> 685
Leu Lys Pro Cys Lys Asp Ala Gly Met Arg Phe Gly
1 5 10
<210> 686
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-2 sequence of Anuroctoxin
<400> 686
Thr Asn Phe Cys Arg Lys Asn Lys Cys Thr His Gly
1 5 10
<210> 687
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-2 sequence of Charybdotoxin
<400> 687
Trp Ser Val Cys Gln Arg Leu His Asn Thr Ser Arg Gly
1 5 10
<210> 688
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-3 sequence of ADWX-1
<400> 688
Asn Gly Lys Cys His Cys Thr Pro Lys
1 5
<210> 689
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-3 sequence of HsTx1
<400> 689
Asn Arg Lys Cys Lys Cys Asn Arg Cys
1 5
<210> 690
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-3 sequence of OSK1
<400> 690
Asn Gly Lys Cys His Cys Thr Pro Lys
1 5
<210> 691
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-3 sequence of Pi2
<400> 691
Asn Arg Lys Cys Lys Cys Phe Gly Arg
1 5
<210> 692
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-3 sequence of Hongotoxin (HgTX)
<400> 692
Asn Gly Lys Cys Lys Cys Tyr Pro His
1 5
<210> 693
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-3 sequence of Margatoxin
<400> 693
Asn Gly Lys Cys Lys Cys Tyr Pro His
1 5
<210> 694
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-3 sequence of Agitoxin-2
<400> 694
Asn Arg Lys Cys His Cys Thr Pro Lys
1 5
<210> 695
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-3 sequence of Pi3
<400> 695
Asn Arg Lys Cys Lys Cys Phe Gly Arg
1 5
<210> 696
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-3 sequence of Kaliotoxin
<400> 696
Asn Arg Lys Cys His Cys Thr Pro Lys
1 5
<210> 697
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-3 sequence of Anuroctoxin
<400> 697
Asn Arg Lys Cys Lys Cys Phe Asn Cys Lys
1 5 10
<210> 698
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Block-3 sequence of Charybdotoxin
<400> 698
Asn Lys Lys Cys Arg Cys Tyr Ser
1 5
<210> 699
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 699
Ser Gly Gly Gly Gly
1 5
<210> 700
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 700
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
1 5 10
<210> 701
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 701
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
1 5 10 15
<210> 702
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 702
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
Gly Gly Gly Gly
20
<210> 703
<211> 3
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 703
Ser Gly Gly
1
<210> 704
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 704
Ser Gly Gly Ser Gly Gly
1 5
<210> 705
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 705
Ser Gly Gly Ser Gly Gly Ser Gly Gly
1 5
<210> 706
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 706
Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly
1 5 10
<210> 707
<211> 3
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 707
Gly Ser Ala
1
<210> 708
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 708
Gly Ser Ala Gly Ser Ala
1 5
<210> 709
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 709
Gly Ser Ala Gly Ser Ala Gly Ser Ala
1 5
<210> 710
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 710
Gly Ser Ala Gly Ser Ala Gly Ser Ala Gly Ser Ala
1 5 10
<210> 711
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 711
Ser Gly Gly Gly Gly Cys Gly
1 5
<210> 712
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 712
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Cys Gly
1 5 10
<210> 713
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 713
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Cys
1 5 10 15
Gly
<210> 714
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 714
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
Gly Gly Gly Gly Cys Gly
20
<210> 715
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 715
Ser Gly Gly Cys Gly
1 5
<210> 716
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 716
Ser Gly Gly Ser Gly Gly Cys Gly
1 5
<210> 717
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 717
Ser Gly Gly Ser Gly Gly Ser Gly Gly Cys Gly
1 5 10
<210> 718
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 718
Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Cys Gly
1 5 10
<210> 719
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 719
Gly Ser Ala Cys Gly
1 5
<210> 720
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 720
Gly Ser Ala Gly Ser Ala Cys Gly Cys Gly
1 5 10
<210> 721
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 721
Gly Ser Ala Gly Ser Ala Gly Ser Ala Cys Gly
1 5 10
<210> 722
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 722
Gly Ser Ala Gly Ser Ala Gly Ser Ala Gly Ser Ala Cys Gly
1 5 10
<210> 723
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 723
Gly Gly Gly Gly Ser Gly Gly
1 5
<210> 724
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 724
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly
<210> 725
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 725
Gly Gly Ser Gly Gly Gly Gly
1 5
<210> 726
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 726
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly
1 5 10 15
Ser
<210> 727
<211> 34
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: MOKA Toxin
<400> 727
Ile Asn Val Lys Cys Ser Leu Pro Gln Gln Cys Ile Lys Pro Cys Lys
1 5 10 15
Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Lys Lys Cys Arg Cys
20 25 30
Tyr Ser
<210> 728
<211> 38
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: OSK1, P12, K16, D20
<400> 728
Gly Val Ile Ile Asn Val Lys Cys Lys Ile Ser Pro Gln Cys Leu Lys
1 5 10 15
Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Gly Lys
20 25 30
Cys His Cys Thr Pro Lys
35
<210> 729
<211> 38
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: OSK1 K16, D20
<400> 729
Gly Val Ile Ile Asn Val Lys Cys Lys Ile Ser Arg Gln Cys Leu Lys
1 5 10 15
Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Gly Lys
20 25 30
Cys His Cys Thr Pro Lys
35
<210> 730
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: HmK
<400> 730
Arg Thr Cys Lys Asp Leu Ile Pro Val Ser Glu Cys Thr Asp Ile Arg
1 5 10 15
Cys Arg Thr Ser Met Lys Tyr Arg Leu Asn Leu Cys Arg Lys Thr Cys
20 25 30
Gly Ser Cys
35
<210> 731
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ShK, K16,Y26, K29
<400> 731
Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Lys
1 5 10 15
Cys Lys His Ser Met Lys Tyr Arg Leu Tyr Phe Cys Lys Lys Thr Cys
20 25 30
Gly Thr Cys
35
<210> 732
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ShK, K16
<400> 732
Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Lys
1 5 10 15
Cys Lys His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys
20 25 30
Gly Thr Cys
35
<210> 733
<211> 36
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ShK-A, K16
<400> 733
Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Lys
1 5 10 15
Cys Lys His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys
20 25 30
Gly Thr Cys Ala
35
<210> 734
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative A sequence of VH4-34_Q5RQ6E
<400> 734
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90
<210> 735
<211> 95
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative B sequence of VH4-34_Q5RQ6E
<400> 735
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys
85 90 95
<210> 736
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative A sequence of
VH4-34_CDR1-G31DY32K_Q5RQ6E
<400> 736
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90
<210> 737
<211> 95
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative B sequence of
VH4-34_CDR1-G31DY32K_Q5RQ6E
<400> 737
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys
85 90 95
<210> 738
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative A sequence of VH4-34_CDR2-E50S_Q5RQ6E
<400> 738
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90
<210> 739
<211> 95
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative B sequence of VH4-34_CDR2-E50S_Q5RQ6E
<400> 739
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys
85 90 95
<210> 740
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative A sequence of
VH4-34_CDR1-G31DY32K_CDR2-E50S_Q5RQ6E
<400> 740
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90
<210> 741
<211> 95
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative B sequence of
VH4-34_CDR1-G31DY32K_CDR2-E50S_Q5RQ6E
<400> 741
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys
85 90 95
<210> 742
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative A sequence of VH4-34_CDR1-Cow_Q5RQ6E
<400> 742
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90
<210> 743
<211> 95
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative B sequence of VH4-34_CDR1-Cow_Q5RQ6E
<400> 743
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys
85 90 95
<210> 744
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative A sequence of VH4-34_CDR2-Cow_Q5RQ6E
<400> 744
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Leu Gly Ser Ile Asp
20 25 30
Thr Gly Gly Asn Thr Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile
35 40 45
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90
<210> 745
<211> 95
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative B sequence of VH4-34_CDR2-Cow_Q5RQ6E
<400> 745
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Leu Gly Ser Ile Asp
20 25 30
Thr Gly Gly Asn Thr Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile
35 40 45
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys
85 90 95
<210> 746
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative A sequence of
VH4-34_CDR1-Cow_CDR2-E50S_Q5RQ6E
<400> 746
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90
<210> 747
<211> 95
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative B sequence of
VH4-34_CDR1-Cow_CDR2-E50S_Q5RQ6E
<400> 747
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys
85 90 95
<210> 748
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative A sequence of
VH4-34_CDR1-Cow_CDR2-Cow_Q5RQ6E
<400> 748
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90
<210> 749
<211> 95
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: V1 Alternative N sequence of
VH4-34_CDR1-Cow_CDR2-Cow_Q5RQ6E
<400> 749
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys
85 90 95
<210> 750
<211> 89
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL of VL1-51 S2A, T5N, P8S, A12G ,A13S, P14L,
K46R, L47T, D51G, N52D, N53T
<400> 750
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys
85
<210> 751
<211> 89
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL of VL1-51 S2A, T5N, P8S, A12G ,A13S, P14L,
K46R, L47T, D51G, N52D, N53T, K54S, P56A
<400> 751
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys
85
<210> 752
<211> 89
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL of VL1-51 I29V, N32G, K46R, L47T, D51G, N52D, N53T
<400> 752
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Asn Gly
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys
85
<210> 753
<211> 89
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL of VL1-51 I29V, N32G, K46R, L47T, D51G,
N52D, N53T, K54S, P56A
<400> 753
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Asn Gly
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys
85
<210> 754
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: CDR3 in BLV1H12 Light Chain
<400> 754
Ala Ser Ala Glu Asp Ser Ser Ser Asn Ala Val
1 5 10
<210> 755
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: J region after CDR3 in BLV1H12 Light Chain
<400> 755
Phe Gly Ser Gly Thr Thr Leu Thr Val Leu
1 5 10
<210> 756
<211> 106
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Human Light Chain Lambda Constant Region
<400> 756
Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser
1 5 10 15
Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp
20 25 30
Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro
35 40 45
Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn
50 55 60
Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys
65 70 75 80
Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val
85 90 95
Glu Lys Thr Val Ala Pro Thr Glu Cys Ser
100 105
<210> 757
<211> 438
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS1:1-BsaI
<400> 757
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc gagacctact atggttcggg tctcggagga 360
agctcttata cctacaatta tgaatggcat gtggatgtct ggggacaggg cctgctggtg 420
acagtctcta gtgctagc 438
<210> 758
<211> 447
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS1:2-BsaI
<400> 758
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc gagacctact atggttcggg tctcggagga 360
agcggaggaa gctcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 420
ctgctggtga cagtctctag tgctagc 447
<210> 759
<211> 447
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS2:1-BsaI
<400> 759
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg agacctacta tggttcgggt 360
ctcggaggaa gctcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 420
ctgctggtga cagtctctag tgctagc 447
<210> 760
<211> 456
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS2:2-BsaI
<400> 760
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg agacctacta tggttcgggt 360
ctcggaggaa gcggaggaag ctcttatacc tacaattatg aatggcatgt ggatgtctgg 420
ggacagggcc tgctggtgac agtctctagt gctagc 456
<210> 761
<211> 465
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS2:3-BsaI
<400> 761
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg agacctacta tggttcgggt 360
ctcggaggaa gcggaggaag cggaggaagc tcttatacct acaattatga atggcatgtg 420
gatgtctggg gacagggcct gctggtgaca gtctctagtg ctagc 465
<210> 762
<211> 474
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS2:4-BsaI
<400> 762
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg agacctacta tggttcgggt 360
ctcggaggaa gcggaggaag cggaggaagc ggaggaagct cttataccta caattatgaa 420
tggcatgtgg atgtctgggg acagggcctg ctggtgacag tctctagtgc tagc 474
<210> 763
<211> 465
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS3:2-BsaI
<400> 763
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gaggaagcga gacctactat 360
ggttcgggtc tcggaggaag cggaggaagc tcttatacct acaattatga atggcatgtg 420
gatgtctggg gacagggcct gctggtgaca gtctctagtg ctagc 465
<210> 764
<211> 474
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS3:3-BsaI
<400> 764
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gaggaagcga gacctactat 360
ggttcgggtc tcggaggaag cggaggaagc ggaggaagct cttataccta caattatgaa 420
tggcatgtgg atgtctgggg acagggcctg ctggtgacag tctctagtgc tagc 474
<210> 765
<211> 474
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS4:2-BsaI
<400> 765
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gaggaagcgg aggaagcgag 360
acctactatg gttcgggtct cggaggaagc ggaggaagct cttataccta caattatgaa 420
tggcatgtgg atgtctgggg acagggcctg ctggtgacag tctctagtgc tagc 474
<210> 766
<211> 459
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-G4Sx1-BsaI
<400> 766
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gatgagacct actatggttc 360
agggtctctg gaggtggtgg atcttcttat acctacaatt atgaatggca tgtggatgtc 420
tggggacagg gcctgctggt gacagtctct agtgctagc 459
<210> 767
<211> 519
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-G4Sx3-BsaI
<400> 767
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gatgagacct actatggttc agggtctctg gaggtggtgg atctggtgga 420
ggaggcagtg gaggtggtgg cagctcttat acctacaatt atgaatggca tgtggatgtc 480
tggggacagg gcctgctggt gacagtctct agtgctagc 519
<210> 768
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: BsaI containing Nucleotide sequence I
<400> 768
gagacctact atggttcggg tctc 24
<210> 769
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized: BsaI containing Nucleotide sequence II
<400> 769
gagacctact atggttcagg gtctc 25
<210> 770
<211> 173
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS1:1-Moka
<400> 770
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Ile
100 105 110
Asn Val Lys Cys Ser Leu Pro Gln Gln Cys Ile Lys Pro Cys Lys Asp
115 120 125
Ala Gly Met Arg Phe Gly Lys Cys Met Asn Lys Lys Cys Arg Cys Tyr
130 135 140
Ser Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val
145 150 155 160
Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170
<210> 771
<211> 176
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS1:2-Moka
<400> 771
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Ile
100 105 110
Asn Val Lys Cys Ser Leu Pro Gln Gln Cys Ile Lys Pro Cys Lys Asp
115 120 125
Ala Gly Met Arg Phe Gly Lys Cys Met Asn Lys Lys Cys Arg Cys Tyr
130 135 140
Ser Gly Gly Ser Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His
145 150 155 160
Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170 175
<210> 772
<211> 176
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS2:1-Moka
<400> 772
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Ile Asn Val Lys Cys Ser Leu Pro Gln Gln Cys Ile Lys Pro
115 120 125
Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Lys Lys Cys
130 135 140
Arg Cys Tyr Ser Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His
145 150 155 160
Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170 175
<210> 773
<211> 179
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS2:2-Moka
<400> 773
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Ile Asn Val Lys Cys Ser Leu Pro Gln Gln Cys Ile Lys Pro
115 120 125
Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Lys Lys Cys
130 135 140
Arg Cys Tyr Ser Gly Gly Ser Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr
145 150 155 160
Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser
165 170 175
Ser Ala Ser
<210> 774
<211> 185
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-GGS3:3-Moka
<400> 774
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Ser Gly Ile Asn Val Lys Cys Ser Leu Pro Gln Gln Cys
115 120 125
Ile Lys Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn
130 135 140
Lys Lys Cys Arg Cys Tyr Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
145 150 155 160
Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly
165 170 175
Leu Leu Val Thr Val Ser Ser Ala Ser
180 185
<210> 775
<211> 194
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-G4Sx3-ProTxII
<400> 775
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Tyr Cys Gln Lys
115 120 125
Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys Cys Glu Gly Met Val
130 135 140
Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp Gly Gly Gly Gly Ser Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu
165 170 175
Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
180 185 190
Ala Ser
<210> 776
<211> 198
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-G4Sx3-GPTX toxin
<400> 776
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Asp Cys Leu Gly
115 120 125
Phe Met Arg Lys Cys Ile Pro Asp Asn Asp Lys Cys Cys Arg Pro Asn
130 135 140
Leu Val Cys Ser Arg Thr His Lys Trp Cys Lys Tyr Val Phe Gly Gly
145 150 155 160
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Thr
165 170 175
Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val
180 185 190
Thr Val Ser Ser Ala Ser
195
<210> 777
<211> 202
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-G4Sx3-OSK1 P12, K16, D20 toxin
<400> 777
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Val Ile Ile
115 120 125
Asn Val Lys Cys Lys Ile Ser Pro Gln Cys Leu Lys Pro Cys Lys Asp
130 135 140
Ala Gly Met Arg Phe Gly Lys Cys Met Asn Gly Lys Cys His Cys Thr
145 150 155 160
Pro Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
165 170 175
Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln
180 185 190
Gly Leu Leu Val Thr Val Ser Ser Ala Ser
195 200
<210> 778
<211> 202
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-G4Sx3-OSK1 K16, D20 toxin
<400> 778
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Val Ile Ile
115 120 125
Asn Val Lys Cys Lys Ile Ser Arg Gln Cys Leu Lys Pro Cys Lys Asp
130 135 140
Ala Gly Met Arg Phe Gly Lys Cys Met Asn Gly Lys Cys His Cys Thr
145 150 155 160
Pro Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
165 170 175
Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln
180 185 190
Gly Leu Leu Val Thr Val Ser Ser Ala Ser
195 200
<210> 779
<211> 199
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: BLV1H12-CDR3-G4Sx3-ShK toxin
<400> 779
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile
115 120 125
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser
130 135 140
Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr
165 170 175
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu
180 185 190
Val Thr Val Ser Ser Ala Ser
195
<210> 780
<211> 216
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL-CL sequence of VL1-51 S2A, T5N, P8S, A12G,
A13S, P14L, K46R, L47T, D51G, N52D, N53T
<400> 780
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 781
<211> 216
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL-CL sequence of VL1-51 S2A, T5N, P8S, A12G,
A13S, P14L, K46R, L47T, D51G, N52D, N53T, K54S, P56A
<400> 781
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 782
<211> 216
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL-CL sequence of VL1-51 I29V, N32G, K46R,
L47T, D51G, N52D, N53T
<400> 782
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Asn Gly
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 783
<211> 216
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL-CL sequence of VL1-51 I29V, N32G, K46R,
L47T, D51G, N52D, N53T, K54S, P56A
<400> 783
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Asn Gly
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 784
<211> 207
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH sequence of VH4-34+CDR3-IL8_Q5RQ6E
<400> 784
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
195 200 205
<210> 785
<211> 207
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH sequence of VH4-34+CDR3-IL8_CDR1-G31DY32K_Q5RQ6E
<400> 785
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
195 200 205
<210> 786
<211> 207
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH sequence of VH4-34+CDR3-IL8_CDR2-E50S_Q5RQ6E
<400> 786
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
195 200 205
<210> 787
<211> 207
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH sequence of
VH4-34+CDR3-IL8_CDR1-G31DY32K_CDR2-E50S_Q5RQ6E
<400> 787
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
195 200 205
<210> 788
<211> 207
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH sequence of VH4-34+CDR3-IL8_CDR1-Cow_Q5RQ6E
<400> 788
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
195 200 205
<210> 789
<211> 207
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH sequence of VH4-34+CDR3-IL8_CDR2-Cow_Q5RQ6E
<400> 789
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Leu Gly Ser Ile Asp
20 25 30
Thr Gly Gly Asn Thr Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile
35 40 45
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
195 200 205
<210> 790
<211> 207
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH sequence of
VH4-34+CDR3-IL8_CDR1-Cow_CDR2-E50S_Q5RQ6E
<400> 790
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
195 200 205
<210> 791
<211> 207
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH sequence of
VH4-34+CDR3-IL8_CDR1-Cow_CDR2-Cow_Q5RQ6E
<400> 791
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
195 200 205
<210> 792
<211> 216
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL1-51 S2A, T5N, P8S, A12G ,A13S, P14L, D51G,
N52D, N53T
<400> 792
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Gly Asp Thr Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 793
<211> 209
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH4-34+CDR3-IL8
<400> 793
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala
195 200 205
Ser
<210> 794
<211> 209
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH4-34+CDR3-IL8_CDR1 Cow
<400> 794
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala
195 200 205
Ser
<210> 795
<211> 209
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH4-34+CDR3-IL8_CDR2 Cow
<400> 795
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala
195 200 205
Ser
<210> 796
<211> 209
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH4-34+CDR3-IL8_CDR1 G31D, Y32K
<400> 796
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala
195 200 205
Ser
<210> 797
<211> 209
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH4-34+CDR3-IL8_CDR2 E50S
<400> 797
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala
195 200 205
Ser
<210> 798
<211> 209
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH4-34+CDR3-IL8_CDR1 Cow_CDR2 Cow
<400> 798
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala
195 200 205
Ser
<210> 799
<211> 209
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH4-34+CDR3-IL8_CDR1 Cow_CDR2 E50S
<400> 799
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala
195 200 205
Ser
<210> 800
<211> 209
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VH4-34+CDR3-IL8_CDR1 G31D,Y32K_CDR2 E50S
<400> 800
Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala
195 200 205
Ser
<210> 801
<211> 216
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL1-51 I29V, N32G
<400> 801
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Asn Gly
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 802
<211> 216
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL1-51 D51G, N52D, N53T
<400> 802
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Gly Asp Thr Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 803
<211> 216
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL1-51 D51G, N52D, N53T, K54S, P56A
<400> 803
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Gly Asp Thr Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 804
<211> 216
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL1-51 S2A, T5N, P8S, A12G, A13S, P14L
<400> 804
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 805
<211> 216
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: VL1-51
<400> 805
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 806
<211> 105
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized: MOKA Toxin
<400> 806
ggcatcaacg tgaagtgcag cctgccccag cagtgcatca agccctgcaa ggacgccggc 60
atgagattcg gcaagtgcat gaacaagaag tgcagatgct acagc 105
<210> 807
<211> 216
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Lambda LC translation
<400> 807
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Arg Val Ser Ile Thr Cys Ser Gly Ser Ser Ser Asn Val Gly Asn Gly
20 25 30
Tyr Val Ser Trp Tyr Gln Leu Ile Pro Gly Ser Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Ser Arg Ala Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Arg Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Ser Leu Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 808
<211> 60
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: Shk toxin
<400> 808
Gly Val Pro Asp Arg Phe Ser Gly Ser Arg Ser Gly Asn Thr Ala Thr
1 5 10 15
Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys
20 25 30
Ala Ser Ala Glu Asp Ser Ser Ser Asn Ala Val Phe Gly Ser Gly Thr
35 40 45
Thr Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro
50 55 60
<210> 809
<211> 60
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ProTxII toxin
<400> 809
Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys
1 5 10 15
Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr
20 25 30
Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr
35 40 45
Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala
50 55 60
<210> 810
<211> 39
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: GPTX toxin
<400> 810
Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg
1 5 10 15
Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr
20 25 30
Val Ala Pro Thr Glu Cys Ser
35
<210> 811
<211> 114
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: OSK1 toxin (P12, K16, D20)
<400> 811
Gly Gly Cys Gly Thr Gly Ala Thr Cys Ala Thr Cys Ala Ala Cys Gly
1 5 10 15
Thr Gly Ala Ala Ala Thr Gly Cys Ala Ala Gly Ala Thr Cys Ala Gly
20 25 30
Cys Cys Cys Cys Cys Ala Gly Thr Gly Cys Cys Thr Gly Ala Ala Gly
35 40 45
Cys Cys Cys Thr Gly Cys Ala Ala Gly Gly Ala Cys Gly Cys Cys Gly
50 55 60
Gly Cys Ala Thr Gly Ala Gly Gly Thr Thr Cys Gly Gly Gly Ala Ala
65 70 75 80
Gly Thr Gly Cys Ala Thr Gly Ala Ala Cys Gly Gly Cys Ala Ala Gly
85 90 95
Thr Gly Cys Cys Ala Cys Thr Gly Cys Ala Cys Cys Cys Cys Cys Ala
100 105 110
Ala Gly
<210> 812
<211> 114
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: OSK1 toxin (K16 and D20)
<400> 812
Gly Gly Cys Gly Thr Gly Ala Thr Cys Ala Thr Cys Ala Ala Cys Gly
1 5 10 15
Thr Gly Ala Ala Gly Thr Gly Cys Ala Ala Gly Ala Thr Cys Ala Gly
20 25 30
Cys Ala Gly Gly Cys Ala Gly Thr Gly Cys Cys Thr Gly Ala Ala Gly
35 40 45
Cys Cys Cys Thr Gly Cys Ala Ala Gly Gly Ala Cys Gly Cys Cys Gly
50 55 60
Gly Cys Ala Thr Gly Ala Gly Gly Thr Thr Cys Gly Gly Thr Ala Ala
65 70 75 80
Gly Thr Gly Cys Ala Thr Gly Ala Ala Cys Gly Gly Cys Ala Ala Gly
85 90 95
Thr Gly Cys Cys Ala Cys Thr Gly Cys Ala Cys Cys Cys Cys Cys Ala
100 105 110
Ala Gly
<210> 813
<211> 1
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 813
Gly
1
<210> 814
<211> 2
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 814
Gly Gly
1
<210> 815
<211> 3
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 815
Gly Gly Gly
1
<210> 816
<211> 4
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 816
Gly Gly Gly Gly
1
<210> 817
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 817
Gly Gly Gly Gly Gly Ser Gly Gly Ser
1 5
<210> 818
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 818
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
1 5 10
<210> 819
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 819
Gly Gly Gly Gly Ser Gly Gly Ser
1 5
<210> 820
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 820
Gly Gly Gly Gly Ser Gly Gly Ser Gly Gly Ser
1 5 10
<210> 821
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 821
Gly Gly Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
1 5 10
<210> 822
<211> 4
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 822
Gly Gly Ser Gly
1
<210> 823
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 823
Gly Gly Ser Gly Gly
1 5
<210> 824
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 824
Gly Gly Ser Gly Gly Ser Gly
1 5
<210> 825
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 825
Gly Gly Ser Gly Gly Ser Gly Gly
1 5
<210> 826
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 826
Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly
1 5 10
<210> 827
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 827
Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly
1 5 10
<210> 828
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 828
Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly
1 5 10
<210> 829
<211> 3
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 829
Gly Ser Gly
1
<210> 830
<211> 4
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: linker sequence
<400> 830
Gly Ser Gly Gly
1
<210> 831
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ShK, Q21
<400> 831
Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln
1 5 10 15
Cys Lys His Ser Gln Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys
20 25 30
Gly Thr Cys
35
<210> 832
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ShK, L21
<400> 832
Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln
1 5 10 15
Cys Lys His Ser Leu Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys
20 25 30
Gly Thr Cys
35
<210> 833
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ShK, F21
<400> 833
Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln
1 5 10 15
Cys Lys His Ser Phe Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys
20 25 30
Gly Thr Cys
35
<210> 834
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ShK, I21
<400> 834
Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln
1 5 10 15
Cys Lys His Ser Ile Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys
20 25 30
Gly Thr Cys
35
<210> 835
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: ShK, A21
<400> 835
Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln
1 5 10 15
Cys Lys His Ser Ala Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys
20 25 30
Gly Thr Cys
35
<210> 836
<211> 504
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS1:1 ProTxII of
plasmid 131-34
<400> 836
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc tattgccaga agtggatgtg gacctgcgat 360
agcgaacgga aatgttgcga aggcatggtg tgccgcctgt ggtgcaagaa gaaactctgg 420
ggaggaagct cttataccta caattatgaa tggcatgtgg atgtctgggg acagggcctg 480
ctggtgacag tctctagtgc tagc 504
<210> 837
<211> 513
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS1:2 ProTxII of
plasmid 131-35
<400> 837
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc tattgccaga agtggatgtg gacctgcgat 360
agcgaacgga aatgttgcga aggcatggtg tgccgcctgt ggtgcaagaa gaaactctgg 420
ggaggaagcg gaggaagctc ttatacctac aattatgaat ggcatgtgga tgtctgggga 480
cagggcctgc tggtgacagt ctctagtgct agc 513
<210> 838
<211> 513
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS2:1 ProTxII of
plasmid 131-36
<400> 838
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagct attgccagaa gtggatgtgg 360
acctgcgata gcgaacggaa atgttgcgaa ggcatggtgt gccgcctgtg gtgcaagaag 420
aaactctggg gaggaagctc ttatacctac aattatgaat ggcatgtgga tgtctgggga 480
cagggcctgc tggtgacagt ctctagtgct agc 513
<210> 839
<211> 519
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 Hc CowV,HuC 1:1GGS G-Moka of
plasmid 131-40
<400> 839
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggcatcaacg tgaagtgcag cctgccccag 360
cagtgcatca agccctgcaa ggacgccggc atgagattcg gcaagtgcat gaacaagaag 420
tgcagatgct acagcggagg aagctcttat acctacaatt atgaatggca tgtggatgtc 480
tggggacagg gcctgctggt gacagtctct agtgctagc 519
<210> 840
<211> 528
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 Hc CowV,HuC 1:2GGS G-Moka of
plasmid 131-41
<400> 840
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggcatcaacg tgaagtgcag cctgccccag 360
cagtgcatca agccctgcaa ggacgccggc atgagattcg gcaagtgcat gaacaagaag 420
tgcagatgct acagcggagg aagcggagga agctcttata cctacaatta tgaatggcat 480
gtggatgtct ggggacaggg cctgctggtg acagtctcta gtgctagc 528
<210> 841
<211> 528
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 Hc CowV,HuC 2:1GGS G-Moka of
plasmid 131-42
<400> 841
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gcatcaacgt gaagtgcagc 360
ctgccccagc agtgcatcaa gccctgcaag gacgccggca tgagattcgg caagtgcatg 420
aacaagaagt gcagatgcta cagcggagga agctcttata cctacaatta tgaatggcat 480
gtggatgtct ggggacaggg cctgctggtg acagtctcta gtgctagc 528
<210> 842
<211> 555
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 Hc CowV,HuC 3:3GGS G-Moka of
plasmid 131-43
<400> 842
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gaggaagcgg catcaacgtg 360
aagtgcagcc tgccccagca gtgcatcaag ccctgcaagg acgccggcat gagattcggc 420
aagtgcatga acaagaagtg cagatgctac agcggaggaa gcggaggaag cggaggaagc 480
tcttatacct acaattatga atggcatgtg gatgtctggg gacagggcct gctggtgaca 540
gtctctagtg ctagc 555
<210> 843
<211> 516
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS1:1 GG-ProTxII-GG of
plasmid 131-37
<400> 843
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggcggctatt gccagaagtg gatgtggacc 360
tgcgatagcg aacggaaatg ttgcgaaggc atggtgtgcc gcctgtggtg caagaagaaa 420
ctctggggcg gcggaggaag ctcttatacc tacaattatg aatggcatgt ggatgtctgg 480
ggacagggcc tgctggtgac agtctctagt gctagc 516
<210> 844
<211> 525
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS1:2 GG-ProTxII-GG of
plasmid 131-38
<400> 844
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggcggctatt gccagaagtg gatgtggacc 360
tgcgatagcg aacggaaatg ttgcgaaggc atggtgtgcc gcctgtggtg caagaagaaa 420
ctctggggcg gcggaggaag cggaggaagc tcttatacct acaattatga atggcatgtg 480
gatgtctggg gacagggcct gctggtgaca gtctctagtg ctagc 525
<210> 845
<211> 525
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS2:1 GG-ProTxII-GG of
plasmid 131-39
<400> 845
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gcggctattg ccagaagtgg 360
atgtggacct gcgatagcga acggaaatgt tgcgaaggca tggtgtgccg cctgtggtgc 420
aagaagaaac tctggggcgg cggaggaagc tcttatacct acaattatga atggcatgtg 480
gatgtctggg gacagggcct gctggtgaca gtctctagtg ctagc 525
<210> 846
<211> 522
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS2:2 ProTxII of
plasmid 131-44
<400> 846
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagct attgccagaa gtggatgtgg 360
acctgcgata gcgaacggaa atgttgcgaa ggcatggtgt gccgcctgtg gtgcaagaag 420
aaactctggg gaggaagcgg aggaagctct tatacctaca attatgaatg gcatgtggat 480
gtctggggac agggcctgct ggtgacagtc tctagtgcta gc 522
<210> 847
<211> 540
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS2:4 ProTxII of
plasmid 131-45
<400> 847
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagct attgccagaa gtggatgtgg 360
acctgcgata gcgaacggaa atgttgcgaa ggcatggtgt gccgcctgtg gtgcaagaag 420
aaactctggg gaggaagcgg aggaagcgga ggaagcggag gaagctctta tacctacaat 480
tatgaatggc atgtggatgt ctggggacag ggcctgctgg tgacagtctc tagtgctagc 540
<210> 848
<211> 540
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS4:2 ProTxII of
plasmid 131-46
<400> 848
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gaggaagcgg aggaagctat 360
tgccagaagt ggatgtggac ctgcgatagc gaacggaaat gttgcgaagg catggtgtgc 420
cgcctgtggt gcaagaagaa actctgggga ggaagcggag gaagctctta tacctacaat 480
tatgaatggc atgtggatgt ctggggacag ggcctgctgg tgacagtctc tagtgctagc 540
<210> 849
<211> 534
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS2:2 GG-ProTxII-GG of
plasmid 131-47
<400> 849
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gcggctattg ccagaagtgg 360
atgtggacct gcgatagcga acggaaatgt tgcgaaggca tggtgtgccg cctgtggtgc 420
aagaagaaac tctggggcgg cggaggaagc ggaggaagct cttataccta caattatgaa 480
tggcatgtgg atgtctgggg acagggcctg ctggtgacag tctctagtgc tagc 534
<210> 850
<211> 543
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS 2:3 GG-ProTxII-GG of
plasmid 131-48
<400> 850
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gcggctattg ccagaagtgg 360
atgtggacct gcgatagcga acggaaatgt tgcgaaggca tggtgtgccg cctgtggtgc 420
aagaagaaac tctggggcgg cggaggaagc ggaggaagcg gaggaagctc ttatacctac 480
aattatgaat ggcatgtgga tgtctgggga cagggcctgc tggtgacagt ctctagtgct 540
agc 543
<210> 851
<211> 552
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS 2:4 GG-ProTxII-GG of
plasmid 131-49
<400> 851
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gcggctattg ccagaagtgg 360
atgtggacct gcgatagcga acggaaatgt tgcgaaggca tggtgtgccg cctgtggtgc 420
aagaagaaac tctggggcgg cggaggaagc ggaggaagcg gaggaagcgg aggaagctct 480
tatacctaca attatgaatg gcatgtggat gtctggggac agggcctgct ggtgacagtc 540
tctagtgcta gc 552
<210> 852
<211> 543
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS 3:2 GG-ProTxII-GG of
plasmid 131-50
<400> 852
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gaggaagcgg cggctattgc 360
cagaagtgga tgtggacctg cgatagcgaa cggaaatgtt gcgaaggcat ggtgtgccgc 420
ctgtggtgca agaagaaact ctggggcggc ggaggaagcg gaggaagctc ttatacctac 480
aattatgaat ggcatgtgga tgtctgggga cagggcctgc tggtgacagt ctctagtgct 540
agc 543
<210> 853
<211> 552
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS 3:3 GG-ProTxII-GG of
plasmid 131-51
<400> 853
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gaggaagcgg cggctattgc 360
cagaagtgga tgtggacctg cgatagcgaa cggaaatgtt gcgaaggcat ggtgtgccgc 420
ctgtggtgca agaagaaact ctggggcggc ggaggaagcg gaggaagcgg aggaagctct 480
tatacctaca attatgaatg gcatgtggat gtctggggac agggcctgct ggtgacagtc 540
tctagtgcta gc 552
<210> 854
<211> 552
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS 4:2 GG-ProTxII-GG of
plasmid 131-52
<400> 854
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gaggaagcgg aggaagcggc 360
ggctattgcc agaagtggat gtggacctgc gatagcgaac ggaaatgttg cgaaggcatg 420
gtgtgccgcc tgtggtgcaa gaagaaactc tggggcggcg gaggaagcgg aggaagctct 480
tatacctaca attatgaatg gcatgtggat gtctggggac agggcctgct ggtgacagtc 540
tctagtgcta gc 552
<210> 855
<211> 582
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 3xG4S ProTxII of
plasmid 131-56
<400> 855
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gatactgcca gaagtggatg tggacctgcg acagcgagag gaagtgctgc 420
gagggcatgg tgtgcaggct gtggtgcaag aagaagctgt ggggaggtgg tggatctggt 480
ggaggaggca gtggaggtgg tggcagctct tatacctaca attatgaatg gcatgtggat 540
gtctggggcc aaggaaccct ggtcaccgtc tcctcagcta gc 582
<210> 856
<211> 597
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 3xG4S ShK of
plasmid 131-59
<400> 856
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaaggagctg catcgacacc atccccaaga gccgatgcac cgccttccag 420
tgcaagcaca gcatgaagta caggctgagc ttctgcagga agacctgcgg cacctgcgga 480
ggtggtggat ctggtggagg aggcagtgga ggtggtggca gctcttatac ctacaattat 540
gaatggcatg tggatgtctg gggccaagga accctggtca ccgtctcctc agctagc 597
<210> 857
<211> 606
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 3xG4S OSK1 (K16, D20) of
plasmid 131-60
<400> 857
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaggcgtgat catcaacgtg aagtgcaaga tcagcaggca gtgcctgaag 420
ccctgcaagg acgccggcat gaggttcggt aagtgcatga acggcaagtg ccactgcacc 480
cccaagggag gtggtggatc tggtggagga ggcagtggag gtggtggcag ctcttatacc 540
tacaattatg aatggcatgt ggatgtctgg ggccaaggaa ccctggtcac cgtctcctca 600
gctagc 606
<210> 858
<211> 606
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 3xG4S OSK1 (P12,K16,D20)
of plasmid 131-61
<400> 858
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaggcgtgat catcaacgtg aaatgcaaga tcagccccca gtgcctgaag 420
ccctgcaagg acgccggcat gaggttcggg aagtgcatga acggcaagtg ccactgcacc 480
cccaagggag gtggtggatc tggtggagga ggcagtggag gtggtggcag ctcttatacc 540
tacaattatg aatggcatgt ggatgtctgg ggccaaggaa ccctggtcac cgtctcctca 600
gctagc 606
<210> 859
<211> 594
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 cowV HumanC 3xG4S GPTX of
plasmid 131-62
<400> 859
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gagactgcct gggcttcatg aggaagtgca tccccgacaa cgacaagtgc 420
tgcaggccca acctggtgtg cagcaggacc cacaagtggt gcaagtacgt gttcggaggt 480
ggtggatctg gtggaggagg cagtggaggt ggtggcagct cttataccta caattatgaa 540
tggcatgtgg atgtctgggg ccaaggaacc ctggtcaccg tctcctcagc tagc 594
<210> 860
<211> 486
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 6xG4S of
plasmid 131-64
<400> 860
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaggtggatc tggtggagga ggcagtggag gtggtggcag ctcttatacc 420
tacaattatg aatggcatgt ggatgtctgg ggccaaggaa ccctggtcac cgtctcctca 480
gctagc 486
<210> 861
<211> 459
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 1xG4S BsaIs (wStop) of
plasmid 131-65
<400> 861
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gatgagacct actatggttc 360
agggtctctg gaggtggtgg atcttcttat acctacaatt atgaatggca tgtggatgtc 420
tggggccaag gaaccctggt caccgtctcc tcagctagc 459
<210> 862
<211> 582
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GLLV 3xG4S ProTxII of
plasmid 131-66
<400> 862
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gatactgcca gaagtggatg tggacctgcg acagcgagag gaagtgctgc 420
gagggcatgg tgtgcaggct gtggtgcaag aagaagctgt ggggaggtgg tggatctggt 480
ggaggaggca gtggaggtgg tggcagctct tatacctaca attatgaatg gcatgtggat 540
gtctggggac agggcctgct ggtgacagtc tctagtgcta gc 582
<210> 863
<211> 597
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 Hc CowV,HuC GLLV 3xG4S ShKtoxin
of plasmid 131-67
<400> 863
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaaggagctg catcgacacc atccccaaga gccgatgcac cgccttccag 420
tgcaagcaca gcatgaagta caggctgagc ttctgcagga agacctgcgg cacctgcgga 480
ggtggtggat ctggtggagg aggcagtgga ggtggtggca gctcttatac ctacaattat 540
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 597
<210> 864
<211> 606
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GLLV 3xG4S OSK1 (K16,D20) of
plasmid 131-68
<400> 864
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaggcgtgat catcaacgtg aagtgcaaga tcagcaggca gtgcctgaag 420
ccctgcaagg acgccggcat gaggttcggt aagtgcatga acggcaagtg ccactgcacc 480
cccaagggag gtggtggatc tggtggagga ggcagtggag gtggtggcag ctcttatacc 540
tacaattatg aatggcatgt ggatgtctgg ggacagggcc tgctggtgac agtctctagt 600
gctagc 606
<210> 865
<211> 606
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GLLV 3xG4S OSK1 (P12,K16,D20)
of plasmid 131-69
<400> 865
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaggcgtgat catcaacgtg aaatgcaaga tcagccccca gtgcctgaag 420
ccctgcaagg acgccggcat gaggttcggg aagtgcatga acggcaagtg ccactgcacc 480
cccaagggag gtggtggatc tggtggagga ggcagtggag gtggtggcag ctcttatacc 540
tacaattatg aatggcatgt ggatgtctgg ggacagggcc tgctggtgac agtctctagt 600
gctagc 606
<210> 866
<211> 594
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GLLV 3xG4S GpTx-1 of
plasmid 131-70
<400> 866
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gagactgcct gggcttcatg aggaagtgca tccccgacaa cgacaagtgc 420
tgcaggccca acctggtgtg cagcaggacc cacaagtggt gcaagtacgt gttcggaggt 480
ggtggatctg gtggaggagg cagtggaggt ggtggcagct cttataccta caattatgaa 540
tggcatgtgg atgtctgggg acagggcctg ctggtgacag tctctagtgc tagc 594
<210> 867
<211> 627
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 CD3 IL8_CDR1-Cow_CDR2-Human of
plasmid 132-07
<400> 867
caggtgcagc tacagcagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcacag caagcgggtt ttcactgagc gacaaggcag tgggatggat tcgccagccc 120
ccagggaagg ggctggagtg gattggggaa atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag tgctagc 627
<210> 868
<211> 627
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 CD3 IL8_CDR1-Cow_CDR2-Cow of
plasmid 132-09
<400> 868
caggtgcagc tacagcagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcacag caagcgggtt ttcactgagc gacaaggcag tgggatggat tcgccagccc 120
ccagggaagg ggctggagtg gctgggcagc atcgataccg gcgggaacac agggtacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag tgctagc 627
<210> 869
<211> 627
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 CD3 IL8_CDR1-Cow_CDR2-Cow of
plasmid 132-09
<400> 869
caggtgcagc tacagcagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcacag caagcgggtt ttcactgagc gacaaggcag tgggatggat tcgccagccc 120
ccagggaagg ggctggagtg gctgggcagc atcgataccg gcgggaacac agggtacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag tgctagc 627
<210> 870
<211> 627
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 CD3 IL8_CDR1-G31DY32K_CDR2-E50S
of plasmid 132-05
<400> 870
caggtgcagc tacagcagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag tgctagc 627
<210> 871
<211> 627
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 CD3 IL8_CDR1-Cow_CDR2-Cow
of plasmid 132-09
<400> 871
caggtgcagc tacagcagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcacag caagcgggtt ttcactgagc gacaaggcag tgggatggat tcgccagccc 120
ccagggaagg ggctggagtg gctgggcagc atcgataccg gcgggaacac agggtacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag tgctagc 627
<210> 872
<211> 513
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC CowV, Human CH1-2-3(107) of
plasmid 131-74
<400> 872
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag ctgtcctgac ggctatcggg agagatctga ttgcagtaat 360
aggccagctt gtggcacatc cgactgctgt cgcgtgtctg tcttcgggaa ctgcctgact 420
accctgcctg tgtcctactc ttatacctac aattatgaat ggcatgtgga tgtctgggga 480
cagggcctgc tggtgacagt ctctagtgct agc 513
<210> 873
<211> 627
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC CowV, CDR3 IL-8, Human
CH1-2-3 (105) of plasmid 131-76
<400> 873
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cccaaggagt gctaaagaac ttagatgtca gtgcataaag 360
acatactcca aacctttcca ccccaagttc atcaaggagc tgagagtgat tgagagtgga 420
ccacactgcg ccaacacaga gattattgta aagctttctg atgggagaga gctctgcctg 480
gaccccaagg aaaactgggt gcagagggtc gtggagaagt tcttgaagag ggctgagaac 540
tcaggcagcg gttcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 600
ctgctggtga cagtctctag tgctagc 627
<210> 874
<211> 654
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 CowV 1xGGGGS linker- IL-8
-HumanCH123 of plasmid 131-71
<400> 874
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gaccaaggag tgctaaagaa 360
cttagatgtc agtgcataaa gacatactcc aaacctttcc accccaagtt catcaaggag 420
ctgagagtga ttgagagtgg accacactgc gccaacacag agattattgt aaagctttct 480
gatgggagag agctctgcct ggaccccaag gaaaactggg tgcagagggt cgtggagaag 540
ttcttgaaga gggctgagaa ctcaggaggt ggtggatctt cttataccta caattatgaa 600
tggcatgtgg atgtctgggg acagggcctg ctggtgacag tctctagtgc tagc 654
<210> 875
<211> 714
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 CowV 3xGGGGS linker- IL-8
-HumanCH123 of plasmid 131-72
<400> 875
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaccaaggag tgctaaagaa cttagatgtc agtgcataaa gacatactcc 420
aaacctttcc accccaagtt catcaaggag ctgagagtga ttgagagtgg accacactgc 480
gccaacacag agattattgt aaagctttct gatgggagag agctctgcct ggaccccaag 540
gaaaactggg tgcagagggt cgtggagaag ttcttgaaga gggctgagaa ctcaggaggt 600
ggtggatctg gtggaggagg cagtggaggt ggtggcagct cttataccta caattatgaa 660
tggcatgtgg atgtctgggg acagggcctg ctggtgacag tctctagtgc tagc 714
<210> 876
<211> 714
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, 3xG4S,
IL-8 of plasmid 132-37
<400> 876
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaccaaggag tgctaaagaa cttagatgtc agtgcataaa gacatactcc 420
aaacctttcc accccaagtt catcaaggag ctgagagtga ttgagagtgg accacactgc 480
gccaacacag agattattgt aaagctttct gatgggagag agctctgcct ggaccccaag 540
gaaaactggg tgcagagggt cgtggagaag ttcttgaaga gggctgagaa ctcaggaggt 600
ggtggatctg gtggaggagg cagtggaggt ggtggcagct cttataccta caattatgaa 660
tggcatgtgg atgtctgggg acagggcctg ctggtgacag tctctagtgc tagc 714
<210> 877
<211> 597
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, 3xG4S,
ShK of plasmid 132-35
<400> 877
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaaggagctg catcgacacc atccccaaga gccgatgcac cgccttccag 420
tgcaagcaca gcatgaagta caggctgagc ttctgcagga agacctgcgg cacctgcgga 480
ggtggtggat ctggtggagg aggcagtgga ggtggtggca gctcttatac ctacaattat 540
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 597
<210> 878
<211> 555
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, 3:3GGS,
MOKA of plasmid 132-36
<400> 878
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gaggaagcgg catcaacgtg 360
aagtgcagcc tgccccagca gtgcatcaag ccctgcaagg acgccggcat gagattcggc 420
aagtgcatga acaagaagtg cagatgctac agcggaggaa gcggaggaag cggaggaagc 480
tcttatacct acaattatga atggcatgtg gatgtctggg gacagggcct gctggtgaca 540
gtctctagtg ctagc 555
<210> 879
<211> 597
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, CDR1 Cow, 3xG4S, ShK of
plasmid 132-38
<400> 879
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcacag caagcgggtt ttcactgagc gacaaggcag tgggatggat tcgccagccc 120
ccagggaagg ggctggagtg gattggggaa atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaaggagctg catcgacacc atccccaaga gccgatgcac cgccttccag 420
tgcaagcaca gcatgaagta caggctgagc ttctgcagga agacctgcgg cacctgcgga 480
ggtggtggat ctggtggagg aggcagtgga ggtggtggca gctcttatac ctacaattat 540
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 597
<210> 880
<211> 714
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, CDR1 Cow,3xG4S, IL-8 of
plasmid 132-40
<400> 880
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcacag caagcgggtt ttcactgagc gacaaggcag tgggatggat tcgccagccc 120
ccagggaagg ggctggagtg gattggggaa atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaccaaggag tgctaaagaa cttagatgtc agtgcataaa gacatactcc 420
aaacctttcc accccaagtt catcaaggag ctgagagtga ttgagagtgg accacactgc 480
gccaacacag agattattgt aaagctttct gatgggagag agctctgcct ggaccccaag 540
gaaaactggg tgcagagggt cgtggagaag ttcttgaaga gggctgagaa ctcaggaggt 600
ggtggatctg gtggaggagg cagtggaggt ggtggcagct cttataccta caattatgaa 660
tggcatgtgg atgtctgggg acagggcctg ctggtgacag tctctagtgc tagc 714
<210> 881
<211> 555
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, CDR1 Cow,3:3GGS, MOKA
of plasmid 132-39
<400> 881
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcacag caagcgggtt ttcactgagc gacaaggcag tgggatggat tcgccagccc 120
ccagggaagg ggctggagtg gattggggaa atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gaggaagcgg catcaacgtg 360
aagtgcagcc tgccccagca gtgcatcaag ccctgcaagg acgccggcat gagattcggc 420
aagtgcatga acaagaagtg cagatgctac agcggaggaa gcggaggaag cggaggaagc 480
tcttatacct acaattatga atggcatgtg gatgtctggg gacagggcct gctggtgaca 540
gtctctagtg ctagc 555
<210> 882
<211> 582
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, 3xG4S,
ProTxII of plasmid 132-31
<400> 882
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gatactgcca gaagtggatg tggacctgcg acagcgagag gaagtgctgc 420
gagggcatgg tgtgcaggct gtggtgcaag aagaagctgt ggggaggtgg tggatctggt 480
ggaggaggca gtggaggtgg tggcagctct tatacctaca attatgaatg gcatgtggat 540
gtctggggac agggcctgct ggtgacagtc tctagtgcta gc 582
<210> 883
<211> 594
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, 3xG4S,
GPTX1 of plasmid 132-34
<400> 883
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gagactgcct gggcttcatg aggaagtgca tccccgacaa cgacaagtgc 420
tgcaggccca acctggtgtg cagcaggacc cacaagtggt gcaagtacgt gttcggaggt 480
ggtggatctg gtggaggagg cagtggaggt ggtggcagct cttataccta caattatgaa 540
tggcatgtgg atgtctgggg acagggcctg ctggtgacag tctctagtgc tagc 594
<210> 884
<211> 423
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-3xGGS of plasmid 132-49
<400> 884
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaagc ggaggaagcg gaggaagctc ttatacctac 360
aattatgaat ggcatgtgga tgtctgggga cagggcctgc tggtgacagt ctctagtgct 420
agc 423
<210> 885
<211> 537
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-1xG4S ShK of plasmid 132-453
<400> 885
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gaaggagctg catcgacacc 360
atccccaaga gccgatgcac cgccttccag tgcaagcaca gcatgaagta caggctgagc 420
ttctgcagga agacctgcgg cacctgcgga ggtggtggat cttcttatac ctacaattat 480
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 537
<210> 886
<211> 537
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-1xG4S ShK-16K of plasmid 132-52
<400> 886
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gaaggagctg catcgacacc 360
atccccaaga gccgatgcac cgccttcaag tgcaagcaca gcatgaagta caggctgagc 420
ttctgcagga agacctgcgg cacctgcgga ggtggtggat cttcttatac ctacaattat 480
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 537
<210> 887
<211> 597
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-3xG4S ShK-16K of plasmid 132-56
<400> 887
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaaggagctg catcgacacc atccccaaga gccgatgcac cgccttcaag 420
tgcaagcaca gcatgaagta caggctgagc ttctgcagga agacctgcgg cacctgcgga 480
ggtggtggat ctggtggagg aggcagtgga ggtggtggca gctcttatac ctacaattat 540
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 597
<210> 888
<211> 501
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
Shk-No Linker of plasmid 132-61
<400> 888
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag caggagctgc atcgacacca tccccaagag ccgatgcacc 360
gccttccagt gcaagcacag catgaagtac aggctgagct tctgcaggaa gacctgcggc 420
acctgctctt atacctacaa ttatgaatgg catgtggatg tctggggaca gggcctgctg 480
gtgacagtct ctagtgctag c 501
<210> 889
<211> 507
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
G-ShK-G of plasmid 132-62
<400> 889
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggcaggagc tgcatcgaca ccatccccaa gagccgatgc 360
accgccttcc agtgcaagca cagcatgaag tacaggctga gcttctgcag gaagacctgc 420
ggcacctgcg gatcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 480
ctgctggtga cagtctctag tgctagc 507
<210> 890
<211> 513
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 MutE GG-ShK-GG of
plasmid 132-63
<400> 890
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggcgggagg agctgcatcg acaccatccc caagagccga 360
tgcaccgcct tccagtgcaa gcacagcatg aagtacaggc tgagcttctg caggaagacc 420
tgcggcacct gcggaggctc ttatacctac aattatgaat ggcatgtgga tgtctgggga 480
cagggcctgc tggtgacagt ctctagtgct agc 513
<210> 891
<211> 525
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
GSGG-Shk-GGGG of plasmid 132-75
<400> 891
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggttctgga ggaaggagct gcatcgacac catccccaag 360
agccgatgca ccgccttcca gtgcaagcac agcatgaagt acaggctgag cttctgcagg 420
aagacctgcg gcacctgcgg aggtggtgga tcttatacct acaattatga atggcatgtg 480
gatgtctggg gacagggcct gctggtgaca gtctctagtg ctagc 525
<210> 892
<211> 525
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
GGGG-Shk-GGGG of plasmid 132-76
<400> 892
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggtaggagct gcatcgacac catccccaag 360
agccgatgca ccgccttcca gtgcaagcac agcatgaagt acaggctgag cttctgcagg 420
aagacctgcg gcacctgcgg aggtggtgga tcttatacct acaattatga atggcatgtg 480
gatgtctggg gacagggcct gctggtgaca gtctctagtg ctagc 525
<210> 893
<211> 519
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
GGG-Shk-GGG of plasmid 132-77
<400> 893
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggaggt aggagctgca tcgacaccat ccccaagagc 360
cgatgcaccg ccttccagtg caagcacagc atgaagtaca ggctgagctt ctgcaggaag 420
acctgcggca cctgcggtgg tggatcttat acctacaatt atgaatggca tgtggatgtc 480
tggggacagg gcctgctggt gacagtctct agtgctagc 519
<210> 894
<211> 597
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E S62G MutE
-CD1_G31DY32K_CD2_E50S_CD3_3XG4S_Shk of plasmid 132-76
<400> 894
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgggcctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaaggagctg catcgacacc atccccaaga gccgatgcac cgccttccag 420
tgcaagcaca gcatgaagta caggctgagc ttctgcagga agacctgcgg cacctgcgga 480
ggtggtggat ctggtggagg aggcagtgga ggtggtggca gctcttatac ctacaattat 540
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 597
<210> 895
<211> 567
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_2xG4S ShK of plasmid 134-12
<400> 895
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggaggcggt ggaagtggtg gcggaggtag cggaggaagg 360
agctgcatcg acaccatccc caagagccga tgcaccgcct tccagtgcaa gcacagcatg 420
aagtacaggc tgagcttctg caggaagacc tgcggcacct gcggtggagg aggcagtgga 480
ggtggtggca gctcttatac ctacaattat gaatggcatg tggatgtctg gggacagggc 540
ctgctggtga cagtctctag tgctagc 567
<210> 896
<211> 597
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_3xG4S ShK (M21Q) of plasmid 134-13
<400> 896
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaaggagctg catcgacacc atccccaaga gccgatgcac cgccttccag 420
tgcaagcaca gccagaagta caggctgagc ttctgcagga agacctgcgg cacctgcgga 480
ggtggtggat ctggtggagg aggcagtgga ggtggtggca gctcttatac ctacaattat 540
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 597
<210> 897
<211> 597
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_3xG4S ShK (M21L) of plasmid 134-14
<400> 897
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaaggagctg catcgacacc atccccaaga gccgatgcac cgccttccag 420
tgcaagcaca gcctgaagta caggctgagc ttctgcagga agacctgcgg cacctgcgga 480
ggtggtggat ctggtggagg aggcagtgga ggtggtggca gctcttatac ctacaattat 540
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 597
<210> 898
<211> 597
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_3xG4S ShK (M21F) of plasmid 134-15
<400> 898
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaaggagctg catcgacacc atccccaaga gccgatgcac cgccttccag 420
tgcaagcaca gcttcaagta caggctgagc ttctgcagga agacctgcgg cacctgcgga 480
ggtggtggat ctggtggagg aggcagtgga ggtggtggca gctcttatac ctacaattat 540
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 597
<210> 899
<211> 597
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_3xG4S ShK (M21I) of plasmid 134-16
<400> 899
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaaggagctg catcgacacc atccccaaga gccgatgcac cgccttccag 420
tgcaagcaca gcatcaagta caggctgagc ttctgcagga agacctgcgg cacctgcgga 480
ggtggtggat ctggtggagg aggcagtgga ggtggtggca gctcttatac ctacaattat 540
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 597
<210> 900
<211> 597
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_3xG4S ShK (M21A) of plasmid 134-17
<400> 900
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gaaggagctg catcgacacc atccccaaga gccgatgcac cgccttccag 420
tgcaagcaca gcgccaagta caggctgagc ttctgcagga agacctgcgg cacctgcgga 480
ggtggtggat ctggtggagg aggcagtgga ggtggtggca gctcttatac ctacaattat 540
gaatggcatg tggatgtctg gggacagggc ctgctggtga cagtctctag tgctagc 597
<210> 901
<211> 522
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-1xG4S ProTxII of plasmid 132-54
<400> 901
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gatactgcca gaagtggatg 360
tggacctgcg acagcgagag gaagtgctgc gagggcatgg tgtgcaggct gtggtgcaag 420
aagaagctgt ggggaggtgg tggatcttct tatacctaca attatgaatg gcatgtggat 480
gtctggggac agggcctgct ggtgacagtc tctagtgcta gc 522
<210> 902
<211> 534
<212> DNA
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-1xG4S GPTX1 of plasmid 132-55
<400> 902
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gagactgcct gggcttcatg 360
aggaagtgca tccccgacaa cgacaagtgc tgcaggccca acctggtgtg cagcaggacc 420
cacaagtggt gcaagtacgt gttcggaggt ggtggatctt cttataccta caattatgaa 480
tggcatgtgg atgtctgggg acagggcctg ctggtgacag tctctagtgc tagc 534
<210> 903
<211> 168
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS1:1 ProTxII of
plasmid 131-34
<400> 903
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Tyr Cys
100 105 110
Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys Cys Glu Gly
115 120 125
Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp Gly Gly Ser Ser
130 135 140
Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu
145 150 155 160
Leu Val Thr Val Ser Ser Ala Ser
165
<210> 904
<211> 171
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS1:2 ProTxII of
plasmid 131-35
<400> 904
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Tyr Cys
100 105 110
Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys Cys Glu Gly
115 120 125
Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp Gly Gly Ser Gly
130 135 140
Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly
145 150 155 160
Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170
<210> 905
<211> 171
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS2:1 ProTxII of
plasmid 131-36
<400> 905
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys
115 120 125
Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp Gly
130 135 140
Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly
145 150 155 160
Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170
<210> 906
<211> 172
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS1:1 GG-ProTxII-GG of
plasmid 131-37
<400> 906
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys Cys
115 120 125
Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp Gly Gly
130 135 140
Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp
145 150 155 160
Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170
<210> 907
<211> 175
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS1:2 GG-ProTxII-GG of
plasmid 131-38
<400> 907
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys Cys
115 120 125
Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp Gly Gly
130 135 140
Gly Gly Ser Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val
145 150 155 160
Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170 175
<210> 908
<211> 175
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS2:1 GG-ProTxII-GG of
plasmid 131-39
<400> 908
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg
115 120 125
Lys Cys Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu
130 135 140
Trp Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val
145 150 155 160
Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170 175
<210> 909
<211> 174
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS2:2 ProTxII of
plasmid 131-44
<400> 909
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys
115 120 125
Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp Gly
130 135 140
Gly Ser Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp
145 150 155 160
Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170
<210> 910
<211> 180
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS2:4 ProTxII of
plasmid 131-45
<400> 910
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys
115 120 125
Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp Gly
130 135 140
Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Ser Tyr Thr Tyr Asn
145 150 155 160
Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val
165 170 175
Ser Ser Ala Ser
180
<210> 911
<211> 180
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS4:2 ProTxII of
plasmid 131-46
<400> 911
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Ser Gly Gly Ser Tyr Cys Gln Lys Trp Met Trp Thr Cys
115 120 125
Asp Ser Glu Arg Lys Cys Cys Glu Gly Met Val Cys Arg Leu Trp Cys
130 135 140
Lys Lys Lys Leu Trp Gly Gly Ser Gly Gly Ser Ser Tyr Thr Tyr Asn
145 150 155 160
Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val
165 170 175
Ser Ser Ala Ser
180
<210> 912
<211> 178
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS2:2 GG-ProTxII-GG of
plasmid 131-47
<400> 912
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg
115 120 125
Lys Cys Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu
130 135 140
Trp Gly Gly Gly Gly Ser Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu
145 150 155 160
Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
165 170 175
Ala Ser
<210> 913
<211> 181
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS 2:3 GG-ProTxII-GG of
plasmid 131-48
<400> 913
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg
115 120 125
Lys Cys Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu
130 135 140
Trp Gly Gly Gly Gly Ser Gly Gly Ser Gly Gly Ser Ser Tyr Thr Tyr
145 150 155 160
Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr
165 170 175
Val Ser Ser Ala Ser
180
<210> 914
<211> 184
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS 2:4 GG-ProTxII-GG of
plasmid 131-49
<400> 914
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg
115 120 125
Lys Cys Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu
130 135 140
Trp Gly Gly Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Ser
145 150 155 160
Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu
165 170 175
Leu Val Thr Val Ser Ser Ala Ser
180
<210> 915
<211> 181
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS 3:2 GG-ProTxII-GG of
plasmid 131-50
<400> 915
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Ser Gly Gly Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp
115 120 125
Ser Glu Arg Lys Cys Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys
130 135 140
Lys Lys Leu Trp Gly Gly Gly Gly Ser Gly Gly Ser Ser Tyr Thr Tyr
145 150 155 160
Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr
165 170 175
Val Ser Ser Ala Ser
180
<210> 916
<211> 184
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS 3:3 GG-ProTxII-GG of
plasmid 131-51
<400> 916
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Ser Gly Gly Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp
115 120 125
Ser Glu Arg Lys Cys Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys
130 135 140
Lys Lys Leu Trp Gly Gly Gly Gly Ser Gly Gly Ser Gly Gly Ser Ser
145 150 155 160
Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu
165 170 175
Leu Val Thr Val Ser Ser Ala Ser
180
<210> 917
<211> 184
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC GGS 4:2 GG-ProTxII-GG of
plasmid 131-52
<400> 917
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Ser Gly Gly Ser Gly Gly Tyr Cys Gln Lys Trp Met Trp
115 120 125
Thr Cys Asp Ser Glu Arg Lys Cys Cys Glu Gly Met Val Cys Arg Leu
130 135 140
Trp Cys Lys Lys Lys Leu Trp Gly Gly Gly Gly Ser Gly Gly Ser Ser
145 150 155 160
Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu
165 170 175
Leu Val Thr Val Ser Ser Ala Ser
180
<210> 918
<211> 194
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 3xG4S ProTxII of
plasmid 131-56
<400> 918
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Tyr Cys Gln Lys
115 120 125
Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys Cys Glu Gly Met Val
130 135 140
Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp Gly Gly Gly Gly Ser Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu
165 170 175
Trp His Val Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
180 185 190
Ala Ser
<210> 919
<211> 199
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 3xG4S ShK of
plasmid 131-59
<400> 919
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile
115 120 125
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser
130 135 140
Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr
165 170 175
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Thr Leu
180 185 190
Val Thr Val Ser Ser Ala Ser
195
<210> 920
<211> 202
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 3xG4S OSK1 (K16,D20)
of plasmid 131-60
<400> 920
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Val Ile Ile
115 120 125
Asn Val Lys Cys Lys Ile Ser Arg Gln Cys Leu Lys Pro Cys Lys Asp
130 135 140
Ala Gly Met Arg Phe Gly Lys Cys Met Asn Gly Lys Cys His Cys Thr
145 150 155 160
Pro Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
165 170 175
Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln
180 185 190
Gly Thr Leu Val Thr Val Ser Ser Ala Ser
195 200
<210> 921
<211> 202
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 3xG4S OSK1 (P12,K16,D20)
of plasmid 131-61
<400> 921
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Val Ile Ile
115 120 125
Asn Val Lys Cys Lys Ile Ser Pro Gln Cys Leu Lys Pro Cys Lys Asp
130 135 140
Ala Gly Met Arg Phe Gly Lys Cys Met Asn Gly Lys Cys His Cys Thr
145 150 155 160
Pro Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
165 170 175
Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln
180 185 190
Gly Thr Leu Val Thr Val Ser Ser Ala Ser
195 200
<210> 922
<211> 198
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 cowV HumanC 3xG4S GPTX of
plasmid 131-62
<400> 922
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Asp Cys Leu Gly
115 120 125
Phe Met Arg Lys Cys Ile Pro Asp Asn Asp Lys Cys Cys Arg Pro Asn
130 135 140
Leu Val Cys Ser Arg Thr His Lys Trp Cys Lys Tyr Val Phe Gly Gly
145 150 155 160
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Thr
165 170 175
Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Thr Leu Val
180 185 190
Thr Val Ser Ser Ala Ser
195
<210> 923
<211> 162
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 6xG4S of
plasmid 131-64
<400> 923
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu
130 135 140
Trp His Val Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
145 150 155 160
Ala Ser
<210> 924
<211> 152
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 GTLV 1xG4S BsaIs (wStop) of
plasmid 131-65
<400> 924
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Asp Leu Leu Trp Phe Arg Val Ser Gly Gly Gly Gly Ser Ser
115 120 125
Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Thr
130 135 140
Leu Val Thr Val Ser Ser Ala Ser
145 150
<210> 925
<211> 171
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC CowV, Human CH1-2-3(107) of
plasmid 131-74
<400> 925
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Cys Pro Asp Gly Tyr
100 105 110
Arg Glu Arg Ser Asp Cys Ser Asn Arg Pro Ala Cys Gly Thr Ser Asp
115 120 125
Cys Cys Arg Val Ser Val Phe Gly Asn Cys Leu Thr Thr Leu Pro Val
130 135 140
Ser Tyr Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly
145 150 155 160
Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170
<210> 926
<211> 209
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 HC CowV, CDR3 IL-8, Human
CH1-2-3 (105) of plasmid 131-76
<400> 926
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Pro Arg Ser Ala Lys
100 105 110
Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro
115 120 125
Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala
130 135 140
Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu
145 150 155 160
Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys
165 170 175
Arg Ala Glu Asn Ser Gly Ser Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp
180 185 190
His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala
195 200 205
Ser
<210> 927
<211> 218
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 CowV 1xGGGGS linker- IL-8
-HumanCH123 of plasmid 131-71
<400> 927
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Pro Arg Ser Ala Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr
115 120 125
Tyr Ser Lys Pro Phe His Pro Lys Phe Ile Lys Glu Leu Arg Val Ile
130 135 140
Glu Ser Gly Pro His Cys Ala Asn Thr Glu Ile Ile Val Lys Leu Ser
145 150 155 160
Asp Gly Arg Glu Leu Cys Leu Asp Pro Lys Glu Asn Trp Val Gln Arg
165 170 175
Val Val Glu Lys Phe Leu Lys Arg Ala Glu Asn Ser Gly Gly Gly Gly
180 185 190
Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln
195 200 205
Gly Leu Leu Val Thr Val Ser Ser Ala Ser
210 215
<210> 928
<211> 238
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain BLV1H12 CowV 3xGGGGS linker- IL-8
-HumanCH123 of plasmid 131-72
<400> 928
Gln Val Gln Leu Arg Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45
Gly Ser Ile Asp Thr Gly Gly Asn Thr Gly Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Ser Leu
65 70 75 80
Ser Val Ser Ser Val Thr Thr Glu Asp Ser Ala Thr Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Pro Arg Ser Ala
115 120 125
Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His
130 135 140
Pro Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys
145 150 155 160
Ala Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys
165 170 175
Leu Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu
180 185 190
Lys Arg Ala Glu Asn Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
195 200 205
Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp
210 215 220
Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
225 230 235
<210> 929
<211> 238
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, 3xG4S,
IL-8 of plasmid 132-37
<400> 929
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Pro Arg Ser Ala
115 120 125
Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His
130 135 140
Pro Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys
145 150 155 160
Ala Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys
165 170 175
Leu Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu
180 185 190
Lys Arg Ala Glu Asn Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
195 200 205
Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp
210 215 220
Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
225 230 235
<210> 930
<211> 199
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, 3xG4S,
ShK of plasmid 132-35
<400> 930
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile
115 120 125
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser
130 135 140
Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr
165 170 175
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu
180 185 190
Val Thr Val Ser Ser Ala Ser
195
<210> 931
<211> 185
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, 3:3GGS,
MOKA of plasmid 132-36
<400> 931
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Ser Gly Ile Asn Val Lys Cys Ser Leu Pro Gln Gln Cys
115 120 125
Ile Lys Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn
130 135 140
Lys Lys Cys Arg Cys Tyr Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
145 150 155 160
Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly
165 170 175
Leu Leu Val Thr Val Ser Ser Ala Ser
180 185
<210> 932
<211> 199
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, CDR1 Cow, 3xG4S, ShK of
plasmid 132-38
<400> 932
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile
115 120 125
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser
130 135 140
Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr
165 170 175
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu
180 185 190
Val Thr Val Ser Ser Ala Ser
195
<210> 933
<211> 238
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, CDR1 Cow,3xG4S, IL-8 of
plasmid 132-40
<400> 933
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Pro Arg Ser Ala
115 120 125
Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His
130 135 140
Pro Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys
145 150 155 160
Ala Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys
165 170 175
Leu Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu
180 185 190
Lys Arg Ala Glu Asn Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
195 200 205
Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp
210 215 220
Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
225 230 235
<210> 934
<211> 185
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, CDR1 Cow,3:3GGS, MOKA
of plasmid 132-39
<400> 934
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Asp Lys
20 25 30
Ala Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Ser Gly Ile Asn Val Lys Cys Ser Leu Pro Gln Gln Cys
115 120 125
Ile Lys Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn
130 135 140
Lys Lys Cys Arg Cys Tyr Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser
145 150 155 160
Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly
165 170 175
Leu Leu Val Thr Val Ser Ser Ala Ser
180 185
<210> 935
<211> 194
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, 3xG4S,
ProTxII of plasmid 132-31
<400> 935
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Tyr Cys Gln Lys
115 120 125
Trp Met Trp Thr Cys Asp Ser Glu Arg Lys Cys Cys Glu Gly Met Val
130 135 140
Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp Gly Gly Gly Gly Ser Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu
165 170 175
Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
180 185 190
Ala Ser
<210> 936
<211> 198
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, 3xG4S,
GPTX1 of plasmid 132-34
<400> 936
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Asp Cys Leu Gly
115 120 125
Phe Met Arg Lys Cys Ile Pro Asp Asn Asp Lys Cys Cys Arg Pro Asn
130 135 140
Leu Val Cys Ser Arg Thr His Lys Trp Cys Lys Tyr Val Phe Gly Gly
145 150 155 160
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Thr
165 170 175
Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val
180 185 190
Thr Val Ser Ser Ala Ser
195
<210> 937
<211> 141
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-3xGGS of plasmid 132-49
<400> 937
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Ser Gly Gly
100 105 110
Ser Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val
115 120 125
Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
130 135 140
<210> 938
<211> 179
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-1xG4S ShK of plasmid 132-453
<400> 938
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala
115 120 125
Phe Gln Cys Lys His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys
130 135 140
Thr Cys Gly Thr Cys Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr
145 150 155 160
Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser
165 170 175
Ser Ala Ser
<210> 939
<211> 179
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-1xG4S ShK-16K of plasmid 132-52
<400> 939
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala
115 120 125
Phe Lys Cys Lys His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys
130 135 140
Thr Cys Gly Thr Cys Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr
145 150 155 160
Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser
165 170 175
Ser Ala Ser
<210> 940
<211> 199
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-3xG4S ShK-16K of plasmid 132-56
<400> 940
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile
115 120 125
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Lys Cys Lys His Ser
130 135 140
Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr
165 170 175
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu
180 185 190
Val Thr Val Ser Ser Ala Ser
195
<210> 941
<211> 167
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
Shk-No Linker of plasmid 132-61
<400> 941
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Arg Ser Cys Ile Asp
100 105 110
Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser Met
115 120 125
Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Ser Tyr
130 135 140
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu
145 150 155 160
Val Thr Val Ser Ser Ala Ser
165
<210> 942
<211> 169
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
G-ShK-G of plasmid 132-62
<400> 942
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Arg Ser Cys Ile
100 105 110
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser
115 120 125
Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
130 135 140
Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly
145 150 155 160
Leu Leu Val Thr Val Ser Ser Ala Ser
165
<210> 943
<211> 171
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 MutE GG-ShK-GG of
plasmid 132-63
<400> 943
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Arg Ser Cys
100 105 110
Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His
115 120 125
Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys
130 135 140
Gly Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly
145 150 155 160
Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170
<210> 944
<211> 175
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
GSGG-Shk-GGGG of plasmid 132-75
<400> 944
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Ser Gly Gly Arg
100 105 110
Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys
115 120 125
Lys His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly
130 135 140
Thr Cys Gly Gly Gly Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val
145 150 155 160
Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170 175
<210> 945
<211> 175
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
GGGG-Shk-GGGG of plasmid 132-76
<400> 945
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Arg
100 105 110
Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys
115 120 125
Lys His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly
130 135 140
Thr Cys Gly Gly Gly Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val
145 150 155 160
Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170 175
<210> 946
<211> 173
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
GGG-Shk-GGG of plasmid 132-77
<400> 946
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Arg Ser
100 105 110
Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys
115 120 125
His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr
130 135 140
Cys Gly Gly Gly Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val
145 150 155 160
Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170
<210> 947
<211> 199
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E S62G MutE
-CD1_G31DY32K_CD2_E50S_CD3_3XG4S_Shk of plasmid 132-76
<400> 947
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Gly Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile
115 120 125
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser
130 135 140
Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr
165 170 175
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu
180 185 190
Val Thr Val Ser Ser Ala Ser
195
<210> 948
<211> 189
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_2xG4S ShK of plasmid 134-12
<400> 948
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile Asp Thr Ile Pro Lys
115 120 125
Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser Met Lys Tyr Arg Leu
130 135 140
Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly Gly Gly Gly Ser Gly
145 150 155 160
Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp Val
165 170 175
Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
180 185
<210> 949
<211> 199
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_3xG4S ShK (M21Q) of plasmid 134-13
<400> 949
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile
115 120 125
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser
130 135 140
Gln Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr
165 170 175
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu
180 185 190
Val Thr Val Ser Ser Ala Ser
195
<210> 950
<211> 199
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_3xG4S ShK (M21L) of plasmid 134-14
<400> 950
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile
115 120 125
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser
130 135 140
Leu Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr
165 170 175
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu
180 185 190
Val Thr Val Ser Ser Ala Ser
195
<210> 951
<211> 199
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_3xG4S ShK (M21F) of plasmid 134-15
<400> 951
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile
115 120 125
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser
130 135 140
Phe Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr
165 170 175
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu
180 185 190
Val Thr Val Ser Ser Ala Ser
195
<210> 952
<211> 199
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_3xG4S ShK (M21I) of plasmid 134-16
<400> 952
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile
115 120 125
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser
130 135 140
Ile Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr
165 170 175
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu
180 185 190
Val Thr Val Ser Ser Ala Ser
195
<210> 953
<211> 199
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E MutE_CD1_
G31DY32K_CD2_E50S_CDR3_3xG4S ShK (M21A) of plasmid 134-17
<400> 953
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Arg Ser Cys Ile
115 120 125
Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln Cys Lys His Ser
130 135 140
Ala Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys Gly Thr Cys Gly
145 150 155 160
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr
165 170 175
Thr Tyr Asn Tyr Glu Trp His Val Asp Val Trp Gly Gln Gly Leu Leu
180 185 190
Val Thr Val Ser Ser Ala Ser
195
<210> 954
<211> 174
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-1xG4S ProTxII of plasmid 132-54
<400> 954
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Glu Arg Lys
115 120 125
Cys Cys Glu Gly Met Val Cys Arg Leu Trp Cys Lys Lys Lys Leu Trp
130 135 140
Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu Trp His Val Asp
145 150 155 160
Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser Ala Ser
165 170
<210> 955
<211> 178
<212> PRT
<213> Artificial Sequence
<220>
<223> synthesized: heavy chain VH4-34 Q5RQ6E, G31DY32K, E50S, CDR3
CowStalks-1xG4S GPTX1 of plasmid 132-55
<400> 955
Gln Val Gln Leu Arg Glu Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Lys
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr
85 90 95
Ser Val His Gln Glu Thr Lys Lys Tyr Gln Ser Gly Gly Gly Gly Ser
100 105 110
Gly Gly Asp Cys Leu Gly Phe Met Arg Lys Cys Ile Pro Asp Asn Asp
115 120 125
Lys Cys Cys Arg Pro Asn Leu Val Cys Ser Arg Thr His Lys Trp Cys
130 135 140
Lys Tyr Val Phe Gly Gly Gly Gly Ser Ser Tyr Thr Tyr Asn Tyr Glu
145 150 155 160
Trp His Val Asp Val Trp Gly Gln Gly Leu Leu Val Thr Val Ser Ser
165 170 175
Ala Ser
<210> 956
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized: VH region of Lambda LC
<400> 956
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Arg Val Ser Ile Thr Cys Ser Gly Ser Ser Ser Asn Val Gly Asn Gly
20 25 30
Tyr Val Ser Trp Tyr Gln Leu Ile Pro Gly Ser Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Ser Arg Ala Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Arg Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Ser Leu Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu
100 105 110
<210> 957
<211> 420
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized: VH4-34 MutE
<400> 957
caggtgcagc taagagagtg gggcgcagga ctgttgaagc cttcggagac gctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt gacaagtact ggagctggat tcgccagccc 120
ccagggaagg ggctggagtg gattgggagc atcaatcata gtggaagcac caactacaac 180
ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtacctc tgtgcaccag 300
gaaactaaga aataccagag cgagacctac tatggttcgg gtctctctta tacctacaat 360
tatgaatggc atgtggatgt ctggggacag ggcctgctgg tgacagtctc tagtgctagc 420
<210> 958
<211> 519
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesized: BLV1H12-HumanJ-CDR3-G4Sx3-BsaI
<400> 958
caggtccagc tgagagagag cggcccttca ctggtcaagc catcccagac actgagcctg 60
acatgcacag caagcgggtt ttcactgagc gacaaggcag tgggatgggt ccgacaggca 120
ccaggaaaag ccctggaatg gctgggcagc atcgataccg gcgggaacac agggtacaat 180
cccggactga agagcagact gtccattacc aaggacaact ctaaaagtca ggtgtcactg 240
agcgtgagct ccgtcaccac agaggatagt gcaacttact attgcacctc tgtgcaccag 300
gaaactaaga aataccagag cggtggagga ggttctggag gcggtggaag tggtggcgga 360
ggtagcggag gatgagacct actatggttc agggtctctg gaggtggtgg atctggtgga 420
ggaggcagtg gaggtggtgg cagctcttat acctacaatt atgaatggca tgtggatgtc 480
tggggccaag gaaccctggt caccgtctcc tcagctagc 519
<210> 959
<211> 110
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthesized: VL1-51 S2A, T5N, P8S, A12G ,A13S, P14L, K46R,
L47T, D51G, N52D, N53T, with CDR3 in BLV1H12 Light Chain
and J region after CDR3 in BLV1H12 Light Chain
<400> 959
Gln Ala Val Leu Asn Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Arg Thr Leu
35 40 45
Ile Tyr Gly Asp Thr Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Ala Glu Asp Ser Ser
85 90 95
Ser Asn Ala Val Phe Gly Ser Gly Thr Thr Leu Thr Val Leu
100 105 110
Claims (1)
- この出願の明細書に記載された発明。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361856010P | 2013-07-18 | 2013-07-18 | |
US61/856,010 | 2013-07-18 | ||
JP2020066669A JP2020114245A (ja) | 2013-07-18 | 2020-04-02 | 極めて長い相補性決定領域を有するヒト化抗体 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020066669A Division JP2020114245A (ja) | 2013-07-18 | 2020-04-02 | 極めて長い相補性決定領域を有するヒト化抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023036970A true JP2023036970A (ja) | 2023-03-14 |
Family
ID=51299010
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016527148A Active JP6687520B2 (ja) | 2013-07-18 | 2014-07-18 | 極めて長い相補性決定領域を有するヒト化抗体 |
JP2020066669A Pending JP2020114245A (ja) | 2013-07-18 | 2020-04-02 | 極めて長い相補性決定領域を有するヒト化抗体 |
JP2023001446A Pending JP2023036970A (ja) | 2013-07-18 | 2023-01-10 | 極めて長い相補性決定領域を有するヒト化抗体 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016527148A Active JP6687520B2 (ja) | 2013-07-18 | 2014-07-18 | 極めて長い相補性決定領域を有するヒト化抗体 |
JP2020066669A Pending JP2020114245A (ja) | 2013-07-18 | 2020-04-02 | 極めて長い相補性決定領域を有するヒト化抗体 |
Country Status (7)
Country | Link |
---|---|
US (3) | US10640574B2 (ja) |
EP (1) | EP3022221B1 (ja) |
JP (3) | JP6687520B2 (ja) |
CN (2) | CN105814074B (ja) |
AU (1) | AU2014290361B2 (ja) |
CA (1) | CA2918370A1 (ja) |
WO (1) | WO2015010100A2 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ599840A (en) * | 2009-12-22 | 2014-06-27 | Hoffmann La Roche | Sequence dependent aggregation |
CA2862979A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
EP3022221B1 (en) | 2013-07-18 | 2021-09-15 | Taurus Biosciences, LLC | Humanized antibodies with ultralong complementarity determining regions |
BR112018010937A2 (pt) | 2015-12-04 | 2018-12-04 | Novartis Ag | composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação |
GB2562933B (en) * | 2016-01-08 | 2022-06-29 | Maxion Therapeutics Ltd | Binding members with altered diversity scaffold domains |
PE20200303A1 (es) | 2017-05-24 | 2020-02-06 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
WO2019012015A1 (en) * | 2017-07-12 | 2019-01-17 | Iontas Limited | POTASIC CHANNEL INHIBITORS |
EP3737696A1 (en) | 2018-01-12 | 2020-11-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
US20210145881A1 (en) * | 2018-04-09 | 2021-05-20 | Mayo Foundation For Medical Education And Research | Methods and materials for treating graft-versus-host disease |
JP2021526830A (ja) * | 2018-06-13 | 2021-10-11 | クリスタル バイオサイエンス インコーポレイテッドCrystal Bioscience Inc. | 複数のジスルフィド架橋によって安定化され、遺伝子変換によって多様化された長いcdr−h3sで抗体を作製するトランスジェニックニワトリ |
AU2020371784A1 (en) * | 2019-10-24 | 2022-06-02 | Minotaur Therapeutics, Inc. | Chimeric cytokine modified antibodies and methods of use thereof |
KR20220160069A (ko) * | 2020-03-27 | 2022-12-05 | 유씨비 바이오파마 에스알엘 | 자율적 노브 도메인 펩티드 |
AU2022264339A1 (en) * | 2021-04-28 | 2023-11-09 | Minotaur Therapeutics, Inc. | Humanized chimeric bovine antibodies and methods of use |
EP4337690A1 (en) * | 2021-05-12 | 2024-03-20 | Applied Biomedical Science Institute | Methods of screening and expression of disulfide-bonded binding polypeptides |
WO2022241057A1 (en) * | 2021-05-12 | 2022-11-17 | Applied Biomedical Science Institute | Binding polypeptides against sars cov-2 and uses thereof |
WO2023192478A1 (en) | 2022-04-01 | 2023-10-05 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
Family Cites Families (206)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3887699A (en) | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
DE3174791D1 (en) | 1980-02-04 | 1986-07-17 | Procter & Gamble | Method of making a pattern densified fibrous web having spaced, binder impregnated high density zones |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
ATE159858T1 (de) | 1983-09-26 | 1997-11-15 | Ehrenfeld Udo | Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
DE3413608A1 (de) | 1984-04-11 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
IT1247472B (it) | 1991-05-31 | 1994-12-17 | Fidia Spa | Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
GB9207479D0 (en) * | 1992-04-06 | 1992-05-20 | Scotgen Ltd | Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
CA2150803C (en) | 1992-12-02 | 2006-01-31 | Henry Auer | Controlled release growth hormone containing microspheres |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
WO1994018221A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing polypeptide binding sites |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
AU695323B2 (en) | 1994-09-09 | 1998-08-13 | Takeda Chemical Industries Ltd. | Sustained release preparation containing metal salt of a peptide |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
AU695207B2 (en) | 1995-03-28 | 1998-08-06 | Fidia Farmaceutici S.P.A. | Nanospheres comprising a biocompatible polysaccharide |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
PT831787E (pt) | 1995-06-07 | 2002-02-28 | Alkermes Inc | Composicao para libertacao sustentada da hormona de crescimento humano |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6027888A (en) | 1996-04-05 | 2000-02-22 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells |
JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク. | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
EP1153005A1 (en) | 1999-02-22 | 2001-11-14 | Symyx Technologies | Compositions comprising nickel and their use as catalyst in oxidative dehydrogenation of alkanes |
EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
CA2385347C (en) | 1999-10-04 | 2009-12-15 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
JP2005500806A (ja) | 2000-09-15 | 2005-01-13 | コーリー ファーマシューティカル ゲーエムベーハー | CpGに基づく免疫アゴニスト/免疫アンタゴニストの高スループットスクリーニングのためのプロセス |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
CA2382766A1 (en) | 2001-04-20 | 2002-10-20 | Azad Kaushik | Novel bovine vdj cassette, bf1h1, suitable for antigenization |
US7196185B2 (en) | 2001-04-20 | 2007-03-27 | Azad Kumar Kaushik | Bovine germline D-genes and their application |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
MXPA05000511A (es) * | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
CA2838062C (en) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
AU2002332041A1 (en) | 2001-10-05 | 2003-04-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US8491896B2 (en) | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
AU2003210060B2 (en) * | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
DE60336548D1 (de) | 2002-04-09 | 2011-05-12 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
WO2003085086A2 (en) | 2002-04-09 | 2003-10-16 | The Scripps Research Institute | Motif-grafted hybrid polypeptides and uses thereof |
AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
US7297348B2 (en) | 2002-07-19 | 2007-11-20 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
BRPI0316779B8 (pt) | 2002-12-16 | 2023-02-28 | Genentech Inc | Anticorpo anti-cd20 humano ou fragmento de ligação ao antígeno do mesmo, seus usos, composição, artigo manufaturado e formulação líquida |
EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
DK2256134T3 (en) | 2003-11-13 | 2014-02-24 | Hanmi Science Co Ltd | IgG Fc fragment to a drug carrier and process for preparation thereof |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
EP1576952A1 (en) | 2004-03-18 | 2005-09-21 | OctoPlus Technologies B.V. | Hydrogel microspheres with improved release profile |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
AU2008276787B2 (en) | 2007-07-13 | 2013-06-06 | Bac Ip B.V. | Single-domain antigen-binding proteins that bind mammalian IgG |
AU2008317495B2 (en) | 2007-08-02 | 2013-08-01 | Novimmune S.A. | Anti-RANTES antibodies and methods of use thereof |
EP2281078B1 (en) | 2008-04-24 | 2014-10-22 | Dyax Corporation | Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs |
CA2736277C (en) | 2008-09-10 | 2016-06-21 | Philochem Ag | Display library for antibody selection |
JP2012508017A (ja) | 2008-11-07 | 2012-04-05 | ファブラス エルエルシー | 抗dll4抗体及びその使用 |
US20100184683A1 (en) | 2009-01-06 | 2010-07-22 | C3 Jian, Inc. | Antibacterial and antifungal peptides |
HUE060624T2 (hu) | 2009-02-13 | 2023-04-28 | Immunomedics Inc | Sejten belüli hasítható kötést tartalmazó immunkonjugátumok |
PL2485761T3 (pl) | 2009-10-09 | 2019-10-31 | Armagen Inc | Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns |
US20120316071A1 (en) | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
EP2717924A4 (en) | 2011-06-10 | 2015-04-22 | Harvard College | MODULATION OF BETA CELL PROLIFERATION IN THE PANCREATIC GLAND |
WO2013106485A2 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
CA2862979A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
US20140200127A1 (en) | 2013-01-11 | 2014-07-17 | Sealed Air Corporation (Us) | System for Producing Packaging Cushioning |
EP2943512A4 (en) * | 2013-01-11 | 2016-06-01 | California Inst Biomedical Res | FUSION BOVINE ANTIBODIES |
WO2015006736A2 (en) | 2013-07-11 | 2015-01-15 | The California Institute For Biomedical Research | Coiled coil immunoglobulin fusion proteins and compositions thereof |
EP3022221B1 (en) | 2013-07-18 | 2021-09-15 | Taurus Biosciences, LLC | Humanized antibodies with ultralong complementarity determining regions |
US20160168231A1 (en) | 2013-07-18 | 2016-06-16 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
-
2014
- 2014-07-18 EP EP14748405.9A patent/EP3022221B1/en active Active
- 2014-07-18 CN CN201480051514.8A patent/CN105814074B/zh active Active
- 2014-07-18 WO PCT/US2014/047315 patent/WO2015010100A2/en active Application Filing
- 2014-07-18 CA CA2918370A patent/CA2918370A1/en active Pending
- 2014-07-18 US US14/905,765 patent/US10640574B2/en active Active
- 2014-07-18 CN CN202010240256.5A patent/CN111518199A/zh active Pending
- 2014-07-18 AU AU2014290361A patent/AU2014290361B2/en active Active
- 2014-07-18 JP JP2016527148A patent/JP6687520B2/ja active Active
-
2020
- 2020-03-26 US US16/831,508 patent/US11530493B2/en active Active
- 2020-04-02 JP JP2020066669A patent/JP2020114245A/ja active Pending
-
2022
- 2022-11-09 US US18/054,045 patent/US20230287598A1/en active Pending
-
2023
- 2023-01-10 JP JP2023001446A patent/JP2023036970A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN105814074B (zh) | 2020-04-21 |
AU2014290361A1 (en) | 2016-02-11 |
EP3022221B1 (en) | 2021-09-15 |
US20200239599A1 (en) | 2020-07-30 |
US20230287598A1 (en) | 2023-09-14 |
AU2014290361B2 (en) | 2019-04-18 |
JP6687520B2 (ja) | 2020-04-22 |
CN105814074A (zh) | 2016-07-27 |
JP2016527234A (ja) | 2016-09-08 |
WO2015010100A3 (en) | 2015-06-25 |
US10640574B2 (en) | 2020-05-05 |
CN111518199A (zh) | 2020-08-11 |
JP2020114245A (ja) | 2020-07-30 |
CA2918370A1 (en) | 2015-01-22 |
US20160159928A1 (en) | 2016-06-09 |
US11530493B2 (en) | 2022-12-20 |
WO2015010100A2 (en) | 2015-01-22 |
EP3022221A2 (en) | 2016-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023036970A (ja) | 極めて長い相補性決定領域を有するヒト化抗体 | |
US11390665B2 (en) | Ultralong complementarity determining regions and uses thereof | |
US20200223944A1 (en) | Humanized antibodies | |
US9644021B2 (en) | Bovine fusion antibodies | |
US20160168231A1 (en) | Antibodies with ultralong complementarity determining regions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230207 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230207 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230720 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231211 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240530 |